



(51) International Patent Classification:

A61K 47/68 (2017.01) A61K 31/7125 (2006.01)

C12N 15/113 (2010.01) C07K 16/28 (2006.01)

A61K 31/712 (2006.01)

(21) International Application Number:

PCT/US2022/073529

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,108 09 July 2021 (09.07.2021) US

(71) Applicant: **DYNETHERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).

(72) Inventors: **DESJARDINS, Cody, A.**; 1560 Trapelo Road, Waltham, MA 02451 (US). **TANG, Kim**; 1560 Trapelo Road, Waltham, MA 02451 (US). **MCSWIGGEN, James**; 19395 W. 94th Avenue, Arvada, CO 80007 (US). **SUBRAMANIAN, Romesh, R.**; 9 Alan Street, Framingham, MA 01701 (US). **WEEDEN, Timothy**; 1560 Trapelo Road, Waltham, MA 02451 (US). **QATANANI, Mohammed, T.**; 1560 Trapelo Road, Waltham, MA 02451 (US). **QUINN, Brendan**; 45 East Newton Street #320, Boston, MA 02118

(US). **NAJIM, John**; 1560 Trapelo Road, Waltham, MA 02451 (US).

(74) Agent: **BUSS, Colin, G.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES




FIG. 1

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Serial No. 63/220108, entitled “MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES”, filed on July 9, 2021, the contents of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present application relates to targeting complexes for delivering molecular payloads (e.g., oligonucleotides) to cells and uses thereof, particularly uses relating to treatment of disease.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (D082470063WO00-SEQ-COB.xml; Size: 729,857 bytes; and Date of Creation: July 7, 2022) are herein incorporated by reference in their entirety.

BACKGROUND OF INVENTION

[0004] Dystrophinopathies are a group of distinct neuromuscular diseases that result from mutations in the gene encoding dystrophin. Dystrophinopathies include Duchenne muscular dystrophy, Becker muscular dystrophy, and X-linked dilated cardiomyopathy. The DMD gene (“DMD”), which encodes dystrophin, is a large gene, containing 79 exons and about 2.6 million total base pairs. Numerous mutations in DMD, including exonic frameshift, deletion, substitution, and duplicative mutations, are able to diminish the expression of functional dystrophin, leading to dystrophinopathies. Several agents that target exons of human DMD have been approved by the U.S. Food and Drug Administration (FDA), including casimersen, viltolarsen, golodirsen, and eteplirsen.

SUMMARY OF INVENTION

[0005] According to some aspects, the disclosure provides complexes that target muscle cells for purposes of delivering molecular payloads to those cells, as well as molecular payloads that can be used therein. In some embodiments, complexes provided herein are particularly useful for delivering molecular payloads that increase or restore expression or activity of functional

dystrophin protein. In some embodiments, complexes comprise oligonucleotide based molecular payloads that promote expression of functional dystrophin protein through an in-frame exon skipping mechanism or suppression of stop codons, such as by facilitating skipping of DMD exon 44. In some embodiments, molecular payloads provided herein are useful for facilitating exon skipping in a DMD sequence, such as skipping of DMD exon 44. Accordingly, in some embodiments, complexes provided herein comprise muscle-targeting agents (e.g., muscle targeting antibodies) that specifically bind to receptors on the surface of muscle cells for purposes of delivering molecular payloads to the muscle cells. In some embodiments, the complexes are taken up into the cells via a receptor mediated internalization, following which the molecular payload may be released to perform a function inside the cells. For example, complexes engineered to deliver oligonucleotides may release the oligonucleotides such that the oligonucleotides can promote expression of functional dystrophin protein (e.g., through an exon skipping mechanism, such as by facilitating skipping of DMD exon 44) in the muscle cells. In some embodiments, the oligonucleotides are released by endosomal cleavage of covalent linkers connecting oligonucleotides and muscle-targeting agents of the complexes. Complexes and molecular payloads provided herein can be used for treating subjects having a mutated DMD gene, such as a mutated DMD gene that is amenable to exon 44 skipping.

[0006] According to some aspects, complexes comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA are provided herein, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 160-195.

[0007] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;

(ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;

(vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or

(vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

[0008] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

[0009] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[00010] In some embodiments, the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG. In some embodiments, the anti-TfR1 antibody is a Fab fragment.

[00011] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
- (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID

NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

[00012] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[00013] In some embodiments, the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

[00014] In some embodiments, the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.

[00015] In some embodiments, the splicing feature is an exonic splicing enhancer (ESE) in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.

[00016] In some embodiments, the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.

[00017] In some embodiments, the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-195 or comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00018] In some embodiments, the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

[00019] In some embodiments, the anti-TfR1 antibody is covalently linked to the oligonucleotide via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.

[00020] In some embodiments, the anti-TfR1 antibody is covalently linked to the oligonucleotide via conjugation to a lysine residue or a cysteine residue of the antibody.

[00021] According to some aspects, oligonucleotides that target DMD are provided herein, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ

ID NOs: 160-195, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.

[00022] In some embodiments, the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00023] According to some aspects, methods of delivering an oligonucleotide to a cell are provided herein, wherein the method comprises contacting the cell with a complex disclosed herein or with an oligonucleotide disclosed herein.

[00024] According to some aspects, methods of promoting the expression or activity of a dystrophin protein in a cell are provided herein, wherein the method comprises contacting the cell with a complex disclosed or with an oligonucleotide disclosed herein in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.

[00025] In some embodiments, the cell comprises a DMD gene that is amenable to skipping of exon 44.

[00026] In some embodiments, the dystrophin protein is a truncated dystrophin protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[00027] **FIG. 1** shows data illustrating that conjugates containing anti-TfR1 Fab (3M12 VH4/Vκ3) conjugated to a DMD exon-skipping oligonucleotide resulted in enhanced exon skipping compared to the naked DMD exon skipping oligo in Duchenne muscular dystrophy patient myotubes.

DETAILED DESCRIPTION OF INVENTION

[00028] Aspects of the disclosure relate to a recognition that while certain molecular payloads (*e.g.*, oligonucleotides, peptides, small molecules) can have beneficial effects in muscle cells, it has proven challenging to effectively target such cells. Accordingly, as described herein, the present disclosure provides complexes comprising muscle-targeting agents covalently linked to molecular payloads in order to overcome such challenges. In some embodiments, the complexes are particularly useful for delivering molecular payloads that modulate (*e.g.*, promote) the expression or activity of dystrophin protein (*e.g.*, a truncated dystrophin protein) or DMD (*e.g.*, a mutated DMD allele). In some embodiments, complexes provided herein may

comprise oligonucleotides that promote expression and activity of dystrophin protein or DMD, such as by facilitating in-frame exon skipping and/or suppression of premature stop codons. For example, complexes may comprise oligonucleotides that induce skipping of exon(s) of DMD RNA (*e.g.*, pre-mRNA), such as oligonucleotides that induce skipping of exon 44. In some embodiments, synthetic nucleic acid payloads (*e.g.*, DNA or RNA payloads) may be used that express one or more proteins that promote normal expression and activity of dystrophin protein or DMD.

[00029] Duchenne muscular dystrophy is an X-linked muscular disorder caused by one or more mutations in the DMD gene located on Xp21. Dystrophin protein typically forms the dystrophin-associated glycoprotein complex (DGC) at the sarcolemma, which links the muscle sarcomeric structure to the extracellular matrix and protects the sarcolemma from contraction-induced injury. In patients with Duchenne muscular dystrophy, the dystrophin protein is generally absent and muscle fibers typically become damaged due to mechanical overextension. Mutations in the DMD gene are associated with two types of muscular dystrophy, Duchenne muscular dystrophy and Becker muscular dystrophy, depending on whether the translational reading frame is lost or maintained. Becker muscular dystrophy is a clinically milder form of Duchenne muscular dystrophy, and is characterized by features similar to Duchenne muscular dystrophy. In some embodiments, exon skipping induced by oligonucleotides (*e.g.*, delivered using complexes provided herein) can be used to restore the reading frame of a mutated DMD allele resulting in production of a truncated dystrophin protein that is sufficiently functional to improve muscle function. In some embodiments, such exon skipping converts a Duchenne muscular dystrophy phenotype into a milder Becker muscular dystrophy phenotype.

[00030] Further aspects of the disclosure, including a description of defined terms, are provided below.

I. Definitions

[00031] **Administering:** As used herein, the terms “administering” or “administration” means to provide a complex to a subject in a manner that is physiologically and/or (*e.g.*, and) pharmacologically useful (*e.g.*, to treat a condition in the subject).

[00032] **Approximately:** As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[00033] Antibody: As used herein, the term “antibody” refers to a polypeptide that includes at least one immunoglobulin variable domain or at least one antigenic determinant, e.g., paratope that specifically binds to an antigen. In some embodiments, an antibody is a full-length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a nanobody derived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgG1, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgA1, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region (abbreviated herein as VH), and/or (e.g., and) a light (L) chain variable region (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain, e.g., an Fc region. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (α), delta (Δ), epsilon (ε), gamma (γ) or mu (μ) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (α), delta (Δ), epsilon (ε), gamma (γ) or mu (μ) heavy chain. In a particular embodiment, an antibody described herein comprises a human gamma 1 CH1, CH2, and/or (e.g., and) CH3 domain. In some embodiments, the amino acid sequence of the VH domain comprises the amino acid sequence of a human gamma (γ) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, the VH domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the variable chain constant regions provided herein. In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or

carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a polypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[00034] Branch point: As used herein, the term “branch point” or “branch site” refers to a nucleic acid sequence motif within an intron of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A branch point is typically located 18 to 40 nucleotides from the 3' end of an intron, and contains an adenine but is otherwise relatively unrestricted in sequence. Common sequence motifs for branch points are YNYRAY, YTRAC, and YNYTRAY, where Y is a pyrimidine, N is any nucleotide, R is any purine, and A is adenine. During splicing, the pre-mRNA is cleaved at the 5' end of the intron, which then attaches to the branch point region downstream through transesterification bonding between guanines and adenines from the 5' end and the branch point, respectively, to form a looped lariat structure.

[00035] CDR: As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known

in the art, for example, by the Kabat definition, the IMGT definition, the Chothia definition, the AbM definition, and/or (e.g., and) the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; IMGT®, the international ImMunoGeneTics information system® www.imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P., Nucleic Acids Res., 29:207-209 (2001); Lefranc, M.-P., Nucleic Acids Res., 31:307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [Epub], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. et al., Nucleic Acids Res., 43:D413-422 (2015); Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also bioinf.org.uk/abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[00036] There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat *et al.*, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as L1, L2 and L3 or H1, H2 and H3 where the "L" and the "H" designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems. Examples of CDR definition systems are provided in Table 1.

Table 1. CDR Definitions

	IMGT¹	Kabat²	Chothia³
CDR-H1	27-38	31-35	26-32
CDR-H2	56-65	50-65	53-55
CDR-H3	105-116/117	95-102	96-101
CDR-L1	27-38	24-34	26-32
CDR-L2	56-65	50-56	50-52
CDR-L3	105-116/117	89-97	91-96

¹ IMGT®, the international ImMunoGeneTics information system®, imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999)

² Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242

³ Chothia et al., J. Mol. Biol. 196:901-917 (1987))

[00037] CDR-grafted antibody: The term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and/or (e.g., and) VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (*e.g.*, CDR3) has been replaced with human CDR sequences.

[00038] Chimeric antibody: The term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[00039] Complementary: As used herein, the term "complementary" refers to the capacity for precise pairing between two nucleosides or two sets of nucleosides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleosides or two sets of nucleosides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (*e.g.*, an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (*e.g.*, Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[00040] Conservative amino acid substitution: As used herein, a "conservative amino acid substitution" refers to an amino acid substitution that does not alter the relative charge or

size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[00041] Covalently linked: As used herein, the term “covalently linked” refers to a characteristic of two or more molecules being linked together via at least one covalent bond. In some embodiments, two molecules can be covalently linked together by a single bond, e.g., a disulfide bond or disulfide bridge, that serves as a linker between the molecules. However, in some embodiments, two or more molecules can be covalently linked together via a molecule that serves as a linker that joins the two or more molecules together through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker.

[00042] Cross-reactive: As used herein and in the context of a targeting agent (e.g., antibody), the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human transferrin receptor and non-human primate transferrin receptor) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross-reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[00043] DMD: As used herein, the term “DMD” refers to a gene that encodes dystrophin protein, a key component of the dystrophin-glycoprotein complex, which bridges the inner cytoskeleton and the extracellular matrix in muscle cells, particularly muscle fibers. Deletions, duplications, and point mutations in DMD may cause dystrophinopathies, such as Duchenne muscular dystrophy, Becker muscular dystrophy, or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. In some embodiments, a dystrophin gene (DMD or DMD gene) may be a human

(Gene ID: 1756), non-human primate (e.g., Gene ID: 465559), or rodent gene (e.g., Gene ID: 13405; Gene ID: 24907). In addition, multiple human transcript variants (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000109.3, NM_004006.2, NM_004009.3, NM_004010.3 and NM_004011.3) have been characterized that encode different protein isoforms.

[00044] DMD allele: As used herein, the term “DMD allele” refers to any one of alternative forms (e.g., wild-type or mutant forms) of a DMD gene. In some embodiments, a DMD allele may encode for dystrophin that retains its normal and typical functions. In some embodiments, a DMD allele may comprise one or more mutations that results in muscular dystrophy. Common mutations that lead to Duchenne muscular dystrophy involve frameshift, deletion, substitution, and duplicative mutations of one or more of 79 exons present in a dystrophin allele, e.g., exon 8, exon 23, exon 41, exon 44, exon 45, exon 50, exon 51, exon 52, exon 53, or exon 55. Further examples of DMD mutations are disclosed, for example, in Flanigan KM, et al., *Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort*. Hum Mutat. 2009 Dec; 30 (12):1657-66, the contents of which are incorporated herein by reference in its entirety.

[00045] Dystrophinopathy: As used herein, the term “dystrophinopathy” refers to a muscle disease results from one or more mutated DMD alleles. Dystrophinopathies include a spectrum of conditions (ranging from mild to severe) that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). In some embodiments, at one end of the spectrum, dystrophinopathy is phenotypically associated with an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, at the other end of the spectrum, dystrophinopathy is phenotypically associated with progressive muscle diseases that are generally classified as Duchenne or Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected. Symptoms of Duchenne muscular dystrophy include muscle loss or degeneration, diminished muscle function, pseudohypertrophy of the tongue and calf muscles, higher risk of neurological abnormalities, and a shortened lifespan. Duchenne muscular dystrophy is associated with Online Mendelian Inheritance in Man (OMIM) Entry # 310200. Becker muscular dystrophy is associated with OMIM Entry # 300376. Dilated cardiomyopathy is associated with OMIM Entry X# 302045.

[00046] Exonic splicing enhancer (ESE): As used herein, the term “exonic splicing enhancer” or “ESE” refers to a nucleic acid sequence motif within an exon of a gene, pre-mRNA, or mRNA that directs or enhances splicing of pre-mRNA into mRNA, e.g., as described

in Blencowe et al., Trends Biochem Sci 25, 106-10. (2000), incorporated herein by reference. ESEs can be referred to as splicing features. ESEs may direct or enhance splicing, for example, to remove one or more introns and/or one or more exons from a gene transcript. ESE motifs are typically 6-8 nucleobases in length. SR proteins (e.g., proteins encoded by the gene SRSF1, SRSF2, SRSF3, SRSF4, SRSF5, SRSF6, SRSF7, SRSF8, SRSF9, SRSF10, SRSF11, SRSF12, TRA2A or TRA2B) bind to ESEs through their RNA recognition motif region to facilitate splicing. ESE motifs can be identified through a number of methods, including those described in Cartegni et al., Nucleic Acids Research, 2003, Vol. 31, No. 13, 3568–3571, incorporated herein by reference.

[00047] Framework: As used herein, the term "framework" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4. Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred by others, represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions, and FRs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[00048] Human antibody: The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[00049] Humanized antibody: The term "humanized antibody" refers to antibodies which comprise heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and/or (e.g., and) VL sequence has been altered to be more "human-like", *i.e.*, more similar to human germline variable sequences. One

type of humanized antibody is a CDR-grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding non-human CDR sequences. In one embodiment, humanized anti-TfR1 antibodies and antigen binding portions are provided. Such antibodies may be generated by obtaining murine anti-TfR1 monoclonal antibodies using traditional hybridoma technology followed by humanization using *in vitro* genetic engineering, such as those disclosed in Kasaian et al PCT publication No. WO 2005/123126 A2.

[00050] Internalizing cell surface receptor: As used herein, the term, "internalizing cell surface receptor" refers to a cell surface receptor that is internalized by cells, e.g., upon external stimulation, e.g., ligand binding to the receptor. In some embodiments, an internalizing cell surface receptor is internalized by endocytosis. In some embodiments, an internalizing cell surface receptor is internalized by clathrin-mediated endocytosis. However, in some embodiments, an internalizing cell surface receptor is internalized by a clathrin-independent pathway, such as, for example, phagocytosis, macropinocytosis, caveolae- and raft-mediated uptake or constitutive clathrin-independent endocytosis. In some embodiments, the internalizing cell surface receptor comprises an intracellular domain, a transmembrane domain, and/or (e.g., and) an extracellular domain, which may optionally further comprise a ligand-binding domain. In some embodiments, a cell surface receptor becomes internalized by a cell after ligand binding. In some embodiments, a ligand may be a muscle-targeting agent or a muscle-targeting antibody. In some embodiments, an internalizing cell surface receptor is a transferrin receptor.

[00051] Isolated antibody: An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds transferrin receptor is substantially free of antibodies that specifically bind antigens other than transferrin receptor). An isolated antibody that specifically binds transferrin receptor complex may, however, have cross-reactivity to other antigens, such as transferrin receptor molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or (e.g., and) chemicals.

[00052] Kabat numbering: The terms "Kabat numbering", "Kabat definitions and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and, Kabat, E. A., *et al.* (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1,

amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[00053] Molecular payload: As used herein, the term “molecular payload” refers to a molecule or species that functions to modulate a biological outcome. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, the molecular payload is a small molecule, a protein, a peptide, a nucleic acid, or an oligonucleotide. In some embodiments, the molecular payload functions to modulate the transcription of a DNA sequence, to modulate the expression of a protein, or to modulate the activity of a protein. In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a target gene.

[00054] Muscle-targeting agent: As used herein, the term, “muscle-targeting agent,” refers to a molecule that specifically binds to an antigen expressed on muscle cells. The antigen in or on muscle cells may be a membrane protein, for example an integral membrane protein or a peripheral membrane protein. Typically, a muscle-targeting agent specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting agent (and any associated molecular payload) into the muscle cells. In some embodiments, a muscle-targeting agent specifically binds to an internalizing, cell surface receptor on muscles and is capable of being internalized into muscle cells through receptor mediated internalization. In some embodiments, the muscle-targeting agent is a small molecule, a protein, a peptide, a nucleic acid (*e.g.*, an aptamer), or an antibody. In some embodiments, the muscle-targeting agent is linked to a molecular payload.

[00055] Muscle-targeting antibody: As used herein, the term, “muscle-targeting antibody,” refers to a muscle-targeting agent that is an antibody that specifically binds to an antigen found in or on muscle cells. In some embodiments, a muscle-targeting antibody specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting antibody (and any associated molecular payment) into the muscle cells. In some embodiments, the muscle-targeting antibody specifically binds to an internalizing, cell surface receptor present on muscle cells. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds to a transferrin receptor.

[00056] Oligonucleotide: As used herein, the term “oligonucleotide” refers to an oligomeric nucleic acid compound of up to 200 nucleotides in length. Examples of oligonucleotides include, but are not limited to, RNAi oligonucleotides (*e.g.*, siRNAs, shRNAs), microRNAs, gapmers, mixmers, phosphorodiamidate morpholinos, peptide nucleic acids,

aptamers, guide nucleic acids (e.g., Cas9 guide RNAs), etc. Oligonucleotides may be single-stranded or double-stranded. In some embodiments, an oligonucleotide may comprise one or more modified nucleosides (e.g., 2'-O-methyl sugar modifications, purine or pyrimidine modifications). In some embodiments, an oligonucleotide may comprise one or more modified internucleoside linkages. In some embodiments, an oligonucleotide may comprise one or more phosphorothioate linkages, which may be in the Rp or Sp stereochemical conformation.

[00057] Recombinant antibody: The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire *in vivo*. One embodiment of the disclosure provides fully human antibodies capable of binding human transferrin receptor which can be generated using techniques well known in the art, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et al., PCT publication No. WO 2005/007699 A2.

[00058] Region of complementarity: As used herein, the term "region of complementarity" refers to a nucleotide sequence, e.g., of an oligonucleotide, that is sufficiently complementary to a cognate nucleotide sequence, e.g., of a target nucleic acid, such that the two nucleotide sequences are capable of annealing to one another under physiological conditions (e.g., in a cell). In some embodiments, a region of complementarity is fully complementary to a cognate nucleotide sequence of target nucleic acid. However, in some embodiments, a region of

complementarity is partially complementary to a cognate nucleotide sequence of target nucleic acid (e.g., at least 80%, 90%, 95% or 99% complementarity). In some embodiments, a region of complementarity contains 1, 2, 3, or 4 mismatches compared with a cognate nucleotide sequence of a target nucleic acid.

[00059] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds”, refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, that enables the antibody to be used to distinguish the specific antigen from others, e.g., to an extent that permits preferential targeting to certain cells, e.g., muscle cells, through binding to the antigen, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a K_D for binding the target of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, an antibody specifically binds to the transferrin receptor, e.g., an epitope of the apical domain of transferrin receptor.

[00060] Splice acceptor site: As used herein, the term “splice acceptor site” or “splice acceptor” refers to a nucleic acid sequence motif at the 3' end of an intron or across an intron/exon junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice acceptor site includes a terminal AG sequence at the 3' end of an intron, which is typically preceded (5'-ward) by a region high in pyrimidines (C/U). Upstream from the splice acceptor site is the branch point. Formation of a lariat loop intermediate structure by a transesterification reaction between the branch point and the splice donor site releases a 3'-OH of the 5' exon, which subsequently reacts with the first nucleotide of the 3' exon, thereby joining the exons and releasing the intron lariat. The AG sequence at the 3' end of the intron in the splice acceptor site is known to be critical for proper splicing, as changing one of these nucleotides results in inhibition of splicing. Rarely, alternative splice acceptor sites have an AC at the 3' end of the intron, instead of the more common AG. A common splice acceptor site motif has a sequence of or similar to [Y-rich region]-NCAGG or Y_xNYAGG , in which Y represents a pyrimidine, N represents any nucleotide, and x is a number from 4 to 20. The cut site follows the AG, which represent the 3'-terminal nucleotides of the excised intron.

[00061] Splice donor site: As used herein, the term “splice donor site” or “splice donor” refers to a nucleic acid sequence motif at the 5' end of an intron or across an exon/intron


junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice donor site includes a terminal GU sequence at the 5' end of the intron, within a larger and fairly unconstrained sequence. During splicing, the 2'-OH of a nucleotide within the branch point initiates a transesterification reaction via a nucleophilic attack on the 5' G of the intron within the splice donor site. The G is thereby cleaved from the pre-mRNA and bonds instead to the branch point nucleotide, forming a loop lariat structure. The 3' nucleotide of the upstream exon subsequently binds the splice acceptor site, joining the exons and excising the intron. A typical splice donor site has a sequence of or similar to GGGURAGU or AGGURNNG, in which R represents a purine and N represents any nucleotide. The cut site precedes the first GU (*i.e.*, GG/GURAGU or AG/GURNNG), which represent the 5'-terminal nucleotides of the excised intron.

[00062] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, *e.g.*, a human patient that has or is suspected of having a disease. In some embodiments, the subject is a human patient who has or is suspected of having a disease resulting from a mutated DMD gene sequence, *e.g.*, a mutation in an exon of a DMD gene sequence. In some embodiments, a subject has a dystrophinopathy, *e.g.*, Duchenne muscular dystrophy. In some embodiments, a subject is a patient that has a mutation of the DMD gene that is amenable to exon 44 skipping.

[00063] Transferrin receptor: As used herein, the term, “transferrin receptor” (also known as TFRC, CD71, p90, or TFR1) refers to an internalizing cell surface receptor that binds transferrin to facilitate iron uptake by endocytosis. In some embodiments, a transferrin receptor may be of human (NCBI Gene ID 7037), non-human primate (*e.g.*, NCBI Gene ID 711568 or NCBI Gene ID 102136007), or rodent (*e.g.*, NCBI Gene ID 22042) origin. In addition, multiple human transcript variants have been characterized that encoded different isoforms of the receptor (*e.g.*, as annotated under GenBank RefSeq Accession Numbers: NP_001121620.1, NP_003225.2, NP_001300894.1, and NP_001300895.1).

[00064] 2'-modified nucleoside: As used herein, the terms “2'-modified nucleoside” and “2'-modified ribonucleoside” are used interchangeably and refer to a nucleoside having a sugar moiety modified at the 2' position. In some embodiments, the 2'-modified nucleoside is a 2'-4' bicyclic nucleoside, where the 2' and 4' positions of the sugar are bridged (*e.g.*, via a methylene, an ethylene, or a (S)-constrained ethyl bridge). In some embodiments, the 2'-modified nucleoside is a non-bicyclic 2'-modified nucleoside, *e.g.*, where the 2' position of the sugar moiety is substituted. Non-limiting examples of 2'-modified nucleosides include: 2'-deoxy, 2'-

fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), 2'-O-N-methylacetamido (2'-O-NMA), locked nucleic acid (LNA, methylene-bridged nucleic acid), ethylene-bridged nucleic acid (ENA), and (S)-constrained ethyl-bridged nucleic acid (cEt). In some embodiments, the 2'-modified nucleosides described herein are high-affinity modified nucleosides and oligonucleotides comprising the 2'-modified nucleosides have increased affinity to a target sequences, relative to an unmodified oligonucleotide. Examples of structures of 2'-modified nucleosides are provided below:



These examples are shown with phosphate groups, but any internucleoside linkages are contemplated between 2'-modified nucleosides.

II. Complexes

[00065] Provided herein are complexes that comprise a targeting agent, e.g. an antibody, covalently linked to a molecular payload. In some embodiments, a complex comprises a muscle-targeting antibody covalently linked to an oligonucleotide. A complex may comprise an antibody that specifically binds a single antigenic site or that binds to at least two antigenic sites that may exist on the same or different antigens.

[00066] A complex may be used to modulate the activity or function of at least one gene, protein, and/or (e.g., and) nucleic acid. In some embodiments, the molecular payload present within a complex is responsible for the modulation of a gene, protein, and/or (e.g., and) nucleic acids. A molecular payload may be a small molecule, protein, nucleic acid, oligonucleotide, or

any molecular entity capable of modulating the activity or function of a gene, protein, and/or (e.g., and) nucleic acid in a cell.

[00067] In some embodiments, a complex comprises a muscle-targeting agent, *e.g.*, an anti-transferrin receptor antibody, covalently linked to a molecular payload, *e.g.*, an antisense oligonucleotide that targets DMD to promote exon skipping, *e.g.*, in a transcript encoded from a mutated DMD allele. In some embodiments, the complex targets a DMD pre-mRNA to promote skipping of exon 44 in the DMD pre-mRNA.

A. Muscle-Targeting Agents

[00068] Some aspects of the disclosure provide muscle-targeting agents, *e.g.*, for delivering a molecular payload to a muscle cell. In some embodiments, such muscle-targeting agents are capable of binding to a muscle cell, *e.g.*, via specifically binding to an antigen on the muscle cell, and delivering an associated molecular payload to the muscle cell. In some embodiments, the molecular payload is bound (*e.g.*, covalently bound) to the muscle targeting agent and is internalized into the muscle cell upon binding of the muscle targeting agent to an antigen on the muscle cell, *e.g.*, via endocytosis. It should be appreciated that various types of muscle-targeting agents may be used in accordance with the disclosure, and that any muscle targets (*e.g.*, muscle surface proteins) can be targeted by any type of muscle-targeting agent described herein. For example, the muscle-targeting agent may comprise, or consist of, a small molecule, a nucleic acid (*e.g.*, DNA or RNA), a peptide (*e.g.*, an antibody), a lipid (*e.g.*, a microvesicle), or a sugar moiety (*e.g.*, a polysaccharide). Exemplary muscle-targeting agents are described in further detail herein, however, it should be appreciated that the exemplary muscle-targeting agents provided herein are not meant to be limiting.

[00069] Some aspects of the disclosure provide muscle-targeting agents that specifically bind to an antigen on muscle, such as skeletal muscle, smooth muscle, or cardiac muscle. In some embodiments, any of the muscle-targeting agents provided herein bind to (*e.g.*, specifically bind to) an antigen on a skeletal muscle cell, a smooth muscle cell, and/or (*e.g.*, and) a cardiac muscle cell.

[00070] By interacting with muscle-specific cell surface recognition elements (*e.g.*, cell membrane proteins), both tissue localization and selective uptake into muscle cells can be achieved. In some embodiments, molecules that are substrates for muscle uptake transporters are useful for delivering a molecular payload into muscle tissue. Binding to muscle surface recognition elements followed by endocytosis can allow even large molecules such as antibodies to enter muscle cells. As another example molecular payloads conjugated to transferrin or anti-TfR1 antibodies can be taken up by muscle cells via binding to transferrin receptor, which may then be endocytosed, *e.g.*, via clathrin-mediated endocytosis.

[00071] The use of muscle-targeting agents may be useful for concentrating a molecular payload (*e.g.*, oligonucleotide) in muscle while reducing toxicity associated with effects in other tissues. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells as compared to another cell type within a subject. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells (*e.g.*, skeletal, smooth, or cardiac muscle cells) in an amount that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times greater than an amount in non-muscle cells (*e.g.*, liver, neuronal, blood, or fat cells). In some embodiments, a toxicity of the molecular payload in a subject is reduced by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% when it is delivered to the subject when bound to the muscle-targeting agent.

[00072] In some embodiments, to achieve muscle selectivity, a muscle recognition element (*e.g.*, a muscle cell antigen) may be required. As one example, a muscle-targeting agent may be a small molecule that is a substrate for a muscle-specific uptake transporter. As another example, a muscle-targeting agent may be an antibody that enters a muscle cell via transporter-mediated endocytosis. As another example, a muscle targeting agent may be a ligand that binds to cell surface receptor on a muscle cell. It should be appreciated that while transporter-based approaches provide a direct path for cellular entry, receptor-based targeting may involve stimulated endocytosis to reach the desired site of action.

i. Muscle-Targeting Antibodies

[00073] In some embodiments, the muscle-targeting agent is an antibody. Generally, the high specificity of antibodies for their target antigen provides the potential for selectively targeting muscle cells (*e.g.*, skeletal, smooth, and/or (*e.g.*, and) cardiac muscle cells). This specificity may also limit off-target toxicity. Examples of antibodies that are capable of targeting a surface antigen of muscle cells have been reported and are within the scope of the disclosure. For example, antibodies that target the surface of muscle cells are described in Arahata K., et al. “Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide” *Nature* 1988; 333: 861-3; Song K.S., et al. “Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins” *J Biol Chem* 1996; 271: 15160-5; and Weisbart R.H. et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIB” *Mol Immunol.* 2003 Mar, 39(13):78309; the entire contents of each of which are incorporated herein by reference.

a. Anti-Transferrin Receptor (TfR) Antibodies

[00074] Some aspects of the disclosure are based on the recognition that agents binding to transferrin receptor, e.g., anti-transferrin-receptor antibodies, are capable of targeting muscle cell. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Accordingly, aspects of the disclosure provide binding proteins (e.g., antibodies) that bind to transferrin receptor. In some embodiments, binding proteins that bind to transferrin receptor are internalized, along with any bound molecular payload, into a muscle cell. As used herein, an antibody that binds to a transferrin receptor may be referred to interchangeably as an, transferrin receptor antibody, an anti-transferrin receptor antibody, or an anti-TfR1 antibody. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00075] It should be appreciated that anti-TfR1 antibodies may be produced, synthesized, and/or (e.g., and) derivatized using several known methodologies, e.g. library design using phage display. Exemplary methodologies have been characterized in the art and are incorporated by reference (Díez, P. et al. “High-throughput phage-display screening in array format”, Enzyme and microbial technology, 2015, 79, 34-41.; Christoph M. H. and Stanley, J.R. “Antibody Phage Display: Technique and Applications” J Invest Dermatol. 2014, 134:2.; Engleman, Edgar (Ed.) “Human Hybridomas and Monoclonal Antibodies.” 1985, Springer.). In other embodiments, an anti-TfR1 antibody has been previously characterized or disclosed. Antibodies that specifically bind to transferrin receptor are known in the art (see, e.g. US Patent No. 4,364,934, filed 12/4/1979, “Monoclonal antibody to a human early thymocyte antigen and methods for preparing same”; US Patent No. 8,409,573, filed 6/14/2006, “Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells”; US Patent No. 9,708,406, filed 5/20/2014, “Anti-transferrin receptor antibodies and methods of use”; US 9,611,323, filed 12/19/2014, “Low affinity blood brain barrier receptor antibodies and uses therefor”; WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”; Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.; Lee et al. “Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052.).

[00076] In some embodiments, the anti-TfR1 antibody described herein binds to transferrin receptor with high specificity and affinity. In some embodiments, the anti-TfR1

antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, anti-TfR1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, *etc.* In some embodiments, anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor.

[00077] In some embodiments, the anti-TfR1 antibodies described herein (e.g., Anti-TfR clone 8 in Table 2 below) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 214-241 and/or amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues in amino acids 214-241 and amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising one or more of residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105.

[00078] In some embodiments, the anti-TfR1 antibody described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 258-291 and/or amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies (e.g., 3M12 in Table 2 below and its variants) described herein bind an epitope comprising residues in amino acids amino acids 258-291 and amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope comprising one or more of residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope comprising residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105.

[00079] An example human transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_003225.2 (transferrin receptor protein 1 isoform 1, homo sapiens) is as follows:

MMDQARSAFSNLFGEPLSYTRFSLARQVDGDNHVMKLAVDDEENADNNTKANVT
KPKRCSGSICYGTIAVIVFFLIGFMIGYLG YCKGVEPKTECERLAGTESPVREEPGEDFPA

ARRLYWDDLKRKLSEKLDSTDFGTIKLLNENSYVPREAGSQKDENLALYVENQFREF
 KLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLV
 HANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNA
 ELFFGHHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCP
 SDWKTDSTCRMVTSSESKNVKLTVSNVLKEIKILNIFGVKGFVEPDHYVVVGAQRDAW
 GPGAAKSGVGTALLLKLQMFSDMVLKDGFQPSRSIIFASWSAGDFGSGVATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARA
 AAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARG
 DFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRRHVFWGSG
 SHTLPALLENLKLRRQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 105).

[00080] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001244232.1(transferrin receptor protein 1, Macaca mulatta) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNHVMKLGVDDEEENTDNNTKPNGT
 KPKRCGGNICYGTIAVIIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
 APRLYWDDLKRKLSEKLDTTDFSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK
 LSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVH
 ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
 LSFFGHHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEKLFGNMEGDCPS
 DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVKGFVEPDHYVVVGAQRDAW
 GPGAAKSSVGTALLLKLQMFSDMVLKDGFQPSRSIIFASWSAGDFGSGVATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELVERIPELNKVAR
 AAAEVAGQFVIKLTHDTELNLDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWLYSA
 RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRRHVFWG
 SGSHTLSALLESLKLRRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 106)

[00081] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence XP_005545315.1 (transferrin receptor protein 1, Macaca fascicularis) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNHVMKLGVDDEEENTDNNTKANGT
 KPKRCGGNICYGTIAVIIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
 APRLYWDDLKRKLSEKLDTTDFSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK

LSKVWRDQHFKVQKDSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVH
 ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
 LSFFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAELKFGNMEGDCPS
 DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEPDHYVVVGAQRDAW
 GPGAACKSSVGTALLKLAQMFSDMVLDGFGQPSRSIIFASWSAGDFGSGVATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELVERIPELNKVAR
 AAEEVAGQFVIKLTHTDELNDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWLISA
 RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRRHVFWG
 SGSHTLSALLESLKLRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 107).

[00082] An example mouse transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001344227.1 (transferrin receptor protein 1, mus musculus) is as follows:
 MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNHVMKLAADDEENADNNMKASV
 RPKKRFNGRLCFAAIALVIFFLIGMSGYLGCKRVEQKEECVKLAETEETDKSETMETE
 DVPTSSRLYWADLKTLLSEKLNIEFADTIKQLSQNTYTPREAGSQKDESLAYYIENQFH
 EFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQSNGNLDPVESPEGYVAFSKPTEVSGKLV
 HANFGTKKDFEELSYSVNGSLVIVRAGEITFAEKVANAQSFNAIGVLIYMDKNKFPVVE
 ADLALFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAELKFGKMEGS
 CPARWNIDSSCKLELSQNQNVKLIVKNVLKERRILNIFGVIKGYEEPDRYVVVGAQRDA
 LGAGVAAKSSVGTGLLLKLAQVFSDMISKDGRPSRSIIFASWTAGDFGAVGATEWLEG
 YLSSLHLKAFTYINLDKVVLTGTSNFKVSASPLLYTLMGKIMQDVKHPVDGKSLYRDSN
 WISKVEKLSFDNAAYPFLAYSGIPAVSFCFCEDADYPYLGTRLDTYEALTQKVPQLNQM
 VRTAAEVAGQLIKLTHTDELNDYEMYSKLLSFMKDLNQFKTDIRDMGLSLQWLIS
 ARGDYFRATSRLTTDFHNAEKTNRVFMREINDRIMKVEYHFLSPYVSPRESPFRHIFWG
 SGSHTLSALVENLKLKLRQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF
 (SEQ ID NO: 108)

[00083] In some embodiments, an anti-TfR1 antibody binds to an amino acid segment of the receptor as follows:

FVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFE
 DLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFHGHAHLG
 TGDYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFHGHAHLG
 TGDYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFHGHAHLG
 MVTSESKNVKLTVSNVLKE (SEQ ID NO: 109) and does not inhibit the binding interactions
 between transferrin receptors and transferrin and/or (e.g., and) human hemochromatosis protein

(also known as HFE). In some embodiments, the anti-TfR1 antibody described herein does not bind an epitope in SEQ ID NO: 109.

[00084] Appropriate methodologies may be used to obtain and/or (e.g., and) produce antibodies, antibody fragments, or antigen-binding agents, e.g., through the use of recombinant DNA protocols. In some embodiments, an antibody may also be produced through the generation of hybridomas (see, e.g., Kohler, G and Milstein, C. “Continuous cultures of fused cells secreting antibody of predefined specificity” *Nature*, 1975, 256: 495-497). The antigen-of-interest may be used as the immunogen in any form or entity, e.g., recombinant or a naturally occurring form or entity. Hybridomas are screened using standard methods, e.g. ELISA screening, to find at least one hybridoma that produces an antibody that targets a particular antigen. Antibodies may also be produced through screening of protein expression libraries that express antibodies, e.g., phage display libraries. Phage display library design may also be used, in some embodiments, (see, e.g. U.S. Patent No 5,223,409, filed 3/1/1991, “Directed evolution of novel binding proteins”; WO 1992/18619, filed 4/10/1992, “Heterodimeric receptor libraries using phagemids”; WO 1991/17271, filed 5/1/1991, “Recombinant library screening methods”; WO 1992/20791, filed 5/15/1992, “Methods for producing members of specific binding pairs”; WO 1992/15679, filed 2/28/1992, and “Improved epitope displaying phage”). In some embodiments, an antigen-of-interest may be used to immunize a non-human animal, e.g., a rodent or a goat. In some embodiments, an antibody is then obtained from the non-human animal, and may be optionally modified using a number of methodologies, e.g., using recombinant DNA techniques. Additional examples of antibody production and methodologies are known in the art (see, e.g. Harlow et al. “Antibodies: A Laboratory Manual”, Cold Spring Harbor Laboratory, 1988.).

[00085] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4,

about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”.

[00086] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VL domain and/or (e.g., and) a VH domain of any one of the anti-TfR1 antibodies selected from any one of Tables 2-7, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.

[00087] In some embodiments, agents binding to transferrin receptor, e.g., anti-TfR1 antibodies, are capable of targeting muscle cell and/or (e.g., and) mediate the transportation of an agent across the blood brain barrier. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00088] Provided herein, in some aspects, are humanized antibodies that bind to transferrin receptor with high specificity and affinity. In some embodiments, the humanized anti-TfR1 antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, the humanized anti-TfR1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, *etc.* In some embodiments, the humanized anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor. In some

embodiments, the humanized anti-TfR1 antibodies described herein binds to TfR1 but does not bind to TfR2.

[00089] In some embodiments, an anti-TFR1 antibody specifically binds a TfR1 (e.g., a human or non-human primate TfR1) with binding affinity (e.g., as indicated by Kd) of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, the anti-TfR1 antibodies described herein bind to TfR1 with a KD of sub-nanomolar range. In some embodiments, the anti-TfR1 antibodies described herein selectively bind to transferrin receptor 1 (TfR1) but do not bind to transferrin receptor 2 (TfR2). In some embodiments, the anti-TfR1 antibodies described herein bind to human TfR1 and cyno TfR1 (e.g., with a Kd of 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less), but do not bind to a mouse TfR1. The affinity and binding kinetics of the anti-TfR1 antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not complete with or inhibit transferrin binding to the TfR1. In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not complete with or inhibit HFE-beta-2-microglobulin binding to the TfR1.

[00090] Non-limiting examples of anti-TfR1 antibodies are provided in Table 2.

Table 2. Examples of Anti-TfR1 Antibodies

Ab	No. system	IMGT	Kabat	Chothia
3-A4	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPENGDT (SEQ ID NO: 2)	WIDPENGDT EYASKFQD (SEQ ID NO: 8)	ENG (SEQ ID NO: 13)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPENGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSVTVS (SEQ ID NO: 17)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLHNSGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54T*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPETGDT (SEQ ID NO: 19)	WIDPETGDT EYASKFQD (SEQ ID NO: 20)	ETG (SEQ ID NO: 21)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)

Ab	No. system	IMGT	Kabat	Chothia
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPETGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 22)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLLSNGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54S*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPESGDT (SEQ ID NO: 23)	WIDPESGDTEYASKFQD (SEQ ID NO: 24)	ESG (SEQ ID NO: 25)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLLSNGYTY (SEQ ID NO: 4)	RSSKSLLSNGYTYLF (SEQ ID NO: 10)	SKSLLSNGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPESGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 26)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLLSNGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-M12	CDR-H1	GYSITSGYY (SEQ ID NO: 27)	SGYYWN (SEQ ID NO: 33)	GYSITSGY (SEQ ID NO: 38)
	CDR-H2	ITFDGAN (SEQ ID NO: 28)	YITFDGANNYNPSLKN (SEQ ID NO: 34)	FDG (SEQ ID NO: 39)
	CDR-H3	TRSSYDYDVL DY (SEQ ID NO: 29)	SSYDYDVL DY (SEQ ID NO: 35)	SYDYDVL D (SEQ ID NO: 40)
	CDR-L1	QDISNF (SEQ ID NO: 30)	RASQDISNFLN (SEQ ID NO: 36)	SQDISNF (SEQ ID NO: 41)
	CDR-L2	YTS (SEQ ID NO: 31)	YTSRLHS (SEQ ID NO: 37)	YTS (SEQ ID NO: 31)
	CDR-L3	QQGHTLPYT (SEQ ID NO: 32)	QQGHTLPYT (SEQ ID NO: 32)	GHTLPY (SEQ ID NO: 42)
	VH	DVQLQESGPGLVKPSQSLSLTCSVTGYISITSGYYWNWIRQFPGNKLEWMGYITFDGAN NYNPSLKNRISITRDTSKNQFFLKLTSVTTEDTATYYCTRSSYDYDVL DYWGQGTTLTV SS (SEQ ID NO: 43)		
	VL	DIQMTQTSSLSASLGDRVTISCRASQDISNFLN WYQQRPDGTVKLLIYYTSRLHSGVPS RFSGSGSGTDFSLTVSNLEQEDIATYFCQQGHTLPYTFGGG TKLEIK (SEQ ID NO: 44)		
5-H12	CDR-H1	GYSFTDYC (SEQ ID NO: 45)	DYCIN (SEQ ID NO: 51)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSED PWT (SEQ ID NO: 50)	QQSSED PWT (SEQ ID NO: 50)	SSED PW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYCINWVNQRPGQGLEWIGWIYPGSGNTRYSERFKGKATLTVDTSSNTAYMQLSSLTSEDS AVYFCAREDYYPYHGMDYWGQGTSTV TVSS (SEQ ID NO: 61)		

Ab	No. system	IMGT	Kabat	Chothia
	VL	DIVLTQSPSTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
5-H12 C33Y*	CDR-H1	GYSFTDYY (SEQ ID NO: 63)	DYYIN (SEQ ID NO: 64)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYYINWVNQRPGQGLEWIGWIYPGSGNTRY YSERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTV TVSS (SEQ ID NO: 65)		
	VL	DIVLTQSPSTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
5-H12 C33D*	CDR-H1	GYSFTDYD (SEQ ID NO: 66)	DYDIN (SEQ ID NO: 67)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYDINWVNQRPGQGLEWIGWIYPGSGNTRY SERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTV SS (SEQ ID NO: 68)		
	VL	DIVLTQSPSTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
Anti-TfR clone 8	CDR-H1	GYSFTSYW (SEQ ID NO: 138)	SYWIG (SEQ ID NO: 144)	GYSFTSY (SEQ ID NO: 149)
	CDR-H2	IYPGSDST (SEQ ID NO: 139)	IIYPGSDSTRYSPSFQGG (SEQ ID NO: 145)	GDS (SEQ ID NO: 150)
	CDR-H3	ARFPYDSSGYYSFDY (SEQ ID NO: 140)	FPYDSSGYYSFDY (SEQ ID NO: 146)	PYDSSGYYSFD (SEQ ID NO: 151)
	CDR-L1	QSISSY (SEQ ID NO: 141)	RASQSISSYLN (SEQ ID NO: 147)	SQSISSY (SEQ ID NO: 152)
	CDR-L2	AAS (SEQ ID NO: 142)	AASSLQS (SEQ ID NO: 148)	AAS (SEQ ID NO: 142)
	CDR-L3	QQSYSTPLT (SEQ ID NO: 143)	QQSYSTPLT (SEQ ID NO: 143)	SYSTPL (SEQ ID NO: 153)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

[00091] In some embodiments, the anti-TfR1 antibody of the present disclosure is a humanized variant of any one of the anti-TfR1 antibodies provided in Table 2. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-

H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 in any one of the anti-TfR1 antibodies provided in Table 2, and comprises a humanized heavy chain variable region and/or (e.g., and) a humanized light chain variable region.

[00092] Examples of amino acid sequences of anti-TfR1 antibodies described herein are provided in Table 3.

Table 3. Variable Regions of Anti-TfR1 Antibodies

Antibody	Variable Region Amino Acid Sequence**
3A4 VH3 (N54T*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVSCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ETGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED AVYYCTL WLRRGLD YWGGGTLVTVSS (SEQ ID NO: 69)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3 (N54S*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVSCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ESGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED AVYYCTL WLRRGLD YWGGGTLVTVSS (SEQ ID NO: 71)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3 /Vκ4	V _H : EVQLVQSGSELKKPGASVKVSCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ENGDTTEYASKFQDRVTVTADTSTNTAYMELSSLRSED AVYYCTL WLRRGLD YWGGGTLVTVSS (SEQ ID NO: 72)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTK VEIK (SEQ ID NO: 70)
3M12 VH3/Vκ2	V _H : QVQLQESGPGLVKPSQTLSTCSVTGYSIT SGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL LDY WGQGTITVTVSS (SEQ ID NO: 73)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYFCQQGH TL PYTFGQGTKLEIK (SEQ ID NO: 74)
3M12 VH3/Vκ3	V _H : QVQLQESGPGLVKPSQTLSTCSVTGYSIT SGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL LDY WGQGTITVTVSS (SEQ ID NO: 73)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYFCQQGH TL PYTFGQGTKLEIK (SEQ ID NO: 75)
3M12 VH4/Vκ2	V _H : QVQLQESGPGLVKPSQTLSTCTVTGYSIT SGYYWNWIRQPPGKGLEWIGYITFD GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DY WGQGTITVTVSS (SEQ ID NO: 76)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYFCQQGH TL PYTFGQGTKLEIK (SEQ ID NO: 74)

Antibody	Variable Region Amino Acid Sequence**
3M12 VH4/Vκ3	VH: QVQLQESGPGLVKPSQTLSTCTVTGYSTIT SGYYWN WIRQPPGKGLEWIGYITFD GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL LDYW GQGTTVTVSS (SEQ ID NO: 76)
	VL: DIQMTQSPSSLSASVGDRVITITCRAS QDISN FLNWyQQKPGQPVKLLIYY TSRLH SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPYTFGQGTKLEIK (SEQ ID NO: 75)
5H12 VH5 (C33Y*)/Vκ3	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARE DYYPYH GMDYWGQGT LVTVSS (SEQ ID NO: 77)
	VL: DIVLTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQP PKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQ QSEDPWTFGQGTKL EIK (SEQ ID NO: 78)
5H12 VH5 (C33D*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYDIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARE DYYPYH GMDYWGQGT LVTVSS (SEQ ID NO: 79)
	VL: DIVMTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQP PKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQ QSEDPWTFGQGTKL EIK (SEQ ID NO: 80)
5H12 VH5 (C33Y*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARE DYYPYH GMDYWGQGT LVTVSS (SEQ ID NO: 77)
	VL: DIVMTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQP PKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQ QSEDPWTFGQGTKL EIK (SEQ ID NO: 80)
Anti-TfR clone 8	VH: QVQLVQSGAEVKKPGESLKISCKGSGYSFT SYWIG WVRQMPGKGLEWMG IIYP GDS DT RYSPSFQ Q QVTISADKSISTAYLQWSSLKASDTAMY YCARFPYDSSGY SFDYWGQGT LVTVSS (SEQ ID NO: 154)
	VL: DIQMTQSPSSLSASVGDRVITITCRAS QSISSY LNWyQQKPGKAPKLLI YAASSLQ SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QSYSTPLTFGGGTKVEIK (SEQ ID NO: 155)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded

[00093] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VH provided in Table 3. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00094] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VH provided in Table 3.

Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00095] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00096] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00097] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00098] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[00099] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[00100] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[00101] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[000102] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78.

[000103] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000104] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000105] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 154 and a VL comprising the amino acid sequence of SEQ ID NO: 155.

[000106] In some embodiments, the anti-TfR1 antibody described herein is a full-length IgG, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprise a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can be of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of a human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000107] In some embodiments, the heavy chain of any of the anti-TfR1 antibodies described herein comprises a mutant human IgG1 constant region. For example, the introduction of LALA mutations (a mutant derived from mAb b12 that has been mutated to replace the lower hinge residues Leu234 Leu235 with Ala234 and Ala235) in the CH2 domain of human IgG1 is known to reduce Fcγ receptor binding (Bruhns, P., et al. (2009) and Xu, D. et al. (2000)). The mutant human IgG1 constant region is provided below (mutations bonded and underlined):

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 82)

[000108] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000109] Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IMGT database (www.imgt.org) or at www.vbase2.org/vbstat.php, both of which are incorporated by reference herein.

[000110] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 81. In some embodiments, the anti-TfR1 antibody described herein comprises heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 82.

[000111] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1

antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000112] Examples of IgG heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 4 below.

Table 4. Heavy chain and light chain sequences of examples of anti-TfR1 IgGs

Antibody	IgG Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKV</u>SCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE <u>TGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYLW</u> <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK (SEQ ID NO: 84) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTPGEPASISCRSSKSLLSHNGYTYLFWFOORPGQSPRLLIYRMS</u> <u>NLASGV</u>PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 (N54S*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKV</u>SCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE <u>SGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYLW</u> <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK (SEQ ID NO: 86) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTPGEPASISCRSSKSLLSHNGYTYLFWFOORPGQSPRLLIYRMS</u> <u>NLASGV</u>PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 /Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKV</u>SCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE <u>NGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYLW</u> <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK (SEQ ID NO: 87) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTPGEPASISCRSSKSLLSHNGYTYLFWFOORPGQSPRLLIYRMS</u> <u>NLASGV</u>PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)

Antibody	IgG Heavy Chain/Light Chain Sequences**
3M12 VH3/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYYDVL</u> <u>QGT</u><u>TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT</u><u>SVNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTV</u><u>PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVSVLT</u><u>TVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK</u> (SEQ ID NO: 88) Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN</u><u>WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTIS</u><u>SLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>P</u><u>REAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH3/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYYDVL</u> <u>QGT</u><u>TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT</u><u>SVNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTV</u><u>PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVSVLT</u><u>TVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK</u> (SEQ ID NO: 88) Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN</u><u>WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTIS</u><u>SLQPEDFATYYCQOGHTLPYTFGQGTKLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>P</u><u>REAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
3M12 VH4/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYYDVL</u> <u>QGT</u><u>TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT</u><u>SVNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTV</u><u>PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVSVLT</u><u>TVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>LSPGK</u> (SEQ ID NO: 91) Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN</u><u>WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTIS</u><u>SLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>P</u><u>REAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH4/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYYDVL</u> <u>QGT</u><u>TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT</u><u>SVNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTV</u><u>PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVSVLT</u><u>TVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>LSPGK</u> (SEQ ID NO: 91)

Antibody	IgG Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVIGDRVTITCRASQDISNFLNWYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOGHTLPYTFGQGTKLEIKRTVAA</u> PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/VK3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWHYQOKPGOPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIKR</u> TVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 93)
5H12 VH5 (C33D*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 94) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWHYQOKPGOPPKLLIFRA</u> <u>NLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIK</u> RTVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)
5H12 VH5 (C33Y*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWHYQOKPGOPPKLLIFRA</u> <u>NLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIK</u> RTVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)

Antibody	IgG Heavy Chain/Light Chain Sequences**
Anti-TfR clone 8	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPG</u> <u>DSDTRYSPSFQGGVTISADKSISTAYLOWSSLKASDTAMYICARFPYDSSGYYSF</u> <u>DYWGOGLTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKHTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 156)
	VL: <u>DIQMTQSPSSLSASVGDRVTTTCRASOSISSYLNWYQOKPGKAPKLLIYAASSLOS</u> <u>GVPSRFSGSGSGTDFLTISLQPEDFATYYCQOSYSTPLTFGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000113] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000114] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95 and 157.

[000115] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000116] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000117] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000118] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000119] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000120] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000121] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000122] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000123] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000124] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000125] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000126] In some embodiments, the anti-TfR1 antibody is a Fab fragment, Fab' fragment, or F(ab')₂ fragment of an intact antibody (full-length antibody). Antigen binding fragment of an intact antibody (full-length antibody) can be prepared via routine methods (e.g., recombinantly or by digesting the heavy chain constant region of a full-length IgG using an enzyme such as papain). For example, F(ab')₂ fragments can be produced by pepsin or papain digestion of an

antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')₂ fragments. In some embodiments, a heavy chain constant region in a Fab fragment of the anti-TfR1 antibody described herein comprises the amino acid sequence of:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 96)

[000127] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 96.

[000128] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000129] Examples of Fab heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 5 below.

Table 5. Heavy chain and light chain sequences of examples of anti-TfR1 Fabs

Antibody	Fab Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) EVQLVQSGSELKKPGASVKVSCITASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE <u>TGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED</u> TAVYYCTLWLRRLDYW GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHT (SEQ ID NO: 97)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 (N54S*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSCASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>SGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKHT (SEQ ID NO: 98)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 /Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSCASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>NGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKHT (SEQ ID NO: 99)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3M12 VH3/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWG</u> <u>QGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKHT (SEQ ID NO: 100)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLN WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYFCQOGHTLPYTFGQGT KLEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 89)
3M12 VH3/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWG</u> <u>QGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKHT (SEQ ID NO: 100)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLN WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYCQOGHTLPYTFGQGT KLEIKRTVAAP</u> PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)
3M12 VH4/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRQPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KHT (SEQ ID NO: 101)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVITTCRASQDISNFLNWYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 89)
3M12 VH4/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGGLVKPSQTLSTCTVTGYSTITSGYYWNWIROPFGKLEWIGYITFDG</u> <u>ANNYNPSLKNRVISIRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDDYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHT (SEQ ID NO: 101)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVITTCRASQDISNFLNWYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAA</u> PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>CGSNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHT (SEQ ID NO: 102)
	Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWYQOKPGOPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIKR</u> TVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 93)
5H12 VH5 (C33D*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVRQAPGQGLEWMGWIYP</u> <u>CGSNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHT (SEQ ID NO: 103)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIK</u> RTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)
5H12 VH5 (C33Y*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>CGSNTRYSERFKGRVTITRDTSASTAYMELSSLRSEDVAVYYCAREDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHT (SEQ ID NO: 102)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDVDGYDNSFMHWYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGTKLEIK</u> RTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)
Anti-TfR clone 8 Version 1	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKLEWMGIHYPG</u> <u>DS DTRYSPSFOGQVTISADKSISTAYLQWSSLKASDTAMYCARFPYDSSGYYSF</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCP (SEQ ID NO: 158)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	VL: <u>DIQMTQSPSSLSASVGDRTTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLOS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOSYSTPLT</u> <u>FGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)
Anti-TfR clone 8 Version 2	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGHIYPG</u> <u>DSDTRYSPSFOGQVTISADKSISTAYLOWSSLKASDTAMYICARFPYDSSGYYSF</u> <u>DYWGGQTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHT (SEQ ID NO: 159)
	VL: <u>DIQMTQSPSSLSASVGDRTTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLOS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOSYSTPLT</u> <u>FGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000130] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000131] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000132] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000133] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 98 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000134] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000135] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000136] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000137] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000138] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000139] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000140] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000141] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000142] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000143] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

Other known anti-TfR1 antibodies

[000144] Any other appropriate anti-TfR1 antibodies known in the art may be used as the muscle-targeting agent in the complexes disclosed herein. Examples of known anti-TfR1 antibodies, including associated references and binding epitopes, are listed in Table 6. In some embodiments, the anti-TfR1 antibody comprises the complementarity determining regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of any of the anti-TfR1 antibodies provided herein, e.g., anti-TfR1 antibodies listed in Table 6.

Table 6 – List of anti-TfR1 antibody clones, including associated references and binding epitope information.

Antibody Clone Name	Reference(s)	Epitope / Notes
OKT9	US Patent. No. 4,364,934, filed 12/4/1979, entitled “MONOCLONAL ANTIBODY TO A HUMAN EARLY THYMOCYTE ANTIGEN AND METHODS FOR PREPARING SAME” Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.	Apical domain of TfR1 (residues 305-366 of human TfR1 sequence XM_052730.3, available in GenBank)
(From JCR) Clone M11 Clone M23 Clone M27 Clone B84	- WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier” - US Patent No. 9,994,641, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”	Apical domain (residues 230-244 and 326-347 of TfR1) and protease-like domain (residues 461-473)
(From Genentech) 7A4, 8A2, 15D2, 10D11, 7B10, 15G11, 16G5, 13C3, 16G4, 16F6, 7G7, 4C2, 1B12, and 13D4	- WO 2016/081643, filed 5/26/2016, entitled “ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE” - US Patent No. 9,708,406, filed 5/20/2014, “Anti-transferrin receptor antibodies and methods of use”	Apical domain and non-apical regions
(From Armagen) 8D3	- Lee et al. “Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052. - US Patent App. 2010/077498, filed 9/11/2008, entitled “COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE”	

Antibody Clone Name	Reference(s)	Epitope / Notes		
OX26	Haobam, B. et al. 2014. Rab17-mediated recycling endosomes contribute to autophagosome formation in response to Group A Streptococcus invasion. Cellular microbiology. 16: 1806-21.			
DF1513	Ortiz-Zapater E et al. Trafficking of the human transferrin receptor in plant cells: effects of tyrphostin A23 and brefeldin A. Plant J 48:757-70 (2006).			
1A1B2, 66IG10, MEM-189, JF0956, 29806, 1A1B2, TFRC/1818, 1E6, 66Ig10, TFRC/1059, Q1/71, 23D10, 13E4, TFRC/1149, ER-MP21, YTA74.4, BU54, 2B6, RI7 217	Commercially available anti-transferrin receptor antibodies.	Novus Biologicals 8100 Southpark Way, A-8 Littleton CO 80120		
(From INSERM) BA120g	US Patent App. 2011/0311544A1, filed 6/15/2005, entitled “ANTI-CD71 MONOCLONAL ANTIBODIES AND USES THEREOF FOR TREATING MALIGNANT TUMOR CELLS”	Does not compete with OKT9		
LUCA31	US Patent No. 7,572,895, filed 6/7/2004, entitled “TRANSFERRIN RECEPTOR ANTIBODIES”	“LUCA31 epitope”		
(Salk Institute) B3/25 T58/30	Trowbridge, I.S. et al. “Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells.” Nature, 1981, volume 294, pages 171–173			
R17 217.1.3, 5E9C11, OKT9 (BE0023 clone)	Commercially available anti-transferrin receptor antibodies.	BioXcell 10 Technology Dr., Suite 2B West Lebanon, NH 03784-1671 USA		
BK19.9, B3/25, T56/14 and T58/1	Gatter, K.C. et al. “Transferrin receptors in human tissues: their distribution and possible clinical relevance.” J Clin Pathol. 1983 May;36(5):539-45.			
Anti-TfR1 antibody				
CDRH1 (SEQ ID NO: 333)				
CDRH2 (SEQ ID NO: 334)				
CDRH3 (SEQ ID NO: 335)				
CDRL1 (SEQ ID NO: 336)				
Additional Anti-TfR1 antibody SEQ ID NOs				
	VH/VL	CDR1	CDR2	CDR3
VH1	348	341	342	335
VH2	349	341	343	335
VH3	350	341	344	335

Antibody Clone Name	Reference(s)			Epitope / Notes		
CDRL2 (SEQ ID NO: 337)	VH4	351	341	343	335	
CDRL3 (SEQ ID NO: 338)	VL1	352	336	337	115	
VH (SEQ ID NO: 339)	VL2	353	336	337	115	
VL (SEQ ID NO: 340)	VL3	354	336	345	338	
	VL4	355	346	347	338	

[000145] In some embodiments, anti-TfR1 antibodies of the present disclosure include one or more of the CDR-H (*e.g.*, CDR-H1, CDR-H2, and CDR-H3) amino acid sequences from any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies include the CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies include the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfR1 antibodies selected from Table 6.

[000146] In some embodiments, anti-TfR1 antibodies of the disclosure include any antibody that includes a heavy chain variable domain and/or (*e.g.*, and) a light chain variable domain of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies of the disclosure include any antibody that includes the heavy chain variable and light chain variable pairs of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6.

[000147] Aspects of the disclosure provide anti-TfR1 antibodies having a heavy chain variable (VH) and/or (*e.g.*, and) a light chain variable (VL) domain amino acid sequence homologous to any of those described herein. In some embodiments, the anti-TfR1 antibody comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (*e.g.*, 80%, 85%, 90%, 95%, 98%, or 99%) identical to the heavy chain variable sequence and/or any light chain variable sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, the homologous heavy chain variable and/or (*e.g.*, and) a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (*e.g.*, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) may occur within a heavy chain variable and/or (*e.g.*, and) a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, any of the anti-TfR1 antibodies provided herein comprise a heavy chain variable sequence and a light chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6.

[000148] An example of a transferrin receptor antibody that may be used in accordance with the present disclosure is described in International Application Publication WO 2016/081643, incorporated herein by reference. The amino acid sequences of this antibody are provided in Table 7.

Table 7. Heavy chain and light chain CDRs of an example of a known anti-TfR1 antibody

Sequence Type	Kabat	Chothia	Contact
CDR-H1	SYWMH (SEQ ID NO: 110)	GYTFTSY (SEQ ID NO: 116)	TSYWMH (SEQ ID NO: 118)
CDR-H2	EINPTNGRTNYIEKFKS (SEQ ID NO: 111)	NPTNGR (SEQ ID NO: 117)	WIGEINPTNGRTN (SEQ ID NO: 119)
CDR-H3	GTRAYHY (SEQ ID NO: 112)	GTRAYHY (SEQ ID NO: 112)	ARGTRA (SEQ ID NO: 120)
CDR-L1	RASDNLYSNLA (SEQ ID NO: 113)	RASDNLYSNLA (SEQ ID NO: 113)	YSNLAWY (SEQ ID NO: 121)
CDR-L2	DATNLAD (SEQ ID NO: 114)	DATNLAD (SEQ ID NO: 114)	LLVYDATNLA (SEQ ID NO: 122)
CDR-L3	QHFWGTPLT (SEQ ID NO: 115)	QHFWGTPLT (SEQ ID NO: 115)	QHFWGTPL (SEQ ID NO: 123)
Murine VH	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSS (SEQ ID NO: 124)		
Murine VL	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFSGSGSGTQYSLKINSLSQSEDFGTYYCQHFWGTPLTFGAGTKLELK (SEQ ID NO: 125)		
Humanized VH	EVQLVQSGAEVKKPGASVKVSKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSS (SEQ ID NO: 128)		
Humanized VL	DIQMTQSPSSLSASVGDRTVTITCRASDNLYSNLAWYQQKPKGSPKLLVYDATNLADGVPSRFSGSGSGTDYTLTISLSQPEDFATYYCQHFWGTPLTFGQGTKEIK (SEQ ID NO: 129)		
HC of chimeric full-length IgG1	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 132)		
LC of chimeric full-length IgG1	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFSGSGSGTQYSLKINSLSQSEDFGTYYCQHFWGTPLTFGAGTKLELKR TVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133)		
HC of fully human full-length IgG1	EVQLVQSGAEVKKPGASVKVSKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 134)		

Sequence Type	Kabat	Chothia	Contact
LC of fully human full-length IgG1	DIQMTQSPSSLSASVGDRVITICRASDNLYSNLAWYQQKPGKSPKLLVYDATNLADGVPSRFGSGSGTDYTLTISSLQPEDFATYYCQHFHWGTPLTFGQGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 135)		
HC of chimeric Fab	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSTVTSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 136)		
HC of fully human Fab	EVQLVQSGAEVKKPGASVKVSCASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 137)		

[000149] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, and a CDR-H3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-L1, CDR-L2, and CDR-L3 shown in Table 7.

[000150] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3, which contains no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 containing one amino acid variation as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system). In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1 and a CDR-L2 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7, and comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system).

[000151] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises heavy chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the heavy chain CDRs as shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises light chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the light chain CDRs as shown in Table 7.

[000152] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 124. Alternatively or in addition

(e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 125.

[000153] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 129.

[000154] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL containing no more than 15 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 129.

[000155] In some embodiments, the anti-TfR1 antibody of the present disclosure is a full-length IgG1 antibody, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000156] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000157] In some embodiments, the anti-TfR1 antibody described herein is a chimeric antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 132. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133.

[000158] In some embodiments, the anti-TfR1 antibody described herein is a fully human antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 134. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000159] In some embodiments, the anti-TfR1 antibody is an antigen binding fragment (Fab) of an intact antibody (full-length antibody). In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 136. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133. In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 137. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000160] The anti-TfR1 antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, Fab', F(ab')₂, Fv), single chain antibodies, bi-specific antibodies, or nanobodies. In some embodiments, the anti-TfR1 antibody described herein is an scFv. In some embodiments, the anti-TfR1 antibody described herein is an scFv-Fab (e.g., scFv fused to a portion of a constant region). In some embodiments, the anti-TfR1 antibody described herein is an scFv fused to a constant region (e.g., human IgG1 constant region as set forth in SEQ ID NO: 81).

[000161] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an anti-TfR1 antibody described herein (e.g., in a CH₂ domain (residues 231-340 of human IgG1) and/or (e.g., and) CH₃ domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000162] In some embodiments, one, two or more mutations (*e.g.*, amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (*e.g.*, increased or decreased) as described in, *e.g.*, U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, *e.g.*, facilitate assembly of the light and heavy chains, or to alter (*e.g.*, increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000163] In some embodiments, one, two or more mutations (*e.g.*, amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (*e.g.*, in a CH2 domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) CH3 domain (residues 341-447 of human IgG1) and/or (*e.g.*, and) the hinge region, with numbering according to the Kabat numbering system (*e.g.*, the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (*e.g.*, an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, *e.g.*, Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000164] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (*e.g.*, decrease or increase) half-life of the antibody *in vivo*. See, *e.g.*, International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000165] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-TfR1 antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human

IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000166] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-TfR1 antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, *e.g.*, Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000167] In some embodiments, one or more amino in the constant region of an anti-TfR1 antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (e.g., and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (e.g., and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000168] In some embodiments, the heavy and/or (e.g., and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000169] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing 'Adair' mutation (Angal S., et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody," *Mol Immunol* 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing 'Adair' mutation.

[000170] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or

carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”.

[000171] In some embodiments, any one of the anti-TfR1 antibodies described herein may comprise a signal peptide in the heavy and/or (e.g., and) light chain sequence (e.g., a N-terminal signal peptide). In some embodiments, the anti-TfR1 antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab') heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide). In some embodiments, the signal peptide comprises the amino acid sequence of MGWSCILFLVATATGVHS (SEQ ID NO: 104).

[000172] In some embodiments, an antibody provided herein may have one or more post-translational modifications. In some embodiments, N-terminal cyclization, also called pyroglutamate formation (pyro-Glu), may occur in the antibody at N-terminal Glutamate (Glu) and/or Glutamine (Gln) residues during production. As such, it should be appreciated that an antibody specified as having a sequence comprising an N-terminal glutamate or glutamine residue encompasses antibodies that have undergone pyroglutamate formation resulting from a post-translational modification. In some embodiments, pyroglutamate formation occurs in a heavy chain sequence. In some embodiments, pyroglutamate formation occurs in a light chain sequence.

b. Other Muscle-Targeting Antibodies

[000173] In some embodiments, the muscle-targeting antibody is an antibody that specifically binds hemojuvelin, caveolin-3, Duchenne muscular dystrophy peptide, myosin IIb or CD63. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a myogenic precursor protein. Exemplary myogenic precursor proteins include, without limitation, ABCG2, M-Cadherin/Cadherin-15, Caveolin-1, CD34, FoxK1, Integrin alpha 7, Integrin alpha 7 beta 1, MYF-5, MyoD, Myogenin, NCAM-1/CD56, Pax3, Pax7, and Pax9. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a skeletal muscle protein. Exemplary skeletal muscle proteins include, without limitation, alpha-Sarcoglycan, beta-Sarcoglycan, Calpain Inhibitors, Creatine Kinase MM/CKMM, eIF5A, Enolase 2/Neuron-specific Enolase, epsilon-Sarcoglycan, FABP3/H-FABP, GDF-8/Myostatin, GDF-11/GDF-8, Integrin alpha 7, Integrin alpha 7 beta 1, Integrin beta 1/CD29, MCAM/CD146, MyoD, Myogenin, Myosin Light Chain Kinase Inhibitors, NCAM-1/CD56, and Troponin I. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a smooth muscle protein. Exemplary smooth muscle proteins include, without limitation,

alpha-Smooth Muscle Actin, VE-Cadherin, Caldesmon/CALD1, Calponin 1, Desmin, Histamine H2 R, Motilin R/GPR38, Transgelin/TAGLN, and Vimentin. However, it should be appreciated that antibodies to additional targets are within the scope of this disclosure and the exemplary lists of targets provided herein are not meant to be limiting.

c. Antibody Features/Alterations

[000174] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000175] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000176] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000177] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (*e.g.*, decrease or increase) half-life of the antibody *in vivo*. See, *e.g.*, International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000178] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-transferrin receptor antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) *supra*). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) *J Biol Chem* 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000179] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-transferrin receptor antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, *e.g.*, U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant

domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, *e.g.*, Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000180] In some embodiments, one or more amino in the constant region of a muscle-targeting antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (*e.g.*, and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (*e.g.*, and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000181] In some embodiments, the heavy and/or (*e.g.*, and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000182] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.

[000183] As provided herein, antibodies of this disclosure may optionally comprise constant regions or parts thereof. For example, a VL domain may be attached at its C-terminal

end to a light chain constant domain like C κ or C λ . Similarly, a VH domain or portion thereof may be attached to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Antibodies may include suitable constant regions (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md. (1991)). Therefore, antibodies within the scope of this may disclosure include VH and VL domains, or an antigen binding portion thereof, combined with any suitable constant regions.

ii. Muscle-Targeting Peptides

[000184] Some aspects of the disclosure provide muscle-targeting peptides as muscle-targeting agents. Short peptide sequences (e.g., peptide sequences of 5-20 amino acids in length) that bind to specific cell types have been described. For example, cell-targeting peptides have been described in Vines et al., A. “Cell-penetrating and cell-targeting peptides in drug delivery” *Biochim Biophys Acta* 2008, 1786: 126-38; Jarver P., et al., “In vivo biodistribution and efficacy of peptide mediated delivery” *Trends Pharmacol Sci* 2010; 31: 528-35; Samoylova T.I., et al., “Elucidation of muscle-binding peptides by phage display screening” *Muscle Nerve* 1999; 22: 460-6; U.S. Patent No. 6,329,501, issued on December 11, 2001, entitled “METHODS AND COMPOSITIONS FOR TARGETING COMPOUNDS TO MUSCLE”; and Samoylov A.M., et al., “Recognition of cell-specific binding of phage display derived peptides using an acoustic wave sensor.” *Biomol Eng* 2002; 18: 269-72; the entire contents of each of which are incorporated herein by reference. By designing peptides to interact with specific cell surface antigens (e.g., receptors), selectivity for a desired tissue, e.g., muscle, can be achieved. Skeletal muscle-targeting has been investigated and a range of molecular payloads are able to be delivered. These approaches may have high selectivity for muscle tissue without many of the practical disadvantages of a large antibody or viral particle. Accordingly, in some embodiments, the muscle-targeting agent is a muscle-targeting peptide that is from 4 to 50 amino acids in length. In some embodiments, the muscle-targeting peptide is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. Muscle-targeting peptides can be generated using any of several methods, such as phage display.

[000185] In some embodiments, a muscle-targeting peptide may bind to an internalizing cell surface receptor that is overexpressed or relatively highly expressed in muscle cells, e.g. a transferrin receptor, compared with certain other cells. In some embodiments, a muscle-targeting peptide may target, e.g., bind to, a transferrin receptor. In some embodiments, a peptide that targets a transferrin receptor may comprise a segment of a naturally occurring ligand, e.g., transferrin. In some embodiments, a peptide that targets a transferrin receptor is as

described in US Patent No. 6,743,893, filed 11/30/2000, "RECEPTOR-MEDIATED UPTAKE OF PEPTIDES THAT BIND THE HUMAN TRANSFERRIN RECEPTOR". In some embodiments, a peptide that targets a transferrin receptor is as described in Kawamoto, M. et al, "A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells." BMC Cancer. 2011 Aug 18;11:359. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 8,399,653, filed 5/20/2011, "TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED SIRNA DELIVERY".

[000186] As discussed above, examples of muscle targeting peptides have been reported. For example, muscle-specific peptides were identified using phage display library presenting surface heptapeptides. As one example a peptide having the amino acid sequence ASSLNIA (SEQ ID NO: 324) bound to C2C12 murine myotubes *in vitro*, and bound to mouse muscle tissue *in vivo*. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence ASSLNIA (SEQ ID NO: 324). This peptide displayed improved specificity for binding to heart and skeletal muscle tissue after intravenous injection in mice with reduced binding to liver, kidney, and brain. Additional muscle-specific peptides have been identified using phage display. For example, a 12 amino acid peptide was identified by phage display library for muscle targeting in the context of treatment for Duchenne muscular dystrophy. See, Yoshida D., et al., "Targeting of salicylate to skin and muscle following topical injections in rats." *Int J Pharm* 2002; 231: 177-84; the entire contents of which are hereby incorporated by reference. Here, a 12 amino acid peptide having the sequence SKTFNTHPQSTP (SEQ ID NO: 325) was identified and this muscle-targeting peptide showed improved binding to C2C12 cells relative to the ASSLNIA (SEQ ID NO: 324) peptide.

[000187] An additional method for identifying peptides selective for muscle (*e.g.*, skeletal muscle) over other cell types includes *in vitro* selection, which has been described in Ghosh D., et al., "Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting" *J Virol* 2005; 79: 13667-72; the entire contents of which are incorporated herein by reference. By pre-incubating a random 12-mer peptide phage display library with a mixture of non-muscle cell types, non-specific cell binders were selected out. Following rounds of selection the 12 amino acid peptide TARGEHKEEELI (SEQ ID NO: 326) appeared most frequently. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence TARGEHKEEELI (SEQ ID NO: 326).

[000188] A muscle-targeting agent may an amino acid-containing molecule or peptide. A muscle-targeting peptide may correspond to a sequence of a protein that preferentially binds to a protein receptor found in muscle cells. In some embodiments, a muscle-targeting peptide

contains a high propensity of hydrophobic amino acids, e.g. valine, such that the peptide preferentially targets muscle cells. In some embodiments, a muscle-targeting peptide has not been previously characterized or disclosed. These peptides may be conceived of, produced, synthesized, and/or (e.g., and) derivatized using any of several methodologies, e.g. phage displayed peptide libraries, one-bead one-compound peptide libraries, or positional scanning synthetic peptide combinatorial libraries. Exemplary methodologies have been characterized in the art and are incorporated by reference (Gray, B.P. and Brown, K.C. “Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides” *Chem Rev.* 2014, 114:2, 1020–1081.; Samoylova, T.I. and Smith, B.F. “Elucidation of muscle-binding peptides by phage display screening.” *Muscle Nerve*, 1999, 22:4. 460-6.). In some embodiments, a muscle-targeting peptide has been previously disclosed (see, e.g. Writer M.J. et al. “Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display.” *J. Drug Targeting*. 2004;12:185; Cai, D. “BDNF-mediated enhancement of inflammation and injury in the aging heart.” *Physiol Genomics*. 2006, 24:3, 191-7.; Zhang, L. “Molecular profiling of heart endothelial cells.” *Circulation*, 2005, 112:11, 1601-11.; McGuire, M.J. et al. “In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo.” *J Mol Biol*. 2004, 342:1, 171-82.). Exemplary muscle-targeting peptides comprise an amino acid sequence of the following group: CQAQGQLVC (SEQ ID NO: 327), CSERSMNFC (SEQ ID NO: 328), CPKTRRVPC (SEQ ID NO: 329), WLSEAGPVVTVRALRGTSW (SEQ ID NO: 330), ASSLNIA (SEQ ID NO: 324), CMQHSMRVC (SEQ ID NO: 331), and DDTRHWG (SEQ ID NO: 332). In some embodiments, a muscle-targeting peptide may comprise about 2-25 amino acids, about 2-20 amino acids, about 2-15 amino acids, about 2-10 amino acids, or about 2-5 amino acids. Muscle-targeting peptides may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a muscle-targeting peptide may be linear; in other embodiments, a muscle-targeting peptide may be cyclic, e.g. bicyclic (see, e.g. Silvana, M.G. et al. *Mol. Therapy*, 2018, 26:1, 132–147.).

iii. Muscle-Targeting Receptor Ligands

[000189] A muscle-targeting agent may be a ligand, e.g. a ligand that binds to a receptor protein. A muscle-targeting ligand may be a protein, e.g. transferrin, which binds to an internalizing cell surface receptor expressed by a muscle cell. Accordingly, in some embodiments, the muscle-targeting agent is transferrin, or a derivative thereof that binds to a transferrin receptor. A muscle-targeting ligand may alternatively be a small molecule, e.g. a

lipophilic small molecule that preferentially targets muscle cells relative to other cell types. Exemplary lipophilic small molecules that may target muscle cells include compounds comprising cholesterol, cholesteryl, stearic acid, palmitic acid, oleic acid, oleyl, linolene, linoleic acid, myristic acid, sterols, dihydrotestosterone, testosterone derivatives, glycerine, alkyl chains, trityl groups, and alkoxy acids.

iv. Muscle-Targeting Aptamers

[000190] A muscle-targeting agent may be an aptamer, e.g. an RNA aptamer, which preferentially targets muscle cells relative to other cell types. In some embodiments, a muscle-targeting aptamer has not been previously characterized or disclosed. These aptamers may be conceived of, produced, synthesized, and/or (e.g., and) derivatized using any of several methodologies, e.g. Systematic Evolution of Ligands by Exponential Enrichment. Exemplary methodologies have been characterized in the art and are incorporated by reference (Yan, A.C. and Levy, M. “Aptamers and aptamer targeted delivery” RNA biology, 2009, 6:3, 316-20.; Germer, K. et al. “RNA aptamers and their therapeutic and diagnostic applications.” Int. J. Biochem. Mol. Biol. 2013; 4: 27–40.). In some embodiments, a muscle-targeting aptamer has been previously disclosed (see, e.g. Phillippou, S. et al. “Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.” Mol Ther Nucleic Acids. 2018, 10:199-214.; Thiel, W.H. et al. “Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.” Mol Ther. 2016, 24:4, 779-87.). Exemplary muscle-targeting aptamers include the A01B RNA aptamer and RNA Apt 14. In some embodiments, an aptamer is a nucleic acid-based aptamer, an oligonucleotide aptamer or a peptide aptamer. In some embodiments, an aptamer may be about 5-15 kDa, about 5-10 kDa, about 10-15 kDa, about 1-5 Da, about 1-3 kDa, or smaller.

v. Other Muscle-Targeting Agents

[000191] One strategy for targeting a muscle cell (e.g., a skeletal muscle cell) is to use a substrate of a muscle transporter protein, such as a transporter protein expressed on the sarcolemma. In some embodiments, the muscle-targeting agent is a substrate of an influx transporter that is specific to muscle tissue. In some embodiments, the influx transporter is specific to skeletal muscle tissue. Two main classes of transporters are expressed on the skeletal muscle sarcolemma, (1) the adenosine triphosphate (ATP) binding cassette (ABC) superfamily, which facilitate efflux from skeletal muscle tissue and (2) the solute carrier (SLC) superfamily, which can facilitate the influx of substrates into skeletal muscle. In some embodiments, the muscle-targeting agent is a substrate that binds to an ABC superfamily or an SLC superfamily of transporters. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a naturally-occurring substrate. In some embodiments, the substrate that binds to

the ABC or SLC superfamily of transporters is a non-naturally occurring substrate, for example, a synthetic derivative thereof that binds to the ABC or SLC superfamily of transporters.

[000192] In some embodiments, the muscle-targeting agent is any muscle targeting agent described herein (e.g., antibodies, nucleic acids, small molecules, peptides, aptamers, lipids, sugar moieties) that target SLC superfamily of transporters. In some embodiments, the muscle-targeting agent is a substrate of an SLC superfamily of transporters. SLC transporters are either equilibrative or use proton or sodium ion gradients created across the membrane to drive transport of substrates. Exemplary SLC transporters that have high skeletal muscle expression include, without limitation, the SATT transporter (ASCT1; SLC1A4), GLUT4 transporter (SLC2A4), GLUT7 transporter (GLUT7; SLC2A7), ATRC2 transporter (CAT-2; SLC7A2), LAT3 transporter (KIAA0245; SLC7A6), PHT1 transporter (PTR4; SLC15A4), OATP-J transporter (OATP5A1; SLC21A15), OCT3 transporter (EMT; SLC22A3), OCTN2 transporter (FLJ46769; SLC22A5), ENT transporters (ENT1; SLC29A1 and ENT2; SLC29A2), PAT2 transporter (SLC36A2), and SAT2 transporter (KIAA1382; SLC38A2). These transporters can facilitate the influx of substrates into skeletal muscle, providing opportunities for muscle targeting.

[000193] In some embodiments, the muscle-targeting agent is a substrate of an equilibrative nucleoside transporter 2 (ENT2) transporter. Relative to other transporters, ENT2 has one of the highest mRNA expressions in skeletal muscle. While human ENT2 (hENT2) is expressed in most body organs such as brain, heart, placenta, thymus, pancreas, prostate, and kidney, it is especially abundant in skeletal muscle. Human ENT2 facilitates the uptake of its substrates depending on their concentration gradient. ENT2 plays a role in maintaining nucleoside homeostasis by transporting a wide range of purine and pyrimidine nucleobases. The hENT2 transporter has a low affinity for all nucleosides (adenosine, guanosine, uridine, thymidine, and cytidine) except for inosine. Accordingly, in some embodiments, the muscle-targeting agent is an ENT2 substrate. Exemplary ENT2 substrates include, without limitation, inosine, 2',3'-dideoxyinosine, and calofarabine. In some embodiments, any of the muscle-targeting agents provided herein are associated with a molecular payload (e.g., oligonucleotide payload). In some embodiments, the muscle-targeting agent is covalently linked to the molecular payload. In some embodiments, the muscle-targeting agent is non-covalently linked to the molecular payload.

[000194] In some embodiments, the muscle-targeting agent is a substrate of an organic cation/carnitine transporter (OCTN2), which is a sodium ion-dependent, high affinity carnitine transporter. In some embodiments, the muscle-targeting agent is carnitine, mildronate, acetylcarnitine, or any derivative thereof that binds to OCTN2. In some embodiments, the

carnitine, mildronate, acetylcarnitine, or derivative thereof is covalently linked to the molecular payload (e.g., oligonucleotide payload).

[000195] A muscle-targeting agent may be a protein that exists in at least one soluble form that targets muscle cells. In some embodiments, a muscle-targeting protein may be hemojuvelin (also known as repulsive guidance molecule C or hemochromatosis type 2 protein), a protein involved in iron overload and homeostasis. In some embodiments, hemojuvelin may be full length or a fragment, or a mutant with at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to a functional hemojuvelin protein. In some embodiments, a hemojuvelin mutant may be a soluble fragment, may lack a N-terminal signaling, and/or (e.g., and) lack a C-terminal anchoring domain. In some embodiments, hemojuvelin may be annotated under GenBank RefSeq Accession Numbers NM_001316767.1, NM_145277.4, NM_202004.3, NM_213652.3, or NM_213653.3. It should be appreciated that a hemojuvelin may be of human, non-human primate, or rodent origin.

B. Molecular Payloads

[000196] Some aspects of the disclosure provide molecular payloads, e.g., for modulating a biological outcome, e.g., the transcription of a DNA sequence, the splicing and processing of a RNA sequence, the expression of a protein, or the activity of a protein. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, such molecular payloads are capable of targeting to a muscle cell, e.g., via specifically binding to a nucleic acid or protein in the muscle cell following delivery to the muscle cell by an associated muscle-targeting agent. It should be appreciated that various types of molecular payloads may be used in accordance with the disclosure. For example, the molecular payload may comprise, or consist of, an oligonucleotide (e.g., antisense oligonucleotide), a peptide (e.g., a peptide that binds a nucleic acid or protein associated with disease in a muscle cell), a protein (e.g., a protein that binds a nucleic acid or protein associated with disease in a muscle cell), or a small molecule (e.g., a small molecule that modulates the function of a nucleic acid or protein associated with disease in a muscle cell). In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a mutated DMD allele. Exemplary molecular payloads are described in further detail herein, however, it should be appreciated that the exemplary molecular payloads provided herein are not meant to be limiting.

i. Oligonucleotides

[000197] Aspects of the disclosure relate to oligonucleotides configured to modulate (e.g., increase) expression of dystrophin, e.g., from a DMD allele. In some embodiments,

oligonucleotides provided herein are configured to alter splicing of DMD pre-mRNA to promote expression of dystrophin protein (e.g., a functional truncated dystrophin protein). In some embodiments, oligonucleotides provided herein are configured to promote skipping of one or more exons in DMD, e.g., in a mutated DMD allele, in order to restore the reading frame. In some embodiments, the oligonucleotides allow for functional dystrophin protein expression (e.g., as described in Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. *Mol Ther Nucleic Acids*. 2018;13:442-449). In some embodiments, oligonucleotides provided are configured to promote skipping of exon 44 to produce a shorter but functional version of dystrophin (e.g., containing an in-frame deletion). In some embodiments, oligonucleotides are provided that promote exon 44 skipping (e.g., which may be relevant in a substantial number of patients, including, for example, patients amenable to exon 44 skipping, such as those having deletions in DMD exons 10-43, 11-43, 13-43, 14-43, 15-43, 16-43, 17-43, 19-43, 21-43, 23-43, 24-43, 25-43, 26-43, 27-43, 28-43, 29-43, 30-43, 31-43, 32-43, 33-43, 34-43, 35-43, 36-43, 37-43, 38-43, 39, 40-43, 41-43, 42-43, 43, 45, 45-54, 45-56, or 45-62).

[000198] Table 8 provides non-limiting examples of sequences of oligonucleotides that are useful for targeting DMD, e.g., for exon skipping, and for target sequences within DMD. In some embodiments, an oligonucleotide may comprise any antisense sequence provided in Table 8 or a sequence complementary to a target sequence provided in Table 8.

Table 8. Oligonucleotide sequences for targeting DMD.

SEQ ID NO	Target sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	Target Site
160	CAGAUUCUGUUGAG AAAUGGCGGC	196	GCCGCCAUUUCUC AACAGAUUCUG	232	GCCGCCATTCTC AACAGATCTG	Exon 44
161	CAGAUUCUGUUGAG AAAUGGCGGC	197	CGCCGCCAUUUCU CAACAGAUUCUG	233	CGCCGCCATTCT CAACAGATCTG	Exon 44
162	CAGAUUCUGUUGAG AAAUGGCGGCGU	198	ACGCCGCCAUUUC UCAACAGAUUCUG	234	ACGCCGCCATTTC TCAACAGATCTG	Exon 44
163	AGAUCUGUUGAGA AAUGGCGGC	199	GCCGCCAUUUCUC AACAGAUUCU	235	GCCGCCATTCTC AACAGATCT	Exon 44
164	AGAUCUGUUGAGA AAUGGCGGCG	200	CGCCGCCAUUUCU CAACAGAUUCU	236	CGCCGCCATTCT CAACAGATCT	Exon 44
165	AGAUCUGUUGAGA AAUGGCGGCGU	201	ACGCCGCCAUUUC UCAACAGAUUCU	237	ACGCCGCCATTTC TCAACAGATCT	Exon 44
166	AGAUCUGUUGAGA AAUGGCGGCGUU	202	AACGCCGCCAUUU CUCAACAGAUUCU	238	AACGCCGCCATTT CTCAACAGATCT	Exon 44
167	GAUCUGUUGAGAA AUGGCGGC	203	GCCGCCAUUUCUC AACAGAUUC	239	GCCGCCATTCTC AACAGATC	Exon 44
168	GAUCUGUUGAGAA AUGGCGGCG	204	CGCCGCCAUUUCU CAACAGAUUC	240	CGCCGCCATTCT CAACAGATC	Exon 44
169	GAUCUGUUGAGAA AUGGCGGCGU	205	ACGCCGCCAUUUC UCAACAGAUUC	241	ACGCCGCCATTTC TCAACAGATC	Exon 44
170	GAUCUGUUGAGAA AUGGCGGCGUU	206	AACGCCGCCAUUU CUCAACAGAUUC	242	AACGCCGCCATTT CTCAACAGATC	Exon 44

171	GAUCUGUUGAGAA AUGGCGGCGUUU	207	AAACGCCGCCAUU UCUCAACAGAU	243	AAACGCCGCCATT TCTCAACAGATC	Exon 44
172	UCUGUUGAGAAAU GGCGGCGUUUUC	208	GAAAACGCCGCCA UUUCUCAACAGA	244	GAAAACGCCGCCA TTTCTCAACAGA	Exon 44
173	CUGUUGAGAAAUG GCGGCGU	209	ACGCCGCCAUUUC UCAACAG	245	ACGCCGCCATTTC TCAACAG	Exon 44
174	CUGUUGAGAAAUG GCGGCGUUUUA	210	UGAAAACGCCGCC AUUUCUCAACAG	246	TGAAAACGCCGCC ATTTCTCAACAG	Exon 44
175	UGAGAAAUGGCGG CGUUUUAUUAU	211	AUAAUGAAAACGC CGCCAUUUCUA	247	ATAATGAAAACGC CGCCATTCTCA	Exon 44
176	GAGAAAUGGCGGC GUUUUCAUUAUG	212	CAUAAUGAAAACG CCGCCAUUUCUC	248	CATAATGAAAACG CCGCCATTCTC	Exon 44
177	AGAAAUGGCGGCG UUUUCAUUAUGA	213	UCAUAAUGAAAAC GCCGCCAUUUCU	249	TCATAATGAAAAC GCCGCCATTCT	Exon 44
178	AAUCAGUGGCUAA CAGAAGCUGAAC	214	GUUCAGCUUCUGU UAGCCACUGAUU	250	GTTTCAGCTTCTGT TAGCCACTGATT	Exon 44
179	AUCAGUGGCUAAC AGAAGCUGAAC	215	GUUCAGCUUCUGU UAGCCACUGAU	251	GTTTCAGCTTCTGT TAGCCACTGAT	Exon 44
180	AUCAGUGGCUAAC AGAAGCUGAAC	216	UGUUCAGCUUCUG UUAGCCACUGAU	252	TGTTTCAGCTTCTG TTAGCCACTGAT	Exon 44
181	UCAGUGGCUAACA GAAGCUGAAC	217	GUUCAGCUUCUGU UAGCCACUGA	253	GTTTCAGCTTCTGT TAGCCACTGA	Exon 44
182	UCAGUGGCUAACA GAAGCUGAAC	218	UGUUCAGCUUCUG UUAGCCACUGA	254	TGTTTCAGCTTCTG TTAGCCACTGA	Exon 44
183	UCAGUGGCUAACA GAAGCUGAACAG	219	CUGUUCAGCUUCU GUUAGCCACUGA	255	CTGTTTCAGCTTCT GTTAGCCACTGA	Exon 44
184	CAGUGGCUAACAG AAGCUGAAC	220	GUUCAGCUUCUGU UAGCCACUG	256	GTTTCAGCTTCTGT TAGCCACTG	Exon 44
185	CAGUGGCUAACAG AAGCUGAAC	221	UGUUCAGCUUCUG UUAGCCACUG	257	TGTTTCAGCTTCTG TTAGCCACTG	Exon 44
186	CAGUGGCUAACAG AAGCUGAACAG	222	CUGUUCAGCUUCU GUUAGCCACUG	258	CTGTTTCAGCTTCT GTTAGCCACTG	Exon 44
187	CAGUGGCUAACAG AAGCUGAACAGU	223	ACUGUUCAGCUUC UGUAGCCACUG	259	ACTGTTTCAGCTTC TGTTAGCCACTG	Exon 44
188	AGUGGCUAACAGA AGCUGAACAG	224	CUGUUCAGCUUCU GUUAGCCACU	260	CTGTTTCAGCTTCT GTTAGCCACT	Exon 44
189	AGUGGCUAACAGA AGCUGAACAGU	225	ACUGUUCAGCUUC UGUAGCCACU	261	ACTGTTTCAGCTTC TGTTAGCCACT	Exon 44
190	AGUGGCUAACAGA AGCUGAACAGUU	226	AACUGUUCAGCUU CUGUAGCCACU	262	AACGTTTCAGCTT CTGTTAGCCACT	Exon 44
191	GUGGCUAACAGAA GCUGAACAGU	227	ACUGUUCAGCUUC UGUAGCCAC	263	ACTGTTTCAGCTTC TGTTAGCCAC	Exon 44
192	GUGGCUAACAGAA GCUGAACAGUU	228	AACUGUUCAGCUU CUGUAGCCAC	264	AACGTTTCAGCTT CTGTTAGCCAC	Exon 44
193	AAAGAUCAAGGUUC UGAAGGGUGAUG	229	CAUCACCCUUCAG AACCUGAUCUUU	265	CATCACCCTTCAG AACCTGATCTT	Intron 44
194	AAGAUCAAGGUUCU GAAGGGUGAUG	230	CAUCACCCUUCAG AACCUGAUCUU	266	CATCACCCTTCAG AACCTGATCTT	Intron 44
195	AGAUCAGGUUCUG AAGGGUGAUG	231	CAUCACCCUUCAG AACCUGAUCU	267	CATCACCCTTCAG AACCTGATCT	Intron 44

† Each thymine base (T) in any one of the oligonucleotides and/or target sequences provided in Table 8 may independently and optionally be replaced with a uracil base (U), and/or each U may independently and optionally be replaced with a T. Target sequences listed in Table 8 contain U's, but binding of a DMD-targeting oligonucleotide to RNA and/or DNA is contemplated.

[000199] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a region of a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a region of a DMD RNA (e.g., the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for

targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a DMD RNA (*e.g.*, the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an exon of a DMD RNA (*e.g.*, SEQ ID NO: 131, 273, or 280). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an intron of a DMD RNA (*e.g.*, SEQ ID NO: 269 or 277). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a portion of a DMD sequence (*e.g.*, a sequence provided by any one of SEQ ID NOs: 268, 270, 271, 272, 274, 275, 276, 278, 279, 281, and 323). Examples of DMD sequences are provided below. Each of the DMD sequences provided below include thymine nucleotides (T's), but it should be understood that each sequence can represent a DNA sequence or an RNA sequence in which any or all of the T's would be replaced with uracil nucleotides (U's).

[000200] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, mRNA (NCBI Reference Sequence: NM_004006.2)

TCCTGGCATCAGTTACTGTGTTGACTCACTCAGTGTGGGATCACTCACTTTCCCCCTACAGGACTCAGATCTGGGA
GGCAATTACCTTCGGAGAAAAACGAATAGGAAAACTGAAGTGTTACTTTTTTAAAGCTGCTGAAGTTTGTGGTT
TCTCATTGTTTTTAAAGCCTACTGGAGCAATAAAGTTTGAAGAACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATA
TACACTTTTCAAATGCTTTTGGTGGGAAGAAGTAGAGGACTGTTATGAAAGAGAAGATGTTCAAAGAAAACATTCA
CAAAATGGGTAAATGCACAATTTCTAAGTTTGGGAAGCAGCATATTGAGAACCTCTTCAGTGACCTACAGGATGGG
AGGCGCTCCTAGACCTCCTCGAAGGCCTGACAGGGCAAAAACCTGCCAAAAGAAAAGGATCCACAAGAGTTCATGC
CCTGAACAATGTCAACAAGGCACTGCGGGTTTTGCGAACAATAATGTTGATTTAGTGAATATTGGAAGTACTGACA
TCGTAGATGGAAATCATAAACTGACTCTTGGTTTTGATTGGAAATATAATCCTCCACTGGCAGGTCAAAAATGTAATG
AAAAATATCATGGCTGGATTGCAACAAACCAACAGTGAAAAAGATTCTCCTGAGCTGGGTCCGACAATCAACTCGTAA
TTATCCACAGGTTAATGTAATCAACTTCACCACCAGCTGGTCTGATGGCCTGGCTTTGAATGCTCTCATCCATAGTC
ATAGGCCAGACCTATTTGACTGGAATAGTGTGGTTTGCAGCAGTCAGCCACACAACGACTGGAACATGCATTCAAC
ATCGCCAGATATCAATTAGGCATAGAGAACTACTCGATCCTGAAGATGTTGATACCACCTATCCAGATAAGAAGTC
CATCTTAATGTACATCACATCACTCTTCCAAGTTTGCCTCAACAAGTGAGCATTGAAGCCATCCAGGAAGTGGAAA
TGTTGCCAAGGCCACCTAAAGTGACTAAAGAAGAACATTTTCAAGTTACATCATCAAATGCACATTTCTCAACAGATC
ACGGTCAGTCTAGCACAGGGATATGAGAGAACTTCTTCCCCTAAGCCTCGATTCAAGAGCTATGCCTACACACAGGC
TGCTTATGTACACCACCTCTGACCTTACACGGAGCCCATTTCCTTCACAGCATTGGAAGCTCCTGAAGACAAGTCAT
TTGGCAGTTCATTGATGGAGAGTGAAGTAAACCTGGACCGTTATCAAAACAGCTTTAGAAGAAGTATTATCGTGGCTT
CTTTCTGCTGAGGACACATTGCAAGCACAAGGAGAGATTTCTAATGATGTGGAAGTGGTGAAAGACCAGTTTCATAC
TCATGAGGGGTACATGATGGATTTGACAGCCCATCAGGGCCGGGTGGTAATATTCTACAATTGGGAAGTAAGCTGA
TTGGAACAGGAAAATTATCAGAAGATGAAGAACTGAAGTACAAGAGCAGATGAATCTCCTAAATTCAAGATGGGAA
TGCCTCAGGGTAGCTAGCTATGGAACAAAGCAATTACATAGAGTTTAAATGGATCTCCAGAATCAGAAACTGAA
AGAGTTGAATGACTGGCTAACAAAAACAGAAAGAAACAAGGAAAATGGAGGAAGAGCCTCTTGGACCTGATCTTG
AAGACCTAAAACGCCAAGTACAACAACATAAGGTGCTTCAAGAAGATCTAGAACAAGAACAAGTCAGGGTCAATTCT
CTCACTCACATGGTGGTGGTAGTTGATGAATCTAGTGGAGATCACGCAACTGCTGCTTTGGAAGAACAACCTAAGGT
ATTGGGAGATCGATGGGCAACATCTGTAGATGGACAGAAGACCGCTGGGTCTTTTACAAGACATCCTTCTCAAAT
GGCAACGTCTTACTGAAGAACAGTGCCTTTTTAGTGCATGGCTTTCAGAAAAAGAAGATGCAGTGAACAAGATTAC
ACAACCTGGCTTTAAAGATCAAAATGAAATGTTATCAAGTCTTCAAAAACCTGGCCGTTTTTAAAGCGGATCTAGAAA
GAAAAAGCAATCCATGGGCAAACTGTATCACTCAAACAAGATCTTCTTTCAACACTGAAGAATAAGTCAGTGACCC
AGAAGACGGAAGCATGGCTGGATAACTTTGCCCGGTGTGGGATAATTTAGTCCAAAACTTGAAAAGAGTACAGCA
CAGATTTACAGGCTGTCACCACCACTCAGCCATCACTAACACAGACAACCTGTAATGGAAACAGTAACCTACGGTGAC
CACAAGGGAACAGATCCTGGTAAAGCATGCTCAAGAGGAACTTCCACCACCACCTCCCCAAAAGAAGAGGCAGATTA
CTGTGGATTCTGAAATTAGGAAAAGGTTGGATGTTGATATAACTGAACTTCACAGCTGGATTACTCGCTCAGAAGCT
GTGTTGCAGAGTCTGAATTTGCAATCTTTGGAAGGAAGGCAACTTCTCAGACTTAAAAGAAAAAGTCAATGCCAT
AGAGCGAGAAAAAGCTGAGAAGTTCAGAAAACTGCAAGATGCCAGCAGATCAGCTCAGGCCCTGGTGGAAACAGATGG
TGAATGAGGGTGTTAATGCAGATAGCATCAACAAGCCTCAGAACAACCTGAACAGCCGGTGGATCGAATTCTGCCAG
TTGCTAAGTGAGAGACTTAACTGGCTGGAGTATCAGAACAACATCATCGCTTTCTATAATCAGCTACAACAATTGGA

GCAGATGACAACTACTGCTGAAAACTGGTTGAAAAATCCAACCCACCACCCCATCAGAGCCAACAGCAATTAAAAAGTC
AGTTAAAAAATTTGTAAGGATGAAGTCAACCGGCTATCAGGTCTTCAACCTCAAATTGAACGATTAAAAATTCAAAGC
ATAGCCCTGAAAGAGAAAGGACAAGGACCCATGTTCTTGATGCAGACTTTGTGGCCTTTACAAATCATTTTAAAGCA
AGTCTTTTCTGATGTGCAGGCCAGAGAGAAAGAGCTACAGACAATTTTGTGACACTTTGCCACCAATGCGCTATCAGG
AGACCATGAGTGCCATCAGGACATGGGTCCAGCAGTCAGAAACCAAACCTCTCCATACCTCAACTTAGTGTCACCGAC
TATGAAATCATGGAGCAGAGACTCGGGGAATTGCAGGCTTTACAAAGTTCTCTGCAAGAGCAACAAAGTGGCCTATA
CTATCTCAGCACCCTGTGAAAGAGATGTGCAAGAAAGCGCCCTCTGAAATTAGCCGGAATATCAATCAGAATTTG
AAGAAATTGAGGACGCTGGAAGAAGCTCTCTCCAGCTGGTTGAGCATTGTCAAAAGCTAGAGGAGCAAATGAAT
AAACTCCGAAAAATTCAGAATCACATACAAACCCCTGAAGAAATGGATGGCTGAAGTTGATGTTTTCTGAAGGAGGA
ATGGCCTGCCCTTGGGGATTGAGAAATCTAAAAAAGCAGCTGAAACAGTGCAGACTTTTGTAGTCAGTGATATTCAGA
CAATTCAGCCAGTCTAAACAGTGTCAATGAAGGTGGGCAGAAAGATAAAAGAAATGAAGCAGAGCCAGAGTTTGTCTCG
AGACTTGAGACAGAACTCAAAGAACTTAACACTCAGTGGGATCACATGTGCCAACAGGTCTATGCCAGAAAGGAGGC
CTTGAAGGGAGGTTTGGAGAAAACTGTAAGCCTCCAGAAAGATCTATCAGAGATGCACGAATGGATGACACAAGCTG
AAGAAGAGTATCTTGAGAGAGATTTTGAATATAAACTCCAGATGAATTACAGAAAGCAGTTGAAGAGATGAAGAGA
GCTAAAGAAGAGGCCCAACAAAAAGAAGCGAAAGTGAAGTCTTACTGAGTCTGTAAATAGTGTATAGCTCAAGC
TCCACCTGTAGCACAAAGAGGCCCTTAAAAAAGGAACCTGAACTCTAACCACCAACTACCAGTGGCTCTGCCTAGGC
TGAATGGGAAATGCAAGACTTTGGAAGAAGTTGGGCATGTTGGCATGAGTTATTGTCTATCTTGGAGAAAGCAAAC
AAGTGGCTAAATGAAGTAGAATTTAACTTAAAAACCACTGAAACATTCCTGGCGGAGCTGAGGAAATCTCTGAGGT
GCTAGATTCACTTGAAAAATTTGATGCGACATTCAGAGGATAACCCAAATCAGATTTCGCATATTGGCACAGACCCTAA
CAGATGGCGGAGTCATGGATGAGCTAATCAATGAGGAACTTGAGACATTTAATTCTCGTTGGAGGGAACCTACATGAA
GAGGCTGTAAGGAGGCAAAAGTTGCTTGAACAGAGCATCCAGTCTGCCAGGAGACTGAAAAATCCTTACACTTAAT
CCAGGAGTCCCTCACATTCATTGACAAGCAGTTGGCAGCTTATATTGCAGACAAGGTGGACGCAGCTCAAATGCCTC
AGGAAGCCCAGAAAAATCCAATCTGATTTGACAAGTCATGAGATCAGTTTGAAGAAATGAAGAAACATAATCAGGGG
AAGGAGGCTGCCAAAGAGTCTGTCTCAGATGATGTTGCACAGAAAAAATTACAAGATGTCTCCATGAAGTTTTCG
ATTATTCCAGAAACCAGCAATTTTGGACAGCGTCTACAAGAAAGTAAAGTGAATTTAGATGAAGTGAAGATGCATC
TGCTTCGATTTGGAACAAAGAGTGTGGAACAGGAAGTAGTACAGTCACAGCTAAATCATTGTGTGAACCTTGTATAAA
AGTCTGAGTGAAGTGAAGTCTGAAGTGGAAATGGTGATAAAGACTGGACGTCAGATTGTACAGAAAAAGCAGACGGA
AAATCCCAAAGAACTTGATGAAAGAGTAACAGCTTTGAAATTGCATTATAATGAGCTGGGAGCAAAGGTAACAGAAA
GAAAGCAACAGTTGGAGAAATGCTTGAAATTGTCCCGTAAGATGCGAAAGGAAATGAATGTCTTGACAGAATGGCTG
GCAGCTACAGATATGGAATTGACAAAGAGATCAGCAGTTGAAGGAATGCCTAGTAATTTGGATTCTGAAGTTGCCTG
GGGAAAGGCTACTCAAAAAGAGATTGAGAAACAGAAAGGTGCACCTGAAGAGTATCACAGAGGTAGGAGAGGCCCTTGA
AAACAGTTTTTGGGCAAGAAGGAGACGTTGGTGGAAGATAAACTCAGTCTTCTGAATAGTAACCTGGATAGCTGTCACC
TCCCGAGCAGAAGAGTGGTTAAATCTTTTGTGGAATACCAGAAACACATGGAACTTTTGGACCAGAAATGTGGACCA
CATCACAAGTGGATCATTACAGGCTGACACACTTTTGGATGAATCAGAGAAAAAGAAACCCAGCAAAAAGAAGACG
TGCTTAAGCGTTTAAAGGCAGAACTGAATGACATACGCCCAAAGGTGGACTCTACACGTGACCAAGCAGCAAACTTG
ATGGCAAACCGCGGTGACCACTGCAGGAAATTAGTAGAGCCCCAAATCTCAGAGCTCAACCATCGATTTGCAGCCAT
TTCACACAGAATTAAGACTGGAAAGGCCTCCATTCTTTGAAAGGAATTTGGAGCAGTTTAACTCAGATATACAAAAAT
TGCTTGAACCACTGGAGGCTGAAATTCAGCAGGGGGTGAATCTGAAAGAGGAAGACTTCAATAAAGATATGAATGAA
GACAATGAGGGTACTGTAAAAGAATTGTTGCAAAGAGGAGACAACCTTACAACAAAGAATCACAGATGAGAGAAAGCG
AGAGGAAATAAAGATAAAACAGCAGCTGTTACAGACAAAACATAATGCTCTCAAGGATTTGAGGTCTCAAAGAAGAA
AAAAGGCTCTAGAAATTTCTCATCAGTGGTATCAGTACAAGAGGCAGGCTGATGATCTCTGAAATGCTTGGATGAG
ATTGAAAAAAATTAGCCAGCCTACCTGAGCCAGAGATGAAAGGAAAAATAAAGGAAATGTATCGGGAATTTGACGAA
GAAGAAAGAGGAGTGAATGCAGTGCAGTAGGCAAGCTGAGGGCTTGTCTGAGGATGGGGCCGCAATGGCAGTGGAGC
CAACTCAGATCCAGCTCAGCAAGCGCTGGCGGGAAATTTAGAGCAAAATTTGCTCAGTTTTCGAAGACTCAACTTTGCA
CAAATTCACACTGTCCGTGAAGAAACGATGATGGTGATGACTGAAGACATGCCCTTTGGAATTTCTTATGTGCCTTC
TACTTATTTGACTGAAATCACTCATGTCTCACAAGCCCTATTAGAAGTGGAAACAACCTTCTCAATGCTCCTGACCTCT
GTGCTAAGGACTTTGAAGATCTCTTTAAGCAAGAGGAGTCTCTGAAGAATATAAAAGATAGTCTACAACAAAGCTCA
GGTCCGATTGACATTATTCATAGCAAGAAGACAGCAGCATTGCAAAGTGCACCGCTGTGGAAAGGGTGAAGCTACA
GGAAGCTCTCTCCAGCTTGATTTCCAATGGGAAAAAGTTAACAAAAATGTACAAGGACCAGCAAGGGCGATTTGACA
GATCTGTTGAGAAATGGCGGCGTTTTTATTATGATATAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTT
CTCAGAAAGACACAAATTCCTGAGAATTGGGAACATGCTAAATACAAATGGTATCTTAAGGAACTCCAGGATGGCAT
TGGGCAGCGGCAAACTGTTGTGAGAACATTGAATGCAACTGGGGAGAAATAATTAGCAATCCTCAAAAACAGATG
CCAGTATTCTACAGGAAAAATTTGGGAAGCCTGAATCTGCGGTGGCAGGAGGTCTGCAAACAGCTGTGACAGAAAA
AAGAGGCTAGAAGAACAAAAGAATATCTTGTGAGAAATTTCAAAGAGATTTAAATGAATTTGTTTTATGGTTGGAGGA
AGCAGATAACATTGCTAGTATCCCACTTGAACCTGGAAAAAGAGCAGCAACTAAAAGAAAAGCTTGAGCAAGTCAAGT
TACTGGTGAAGAGTTGCCCTGCGCCAGGGAATTTCTAAACAATTAATGAACTGGAGGACCCGTGCTTGTAAAGT
GCTCCCATAGCCCAAGAGCAAGATAAACTGAAAAATAAGCTCAAGCAGACAAATCTCCAGTGGATAAAGGTTTC
CAGAGCTTTACCTGAGAAACAAGGAGAAATGAAGCTCAAATAAAAGACCTTGGGCAGCTGAAAAAAGCTTGAAG
ACCTTGAAGAGCAGTTAAATCATCTGCTGTGTTATCTCCTATTAGGAATCAGTTGGAAATTTATAACCAACCA
AACCAAGAAGGACCATTTGACGTTTCAGGAACTGAAATAGCAGTTCAAGCTAAACAACCGGATGTGGAAGAGATTTT
GTCTAAAGGGCAGCAATTTGTACAAGGAAAAACCAGCCACTCAGCCAGTGAAGAGGAAGTTAGAAGATCTGAGCTTCG
AGTGGAAGGCGGTAAACCGTTTTACTTCAAGAGCTGAGGGCAAAAGCAGCCTGACCTAGCTCCTGGACTGACCACTATT
GGAGCCTCTCCTACTCAGACTGTTACTCTGGTGACACAACCTGTGGTTACTAAGGAACTGCCATCTCCAACTAGA
AATGCCATCTTCTTGATGTTGGAGGTACCTGCTCTGGCAGATTTCAACCGGGCTTGGACAGAACTTACCGACTGGC

TTTCTCTGCTTGATCAAGTTATAAAATCACAGAGGGTGATGGTGGGTGACCTTGAGGATATCAACGAGATGATCATC
AAGCAGAAGGCAACAATGCAGGATTTGGAACAGAGGCGTCCCCAGTTGGAAGAACTCATTACCGCTGCCAAAATTT
GAAAAACAAGACCAGCAATCAAGAGGCTAGAACAAATCATTACGGATCGAATTGAAAGAATTCAGAATCAGTGGGATG
AAGTACAAGAACACCTTCAGAACCGGAGGCAACAGTTGAATGAAATGTTAAAGGATTCAACACAATGGCTGGAAGCT
AAGGAAGAAGCTGAGCAGGTCTTAGGACAGGCCAGAGCCAAGCTTGAGTCATGGAAGGAGGGTCCCTATACAGTAGA
TGCAATCCAAAAGAAAATCACAGAAACCAAGCAGTTGGCCAAAGACCTCCGCCAGTGGCAGACAAATGTAGATGTGG
CAAATGACTTGGCCCTGAACTTCTCCGGGATTATTCTGCAGATGATACCAGAAAAGTCCACATGATAACAGAGAAT
ATCAATGCCTCTTGGAGAAGCATTATAAAAGGGTGAGTGAGCGAGAGGCTGCTTTGGAAGAACTCATAGATTACT
GCAACAGTTCCCCCTGGACCTGGAAAAGTTTCTTGCCCTGGCTTACAGAAAGCTGAAACAACCTGCCAATGTCTTACAGG
ATGCTACCCGTAAGGAAAGGCTCCTAGAAGACTCCAAGGGAGTAAAAGAGCTGATGAAACAATGGCAAGACCTCCAA
GGTGAAATTGAAGCTCACACAGATGTTTATCACAACTGGATGAAAAACAGCCAAAAAATCCTGAGATCCCTGGAAGG
TTCCGATGATGCAGTCTGTGTACAAAGACGTTTGATAACATGAACTTCAAGTGGAGTGAACCTCGGAAAAAGTCTC
TCAACATTAGGTCCCATTTGGAAGCCAGTTCTGACCAGTGGAAGCGTCTGCACCTTTCTCTGCAGGAACCTCTGGTG
TGGCTACAGCTGAAAGATGATGAATTAAGCCGGCAGGCACCTATTGGAGGCGACTTTCCAGCAGTTCAGAAGCAGAA
CGATGTACATAGGGCCTTCAAGAGGGAATTGAAAACCTAAAGAACCTGTAATCATGAGTACTCTTGAGACTGTACGAA
TATTTCTGACAGAGCAGCCTTTGGAAGGACTAGAGAACTCTACCAGGAGCCCAGAGAGCTGCCTCCTGAGGAGAGA
GCCCAGAATGTCACTCGGCTTCTACGAAAGCAGGCTGAGGAGGTCAATACTGAGTGGGAAAAATTGAACCTGCACTC
CGCTGACTGGCAGAGAAAAATAGATGAGACCTTGAAAAGACTCCAGGAACTTCAAGAGGCCACGGATGAGCTGGACC
TCAAGCTGCGCCAAGCTGAGGTGATCAAGGGATCCTGGCAGCCCCGTGGGCGATCTCCTCATTGACTCTCTCCAAGAT
CACCTCGAGAAAGTCAAGGCACTTCGAGGAGAAAATTGCGCCTCTGAAAAGAGAAGCTGAGCCACGTCAATGACCTTGC
TCGCCAGCTTACCACCTTTGGGCATTAGCTCTCACCGTATAACCTCAGCACTCTGGAAGACCTGAACACCAGATGGA
AGCTTCTGCAGGTGGCCGTCGAGGACCGAGTCAGGCAGCTGCATGAAGCCACAGGGACTTTGGTCCAGCATCTCAG
CACTTTCTTTCCACGTCTGTCCAGGGTCCCTGGGAGAGAGCCATCTCGCCAAACAAAGTGCCCTACTATATCAACCA
CGAGACTCAAAACAACCTTGCTGGGACCATCCCAAAATGACAGAGCTCTACCAGTCTTTAGCTGACCTGAATAATGTCA
GATTCTCAGCTTATAGGACTGCCATGAACTCCGAAGACTGCAGAAGGCCCTTTGCTTGATCTCTTGAGCCTCAGCA
GCTGCATGTGATGCCTTGACACAGCACAACTCAAGCAAAATGACCAGCCCATGGATATCTGCAGATTATTAATTG
TTTGACCACTATTTATGACCGCTGGAGCAAGAGCACAACAATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTC
TGAAGTGGCTGCTGAATGTTTATGATACGGGACGAACAGGGAGGATCCGTGTCTGTCTTTTAAACTGGCATCATT
TCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATACCTTTTCAAGCAAGTGGCAAGTTCAACAGGATTTTGTGA
CCAGCGCAGGCTGGGCCTCCTTCTGCATGATTCTATCCAAATCCAAGACAGTTGGGTGAAGTTGCATCCTTTGGGG
GCAGTAACATTGAGCCAAGTGTCCGGAGCTGCTTCCAATTTGCTAATAATAAGCCAGAGATCGAAGCGGCCCTCTTC
CTAGACTGGATGAGACTGGAACCCAGTCCATGGTGTGGCTGCCGTCTCTGCACAGAGTGGCTGCTGCAGAACTGC
CAAGCATCAGGCCAAATGTAACATCTGCAAAGAGTGTCCAATCATTGGATTACAGGTACAGGAGTCTAAAGCACTTTA
ATTATGACATCTGCCAAAGCTGCTTTTTTCTGGTGCAGTTGCAAAAGGCCATAAAATGCATATCCCATGGTGGAA
TATTGCACTCCGACTACATCAGGAGAAGATGTTGAGACTTTGCCAAGGTACTAAAAAACAAATTTTCAACCAAAAG
GTATTTTGCAGAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGGACAACATGGAAACTCCCG
TTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCCCTCAGCTTTCACACGATGATACTCATTCA
CGCATTGAACATTATGCTAGCAGGCTAGCAGAAAATGAAAAACAGCAATGGATCTTATCTAAATGATAGCATCTCTCC
TAATGAGAGCATAGATGATGAACATTTGTTAATCCAGCATTACTGCCAAAGTTTGAACCAGGACTCCCCCTGAGCC
AGCCTCGTAGTCTCTGCCAGATCTTGATTTCTTAGAGAGTGAGGAAAAGAGGGGAGCTAGAGAGAATCCTAGCAGAT
CTTGAGGAAGAAAACAGGAATCTGCAAGCAGAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCCTGTCCCC
ACTGCCGTCCTCTGAAATGATGCCACCTCTCCAGAGATCCCCGGGATGCTGAGCTCATTGCTGAGGCCAAGC
TACTGCGTCAACACAAAGGCCGCTGGAAGCCAGGATGCAAAATCTGGAAGACCACAATAAACAGCTGGAGTCAAG
TTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGCAGAGGCCAAAGTGAATGGCACAACGGTGTCTCTCCTTC
TACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTATGCTGCTCCGAGTGGTTGGCAGTCAAACCTTCGGACTCCATGG
GTGAGGAAGATCTTCTCAGTCTCCCCAGGACACAAGCACAGGGTTAGAGGAGGTGATGGAGCAACTCAACAACCTCC
TTCCCTAGTTCAAGAGGAAGAAATACCCCTGGAAGCCAATGAGAGAGGACACAATGTAGGAAGTCTTTTCCACATG
GCAGATGATTTGGGCAGAGCGATGGAGTCTTAGTATCAGTCATGACAGATGAAGAAGGAGCAGAATAAATGTTTTA
CAACTCCTGATTCCCGCATGGTTTTTATAATATTATACAAACAAAGAGGATTAGACAGTAAGAGTTTACAAGAAATA
AATCTATATTTTTGTGAAGGGTAGTGGTATTATACTGTAGATTTTCAAGTCTGTTATTGTTTTGTAA
CAATGGCAGGTTTTACACGTCTATGCAATTGTACAAAAAGTTATAAGAAAACCTACATGTAAATCTTGATAGCTAA
ATAACTTGCCATTTCTTTATATGGAACGCATTTTGGGTGTTTAAAAATTTATAACAGTTATAAAGAAAGATTGTAA
ACTAAAGTGTGCTTTATAAAAAAAGTTGTTTTATAAAAAACCCCTAAAAACAAAACACACACACACACATAC
ACACACACACACAAAACTTTGAGGCAGCGCATTGTTTTGCATCCTTTTGGCGTGATATCCATATGAAATTCATGGCT
TTTTCTTTTTTGCATATTAAAGATAAGACTTCTCTACCACCACACCAAATGACTACTACACACTGCTCATTGAG
AACTGTGCTGAGTGGGGCAGGCTTGAGTTTTCATTTTATATATCTATATGTCTATAAGTATATAAATACTATAGT
TATATAGATAAAGAGATACGAATTTCTATAGACTGACTTTTTCCATTTTTTAAATGTTTATGTCACATCCTAATAGA
AAGAAATTACTTCTAGTCAGTCATCCAGGCTTACCTGCTTGGTCTAGAATGGATTTTTCCCGGAGCCGGAAGCCAGG
AGGAAACTACACCACTAAAACATTGTCTACAGTCCAGATGTTTCTCATTTTTAAACAACCTTTCCACTGACAACGA
AAGTAAAGTAAAGTATTGGATTTTTTAAAGGGAACATGTGAATGAATACACAGGACTTATTATCAGAGTGAGTA
ATCGGTTGGTTGGTTGATTGATTGATTGATTGATACATTACAGCTTCTGTCTGCTAGCAATGCCACGATTTAGATTTA
ATGATGCTTCAGTGGAATCAATCAGAAGGTATTCTGACCTTGTGAACATCAGAAGGTATTTTTTAACTCCCAAGCA
GTAGCAGGACGATGATAGGGCTGGAGGGCTATGGATTCCCAGCCCATCCCTGTGAAGGAGTAGGCCACTCTTTAAGT
GAAGGATTGGATGATTGTTTATAATACATAAAGTTCTCTGTAATTACAACATAAATTATTATGCCCTCTTCTCAGAT

CAAAAGGAAGTGGGTGGTTTTGGTTTTTGTGCTTTTTTAGATTTATTGTCCCATGTGGGATGAGTTTTTAAATGCCA
 CAAGACATAATTTAAAAATAAAATAAACTTTGGGAAAAAGGTGTAACACAGTAGCCCCATCACATTTGTGATACTGACAG
 GTATCAACCCAGAAGCCCATGAAGTGTGTTTCCATCCTTTGCATTTCTCTGCGAGTAGTTCCACACAGGTTTGTAAAG
 TAAGTAAGAAAGAAGGCAAATTGATTCAAATGTTACAAAAAACCCCTTCTTGGTGGATTAGACAGGTTAAATATATA
 AACAAACAAACAAAAATTGCTCAAAAAAGAGGAGAAAAAGCTCAAGAGGAAAAAGCTAAGGACTGGTAGGAAAAAGCTT
 TACTCTTTTCATGCCATTTTATTTCTTTTTGATTTTAAATCATTCAATAGATAACCACGTGTGACCTATAATT
 TTGCAAATCTGTTACCTCTGACATCAAGTGAATTAGCTTTTGGAGAGTGGGCTGACATCAAGTGAATTAGCTTTT
 GGAGAGTGGGTTTTGTCCATTATTAATAATTAATTAATTAACATCAAACACGGCTTCTCATGCTATTTCTACCTCAC
 TTTGGTTTTGGGGTGTTCCTGATAATTGTGCACACCTGAGTTCACAGCTTCACCACCTTGTCATTGCGTTATTTTCT
 TTTTCTTTTATAATTCTTTCTTTTTCTTTCATAATTTTCAAAAAGAAAAACCCAAAGCTCTAAGGTAACAAATTACCAA
 ATTACATGAAGATTTGGTTTTTGTCTTGCATTTTTTCTTTTATGTGACGCTGGACCTTTTCTTTACCCAAGGATTT
 TTAAACTCAGATTTAAACAAGGGGTACTTTACATCCTACTAAGAAAGTTAAGTAAGTAAGTTTCATTCTAAAAT
 CAGAGGTAAATAGAGTGCATAAATAATTTTGTTTTAAATCTTTTTGTTTTTCTTTTAGACACATTAGCTCTGGAGTGA
 GTCTGTCTATAATTTGAACAAAAATTGAGAGCTTTATTGCTGCATTTTAAGCATAATTAATTTGGACATTATTTTCG
 TGTGTGTCTTTTATAACCAAGTATTAACTGTAAATCATAATGTAAGTGAAGCATAAACATCACATGGCATGT
 TTTGTCTATTGTTTTAGGTAAGTCTTACTTGAGTATCATAATATATTGTGTTTTAACCAACACTGTAACAT
 TTACGAATTATTTTTTAACTTCAGTTTTACTGCATTTTCACAACATATCAGACTTCACCAAATATATGCCTTACT
 ATTGTATTATAGTACTGCTTTACTGTGTATCTCAATAAAGCACGCAGTTATGTTAC (SEQ ID NO: 130)

[000201] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 43

(nucleotide positions 6362-6534 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1056909-1057081 of NCBI Reference Sequence: NG_012232.1)

AATATAAAGATAGTCTACAACAAAGCTCAGGTGCGATTGACATTATTCATAGCAAGAAGACAGCAGCATTGCAAAAG
 TGCAACGCCTGTGGAAAGGGTGAAGCTACAGGAAGCTCTCTCCAGCTTGATTTCATGGGAAAAAGTTAACAAAA
 TGTACAAGGACCGACAAGG (SEQ ID NO: 131)

[000202] *Homo sapiens* dystrophin (DMD) exon 43/intron 43 junction (nucleotide

positions 1057052-1057111 of NCBI Reference Sequence: NG_012232.1)

AGTTAACAAAATGTACAAGGACCGACAAGGGTAGGTAACACATATATTTTTCTTGATACT (SEQ ID NO: 268)

[000203] *Homo sapiens* dystrophin (DMD), intron 43 (nucleotide positions 1057082-1127546 of NCBI Reference Sequence: NG_012232.1)

GTAGGTAACACATATATTTTTCTTGATACTTGAGAAATGATTTGTTTTTCAGGGAAGTGTAGAATTTATTTTCAGTAC
 CCTCCATGGAAAAAAGACAGGGAAAAAGAGTATCACTCTCATTGAAAAATGGTAAGTAAATGAGAACAATAATG
 ATGAACAATTCAGACAAATGAGCTGAAGTGTAGAAATTTATTCAGTATTAAATTTAGCGTTATGTTGAAGCATTATAT
 CTTCTAAAATTTTCAGGTAATCGTAAATCAGATTGGGGCATTGAGGTGCTATAAACAGTTGTTTCGATATAACATATTT
 ATCTTTAGTCAAATCTGTATCTACAAATTTATAGGAGTTTGATACTTAGATTAACATGTTTTAAATACTACCTATCA
 ATAAAAAATTTGATTTTCATTTATTTATATTTTGGAGGGTGACACTTTACACTTTGCATTACCCCTCCCCACATTTT
 TTTTTGCCATGGGGAATTTGTTAAGTTGATTTAAATCATGTTTCTTTTTATCTTAATTGAAATATTTAGCTGTTGA
 CTTAATTGGGGGGTGGCAGAAATCAATTACATTATTTAGCTTCACATCACAAGAAGTGGATTACTCTTTCTTTTAC
 ATTTTATAGATTAAAGTAAATAAGTCTCTAACAGCTTAAAGTATTTCATTTCAGAAAGTCTTTTATCTCTCAAGGTAGG
 CTTCTTAATTATTTCTAGAGGAAATCAATCATTCGTCTAATAATTATAGGGAACCTCCATTGTTATCTCTTACATCT
 GTCCATTTCTAACCATCTTTACTCCTATTTTAGTTCTTGTTTACTACATCAGGCACCTAAAGAGAGATTTCTAGCA
 TTAATCTCAGTTGTCTCAAGTATTATCTCCACTTTGTTCTCAACGATCTTTTCAGTGGCCGTCATTTTTCTAAAGTG
 TAAGAGCTTTGGTACTATAATCTCATTCCCTTGAGAATGAAACCTGACTCCTTAATTGTGCAAAATTATCTGGTCA
 GCCTCACTGCTTATTTCTTCGTGCCTGCCCTATAGCAAGCCCCCTCAATTATGTTCTAGCGATATTAATCAATTTG
 CAGATGCCCAAGTGTGTTTGTACTCCCTCTGACCTGCCTGTTCTTCAGGTCTCACTTCAGATGTTGTCTTTTTCTAGA
 AATCCTAAACTATTAGTCGCTCCTAACATCTGGAACCTTGATATTGTTTCATCATTTAATGTAATTTAATATCAA
 TAAATCATTTATGCATTTGTAAATTTCCAGACTTGGTGGCTACCGTGTAGAATATATGATCTGATGTGCCTGCTCC
 TAAAACCTAACACATAGTAATCAATTTGTTTACTTTCTGCCTCCACACAAGCTCCTTATAGAAAAGGGCTATGTT
 TTATTTGTGTTATATGCTCAGGACTGATATAGTGCTGAGCACAAAGTGGGTGTTCAATGTGTCTGGACTCAAGCCTC
 CTCTCCGAAACCTGAGAATATTTCCCTTTGGATAGTCTACCAGATTTATCTCACTGCACCTTCCAGGGCAGGTGCG
 GTGGCTCATGTCTGTAATCCAGCACTTTGGGAGTCCAAGGCGGGCACATCATTGAGGTGAGGAGTCCGAGACCAG
 CCTGGCCAACATGGTGAAACCTTGTCTCCATTAAAAATACAAAAATGACCTGTGCGTGGTGGCATGCGCTTGTAGTC
 CCAGCTACTCGGGAGGCTGAGGCAGGAGAATCCCTTGAAACCCAGGAGGCAGAGGCTGCAGTGAGCCCAAATCCACCA
 CTGCATTCCAGCCTGGGTGACAGAGCAAGGCTCCGTCTCAACAAAAACAAAAACAAAAACAGATTTATCTC
 AACTTCCTTGAAATAGCTGGTCCACAGTATCCAAAGCCAGGCTTGATAAAGGCAAGAACTCAGCCACTCTGTG

TATATGCTACAAATACAACTTAACTTATAAAATGGTGGCTCATGCCTGTAATCCCTGTGCTTTGGGAGGCTGAGG
CAGGAGGGTCACTTGAGCCCAGGAATTCAAGGCTGCCACGAGCCATGATTGTGCCACTGTACTACAGCCTGAGTAAC
AGACTCTCTCTAAAATAAATTAACAAAAATATTTGAATAAACTTATATCGCCACCATGGTGTACTTTCTCCCAGCAT
TTCACATTGAGACATTATGAGGCTCTGCGGGCTACTCCAATGATGTCAGTTTCATTACCATCTTTTGGGATGTTTCT
TCCACTCTTGGGAAGTTCTTCCCCCTCTGGTTTGTCTTCTTATAGTCAGTGTTTTCTCCAAGCATTCTAGGCCACCC
ACACCATCCCCTAAGGACCGTTGAGGTTTCTTGATAGCCAGTGATTACTGTGCTTCTATATACACCTACCAGTTTT
GCATAAAGTAGAAATAACGCTTTCTGCTTTTTGAGGTTTCTCCTCCGCTTTACTCATGAGTAATTTTTGGCAAATG
ATCCAGGTATTCCTTCTCACTGGGTCATATGGACATTTCCTTTTCACTTTACCTTCACCTTAGACTTAAACAGAAA
CACTAACGCCATTCCACAGAGAGGGTCTGCTGAAATCTCACCCCAACTCTGAGGACTTTTTCTGGTTTTGACAAAAGGAT
AGAGTTTTCTCTAGCCCCAATAGATCCACCCTGTCTTATCCAGAGGTTGAAATTGTACTTCCATTGACATTCTATAG
GAATTGGTCAGGAGCTGTTAAATTTTCTATGACTTTTAGTACAATCTCAGATACAAACTGTTTTAAGTAATTGCTTA
TAAGCACAGGCTCTAGAGTTCCAACCCGTTTTTGGAAATTCTGGCCTTTCTGCTATCTATGTGCCCTTGAGCAAGTCTC
TTAAATCTTCTGCTCCATACATTTCTGATGTATAAAATAGGATAAGAATAGTGTCTATGTCACAGGGTTGTTATGAG
GATTATCTGACACAATATATGTGGGGAGCTTAGTGGGTTGCTTAAACACGATAATGGCTCAGTTAAGGTTGGCAATT
TTGATGATGAAAATGGTGATCTTATGGTTCTGATAGTCATGATATCTGTTAATTCATTCTTACATGCTTTCAAATTT
CCCTGAGAAGTACAGAGAGAAGAATTAGACTCAGTCCCTGCTTTGAAGAGCTTCACAGTCTTGAGAGAGAAAAGGCAC
AACCAGCCAGTAAAATAAGGGTTGATAGACTGGAGCTGTACAAGAGGGCAAGAACAAGATCCCTGGGGAATGGAATG
AAGCTATCTTACTAAGAATGGGGAATAAGTCAAGGTCTATAGACCATTCAGGTTCTGAGTTACAACCTAACAGAAAAG
TGACTCTAGTTACTTTAGGTAGAATTATATAAAATTACTAGAAGGATATCAGATACCTCATGGAATCAATAGGAAAGC
CTGAGAGCTAGGTTTAAACAATGGGCAGAACTATAAAGGAAGAGCAGGCTAGGCATCCAGAATATATCTACTATCAA
GCTATGAGGTAAATCTGAATTATTTTGTCTGTCATGCCAGAGTCCATTGCTTTACCAGGAGCACCATTGCACTGGACA
TTGCTTGTCTATCGTCACTGCAAAAAAAAAAGTATCTAAATATTTTATTCTTGTCTGTGTCTCGTCTATTCTACAACCTAG
GGTCTCTGGCAGAAGCATCTGATAGTCAGAGGATGGATATTTTTTCTGTAAAGGGGCAGTTAGTCGATATTTTTGT
CCCTGCAGGTGATGTAGTCTCTGTGCACAACTACTCAACTCTGCTGTTTTAGGGTGAAAAAACCATGTATAATATAT
AAATGATGGACATGTTGTGTTTTAAATAAACTTTATTTACCAAGGCAGATGGCAGGCTGGAATTGCTGATGGGCCCA
TAGATTGATGACTGCTGTTACAATACAGGTTTAGGCCACAGAACTAGGTTCTTATTGCCAGAGATCAGGGAAAAATAA
ATAGCTGAATTTGTTCTTCTATTGTAGTGGCAGTCAACACCTCGTGTCTACTAAGTCCCATACAATGGTAGATTCTT
GAATCCTTGGAGAGATTTAGAAGCTATGCATTCTGAATACACAAATGTTTCACTACAGCCTTCATGTGGTGTCTCTCA
ACAAAAATCTGCTGAGTTTTTTTAGTAAGCCAATTTGGGTTAAATCAAAAATAAATTTGAGCTAGTAAGAAGGGCTATA
TTGGTATTTTTCTTAAATGGTACATGTATGGTAGTATTAGCTATGACCGCAATAATGCTGTGACACAAATCACCCCTA
GAACTTGTGACTGAAAACAACAGGCATTTCTGGCTGTTTAGGTTACTTGTACCTTGACTGACTCAGCTGGGCTTGG
CCGGGAAGCTCTGCTTCAAGATGTGGGTTAGTAGAGCTAGGTTCCATGATGCATGTTGGATTAAAGGTCTGCTATATA
TGTCTTTGCTCTGGACCTAAGATGAAGGGTCAGTGACATGTTTTTTCATGACCAGTCACCAAAGTATAAACCTAAACCT
CCCAAGAACACTCATGGCCTCTGCTCCTGTGAAGTTCACTGACATTTGATTGGCCAAAGCAAATTACGTTGCCAAAT
CTGACATCAATAGAATGAGAAAGTAGACTCTTCTACAGTGGAAGGGGGGAGAGATGTTAATATTTGCTGAACCATA
ATTCAAATTATTAGAGATAGTTAATAATTTATAACAGGATTGTTTTACAGCTAGAAAATGCCTTAGTGGTTTTGCCC
TGCTTCATTATTTTATAAGGGAGAAAACTATATTTCAAAGATGTTATGTGACTTGCCTAAGCACATACTAAATAGTA
CATCTGCGTATTTCTCGTTTCACTCATCTCTATTAATGTCATAAGGTAAAAACAGACATTACGCTTTAGATGAGAACA
GGAAGATATTTAAAAAGCCAGACTAATTTATGACTGCTCATTCTATCTAACATAACCTGCTTCCATACATTGTCTT
TCAGCAAATAGAATTTCAACATGTATCTCAACAAGTTACACATCATCAAAGTATTTAAAGCCTTATTTTCACGGACA
TTCTGATTGTTTCACTAACAGTCAACACAGTCAACAGTAAATCCACAAGCACCATGAACGTATGGATAGATATGCCATA
TATGAAGATTACTAGTTAACTTTTTGGGAAATTAATATTACTGCTAAATTCAGTTTTTCACTTATTTTCGGGTGGGT
AACTAAGTCTTATAAAATATACCTATAAGGAAACATGTAAGAAACAAAGAAATTTACATAAGATCTATCTGGGATTAGA
GAAACAAAGCTCTTTTCTTCTTCAATGAACACTTAAGAGGGCCTACTAAATGTGAGATGTTTACTCTATTGTCTG
TTAGTTTTCTTCTGATACCATCTTTACTATCTGTGAAGCCATTAGTGAGTGTTTTCCCACTTTTAGAAAATGACTTCC
CAAAGACTAAGAGGGTAGAACAGTTCAAATGCTATCATCAAAATGAAGGCAGTTTCTAGACTACAAATTGCTGTACA
GCCATAAGATGGCATTATTGTGTAACAACAAGGTCCCTGTCAAACATCAAGAAAGTAATGTTTTAAATCAGTATTT
CCTTCTTGGAAATTCTACTTAGTCAGATATGTTGGGTTGACTTACCCACCCATATAAGTAGTTAAATTCAGATGGTT
CTGAGCTTTAGATATGATGTAAAATAGACATGAGACTAAGAGTATTTATTTCTATATTATTACATTTCTATAGCAAA
AAAAGAAACCTCTAAAAAAATTAGAGAAAGAAGTATAAGGGCATTTAATTAATCAAATGTTCTTATTAATAATATTT
CATAAAATAAAGGAAATGTTGAAAAATAAAATATGAACACAGTGTTGTATAAAGTAAGTCAGAAATAAGAGAACACT
TACTGTATGAATCTATTATATGAAACTAAAAAATTAGGCACCTTTGGAGTTTAGAGGTCAGATAGGAGTTACCTTTGT
GAGTTGTGATTAAACAAGGGCTGAAGCAGGCTTCTAGGGACTGGGTAATGTTTTGTTTTCTTGATGTGGATGCTGCTTG
CATTGATGTGTTTTCTTTAGGGAAGTTTATGGAACCATACACTTGTGATGTGTACACATTTCTGTGTGAATGCTGGA
CTGAACATAAAATTTATACTTACATTTTAAAAATAATAAATATGTACTTTAAGTACAGGAGGGACATAAATCATAATT
GTTTTAATAAAGAAGGTGTAGCTTTAGGAAAAGCATACCGCATTGTTCTATTTTTGGCATTTTACCATGGACCCCTG
AACATTTTATAATTGCCAGTACAGCCTGTCAGATAAATATGTGGGCACTACTGCTTTAGAGAAAGTATTTTCCAAA
TTTATCACCACTTCTGGAACCACAGTTCACAGGTCATTAGGATGCTGAGGGTGGGACAGTTGGAAGCTGCTTCC
CCAGGCAATTTCTCCATTGTTTCACTTCTCATAGCAGTAAGCCTGCAGCATTAAGCACTACAGGCTCTGGCTGCCAT
TTGTGCTACATGAGAAATAAGAGAAATGAGAAATGAAAGAAACGAAAGGAGAGAAAAACAGGAGTAGAAACCAATAAATCAG
ATTGCAAGAGAAAGTCCCTAATCGTCTCTGTATTTCAGACAGTAGGGGAATGAGCATGCAATTTCTGCAAGCCCATTCCT
AATGTGAGTTTTCTGATAAGAATTTGCTATCTCAGTTGTAATCTTTCTACTGAGACATTCAATAAATAATTTTCTTTC
ATGTCAAGGTAAGGAAATAACCTCACATTACCCATATAAGGAAAGAATAGTATACTAATCCTCACGTTATCACTATA
GAATTTTATCTTTTAAAGTGGAAGCTAGAGGGACAGATGCATAATCTGGGAGCTTTTCCAGAATTGTTTGTTCCTAA

75

TGTTCTGGTTTTTACCCTCAAGATCTTCTTTGAAAAATCATGATTACTAAGTAACTAGTTGGATAGAATTCATTTTT
AAGAAAAATAATGAATAAGTAGTTCCCTTAGATATAGCAAGCAATGTTCTTATAAACTGACACACCAAAACACTTACC
AGTTCACCTAAACACTGAAAGTATTTAAAAATTTATTTTTAACTTTAAGTTTTCTCCATTTGAGTATCTTGTGCA
CTATACGCTCTCCTACATATGTCTACAATCTTTGGTCTGATTATTTTTATTGGTTGTTGAATGTCAGAAACCACCTG
AATTTTGCTTGTATATATAATGCCAGTAGAGTGCACATTGGTAATCAATACGACTTGATGATAATAATGGTAATGA
ACACTATAATTTGATAGCATCAACTTGGCATGTATGCCAGAAAATAAACCATCATAAACTTCGAGAAAAACAAGTCTC
ATTAATCTGTCAATTTATTATAATCTCCCTCCATCAAGCGTAGCCTCTATATACTGTCTTTTTTGGCATATGTAAGTT
TCTTCTTGATATATTTAGATTAGAGCTTGCCTCCTCCACACACTATCTTCTATTTACACTGCTCTGTTCAAGTGT
TTATGTTTTCTGCTGAAGGCTGTATAATCTAAGATAAATCCCTAGCTATTGTAAATATCATTCACCTGGCCAGTCATTGC
ATTTTGCACACCACTGAGAGAGTGATTGTGAGCCAAATAGAGGAGATTTTTGTTTTCCACCCAGCAACCCAAAATGAAT
TGTGTGATTTGACTATTGATGCCAATTACATGGAAGTTTTACTACCAGAGGCAAAGCTTTAACTGCAAAAGATTAA
CCCCATATAGTTGGTGTGATGAGGTATTTAATGTATATTGGACTATCAAAGCGTCTCCTTACAACAAACCAATTATC
AATGAATAATATTCTTATCTTATTGTGACTTATTGAACTCTTTAAAAAACATGAACCATTTCAGCACACTATACCGT
CTAAATTAGATATCTAACTAGCCTTCATTTACATTTCTTGTGTTAGTTTTAAATATAATTTCTTCTGAATTCCTAG
TTGTTAAGAGCAGGTGGTGAAAGAATTTAAAGAAGAAAATTTGTTGTATTTATTAAGTGAAAGAGCTTTTTGAAATG
CATTAAATAGAAGTTTGTCTGCCCATCAGCTTATCTTCTGCATATTCCTATTTATAGTTCAAAGCACTTAAGAGT
TGCAGAGTGATTTGCTTTTTATGATCACCGCTTCATCCAGGATCATTTGCCTTATATCTTCAACATTTTCAGATTCT
TATAAATCTTCACAGTTCACTTAGAGGTTAGTTTTAAACTTTCTTCAGATAAGAAATTGACTAGATATAAAATTCAC
ATAATCTCAGAGTTAGCCATAGATCAATATCCCCAGTCTTTTTCTCAAAGTAATTGAACATTTTTGTTTTCCAGGAT
AGTTGTATACAAGCATTTTCATCCTCACCATAGATGATTCTTGTCTTCAGTATATGAGGGGACTGTATTTGCCTGC
TTGTTATCTAAATAAACATTTTTATTATTGTCAAAGGAAAAAGACTCTAATACAGAAAGAAATTTGTGTCCATAGG
ACTAGCCTCATTTTGGAGGCTGATATTAATATTGACTTTATTCATTGTGTATTTCTTGGTTTTGTCAATTCACAAA
TTTCCCTTCTCTAAATATGCATTTTTTCTCTACCTGGAATAGATGAGTTTTAAAAGACATTACTGTAAATAAACT
GTGCTAAATGTACTTTTCCAGAACTCTCTTATTTTATCAATTATAATTTGCTTTGGCTAAGTTTACAGAAGCT
CAAGGTAGAAATGACTTAAATAAAGAGAAGCCTATTTCTTCTCTGAAAAACCCTGGAAGTTTGCAGCCAAGGCA
GATATGTTGGCCCCGCTCATTTCTGTTTTCTACTGAGTGAGTTATCTTTACTTGGTGGAATTTTCATCCACATGTTGC
AAGATGGAGCTCTCATGACATCCACATTCCAAGAAGGATGTAAGAAGGCCAGAAGAAGGGTCAAAGGGTGCATACCA
ATTGTCTTTTAGGGAAGTTTCGTGGGAGCTGCCATGTTATATTTCCACTTACGCTTCATTGGCCAGATGTCTGTCAC
ATGGCCACATCTAAGCTGCAAGTGGGGCTGGGAAATGTGTTTATTTACATGTGCTCTGCTAAAACTGTTTCAGTCA
TGAAAAAAGAAAAAGAATATTGGAAGAGAACTAACAGTCTTCAACATGTATATTTAAAAGAGCGTTATTTTTCTT
TTACTTATTTATTTTTTTTTTGTAGTGAGAGTGTTGCTGGGGCTGGTCTCAAACCTCCCTGGATGAAGTAATCCTCCCAC
CTCAGCCTTCTGAGAAGATGGGATTACAGAGGCACACCACTGCACCCGGCTCCTGTTTTGTTTTGTTTTGTTTTGTT
TTATTTAAGGAGCCCTAAGAAGAGTGTAAGAGGGCACTTTGTCTTTAGTTAACCTTCCCTTTTTTTTTCTTTCC
TAATTTTATGAATCTGATTCAGCCCGCATCTTACTCTGGCTTACTAAATCTGCCAATATAAGAGTAGAAGTTTTC
ATCATTTCCCTAGGTACCTACTCTTCTGTTTCTCCATATCTCAAAGTAATTTCTCATTTCATCAACTTTTGTCTGAC
TTAGATTTAAGCTACTGCTTAGGAAATGTGAGAAATGGAGAATTTGGTTGTATAGCGCTCCTACTTAGAGGGCTAA
TGCTTTCTAAATTTTACTAAAGTTGGATCCTAAGTTATATAAGTTACCTAAATTTAATTAGCAAGTTTTGCTTACT
AATTCACTGACTAACCACTATAAAACAAGGACCTAAGTTTAAAGCTGATATTATGACAATGTACTGAAATTTCAAGA
CATTACTTTTTCTGGACACGTAGGATGGACCTTGCAATAAGATAAAAGAGCTTATTTTTAGGCACACCTATGTGCCAG
GCATGGGTTTCAGAGCCTTACATATATCATTTTCTTCAAGAGAACCTTAATTTTAGAGACGAATAATTTGAGTTT
TAGAATAAATAATTTGTCTTAAGCTCACACATGAAGTATGTGCCAGAGTCTATATCGTGACCCAGTTATGAATTCAT
TTCCACTACATAGCCTGCCCTCCATGCAATTCACATAGGATTTCTTATGCTCAAGGATTATGTTCTTCCCTCCAGT
CTATAGACATCAGTAGAAACAACACAAATACGTATAATGACTTTTTAAAGTCTCATATACAAGACCAAGTACTTTA
AAAAGATGTTTAAATTTTTGAAGGTGATATCTTTATGTTTCGAGATCAGTAGCAGAAATGGATTGTAATTCATTACAA
GATGCTTAGCAAAGCCAAGTGGTAAAGGATTTTCTGATGTGCTTGAGGAGTCCCTGACTTGCTCCTTAGCAAATTCCT
ACACACCATTTCAGCATTTCAGTGCAAAATACCACCTCTTGAATCCTTCTCTGTTCTTGATCAATTTCCATTGTCTG
GATTCATAGAATCTCTGTTTACCTATTTATCTTACAGGTTATTTATCATGAGTTTATATGCTTTACATAGCTGTTTG
CAACATGTTACCATTTCAGTGGAGTACTTTTTCTTACAGGGAAGAGGCTGTACTATATACCTTTTGTACCCCTAAGT
GGAATGCAGTATGGTTTCATGTTAGATGTTCAATACATGTTAATATTTTATTGATGAGCCCTTAAATGTATATAATA
AGCTTCTCACTCAAAAGCTGTAATATTCTAGAATGAATAAGTTTCTTGAGAACTCTTTGGTTAACAGAATCTCCAT
TTCCATCATAGTGTATTCAATAAATTATTAATGCAGGGTAAATTTCTTATATTTCTTTTCAATTCGCTATACTAAG
GTCAAATCATGACTTTTAGGTGTGGATACAGCAATATATAAAATAATCTAAGACCTGGATATATGTTTTCTAATTA
GGGAATTGGAGATACATGAACAGTCTCTCATAGAGAAAAATATATCCATTAGTCACTAAAGTCAGTATAACATTCTG
GTGAAAGGTTTGCTTGCTTGCTTGCTTACTTGCTTGTTTACCTTCTATTCTAGGAGGATGTTTGTACAAAT
ATGAAATTCTAACGCTTTAAAAATCTGTTTACCCTATGAAAGTTGCAAATTTCTTGCTGTAAGGCAATTTTCACAAG
AATTATTTTCATATTAGTTTTAGTTTATCCGTGGATAGTCTCAAATTCCTCTTGAAAATATCAGTGTTCTCAAGGGA
AACTGCCCATTACAAGCCACAGATGTGGTTTTTGTAGAGATTTCTGCCTGAAATACAAGTTTTAAATATTCTTTG
TAGTTTCTTAGTATGGCTAGATACTTGTAGGAAATGACAATTTAGATGCACATTTGAAAATTTTAGCCTTTGAGTA
ATTTATATGTTTGAATAATTTTAACTACTTCTTGTCTGATAAAAGGCAAAATTTGTCTGTTTGTCTTGAATGCTTT
TTTAGTTTCTTCTTCAAGTTCTTCACTTGCTTTCTGTAATATTCAAAATTATAGCATAGTACTTTGAAAACCAAGGA
TGGTCCAGTCTGTGCTTTTGTGTTTGAAGGAATTTTGAAGATCATCAGAGATATAATTTCTGGAATTTCTTTGGGTACC
TTCCATAAAATAGTAGCATCCTGATAAGGACGTAGATGCTAACTTTTATTTTTATCTCATTTTCTTTCCCTATCTC
TCAGTAATGTAGGAGTGACCAAGGTAGCTGTTTATTGGGCCCTCACCAAGTCAATCAATATTAGTCAGCTACAAC
CACAATAATGCTGTGTGACAAGCATACCCCAAAAGAACATAAGCACTTATCCTCATATTCACAGGCCTACTTTGAG

TAATCTCTGATTGAGAACTCTGACTGTAGGTTGACCAAAACATGTCTGATCTATGTGTCTCATTCTGGGGCTCAAGCTG
GAATGGCAGTAGATATTTGGGGCACATTCTCCATGGCTGAGTTCTAAAGATCTCAGAAGGGTAAGCAGAAACACAT
GATGGTTCTTAAGACCCAGATTTATAACTAGCGTTCTCTCTTCCATCCATAGTCAATTGTCAAAGCAAGTCACGTGG
CATATCCAAAGATCAGGGATAGAGAAATACACTTGGCAGTTAGTGAAACCCATTTCAAGAGTGTGGGTGTATAACACT
ACTACAAAACAGAACTGAGACTTGCAACTTGAAATACCACACCATTCTAGTAGAATTTTATTACAGTATTAATTAAA
CATTTTTGATAAAACACAGACAACTCTGTTAGAAAAGCCCAACTTACAATTTGTTGATCCCACTTGGAAAGGTATTCT
GAATCCATTTTTTACAAAGTTTTCTTCTAATTCATGTGTTGGGGTACTTTTTATTTTACCCAGAAAAGTAATATTA
TAAAGCATAAAGTTAATGCCCCCTGTAAAAATAGAATACTGAAACAACTTTAAGTCACAATTTTATTATTACTGA
CTTGAGAATCTCCTTGTGCTTCAGCACACTTGGTAGTTGGATTTCCAAATAGCATCATGACTTTCCATACCCAGCTG
TCTGCTGCTCAAAACTACCATAAGCTGACTATCACAGCTCACAGGATACCCTTGAAGAAGACCATCTGGTTTATGTC
TCTTGGCAAAATTTGTTTAAAAACAAGCAGCTGCATGACAAAAGTAAGAAAAGAGTCTCTGTCTAGCTGTGGTAAATAA
GTAGCTTTGCAATACTCATAATAAAGCATTTTTCTAATCCAAGCCAACATCTTCAAAAGGAAAGCATTATTTTCTTA
CAACTGAAAGAAAAATCTACAGAATTCAGTGATGAGGGAAGGACTCCATTAAATTTGTTTCAGCAGCTTGAGATAGT
GAGAAAAACAAAACAAAATAAAAACTGTTTGTGATTAGATACAGTCTTGTAATAACTAGTTTTTAAAAGTATTTATT
TAGAATCTAATACTTGGATATTATTTAATTCTTTATATTAAGAGATTTACATTTTCAAAAAGCTTGTCCTTTGAAC
CCTAATACTCATATTGTGATGGTGAGCCGAATGAGTAAGGTCATTACTATATAGTCGGTATATAATAATTCTGTTG
AATAACTCTCTCTCCTCTGTTACTGGCAGTGAATCCATACGGGTCTTCAGCAACCTTAATTCATGCCTCCTCAGAA
GAAAGAATTCGACCAAGGAGGCATAAGGCAGAAAGAGAGACTGAGGCAAGTGTTAGAGCAGGAATGAAAGTTTATTT
AAAAACTTTAGAGCAGAAATGAAAGGAAATAAAGTACATCTGGAAGGGGGCCAAAGTGGGCGACTTGAGATATTAAGT
GTCCTGTTTGAACCTTTGATTTATGGTTTTGTATTTTGGCATACTTCCATGGTCTTATATACTTCTCCCAATTCTT
CCCTTGGGGTAGGGGGCTATCTGCATGCACAGTGGTCTGCTGACACTTGGGAGGGGAGCATGCACGGTGTATTTACT
GGAGTTGTATTCAAGAGGTGTTCCCTTACCAGTCAAGTGTTTCCAGAGGAAGGTCGTATACCAGTTACACTATGACA
TTTTGCCTCTTAGTGCGCACGCGGGAGCCCATTTGCCCAACTCCTGCGATCTTATCGGGAAGCTGCTGATCACCAT
TTCAGGTGTTTTTATCTATTGGGAGACTGCCTTTCCCTGGTATTGGCTGTGACCAATTATTATTTTAAAGACACAGT
TTAATAACCACTGACTGACCATCACTTGATGGTTGCTTGACATTCTGGTTGGGGTGGCGGGGTGGGGGCTTCC
TACCCTGCTCATATCTGACTAGCTATCTACTGTAACTACTATTTAGGTATGTCTGTATCCCATTTACACTCACTCTC
TATTACAAAAAGAGTACCTTATTCATTTTTTCAAAAAGATGAGTGAATTTTCTGCTCCAGTTAAGTGCTTTTCCTTA
CCTCTATGTAGAGTGTCAAACTAGCCATGCTTAAGGATTGATTCTGGTATTAATAATATAAATTCTTGCAATTATGAG
TGTCTCAGTTTGGGTCTTTACATAAGCAAACTCTGAGACAAGGATGTGAGTTCAAATAGTTTCTTTGGGCAGTGATT
CTAGGAAGCTGTGGTAGGATGTTGGAGTTGTGAGAAAAGTTAAGAGAAAAGCAACCTGTAAAGAGTATGTTATCAAGCC
AAACACCACTGTGAGAACTAGGGCTTAATTCCTGGAGAAAAGTCTGGGAAGGCATAAAACACTTGTCTCAGAGTTAT
CTTAGACAAGGTGCAGGAGCTGAGGTGTTTATATTTCAACTCTTGTTAGTCACTTTTAAAGGGCCGCTCAGGGTGTG
AGGGTATTAATTTCTCTTGCAACTACTTCCAACCTGTTTTTGCATGTGGTTGTAGCTACTTTTTCTGCGTCAAAGA
TAGACTTTAGGCTAAGACATGCAGTTTCCGGCTGTAGGACATCAACCAGAGTACCCTGGAGTGTCCAGGCCCAAGAT
AATGGGTGAGCTCCACCTGGATCTGTGGCAATGTGAGGGAGGGGCAATATTACCCTAGCAAGGGCCACTGCATTCC
CTATCCAGCTGGTCACTCTTCTGCGTATTTGTGTTACTTTTTCTGACTCCTGCATTCTCTGGATCCTGATTACCAT
CAGCTTTTGTATTCTGAGGCTTGTGTGGCTGTGTCTTTCTATTTCTTCCCTTATTGACTTACTTGTTTAACTTTTGC
TAATGTATACCTTTGATATTCTATGTACTCACCTTTGGTTAGCTCTGTGAATTATTGAGTCTTGCTTTACAGCTTT
AAAAAGATCATAGCCATGGTTTGTTTTTTAAAGTGTGATTCAACAGTTAGTGACAAAATTAGAAGTGGAATTA
GGTCACGTGCACAATCCTACACAAGCCAATTTCTGAAACGACATAAAAACTTGAATTTGTCTTTTACTATCACC
TATAGAAAATATTTGGGGTATTTCTCAAAGTATTGATTAAACAAAACCTTTATTTTTGTGTGAAGATTTTTCAGT
CTCCTGGAATATTTCAAATTATTGTCTTTAAAGTCAAAGGAAAGTTAATATTAGGGTTACTTTTTCTTTGGTCA
GAATTGCTGGAGGCTTCTAGCTTGTCTTGAAGCAGCTGACTTTATGCACAGTTTTTGGTTAGAAATTTCACTACCA
TTCCAACATTTTTCAAAGTCTTAAAGACCAAAAGTACAATTTTGAATATCCCTAGAGAAAGCAAGAAATAAATTAG
TTTTCACTAGAAATGAAGACAAATTTTTCTCATTAGTTCAATTTTGCTCATGATCAGAATTTCTTGCCACATGAAAA
TATTTTGGTTAATAGGTTGTAACATAAAGAGTAATATGAATAGAGATCTAGCCCAATTAGATGACAGAAAAAGAGCA
AAGCTTTTGAATGTATAAAGAAGAAAGTTAAGAGAGACATGAACAAGGCTGGATGTAGTTTAAAGGTTGAAGAACA
CAGAAAAATGAGATAAGTGAAGTTAAGTGAATACTTCCCTTACTGAGAAGAAAGAGAACTCAAAATTATGTGAAG
GTTTTTGTCTTACTTTGTTTTGCTTCTTAATAAGGAAACAACAGTGGCAAATCTGGGGCATTAGGAATGGTGAAC
TCTATAACAGTGATGTTTCAAAGGTCACAAAGGAAATTAATTTGTAGATTGGGTTTAAAAGCACTGGAATTACTTCC
AGCCCCATTTTTTCAAGGATTTTGTATGTAGCAGGAAATAGATCACCGCATAGCTAAAGGGGAGAATTTAGGTTTAA
CTGGTCTCAGTGCAAACTGCTTCATAGTTCTTTGCATTTGGTGGTGTATGTAAAACATGAAAGGTATAAACATTTA
TTATCATAACTTTTATTATTATACAACATTTTATTGGCTGCATAGGACCATGTGTCTTCTTGCAAGGTATAATCAAAAA
TAAAAAGACAGAAATGTATCTTATATGAAGGCTGCCATTATCGCTCTTATCAATGGCCATAAAATCAGATTTCTTAC
ATGTACAACATATGAAAATATATTAATATGAAACGTTTTCCATTAAATAATTCTGTAAATGATTTTCATAACATTT
CTGTCCATGATGTGTAATCTGTAGATCAAATACTGCAAGTGACAGAACTTAAATGCTTTGGTCAAAAAATTTCT
CTTATTAATATGACAATGGCGTTCAAAAGTAAAAAGGTAAAAATACAGTTTAGCATTAATAAGTAACTCAGAAAGT
AAAATATATTGATCATACAGTCTGTATTAGTCTGTTCTCATGCTGCTCTAAAGAACTGCCCAAGACTGAATAATTTA
TAAAGGACAGAGGTTAATTGACTCAGATTCCAGATGGCTGGGGAGGCTCAGGGAAAACTTACAACCATGCCAGA
AGGGGAAGCAATCAGATCCTTCTCATATGTGTGCGAGAAAGGAGAAGTGTGAGCAAAGGGGAAAAGCCCCCTTATA
AAACCATTTGGATCTCATGAGAACTCACTATCACAGAACAGCACCATTGGGGATAACCGCCCCGTGAATTCAATTACC
TCCAACCTGGGTCCCTCACATGACACATGGGGATTACAGGAACTACAATTCAGAATGAGATTTGGGTGGGGACATAGC
CAAACCATATCATTTTATCCCTGGCCCCCTCCCAATGGCACGCTTTCACATTTCAAAACACAATAATGCCTTCCCAA
CAGTCACTCAAAGTCTTAACTCACTCTAGCATTAACCCAGGAGTCCAAGTCCAAGTCTCATCTGAGACAAGGCAAG

TCACTTCTGCCTAGGAGCCATAAAATCAAAAGCAAGTTAGTTACTTTCTAGGTACAATGGAGGTACCAGCATTGGTT
AAATACACCCATTCCAGATGGGAGAAAATTGGCCCCAAACAAAGGGGCTCCAGGCTCCATGCATGTCAAATCCAATGAG
GCAGTAATTAAATCTTAAAGCTCCAAGATAATCTCCTTTGACTCTGTGTCTCACATCCAGGTCACGCTGATGCAAGG
TGGGCTCCACAGCCTTGGGTAGCTCCACTCCTTTGGCGTTGACAGGTACAGCCCCCTTCTGGCTGCTTTACAGG
CTAGCATTGAGTGTCTGTGGCTGTTCCATGCACACGGTGGATCAAGCCCTCTTCTCACAGCTCTACTAGGCAGTGCC
CCAGTGGGGACTCTATGTGGGGGCTCCAACCCACATTTCTCTTCTGCACTGACCTAGTAGAGGTTCTCTCTGAGGG
CCCCATCTCTGCAGCAAACCTTCTGCCTGGATATCTAGACATTTCCATATATCCTCTGAAATCTAGGTAGAAGTTCCC
AAAGCTCAGTTCTTGACTTCTGTGTACCCACAGGCTCAACACCACATGGAAGCTGCCAAATCTTGGGGCTTGACCC
TCTGTAGCCATGGGCTGAGCTCTATCTTGGCTCCTTTAGCCATGGCTGGAGTGGCTGGGATGCAGGGGCACCTAGTC
CCTAGGCTGCACATAGCAGGGGGGCTCTGGGCCCGGCCAGGAAACCATTTTGCCTTCTAGGCCTCTGGTCTATG
ATGGGAGGGGCTGCCATGAAAACCTTCTGGCATTTCCTGGAGACAATTTTCCCATTGCCTTGGTGATTAACATTTGGC
TCCTCGTTACATATGCAAATTTCTGTAGTCAGATTGAATTTCTCCTCAGAAAATGAGTTTTTCTTTTCTATTGCATC
TTCAGGCTGCAAATTTTCTGAACTTTTATGCTCTGCTTCCCTTTTAAACATAATTTCCAATTTCAAACCATATCTTT
GTGGATACATAAACTGAATGCTTTTAAACAGCACCCCAAGTCAAATCTTGAACACTTTGCTGTTTAGAAATTCCTTCC
ACCAGATGCCCTAAATCATCTCTCTCATGTTCAAAATTTCCACAGATCTCTCGGACAGGGGCAAAAAGCCACCAGTCT
CTTTGCTAAAGCGTAGCAAAAGTGACCTTTACTACAGTTACCAAGAAGTTTCTCATCTCCCTCTGAGACCACCTCAG
TCTGGACTTTATTGTCCATATCACTATCAGCATTGGGTCAAAGCCATTCAACAAGTCTCTAGGAAGTTCCAAACTT
TCCCACATCTTCTGTCTTCTGACCCCTCCAATTCTCTAGGAAGTTCCAGAGTTTCCCATACTTTCTGTCTTCTTC
TGAGTCTTCCCAACTGTTTCAACCTCTGCCTGTTACCCAGTTCCAAAGTTGCTTCCACATTTTTTGGGTTTCTTTATA
GCAGTATCCCACTCTCTGTGGTACCAATTTACTGTATTAGTCTGTTCTCATGCTGCTATAAAGAACTACCTGAGACT
GGGTAATTTATAAAGGAACGAGGTTTAATTGACTCACTGGTTTGCATGGCTGGGGAGGCTCAGGAACTTACAATC
ACTGTGGAAGCAGAAGCAAACACATCCTTTGTACATGATGGCAAGAAGGAGAAGTGCCGAGCAAAGGAGGAAAAGC
CCCTTATGAAACCATCAGCTCTCATGAGAGCTCACTATCATAAGAACAGCAGCACGGGAGTGACCACCCCCCATGAT
TCAGTTACCTCCCACCTGGATCCCTCCCATGACATCTGGGGATTATGGGAACTGCAATTCAAGACGGGATTGGGTGG
GGACACAGCCAAACCCCTACTGCTTTAAGATCTATGAATTTGTTTTCTACATTGAAGAAATTTGTAGACATTTG
TTTTTATTCTCTTTTTGGTTTTGCTGAGAGCAGTAGTCTCTTGGAAAGTGAGTTTCATTTACATTTTTTCTTTGGGT
GTCAAATATATAAAATATTTTTTAAATCAATGGCTGAGGGATAAATGAGGGTTGGTAGAAAGGGAAAGGATAAGGG
TTGTAGTTAACGGACCATGTTTTAATGTGTCTATAATTAGATGGAAGTTGTCTCTTACCATTCAACATCCTGGATGG
CCTTCTATAGAGGACATTTTCATCTTCTTTTGTCTGTCAGAGCTAGCATATGTGTTTCATGCTTTTAGATAGTGAA
AATCAATTCAGATTTTCATGAAAATGCTCTCTCTTCACTTAAAGACAGAATTGTCACGGCTATTTCTGTTTATTGA
AAAGTGAAACCTGCTACAGTTAGCATATAGTTAATTCATATATGTTACCTGTATCATTTAATACATTCACAAAGTA
AAAAACCAATTTTGGCAAGTTCTTGATAGTAACAATAGTAAATGGAATTTCTGTTGGCATATTTTCATGTTATTC
TGAAATGCTGAATGGATTTATTAAGATTGATAACAATATGTTGTACCTTTATGTTCTAAAATTTAATAACAGTTATT
CTTCCAAACATGCCAGCGTCTCAATAGTTGACAGCTCTGCAAAATATTCTATTATGCAATCAGCCATATCTCCTTCT
TGAGCTTTCTTTAAGTACTTGTATCCTGTATTTTTCCCTGAAATCTAGCAGTAAGTTGAAGAAATGATAAACAAAAT
TGTATCATTGTATATAATGGCTATTTATAAAATACTGATGTACATTTTCATAATGTTATTTAAATGATTACTTCAGAT
ATGTATTTCTGTTTTCTACATTTTAACTTCTCAACATATTAGGTTGTTATCTTAGATTGGATTTTCTAAGACATAGA
CTCTAAGACAGAGATTTCCATGCAGATGGTTTTCTTAGTGAGTGCTTTTAAAGAAAAATGCCGGGAGGGAGTAAAGGC
AGCAGGATTGAGGAGAGAGAGGAGTTGAATGATGATGCAGTGAAATGGAAGATCTTATCTGGTCCCATGTGGGGTTG
GGATGACCATTTAGAGTATTACCGTATGAAGCAAGGAAGGTGGACCATTGTATCCCTAATCCATTAGTCATTAGATG
TGAGCCTCCCACTACCAGCTTCCGGGCAATATCATCTTGGTCAAAGAAGTGCTGTCTGCTGAGAGAAATTTCTTG
GAAGAGCTTAGGTAGTCTGTTAGTAGATAACAATCCAGCACTGGGAGAATGAATGCTTTCATTTGTAATTTGGTG
AATCTCGGTGGCACACCAGTGTTCTGCTACGGTAATCTTATACTTATTGAGACATATATTGTTTTTAAAGTAAAC
TTGTATACCTAGTAATGCATTTAGGTAGTGATTGGCCAAGCTAGTCTTTTGGAAACAATTTTCATTGTGGTATAA
ATGATATACAATAAGCTACACATTTAAATAGTACAATTTGATAAGTTTTGACATATGCAATACCAGTGAAACTATT
AGCACAGTCAAGATAATAACATATCCAATATCCTCACAACTGCTGTTTTCGGTAATCACTCTCTCCTGCCCTCCCT
TGATTCCCAGGTTACCACTGATGCTGACTGGCATTATAGATAAGTTTGCCTTTTATAGAATTTTATAAAAGTAGAAT
CATGAAGTATGTACCTTATTTCTGGTCTGCCTTCTTCACTCACAACTACTAATTTTCAATTTTGTGAATAATATGA
TCTCCGTGTGATTACACACATTAAGAAAGTCAATAAAAACATTGTAATTTGATTCCGATACTAGTTTATGGGTCTAC
ATTATGTATTTAAAGATACTATCATGTTTGGATTAGCCCTTAGGTATCAAGTAACCCTGGAGTTGAGGCAGTTACTG
TTTTATTTGCTATCAATCTTTTTATAAGCTCACCTTCCACTAATTACCCAAAAATATTTGATTTAATACCTGAGTAC
AGAAAAAGAACATATTCACAATGTTTAAATTTTATAATTTAATATATAATTTACAACAGTTTAAATAACTAGTCC
TGAAATTGAGTATTTCTCACCTAATATTCTGCTCTATTTATTACCCACTCCACGAAAAAATTTCCAGAAAAATCAC
AAACATGTCTCTTGAGTGTATTATTACCCAACCCACAGAAGAATTTCCAAAAACAGTCGCAACATTTCTCTCTGAG
TGCAACCATTTTCTCGGGCCAGCCATTCATTGAAACAAAATAGCCTGTATAACTTCTGTGGGTAGACATTTGTAGGT
TGTTCTTTTGGAGCATTAGTGCTATTGCATTTAAGATAAAGAAATAACGAATTCACAAATTTTATAAAGTTCTCTTA
AATTTACCAAGTCAATAGCACCACTTTGATTCTATAACCTGTGACTTAGTTAGGCTTCTCAATTTCAAAGAACA
TACCACCATTTTCTTATAATGTCTCAGATTAAACATGTGTTGTCCTTTCTTTATACCTCCCTGCACTTTAAAT
GAATATTTTGGCATTACTGGATTCTGTACACTTTTATGTTTTTCATGCCCTCCCTTTTCACTTCTGGACATCAA
TCGCAAGTCAGTAGATACCTTGAAGAGACTCTCTCCACCCAACTCACTGTTTCTTTTGAAGAGTTAACCTTTCT
GAAGCAGCACTCCTGCTTTCACATTTCCAGCAGCAAGAACCTTCAGTGTTTCTCTGTTGATAGCTTTGATTTCAAACG
GGTAGCCCCAGGAGAAAAAGAGAGCTGAAGGATATGTTTTGCTTGGCTGCTTTGTTTGACCTGCAAGGAACATTAATA
GGCAATGAAACCGGGCAGAGACTGGACTGATCAACACCATCAGTTTAGCACTTATTGCTATACTTTCTAAGGCTTTA
CAATTTTATGTGTCCACGTGTCCCTGAAGGCATTTGATTTTCTAACCTCCTAGGCCAGAGGCTAACATCCAGAAT

TCATAGTCTGGCACTTATAAACCCCTAACTTAGCTTCTGTCACTTGTATCTCTATGCAACTCTACAGCAAAATGTACT
TATTTTCTCTAAAATACCCCTTATTCCATACTTCTTTGGAGTGTAATTTTATATATAAAAGTCCTCACCACCTGTAAA
CATTAGGAAGCTTTGATTGCGAAGAAGCAGAAGCCATCTCCATTTAACTGAAAGTAAATGAACTTACTGGAGGGATA
ATGTATAGTTCTTTGGAAATGAAGGAAAAGAAGGCAACTGTGGCAGAGGGAGGGCAGCACTGAGAGTCAGGAACCTCCA
GGGAAGTTACTTTTTGGATGCTGTCATTAATAATGCTTCAGCTTCAAATGTACTGACTCTACCTTTCTCAATTCTAG
ATTCAAATTTCTAAATGTAATTGGCATAAATTAGGAACTTGTCCACCAGTTTATAGAGTTTACAGAGCACTATGAT
TATAGGTCCCCCTAAGATCATGCAGAATGAGGGAAGAGTAATTTTCATCCAAGGAAAAGCAGGGTACCATTACACAAA
GAGTGGAGATACTTTATTCAGAACAATTAATGTTAGATGCCACAAAAAACTAACCTGAAATCAAAGTGGCCTAATG
AATGCTTATTTATTGCTCATATAAAGTCTGATATAAAATCAGGTAGCATTCCTTCACAGTGACTCAGGGACCTAAAT
GCTTTCATCTTGTGGCTCTGCCATGTCAACATTGAACTTCAGAGGTATTGACAAAAGGAGAGCTGAGAAATTGACAC
TAACTATCAAGTACCTCAGGCAAGAAGTGATGCATCACTTCTACACTTTCCCACTTTCCAGGATTCAATCACAATT
GCACTCACGAAACCTCAAGGGAACATGAGAAAACATAATGAAATCAATACCAAGATATCCAAAGAGTACTAATTTTCT
TCACCACAGAAGGGATATTGGACAGACAAAAAATTTGGGACAGAGGAATATCCACTAAATGATCCTTCCATGCCCT
GCTCAGATGCTACATTTTCCATTAAGGCTCTCTTGACCAACCCATAAGGAGATGATCTCCAACCTCCTCTGAACATCT
GGAACATTGCATTCTACTTATTTTACTGTCTCTATTGTAATAATTGTTGGCTATTCTTATTAGACAAATTATAA
GCTTTTATGGGACGGTGATCAAAAGTCCTAATTTATCTTGTCTTCTACAGCATTCAAAGCATTGTAGACCTTCAAT
ACATAGCAGTCTTCGAAGCCAGAGTATTAGTATTTTTCTAAAACCTGTATTCATCGCAACGAACCTCGATGGATGTT
AATAAAAATGTATTGAATAGTCATTTCATGCAGATAGCAAAATTTCTTAAAACATTTCTTACTCAATGTTTACTTATAT
TCATCATGAATATAAAATTTAATATAAATAATATCAAAATCCCATTACATTTAGTACAAAGTAAATATACCAATAATTTT
ATATATGTTTAAAGTGAATTTTATATTTTCATATTATTTGTGAATGATACACATCGTCGTGGAAAATTTACAACGTTG
AAGTAAATTATACAATATAGGGTATTTGTATTAATAATACATTTTCATAGAAGGTGCTTTAAATTTAAAAAGTTAGCAT
GAATACATATTAAATGTAAAAGAGTCTTTAAATGAAAAATATTTTCACTTGTGGGTTTGATCTAAAAATATCAGT
CGCTATATGATATGGCTAGACAGATTTGAGTAGGTATAATTTAATGAATAATATTGTGTGATATTTTAGGGTCCAA
AATTTGAATGTTTCTATTAAAGTAACAGATATTTAAATGCCAAGCAGAAGCTACACTGGCAAAAACAAGATTTAGTAGT
TATCTTAAAGTGTATCTAAATCCTCTTTCATCTTATGGAGAAGAAATACATGCTTTTAGTTTCCAGCCACTCCTGTG
TATATTCATTTAAAAATAAACTATTATTTATATCAGATATGATGCCATGTGAGTCCACAATTTGTAGTATAGAGAAAT
AATTTTCATTGAATTATTTTGGCTGTTTGTACCTGAGACCTGATTCTGAATCATTATTTTTTCTATTTAAGTTGTGCT
ATTTTATGATCCTACCTATGGCTATGTTCAAAAACATGACAAAAATATATTTTACCCCTGATCTTTTTTTCATTATTAT
ACTTTAAGTTCTGGGACACACGTGCAGAACGGGCAGGTTTGTTCATAGGTGTACACGTTCCATGGTGGTTTGTGCTG
ACACATCAACCCATCATCTACATTAGGTATTTCTCCTAATGCTATCCCTCCCCCTAACCCCCATCCCCCTGAGAGGCC
CCGGTGTGTGATGTTCCCCGCCCTGTGTCTATGTGTTCTCATCGTTCAACTCCCACTTATGGGTGAGAATATGTGGT
GTTTGGTTTTCTGTTCTGTGTTAGTTTGTGAGAATGATGGTTTCCAGCTTCATCCATGTCCGTGCAAAGGACATG
AACTCATTCTTTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCAATTTTCTTTATCCAGTCTATCATTGAT
GGGCATTTGGGTTGGTTCCAAGTCTTTGCTATTGTAAATAGTGTGCAATAAACATACGTGTGCATGTGTCTTTATA
GGAGAATGATTTATAATACTTTGGGTATATATGCAGTAATGGGATGTCTGGGTCAAATGGTATTTCTGGTCTGTAT
CCTTGAGGAATCGCCACACTGTCTTCCACAATGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAGGCGTTTCT
TTTTCTCCACATCCTCTCCAGCATCTGTTGTTGCCTGACTTTTGAATGTTTCGCCATTCTAACTGGTGTGAGATGGTA
TCTCATTGTGGTTTTGATTTGCATTCTCTAATGACCAGTGATAATGAGCTTTTTTTTGATATGTTTGTGGCTGCAT
AAATGTCTTGTTTTGAGAAGTGTCTGTTTCATATCCTTAGCCCACTTTCTGATGGGTTTTTTTTTTTTCTTGTAATTT
GTTTAAAGTTTCCTATAGATTCCGGGTATTAGCCCTTTGTCAGATGTATAGATTGCAAAAATTTTCTCCCAATCTGTA
GTTTGCCTGTTTCACTCTCATGATAGTTTCTTTGCAAGTGTAGAAGCTCTTTAGTTTCATTAGATCCCATTGTCAAT
TTTGGCTTTTGTGCTGTTGCTTTTGGTGTTTTGTAGTCATGAGTCTTTCCCGTACTTGTGTCTGAATGGTATTGCT
CTAGGTTTTCTTCTAGGGTTTTGATGGTTTTTCGGTTTTTAGGTTTAAAGTCTTTAATGCATCTTGAGTTGATTTTTGTA
TAAGGGGTAAAGGAAGGGGTCCAGTTTCCGTTTTCTGCATATGACTAGCCAGTTTTCCCAACACCATTATTAATAAG
GGAATCCTTTCCCCGTTGCTTGTTTTTGTGAGGTTTGTCAAAGATCAGATGGTTGTAGATGTGTGGCATTATTTTTT
TGGCCTCTGTTCTGTTCCATTGGTCTATATATCTGTTTTGCTACCAGTACCAGTCTGTTTTGCTTACTGTAGCCTTG
TAGTATAGTTTGAAGTCAGGTAGCATGATGCCTCCAGCTTTGTTTCAATTTTACTTAGGATTGTCTTGGCTATACAAGC
TCTTTTTTGGTTCCATCTGAAATGTAAAGTAATTTTTCTTAATCTGTAAAGAAAGTCAGTGGTAGCCTGTTGGGGA
TAGCATTGAATCTGTAAATTAATTTGGACAGTATGGCCATTTTCACTCCACTGATTCTTCTTAACCACGAGCATGAA
ATGTTTTTTCCATTTGTTTGCCTCTTTCGTATTTTCTTGAACAGTGGTTTGTAGTTCTCCTTGAAGAGGTCCTTCA
CATCCCTTGTAAGTTGATTTCTTAGGCATTTTATCTCTTTGTAGCAATTGTGAATAGGAGTTCACCCACGATTG
CTCTCTGTTTGTCTATTCTTGGTGTATAGGAATGCTTGTGATCTTTTCACTTTGATTTTGTATTCTGAGACTTGGCT
GAAGTTGCTCGTAATGTTAGGGGCAGCCAGAGAGAAAAGGCTGGGTTACCCACAAAGGGAAGCCCATCAGACTAACAG
TGGATCACTCTGCAGAAACCCCTACAAGCTAGAAGAGAGTGGGTGCCAATATTCAACACTCTTCAATAAGGGAATTT
CAACCCAGAATTTTCATATCCAGCCAACTAAGTTTCATAAGCAAAAGGAGAAAATAAATCCTTTACAGACAAGCAAT
GCTGAGTGATTTTGTACCACCAGGCCTGGCTTACAAGAGCTCCTGAAGGAATCACTAAACATGGAAAGGAAAAACC
GGTACCAGCCACTGAGAGAAACATACCAAAATGTAAAGACCATCGACCCTATGAAGAACTGCCCTCACTAACAGGC
AAAATAACTAACCAACATCATAATTACAGGATCATTACACATGACAAATTAACCTTTAAATGTAAATGGGCTAA
ATCTCAGATCAAAACACACATAGGCTCAAAGCAAAGGATGGCGGAATATTTTCCAAGCAAAATGGAAAGCAAAAA
AATAAAAAATTAATAAAAAATAAAAAAGAGGGGTACAATCCTAGTCTCTGATAAAACAGACTTTAAACCAAC
AAAGATCAAGAAAGACAAAGAAGGGTATTACATTACATAATGGTAAAGGGAGCAACGCAACAAGAAGAACTAAT
TCTAAATATATATGCACCCAATACAGGAGCACCCAGATTTCGTAAAGCAAGTTCTTAGAGACCTACAAAGAGACTTAC
ACTCCTACACAGTAATAGTGAGAGACTTTTATACTCCACTGTCAATATTAGATTAAACGAGACAGAAAATTACCCCTGA

TCTTTAACATTCCAGGCAAGTATGTTTTTCAGTCATACATAGTACGTGAATCTGTTATATTTTTAAATCCAAGCTTTTG
GAGGACAAATGATTTTACAGTTATACAACTCAGCCTCTCCAGACTCAAGTCTCTCACTTGATGCAGTATTTCCACC
CCATCTTCAATAAAAAGAAGAAAGCATGAAACATCGCATTGATATAGGGAAAGTATATCTGAGTTTTCTATATAGCAT
ATAAAGAAGTAAATAAATCTGTGATTTGTGATGAGATAGATTTAGCTGCAACAATGAGGTCTGGATATTAATATTG
GATTAACCTTCTTTGAGATTGCAACTTCCATGTGGCATTTCAGCACTTTCTTGTCTTCATATGTAGGCCGAGAAT
AAAATTATCTGTCTTATTTCCCAACATGAAAGGTCTTTTAACTGTTTGAAGACATATGTTTCATGTGAAACCAAG
GAATTGCTACTGCAATTTTGTAAAGACAGAAGTTAGCAAACTTATTCTGTAAAGGAACAAGATAGTAAATATTATAGGC
TTTGCGGGCCATATGGTCTATCTCACAACATTTAACTCTGCCATTTTTTTTTTTTTTTTGCAAAAGCAACCATAGAC
AATATGTAAATGAATGAGTGTGATTATATTTCCAATAAAAACCTTTATTTTAAACTACAAGACTAGTCTTTAAAAATAAA
ATTTAACAAAGAAGTATTATATGATCCAATAATTCCACTTCTGGGTATATACCCAAAATAATTGAAAACAGGTATTC
ACACAGATATTTGTACACCCAAGTTCATAGCAGCATATTTTACTGTAGAGAAAAGGTAGAAAACAAATGTACACTGTG
TACACTGACCAAGAATGGAGAAAACAAACGTGGTGTATCCATACAGCAGAACAGTATTCTGCTTTAAAAAGGAATGA
AATTCTGTACATCCTAAATAGGGATGAACTTTGGAGATATTCACCTAGAGTAGTTAAATCTTTAGACAAATAGT
TGCATGGTTGCCAGGGACCAGGGAGGGGTAGGGGAAATGAGCAGTTCTTGTGTCATTGGTATAGAGTTTCAGTTTAG
AAAGATGAAGAGTTTTGGAGATAGATGGTGGTGTATTTACATATCCATGTGAATGTATCTAATGCCACTGAACTGT
ATACACTTACAATGGTTGAAATATTTGTATATTTTCCACAGTTAAAAAGACAAGCCCATGTGCCCAAATTGCTG
ATATAAATCTGTATTCTATTAGTGAGCAGTAATGAGCCATGTTTAGTGACGTGATATGGTTAAGATGGAACAATT
GCATGTAATGCAATGGTGGGTAAACATCTAATAAAAAATTGGTACTCACCAATTTCCATTTCCATTGTGGATATAACA
CCCTTCACATTATGAATCATGTTATTTGTTATTTGTGTACTTACTTATTAATCACTTTTCTCCATCTCTCTCACCT
CTATGACTCTGTACATGTACAAACAACATACACACTGTGAACTTCTTTAGAAATGACAGTTACATTTTCGTTACTTGA
TTCATTGTTTGGCCAAGTAGATACCCAGTAAGCATAACTAGCAAGTGAATAATGTATATGTGATCATTTCCTTTTC
AAAAACCACTTCTTATCTCTACCAACACCACACATTATTATATGCTACACTTCTTATATAAAAACAAAAAGAATA
GGCCAGGTGTGGTGGCTCTCGCCTGTAATCCCAGCAATTTGAGAGGCCGAGGTGGGCAGATCACTTGAGGCCAGGAG
TTAGAGTCCAGCCCAGCCAACATGGTGAAACCCCATCTCTGTCTAAAAATACAAAAATTGGCCAGGCGTGTGGCGCA
TGCTTGTATATCCCACTACTTGGGAGGCTGAGGCAGGAGAATCACTGGAACCCAGGAGGCGAGGTGCGATGAGCT
AAGATCATGCCACTGCCCTCCAGCCTGGGCAACAGAGCAAGACTCTGTCTCAAAAACAAACAAGAAATAAATAAGCT
TTAATAAACTCTTTTGCAGAAGAGTTTTTCATTTTTTAAACATAGAGGAAAAAGAAGATGAGGATGAACGATAGTGATG
CCCAGAAGAGAAAAATTGTGTAAGACAAAAATCAATTGACCAGGCGTGGTGGCTCACGCCTGTAATCGCAGCACTTTGG
GAGGCTGAGACGGGCAGATTATGAGGTGAGGAGTTTCAAAAAACAGCCTAGCCAATATGGTGAAACCCCTGTCTCTACTA
AAAATACAAAAATTAGCCGGGCTTGGTGGTGCACGCCTATAGTCCCAGCTACTTGGGAGGCTGAGGCAGAAGAATCT
CCTGAACCCAGCAGGCGGAGGTTGCAGTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACT
ACATCTCAAAAAAAAAAAAAAAAAAGATTAAATCAATTTTAGATTGATATAGAGATAAATAATTCCCTAAGTACAATTA
AAGCAAGGATCAGACCCTGATGAGTAAGGATGATCTAACAAAGGGCTGACAATATAAAGTGAATGCGATTGTCACCA
AATAACATCTCCCAAGAGCTTTGGGACAATCTTCAGCTAAGCATATTCTGCACCTTACATCGTTCTGCCATATGCC
CTATGTAGCTTTTCATCTCCAGAAATTTGAATAGCACACAGTATTTTTTGGCACCAGTAATTGTGGAACCTAAAC
TTCCTACAAAGAGAGAAGCTGTTTTTCAGTCAGCTAAGTGACCAGTTAGTAAGCAACTTCTATTCTCTTAGTGTCGATA
GGGTTAAAGACAGTCATAAGCTCCCCAAACCTTGGCCGCCTCAATTTTTTTCATTTAAATACTTATCTTCTTATCTT
CATCTATTTTTTTAGAGTCACACATAAACTCTGTCTATGAGGTTCTTAAAGACCTGGACAATATATTTAATCTCTGTA
TCCTTAAATCTCACCATGATATCTCAAAGATGGTAGATAAACTGTTTTCCCTCACTTCTCTGACTCCATACCAATA
CTTAATCGATCGGGAAAGTTTTATAAACCATTTACCGTTGAATATAAATATATATACACACACAAACATATATATAT
TTATATATATTTATGTATATATATATTTATATATCTATATATATTTATGTATATATTTATATATATTTATATATAT
TTTATATATTTATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATAT
ATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATAT
TATATATATTTATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATAT
ATATATATTTATATATACACATATTTATATATTTATTTATATATGTTTATATATATATATATATGGCATATATATC
AGTGAGCAAAGGCATCATAATCTTTATTTTTTATTTCTGTATTCAATTTATTCAACATATAGTAATTTCTGATCCTGTCT
CAAAAACCTCTACAGAAATTAACAAAGAACACATTGTTTCTGCCTTTTTTGGAGCTGAATGTTTAGTGGGGGAAAATGT
ATTTTAAAGGCAATAATCATATACATGAGTGTATATTTACAAGCCGAGTAGGTGCTATGAATGAAAAGTATAAGGAG
CTATGAGATATTCTAACAAAAAGAAATGCTGCAGTCTAGAGACTGAGAGTAATTATCTGTGAGGAAAAGTATTGAAG
CAGAGACCTGCAACTCAGTAAAGAGTGTAGGGAGTCACATGAACAAAGTCTTGAGATGTTGGTAGAGATCTTGAAT
GTTGCAAAATCTAAAAGAAAGCCCTTGTGTATGGGTATGGTGAGAGAGGAGAGCGTGGCAAGTTTTACGTTGTAC
AAGTCATTGTAGGCCACAAAAATAAGTATAGATTTTATCTAAGTGCAACGAAAACCATTACAAGTTTATTTTTTGA
TTCTTAAATTTTTGTTTTACTTATTTATTTATTTTCAAGACACAATCTCACTCTGTTGCCAGGCTGGAGTGCAGTGAC
ATGATCACGGCTCACTGCAGCCTTGAACCTTGGGCTCAAGCAATCCTCCCATATCACCTCCTACCTCAGCTTCC
TGGGTAGCTGGGACTACTACAGGCATTTGCCACTATGCCTGGCTAACTTTAAACAATTATTTTTGAAGAGACAGGGTC
TTGTTACGTTTCTAAGTTTCTAAGGCTGATCTTGATTACTGGGCCAAGCAATCCTCCCGCCTCATCTCTTAAAA
TGGTGGGATTACAGATATGAGCCACCTCACCCAGCAAGGTAGTGACATAATCATTGTTTTTGTGAAAACAATGTAC
TTTAGGGAACCTCCCTGAAAACAGAATGGCCACTTAGAATACCAAAGCATAGACCAAGCCTTGAGATGGCAATGGAA
GTGGAAGATAAACATGTCTTTGATACTTATGTTAATGGAGCTATTAGTAGCAACTTTTGACAGATTGAAAGTGGAGT
TGAAAGACAGTGAAGTGTCTCAGGATGATCCCTGAGCATATTAGATAAATATTGAGCTGGAGAACAGAAAAGAAGGGGC
AGATTTGGAGGTGGAGACCTTTCTAGATTTATATTCAATTTGAGATACATCTGAAACATCTACATGAAACGTGGATG
AAATATCTGTGACCAAGATACATACGTGGGATACCTAGGCATGTAAATAATATTTTAAAGTTATGTGAGTGGGTGCAA
TAACCTAAAGAGAGACTGTAGGTAGAAGATTGATCAGGACAAATCTTTGAGGAACTTTTTTTTTTTAAATTATTATTAT
ACTTTACGTTCTGGGATACAGGTGCAGAACGTGCAGGTTTGTACATAGGTATACACGTGCTATGGTGGTTTGTCTG

ACCCATCAACCCGTCATCTACATTAGGTATTTCTCCTAATGCTATCCCTACCCTAGCCCCCACCCECAACAGGCAC
CAGTGTGTGTTGTTCCCTCCCTGTGTCCATGTGTTCTCACTGTTCCACTCCCCTTACGAGTGAGTCCATGCAGTG
TTTCATTTTCTGTTCTGTGTTAGTTTGTCTAAGAATGATGGTTTCCAGCTTCATCCATGTCCCTGCAAAGGACATGA
AGTCATCCTGTTTTATGAGGTACTTTTAAATGCATTTAGTGACTGGGTAAAGGAATAACCTGAAAAGGAGCACAAAA
CCATCGAGGTATGAAGAAAGCCAGGAGATGTAGTTTACAAAAGCAGCCAGTGACAGTAATGGACACCAGCATAAGC
TTAAGACAGCAGTGATAGTGTTCATCAGTGCTGAAAACCTATTGGAAGTGGCTGACCATATGTTGATTGCCAATGCA
ATGCCCTTCTCCCATCTCCTATTGCTTTTCACTGTTTCCGTCATGTCCAGAGTGAAAACACTGGGGAGGCAGAACTGT
GTACCAAGAAAAATGTTTTGTGTGTCAGAGGAAACAAGAGCTCATTAATTTCCCTTTTGACCCGCATGGATAGGAATACG
ATAAGCAGGAGAAAAATAAAACCTGCTAAACTAGGCAAAATAAGCTTAATAGAAAAAGAGAGAAAAATATTGCTTACAA
AGGGAAGAAGACATTTGCCACAATATTAGCTAAAAAGAGAGTGAGGAAAAATCCACATTTTACCATTTTTATTATGTGT
TTCCAAAGTCGACATTAAAGTGAATATTATCACTTTGAAGACAGAGAATAGATTGTAAGCAGAAGAGGAAGTGGGATT
TTTTAAATGGCATATATTTAAATGTTGAAAAACCATTTCCAATACTCCCCTGAGATATATGCAATAAAAAACACTC
CGCAATCAGTAATATACATGTGAAGCTCCTAAAAATCCTCCATTGAGAAGATTCTATAAACTATAAAGTATTATTA
TTTCTGCTATCAGAAAATAAACACATACTTTCTAAGAACAAGATGAAGACCTTAATTCATCTTCCCAGGAATATACT
TGTGTACTTAATGGTTCAAGGCGTTTGTGATGCAAAAAAGTGGGACATTATGTACAAAATAGTTTAAATCAGAAAA
TGAAGGAAGTTTGGTATGGTATGGTCTAGGGTTCAGAGTTTCCCTGCAAAAAGGGAGTACTTATGGCTAGGTGATG
CAGCCAAGGAAGCATCTCTGAGGACAGGTTATCCTGGCTCCTATCCAAAATATTTAGGTCTCCTTGAGTGTTCGAT
CCTTGAACCAAGGACAAGAATAGAAAAGAAATAAAAGCCACTTGTATAAAGGTTGCCTTCATTTTGTGTGCAATATTG
ACAGGAGAAAGCCAGATTTGTAGCTTTTCCAGGGATAAGTGAGTCTCAGACACAGTTAAGAGCTTGGCTTTGGAATT
AGATTGACCTGAGTTTGAATCGTGGCTCCATCAATCTCTGATTGTGTGAATTTTGGCAAGTTTGTAGCTGAACCTCA
ATTTTCTCATAAGTAAATAGGCATAATACAGCTATGATTCTGACCTTGCCATTAGCACTCTGAGCTACTTGTGAG
TGTATCCTGGTCTCTTCTCAAGCACTTTTCCACTTTGTTATTTCAAGATTCTTTGAAATTATGAACAGTAGCTCTT
GATCACCAACAAATGGGAGACCATAGATTCAAAGGAACATTTTAGTAGGATATTTGATAAGCTTTGTATTTTTTG
TGCTTTGAAAATTAGAGTAGATTAGATTAAAGGAACATAAAGCTATATGTTTACAAAACCTTTATTCAGTTGGGCA
GTTCTGACTCAGTAACTGAAATAAAATTGATGAAAACAAAACATATGTTTACTGTTGTGTTTACATTTAAAGATTA
TTTAATGCATAAACCAAAATAGGTTTCAGCAAAATGTTTATACATACATGTACTTAGATATTTGTAATTTCTTATGGTAGA
GCATGGGAATGAATGAGAATTCTCCTAGGCTGGAATAAACTAATGTCTAATAAGAAATTGGCCTTTCACTTCACGA
ATATATATCATTATATATAAAAGATTCACTCTTTGTTAACTTATTTGTTTAGCTTAGTACTTTCTAAGTACTTTTCT
ATCCTGTCTTGGTCCCTATATAAGAATGATACTATTATAAAAAATGAACATCCTATTATTTTATAATGATTAGCATAT
CAGCATATTTAAGAGCAATGCCTATATCTTTACCTTCATTATTATTTTCATGTTTAAATCCTGATAATTCTAGAAA
AACAAGGTTGTAATTATCCATTATAATAAAGTCACACCAAGTTATTCTTGATAATTAACCTTGGCATAGTGGAGTG
CACTGAGCAATTAATAATTAATTACGTGGTTACTAGCTCAAATTTTATTGAGAACCAAGGAGTTAAATTAATAGTA
TTGTGTTTGCAATGAGTTAATTACTTTGTTTCTTGTTTTTTTTTTTTGGAAATAGTGCCATAATTAGTATCCTAATAG
AAACAGAATATAAAGTGGGTTTCTGAGTGCTTGCTTGTCGAGGTGTGTAACAACATATATTTTAATTATAATTTGAG
TCACTAATTGTTGTCAAATACAATTTTAAATTTCTTAGTTTCAGAGATTAAAAGATATGTAAACAGCTCCAAAAAGAA
TATGATAAGATGGTTTATACAAGTAAATAAAATAACTATATGACTTCAGAAAGTTTATTTTAAACACAGTTGTATAAGT
GTTTTAACTAATGTTAACAATGCCTTTTTTGTAAATCTCCTCTACCACAAATATGAGATAAATTTAAGAAGGCATT
TTCATTAAATATTGATTATTAATAATTCATATATAAGTATTGGCTGTACCTGAGCATTACAGTGAAACCATGAAGGA
CTGGCAGGTTTGGGGCTGTTTGATAATATCCTTCCCTAATCTTTCTTCGTAGCATCATTGTTTAAATTTGGCTGACC
ACAATCACTTATGAAAAGAAACAGCTCAAATAATTAGTATAACCTCTTTCTCTTCAAAAACCTTCAAATCAATGTG
GTCATAATTATGAAAGTGTAAGATTATAAAATCTTCTCATTTAAATATACATCTTCATATTAGCAGTATTGGCTAAT
TTCTTCACTTTATCCTTGCATCCACACTTAACTCTGTCAAACCTGGTCATTTCATAGACTCATTATTCATTCAACAAA
GATTAGTGTGACCTTACTATTGATTCTGAGGGCTAGAAATATAAACTGAATAACATATAAACCTTGATTTCTGTATT
TATATATACAGAAAGGAATTATGAACCTCACAGTTTTAATGCACAGTGACGAGTCCCTCAGTTCATGTCTGCCTTGGGA
GCTAGGCATATACCAAAGCAGGACTGTCTAACACAGTTTGGGGGTCTCAGTCTGGAAGGATCCGGGTGAGATGATCC
TTGAATTGAGTTCTAAAAATGAGGAGAAATATCCAGATAATGGAAGTTTAGGAGAAATTAACCAGATAATGGAA
AGTTTAGGAAAGAAACACTATTTATATGTCAAGGACAAAGTTTGACCAAAATGTGTCTCTGAATCTAAGTGGCTTTAT
GTAAGATAAAATTAATAAATAATTGTCATAAGGTTTTTTCACATCTGCAGCAACTACCATCATATCTGGCTCAATAT
TTAAAGAAATACTTAACGATTTTTTGGCATTATTGTCTACTATAATAGATTGTGCTATTTAAAGAGAAATCTAGAT
ACATGCCAAAGTATTTTTCAGGTGAAGTAATGTGATTCTGTGGGTTTTGTTTTGACAACTTCCAAGGAAATATTTTT
AATATAAAGAGCAATGGAGGAAGATTAAACAAGATTCGCAATGTTGATAATTGCTCAAGGTGGTGACAGGTGCATG
GGGGTCCATAATATACTGTTCTCTTTACTTATATATGTCTTTGAAGATTTTCATGATGTAAATTTTAAATCAGAA
TTACAGTAATACCTCTTTCTTTTGACAATCGTTTTTCAAACCTGGTTCAACAACCTGAATTTAAATTTACCTACATGGCTA
TAAAAATAAATTAGATATCCTGGTTATTTGGTCTGGGGTGGGTCCTGGCCATATCTGTAGGGTGTGTGGGTGTGTGT
GCATTTAGCTTCACATTTGACTCTGAAGTACGTGGAAAACCAATTCTGGGCTCTACATATGCAATTTCAATGCCTGA
CATTAGGTGGTGTGTTGTGAGCCATGATTTTCAGGTTTGAAGTTAGAGTTAACAGAAGTGATATCACCACCGATC
CCACAGAAATACAACTACCGTCAGAGAATACTACAAACACCTCTACACAAATAAACTAGAAAATCTAGAAGAAATG
GATACATTCCTCGACACATACACTCTCCAAGACTAAACCAGGAAGAAGTTGAATCTCTGAATAGACCAATAACAGG
AGCTGAAATTGTGGCAATAATCAATAGCTTACCAACCAAAAGAGTCCAGGACCAGATGGATTACAGCCGAATCT
ACCAGAGGTACAAAGGAGGAATGTTACCTTCTGAACTATTCCAATCAATAGAAAAAGAGGAATCTCCT
AACTCATTTTATGAGGCCAGCATCTCTGATACCAAAAGCCGGGACAGAGACAAACCAAAAGAGAAATTTAGACC
AATATCCTTGATGAACATTGATGCAAAAAATCCTCAATAAAAACTGGCATACCGAATCCAGCAGCACATCAAAAAGC
TTATCCACCATGATCAAGTGGGCTTCATCCTTGGGATGCAAGGCTGGTTCAATATACGCAATCAATAAATGTAATC
CAGCATATAAACAGAGCCAAAGACAAAAACCATGATTATCTCAATAGATGCAGAAAAAGCCTTTGACAAAATTC

82

GATGCACATGCAACTACTAAATGCTAGATGAGGATACCTGAGGAGAGAGAACAAGACACAAACGTGAACATGGACCT
CCAATAGAAATGACAATCGAAAAACATACATTTATCTTCTCTCTCTCCCAAATTGTTCAAAGATTACGCTAAGGGAAT
AAAAACAATACAGTCATAAAATGACAAATAAAATGGAAGAAGAGACATCTGCACAGACATATCAAGTCAATGAGATG
AAAATTAGGACAAGTAAGCCAATTTGTTTTTTCAGGATCCCAGAAAAACTTGTGGATTGAAGACGCTAGGTGTTTTAG
AAGGCCATATATTCCCAGAGGGGGCTGGAAATAAAGGGGTGTTTTGAATCCCTTAAAAGGGGCAATTACATTTTCAT
GTCCCCAGCTCAGGGTAGTTAATTAGACACTACTCTCTCTCATCCCAGCAGACGTGAGTGAGTGGTTTGCTTTCTG
GTGAGGCTGAAACAACCTTTTGGCATTGAGACAACAGGATTAGTTGATGGAAGAGAGAGCCACCATACTGAAAAATACA
GGATTAAGTTAAAGTCAACATATTTAATGGTGAGACCAGCAGTCCCTCTTCACCTTCTTGGCTCTTAAGTTTCTATC
CTCTGGGCAGTAGATTATAAATTTATTCTCTGAGAGCCTACCTGCAATACGAAAACTATTTTTAGTCAAGTTTTAT
TGCTATAACAAAATACCATAGACTGGATGCCTTATAAAACAACAGACCTTTATTTCTCACCGTTCTGGAGGCTGGGAA
GTTCAAGATCAAGGCACTGGCAGGTTTGGTGTCTGGTGAAAGCTCATTTCCTGTCTTCTCACTGTAACCTCACAAGG
CAGCAGGTCCAAGGGAACGTGCTTGGGCCTCTTTGTAAAGGGTACTATTCTCATTCTGGATGGCTTTGGCCTTATGA
CCTAATTACCTTCCAAAGGCCCCACTTCCTAATGTCATCACCTTGAGGGTGAGGATTTCAACGTATAAATTTTGCAA
GAACACACTCAGATCATAGTAACCTACAATTAATGATATGTAATGATCCACCAGTGAAATAGCCAGATCTGTGCCTA
ATGACCATATATTGAAGCCCACCAAGTATAAGCCCTACATACGCACAAGGAATTTCCAAAAGCATTTAATGCCTCAG
TTTTAAGAGACAATCAAGGATTTCCAGATATTTGAACATGTCTCAAAGATGGAAGACAGAAACCAACATAAAAAACAA
AAAGCAGAAATATTGGGAAAAAAACAATAGCCACATAAATGAAACAGAAATCTCTGCAGAAAGAGAGACAAGGCATA
GACCTTAAGAAAACCTTTTTAAAGATAGCTATAAAATTATTATCTCACAGTGAGACTAGTCACTGTATTTCATAAGAAA
GAACAAGAGACTATAGAAGGTGGTATTTCCGAGAAAAGATAAGGGTTATTTAAATTAATAGTATAGCAGGTAAAGTTT
TTAAATTTCTTAATTGTATAAATTTATGGGTTACCAGTGTAATTTTGTTATATGAATATATTTTATAGTGGTGAAGGC
AGAGCTTTTAGTATATCCACCCTGGAATAACATACATGGTATGCATAGCAGTTTTAGAGCAATGAACTACTCTGT
GTGATACTATAATGGTGGATACCTTTTATTATATATTTGTCCAAACCCATAGAAGATAACAACATCACAAGCAAACCTC
TAATGTAACTATGGACTTCGAGTGTTAATGATATATCAATGTATGTAAGTCAGTTATAACAAATGTACCCTCTGG
TGTGGGATGTTGATAGCGGGTAGGCTGTGTGTAATGAGGAAGGGGGCCAGAGAGTATACGGGAAATCTCTGTACTT
TCCCCTCGATTTTGTCTATAAATGTAATTTGCTTTAAAAATCAAGTCTATTAAAAATGAAGAGCAGAAATAAAGT
TCAAAAGTAGAAGATAAATTTGAAGAAATATCTCATAAAGCAGTATAAATAGCCAAAAGCATGGAATTTGGGAGAGT
ATAAGAATCTTAGAAGATCATTCTAGGTAAGTGTTTTACAAAATAGAGGTGATTTTGTCTGCAGAGGACGTTTGACA
ATGTACGGAGACCTTTTTCGTTGTACAAAATAAGGAAAAGGATGTACTACTGGCCTCTTGTGAAGAGTGACGCAAGAG
GAATGCACCATGCAGCCATCCACAACCAAGAATTACTCATTTCAAAAGTGTCATAGTGTTTTATGTTTAGAAACCTTG
TTCTATGTAATCCAACATTCAAATAATAGATGTTAAAAATAAAAACAGAAGAGAGGCAACTGTGGAGAGAAAATTATC
AAAGAAGTGACAACATCAGTTTTCTTAGAAGTGAAGAAAATGAGTGTCAGGTTTTAAAGGGCTTACTAAATGCCAG
CACAGCAAATGAGCTAAAAATCTACACCAAGGCTCATCATATAAATTTTACAAAAACAAGGACAAAGAGAAGTTC
ACAGATCAGAAATCAGAATGGCTTTGGACTTTTTCAGCAATAGCCATGGAAAATAGCAGAAAGGAACACTTCCTTTAA
ACTTCTAGGAATAATTAACCTTTGGCTTTGATTTCATATCCTATATGAAATTATGTTACAAAATCTGTGATGCTCTT
CTATTCAAGAGTTACAGCTAAATGTCCCTGTCAATTGAGTGTTGAGTACTAGATTCAGTGACTCTTTTGTGATGATATGTC
ATTTCCAAGTGATAGTTGTAGAAAAGACTGTGGTTTATGTCTTGTGTTCTCCATCCACGCCTATCTCTCTCTGTGTCT
CTCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCATGCATTGCTTCTTCTGTGGGAACACATGTCATGAGCAGCCC
TATGGAGATGCACGTATGCTGAGAACTAAGGCCTCCTGCAAAGAGCCACAAGAATGAGCTTAGAAGTGATCATT
AACACCAGACAAATCTCGAGAGGCTGCAAGCATAGACAACAGCTTAACACAACCTCATAAAATAAGCTATGCCAGT
CCCACCCTGCTAAGCCACTCTCAGATTCTTGACCTTCAGAACTGCCAAATAATAAACATTTTTGTTTTTAAAGCTGC
TAAATTTTGAATGACTTGTTATTCAACAATATATAAATTGTACACCCTGATAAACTATAAATTGTGCGGAGAAAAAT
AATTTTCAGAGATAGCCTTATGTACTCCCCCTAAACCTTTTTTCCCCAGAAATCTATTTTCAAAAATATATCTTACCA
AGTGAAGAAGAAACCAAGAAAGACAAAGAAATGTTTAGTTGATTTGGAGATCAGAAGGAGATGTTTTAGGCTATGA
TTGCGCTTGTTATGCTGCAATAATAAGCAATTCCAAAATATGATGGCTAGAAAACACAAGGTTGATTTTGTATCTT
TGCAACATATCCAACACAAGTCAGTCAAGGGTTCTGATCATTGTAGTCACTCAGGAATCTAAGCTGATTTCAGTCTCT
AGTATTCTATCATTCTACCGTAACAATAAGAAGCTTTAGCGTTTACCATGTGAGTCAAAAATGCGTGGAATAATTTTA
AACTGACTCTTACATGCCTCTATGTAGGAGTGATATATGTCATTTTTCATTTCACTTCATCATCCAAAGGAAGTCACG
TGGTCTATGCCTAACTCTGAGGGGACAGGGGATTATAATCACTAATATTTTTTAAAGAGAGGTAAGAGAATTAGGAAAT
ATTGGAGCATTAGTATTACCTGCAAAGCCTAGGATCCGGAACACAGAGAACCCAACGTGGGAGGAAGATGCAAAGTG
GTGCCAGAAAGATGGTGGAGGAGATCCTGTAACAACAGCTGTATAACAGTTGTAGAGAGAAACCTGTACAGATTGGA
GAAGAAAATAGTGCTCCAGGAATTTTGTACCAAGAAAAAATACTAATGTATTGCAATGTATTGAGAGGTGGTA
TTCTTATTGTGTAAGAGTATAATATATGACATGTATGACAGACAGAAAGTACCATTTAAATTTTATTAAACATAAGA
ATTAGATCCCTATCTCACACTGTACATAAAACATAAAAAATGGTAAATTGATGGATTGCCTAAACATGAAAGGCCAAAGC
ATTAAAAATATATAAAAAATATTTTGGGGCATGTAGGGCAAAAAGAGGTGTCCCTTAAGCAACAGCACAAAGCAAAAAT
GTAAAGAAAAAGACATATATTTGATCATTTTAAATTA AAAACCTGTACAATGCAAAGACTTCATAAACAAAGAAAAGA
CATAGGCTCAGATAGTATATTTGCAATACTAAAAACAATAAAGGATTTATGTACATAATTTAAGAAAAATATTTACCTA
TCAATAGAACAAAATAAAAAATAACCTAACAGGAAAAATATTTTTAAAGTTTAAAAATAATAGACAGTTTACAGAACA
TCTGTATGTCAAATACACTTATGAATAGATGCTAACTCTCATTATTATTGGAAAAATTACTTCATATTAGTCGGTT
TTCATGCTGCTGATAAAGACATACATGAGACTGGTCAATTATACAGGAAAAAGGATTTAATGGACTTACAGTTCCA
CACAGCTGGGGAGGCCTCACAATCTTGGCAGAAGGCAAGGAGGAGCAAGTCACATCTTACATGAATGGCAGAAGGCCA
AAGAAAGTCCCTTTTATAAAACCATCAGATCTCATGAGACTAATTTACTATCACGAGAACAGCATGGGAAGGACCTG
CCCCCATGATTCAATTACCTCCACGAGGTCTTTCCCAACAACATGTAGGAATTCAGATGAGATTTGGGTGGGGACA
CTGCCAAACCATATCGTACTAAGTGAGATAACGTACTCCCATCGGACTGGAACAAGTAAAAAATAAAATAAGATTGT
GAAAGGTCACAACTCTCATTCTTGTAGAAATTTAAGTTGGTACAACCAATTTAGAGTGTAATTTAGCAATAATCTA

GT TAAACTGAGGATGGCATGTCCTACCAAACAGCATTCCAGTTAATCACATTGAAGATAGCATGATTGTTCTCAGGC
TTCCATATTTTCTGTTGAACGGTAAGTTGTCAGTCTAATTGGCATTCCCTTTAAAATAGACTTGTTTCTCTTGATGA
TTTTACATTGTAATTTTGTCTGATTTTCAGCACTTCACCGGTCTTTAAATGATTATGTAAGATTTTCATTGCTGAG
GAGGAAATCCTATCACCTCAAATACTATCTTATTAGTTATATTTTCATTTTATTTTACCATGATTTTAAATGAATTC
CTTAAAAAATTAGGTTAGAGAACTAATAAATGATAAAGAGAAAAATTATTCTTCATCCTGATAGCTGTTATGTGAGG
GTGGAATGGTATGGCTGGTTTTTTTCTACTGTCATTTTGTAACCTGGAAATCTTATTTTTTAATACAATGACAATAT
TTTCATAGTTAAAAAACACTAAACTAAACAATAGTCTGTTAATGACAAATTTAAGGGCGATTTCATTAAGTTAAA
AATCCATGTTAAGGCATTATAAGATGAATAAATACTCCAAATGAAAACAAAGTGAAGGCCACTTTTATTACCCCTTT
GTACATGATACTTATTTTTCAACAGTTGTCATGTTAGAAAAAGTTGAAAAAATAAAACAAGATACACCCCTTTTGG
CCTCTAACCTTCCAAAATTGTAATGGGTAGACTTCAAATTAATAATCTAATTCGACTCCTTTCCACTTCTACCCCTCA
TAGCATTAGAGACATTTGGAAAAATGAAAAAATATAGTATTTTATGGCAGGGTACCTCAACCCAGAGCCACAGAC
CCGTACCAATCCGTTGCTGTTAGGGACCCGATTGCAAAAGCAGTAGGTGAGCAGCAGCGGGCTAGGGAAGGAAGCT
TCATCTGTATTTACAGCTGCTCCTCATCACTCCATTTCTGCCTGAGCTCCACCTCCTGTCAGATCAGCAGCCACATT
AAATTCCCATAGGAGCACAAACCTATTGTGAACACTCATGCAAGGGATCTAGGTTGCATGCTCCTTATGAGAATC
TAATGCTGCATGATCTGTCACTGTCTCCCATCACCCCCAGATGGGACCATCTAGCTGCAGGAAAGGAAGCTCAAGG
CTCCCACTGAATCTACATTATGGTGAGTTGTATAATTATTTTCATTATATATTATAATGTGATAATAATAATAAAT
GTGTGCAATAACTGTAATGCACTTGAATCATATGGAAACCATCCTCCAACCCGGTCCACGGAATAATGTCTTCCAC
AAAATCAGTTCTGGTGCCAAAAGGGTCAGGGACCCTGTTTTATGGGATAAGTGAAGCTGGATTGTAATCCAACCT
CTACCTTTTACTTCCCATGTGAACATTAAAAAGATGACTTAATGTCTCTGAATCTTTTTTTCTTCTAAGTAATAACT
ACCTTGAGAGTTATTACTTGAAATGGCCATAAGGTAAAGAGGACACCAAATACAGTAAATAATAACATAATAATAA
AGAAACCTTATGAATCTATTTCAGTGATATCCATATTGAGGTATTTAAGGTGAATGATACTGATGTCAGCAGTTTAC
CTGGATATGCATCAAAAATATGATTGATTGATGGATGGATCGGAGGAAGGAAAAAGATATGTGATCAAAACGAGTATA
GTAAATGTTTCATGGTGGAATCTAGATATATAGATATCACTTGTAATTTTTAAAAATGTTATTGCATTTTTGAAATT
TGTTATGTTAAATATTGGGTGAAAATCTGATGCCCTGGCCATGTCCCAATCAGTTGAATCAGATCTCTGGTGTA
TTTTTTTTTAAAGTCTTGGATGACTCCATTGTACAGCAAGTTTGCAAACTACTTCTAATCTCTCACCACCCCT
TTCTTTATAGCTTACAAAATTATATTTTTTAAATGTCAAATGTCAAAATTTCACTTTCTTCTTCAAGAAGCTGATTAG
ACTTCTAGCTTCTCCTATGCTCTCATCTTGCTAACGTTTCATTTGCACGTGGTTAAAACTGATAGGCAATAAATAAT
AACCCTCTGTCTTTTCTGACCCAACATAACTAAAACTTCTTTTCAAGGCGAAAATGAATATAATCTCACAGAC
AAGAGTAGCTATAGACAATAATTCTTTCTGGTCTCTCGTGGTTCATGGGACTATTCACCCTGCGCTCCCTGCTGTC
TATTTGGTGGACAGCCAGTTTTACTGTGACCCATACCATGGCTCTTGAGAAGCATGAAGCTGCCGAAATCGCAGTT
GTAGGGTTAATGGAAAACATGGTGAAGTATAGCTTACATATATATACAATTTTGGCACAAAATGAAGCCTAAGAAAT
TGTACCGGGCTGGGTGTGGTGACTCATGCCTGTAATCCAGCACTTTGAGAGACCAAGGTGGGCGGATCACCTGAGG
TCGGGAGTTTCAGAGACCACTGAGCAACATGGAGAAACCTCTCTACTTAAAAACAAAATTAGCCAGGCATGGTGG
CGCATGCCTGTAACCCAGCTACTCAGGAGGCTAAGGCAAGAGAATCTCTTCCACCCTGGAGGCATAGGTTGTGGTG
AGAGAAGATCACACCATTCAGCTCCAGCTGGGGCAACAAGAGCGAAGCTCCGTCTCAATAAATAAATAAATAAATAA
ATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA
CTCCCCCTCCAAGAAGTTTTTTTTAATTTATTGTATTGTGAAAAGATCTGCAGCTATTTTATTTTGTGTGGTACTCTTT
GCAATAAACTACTTCTGCATAAATGAACTCAAAAACTTTGATATTTCATGAACCTTCATAATGTTGATCTAGTACATC
TTGCCCACTAGCCCTTGGGCCATTCTTCCATGCCACTGGTTGAAAAATATGCTCCCCACCCAGTAACATCAGCA
TCAGACCTCTGCAACCAGAAAGATTCCATAGGTAATGAAATCCAAATGCTGGCATTGGAAGTCAAACAGTGTATT
TTGAAATGGAAAGGCAAGGGGAAGTGCATGGAGCAAGTACAGCATGTGCTACAACCTTCAGTTTCATACCTCTCTTAA
ATACTGTGCAACTAACTGTCAATTGCCATTGATAGATAGTATCTTTTTTCAGCTTTACACCTTCCGAATTTCAAC
ACACTGTAGCCTCAGGACTAAGCGCTCAATAAATGTTTATCAAAAGATTGAGTAAATGAATCAGTGGTGAAATAAA
ATGTACAAACACATACGCTTCATACACGTTTAGGAAGCATTTCTAGTGAGCTTTGTGGATATTTTTATTCTTAAAGG
TTCTTTTTCTTTCCATGTTTCATGTTATTCTTTATTTTTTAAAAATGTTGCTTCTGCTTATTTCTCTTTCTACGGCAGC
TATATTTACTTGCTGAGAGCACAGCATATACTGATGTTAATCAAACCTTTAGATGAAACACCTAAAATGATAGAAAA
GAATCTGCTCTAATTAATAATAAAGCAACCCCTACAGGTTTAGACATGTGCCCTCCGGTGTGGGAAAGAAAAAATT
TAATGAATGTAGTAGTTTTATGCCAAGAATTTCCCTCGTGACCTGTGTTTTAATAAGATAGAATATAAATAAGC
AAAAGGGGCCCCGACTTTTGTGATGATATTTACTCATAAGGTAGTAAGTCAGATGTGATGACATTTCTTTGACTTAG
AGCTGCTATACTTGGGTGAGATTTGAGTTGAGTAAATTTGCAGTGAAGTTGTCTTTCTAACATGGTGTCTCCTGGA
ACTGCCCTGCTCCCACAGTTACATACAGGCTAGGGAGTGGGTAGGAGTGGGGGTGAAATCCTCTTAATGTTTATGGT
GTCAGTAGATTCAAATAAATAAATAGCCTTACAGCCATACTCCTAATAAGGGGCCCTGGCATATTTAATTGATTTAA
CAAATTTATCAAAAATAGATAAACTGAAATCTGCCTTGAAATTAATTACTGTATCTCTATTTTTATAAGAAAAATATT
TTGGACCCGTTCCCTCTGCCTTATGGGTGCAACTCCCGGCAGAAATAGGTCATGTCTCCTGAAAAATAGTTCTTATTTT
CTTTACTACTTATGACCTCTTATAGCCTAGAAAGTTTTCTTGTCTATTTCTAGTTGAAATGCTAATCTGGCATAATT
TCTAGTTGAAATGCTAATCTGGCATAATTTCAGAACTAATTTCTGTTAATGCCACTTGGAACATCTAAATTCCTCC
TTTTTCAATAATACTATATTTGTGTGTTGCAACACACACAAATCATACTATATTTGTGTGTATATATAGTAAATTC
CAACTTATAAAAGTAAATTTGGAATTTTTTCTTTCTTTGGAAAAATTTTTATAAATTGAGAATTATAAATGTCACCT
TATGTTCACTAATATGGTAAATGAAAACCTTTATGTGTGTATAGGCTCTTGTTAATTATAACCTACCTTACAGGAAA
AACAGTCTTGTGGAAGGTAATGGTGCCAGTTGAGAGAAAAATAGAGAAAGTAGAATAGTAGTAAGAGAGAAAAATAGAAT
TTCCCGTTTGAATAAAGCTAAGTAAAAAGTGAATTGTTTCAGTTTTATTTATGTATTTGTAAGTGTGGTCTCATGC
CATATATATTCAAAGATAGACAGAGATCTTAATCTTTAATTTTTTATGGCCAAAGAAAAATGAGTCCCATGTAAAAGG
GACATTTTCGTAAGCTGATCTCAAGTGGTGTATTTTGATTTGCCGCAGCAGCCTATGGAAGAAATATCATTTTGGCT

85

CTTGTAATAACATAATTAGAACATGAAGTAGTATGTTAATAGAGGTTTTACAAAAGCTGTGGAAGCTTGTCTTATGA
AGTAACTAATTCCAAGGGAGAGAAGCCTTATGGAATAGTGACATTTTAGATAGGGTGTCAATTCTAAAATACAGCAAA
AGGCCACAGTAAAAAAGGAATTTTGGTTGTTATGAAAAATTTTCAAGATTTTCTATGTTTTTCACTACAGTATACATGG
TGGGCTATGTGAATGTTTGTATAGGGACCAAAGTAGGAAAGTGAGGTTGTCTGTTAGAGAGCGCTGAGAAAACCGAAAA
TAGGGAGAGATGAGTTGGAATATGCTGAGGAAAAAGTTATTAGGAGTTTTCAAGAAAAGGCCACGACAGTGGGGCTAGA
GAGAAGAGGCTAAATTAAAGAGTCATTTCTGGTTTAGAATTGATAAAATATAGAGACAAGCATGATAAGAAAAGAAGT
CGAGAAGTAAACGATGGTCTCAAGATTTCTAGCTTGGAATCATTGACTAAAAATTAAACTAAGGACTGGATTAGGC
CATTCTTGCATTGCTATAAAGAAATACCTGAGACTGGGTGTTTATAAAGTAAAGAGGTTTAATTGGCTGACGATTCT
GCAGGCTCTACAGGAAGCATAGCAACATCTGTTTCTGGGAGGCCCTCAGGGAGCTTTTACTCATGGTGGAAGGCAGA
GCAGGTGTAGGCATTTTACATGGCGAAAAGCAGAGAGAGAGAGTTGGTGGTGGGGGTGGGTGGCTACCTACTTTTTAAA
CAACCAGATCTTGGAGAACTCACTCATTTTTCATGAGGACAGTACCAAGAGGATGGTATTAAACCGTGAGAAACCACC
CTGATGATCCAGTCACCTCTCACCAGGCCCCACCTCCAACATTGGGGATTACAATTTAATATGAGATTTGGGTGGGG
ACACAGATCCAAATCATATCAAAGACTTGCATGGGAAAAATAAGGAATTGTTGACATAACATCTTTGAGGTTACATC
AAATGTTCTGATGAGGATAGTCCAAGTAGCAGTTGGCTATATACCTCAGATAAGGGCTGAAATTTGGAGCTATGTCA
TAATCAGCCTAGATTAAAGAGTCAATAATCTCTGCCATGGGCCAATTACACCCACCCTTGTTTTTGTAAAGTAGT
ATTGAATCCCAGCCATATCCATTTGCTTATGCTCCATGTATACCTTTTTTTTTGAACTTCAAGGCAGAGTTGAGTAGT
TGTAACAAAAACCATACGGCCCAAAAGCCTGAAATATTTGTTCTCAAGATCTTTATCTATAAAGTTTGCCAATACC
TGCTGTAGATGTTAGTTGAAGCTTTGAAAGCAAAATGAGGTTTTCATAAGGCAGTGTCCATACAAGACATTTAACAAGT
TTACCTATAAAAACTAGAATTCCTTTGAGGGGAACACATCCTAGTCTCCATTAAAGCACAGTAGAAGAGTCCCTTATA
ATGGGAAAGAGGTCACTTTAGGTGTTGATGTTGGTGGTACAGGTCAAAAGAAAATTTATCTTTGCTGTTTATTCAGAA
TGCAATAAGTGAAGTTATGAGAAATAAGGGAAAAAATGTGTAGAATTTCAACAGCGAAGAGAGGGGATAAAGGCATG
AGAATGAGTTCCTAAGCTCAAGTATTATAAACACTGTGAGAACTTAAAAATCAAAGTATGACTCCAAACGTATTTGA
AGCCTGAGAACAAGGCTCACAACTAGGGAGGATTAGGGATCAATAAAATAGAGTGTTACAAAGTATAATGTCAATC
CAGAGTTGTAAAAATATCAGCATTGAATATATTGAAAGCAGTAAACTGAATGAGGAGACTATCATTTTATATCATC
GTGTTTATTTCTTTGCTTGTCTATAAATATTTAAATTTATAAAATTTTTATTAAACAGTGAAGCAGAACTACCAG
AGTGAGCAGATCAAAATTTGGGACAGATGCTTTTCACTGCACACACTTTTATTTTTCTGCTGTTTCATGCATTATCTTG
TACAGTGCACATGTTTTACCTAAAAAATTTAAATGGAGTCTCCTGCTTAGGAAAAAAGTATATATTCTGTTTCAAAC
TATATACAAAAATAAAATCCAGGTGACTAAAAACTGACATGAGAAAAAAACAAATTGATAAAGCTTTTACAGTAAA
ATAGAGGAGAATATGTTAATTAATATAGGGTAAGAAAAAATGCTTACACAAATGATGAAGCACTAATCATGAATAA
AAATAATAAAGTGGACTACCTTGTATATTAATAACATCTATACATCAAAAGACAGCACTGAGAGAGTAAAAATGAAA
CCCACAGAGTAGGATAAATTATTTGGAATACACACATAATGGATGAAATGTGTGATTTCATAATTATAAAGAATTCC
TACAAATCTTTAGAAAAGAACAGATAATCCAATAGAAAAATGGGAAAAGTCTTGAAAAGTGAACCATGGCACAAA
AAGGGCTTGTGGCCTGCTGGCAATATTCTGTATCTTGACCTGGATGGCATTTTTTAAGGTGATCACTTTATAGTAAAT
AACTAATGTGTTTTATGCATCATAGTAACGTTAAGATTTTTGTCTATCTTTACAAAATAAGAAATCCAAACGGCCAAT
AAATATATAAAGAATTTCTAAGTCCCATTAAATGGTCCAGGCCATGCAAAATTAAACTAAAATGAAATATCACTGCTT
ACCAACCAGAATCATTGAAATTTATAAGTCTGACAATTCATGTGGTGGTGAGAATATACAGCAATTAGAAATTTCA
CACAATGTTACTTGGTCTGTGAATTGTAAATAGAAAGTGAAAAATTACACTACTGCTTCTTGGAGTGAAATCCATTG
GCACTATTTAGTAAATTCAAAGATCTGCATAACCTATAGCCCACCAATTTCACTTCTATATATACACTCTACAGAAA
TGCATATGTTTATATCCAGGAGACATGTTTGGGAATGTCATAGCAGCATAGTAATAGCCCCAAACCAAACTACTT
CAGTATTTATTAATAGTAAAATTTGCTATAGTTTGAATGTGTCTCTTTCCAAATTCAGGTGTGATAATGTGCTAGT
ACTAAGAGGTAGGGTGTAAAGTGGTGATTAGGCCATGAGGGCTCCTTCTTTGTTAATAAAAAATAAGACCCTTATAA
ACAAGGCTTACGACAGCAATTCAGTCAGCTGCTTCTTCTGCTTCTTACCTTCTGCTTGTGAAGATACAGCAGGAAG
GCCCTCACCAGACACCAATGCCAGAGCCTTTTCTTGGACTTCCAGCCTCCAGAACTGTGAGTGAATACATATTGGT
ATTATTTGTAAATTACCCAGTCTCAGGCATTTTGTATATAACAGCACAAACAGACTAAGACAATCATACAGTGAGAAA
TTAATCAACAATAATAAGCAAAAGAGGTAGATTAATCTTGAAACTATGATATAGAGTGTTCCATTTGGCTGCTGGAA
GTTTTATTTCTTGGTCTGGGTGATGGTCACCATGGGTTTATATGAATGGTTCCCTATATTATGTTTACAAACAAAAA
GCATTTAAAAAGTAAATATATGTAATGTACTCAGGGATAGGCATGGCCAACCATGGATTCTATGCTGAAATAATGAT
TCAGATTTTATCAGCAGGCTAATGACACTGCCTATTTAAATACTTTAAGTCTGAAATTAAGAAGGTAATTTCTCA
AGAAGGAATTTCTAATTTATGGGTGGGTCTATTCCCCACCAGAGAGACACTAGCATGGCTCAGATTCTATGTTGGTC
ATTTTATTTGCATTTAAAGTCTTAAGCCAAATAGAGGTACACTAATAATGACAACAATACTACTACTACTACTTGT
GGAACACTGCCAGATGCTGTTTTAAGAAATTTGCATTTTCAATTTGTAAGTACTGAGCTTACTTGAATCTTCTCTCTTTT
TTCTTGGTTAATCTAATACTAGGTCTATCAATTTTACTTATCTTTTCAAAGAATCAACATTTTGTTCATTGATCTT
TTATATTTTTTGTTCATTTTCAATTTTCAATTTAGTTCTGCTCTGATCTTTGTTATTTCTTTTCTTCTGGAGCTTTGTTGGCT
TTGTTGTTGATTCTCTAGTTCCTTCAGGTGTGATGTTAGGTAGTCAGACTGTGAACCTTCAGGCTCTTTGATGTAGG
CATTTGGTGCTAGAAAATTTCTCTTAGCCTTGCTTTTGTCTGATCCCAGAGGTTTTGAATAGATTTTGTGTGAAT
GTGATGAAAACGGAACATTTGTACACTGCTGGTGATTGTAAATTAGTACAACCTACATGGAAAACAGTATGAAGATT
TCTTAAAGAACTAAAAGTAGATCTAACATTTGATCTGGAAATCTCACTACCGATTATGTACCTAGAGGAAGAGAATT
CATTATATCAAAAAGACACTTGCACGCATATGTTTATAGCAGCACAATTCACAGTTGCAAAGATATGGAACCATCT
AAGTGCCAGCCGACCAATGAGTGGATAAAGAAAAATGTGGCATATATTTTATATACCGTGAAATACTATTACGCCAC
ATACCATGCAATACTACTCAGCCGTAGAAAAAATGAAATAATGTCTTTTGAGCAACTTTGATGGAGCTGGATTGCC
ATTATTTCTAAGTGAAGTAATTCAGGAATGGAAACCAAAATCTGTATGTTTCTCACTTATAAGTGGGAGCTACGCTGT
AGGTACACAAAGGCAGACAGAGTGGTAGAATGGACTTTGAAGACTCAGAAGGGGCAGAGTGGGAAGGTAGTGAGGGA
TAAAAAATTACCTTTGGGGTGTAATGTACACTACTTGGGTGACACGTGCACTAAAAATATCTGATTTTACTTCTATAC
AATTCATTATGTAACCAAAAAATCACTTGTATTCCAAAGACTATTGAATTTGAATTTTTTAAAAACATTAATAAAAT

AAAAGATGTAAAAAAGAAAATTTATATATACTCATTATTGAGCTCCCACTTAACCTTAGGAGGTAAGTACTTCA
TAATTGGTAGTATACTTATCTTTTACTAAATATTTGTATTACTTGGGAAGTTGAGGGTTGGGGAGAAGTAGCAAGGT
ACTATGATTTGGGGCAGATAACTAACTTATTTATTCGCACATACAGTTTGGACCATGAGACACGAGCTCAGGTCCCT
CCTCCTCACCTAATCAAAGATGAAATATGTGGGATGGGATGAAATAATCAGCAGTCCAATGCTGAGTTTCCAGACCG
AAGTATAAAGCAACAATGGATATGTCAGAAGTCTACTAGGGTGTATTATTTAAATCTATTTTCATGGAATTTACTA
CCACCTTAATGGCCCGAAAGTGTTAAAGTATGCCCCAGAGTACCGAATTACTCCCTAAATGTAATTTATGCTTGAGA
ATAATCTGACTAACTTGATTTAGAACATCAGAAAAATAAGTTATGCTGCACATAAATGAAGCAGCAGTGAATTTTAA
ATACCGGTTGCACGGTGAATGAGAATTTTAATATTTGCAAAATCTAAATCACTTGATTTATTTATCCTTATGTTTA
TACTGACATTTTTTTGCCCTTTGTAAAGTTCCATCCATATTTCTTCTTACTGCCAAGAAAAAACTTTTTTTCCTA
GAAATATTACAGAAGGCAAAAATTATATTTGTTTTCCCTGAATGCTATTTTTTGATGTCTCTACTTGTTCCTATTGTT
ACCATTTGCTTCATTCATGCGCAGCCCAATTAATGGAGCGAGACAAATTTAGGGAGCACAGTACTAATTAGATATT
AAATTGGTAAATCTAACTTTGTAAAACAGAAAAAATATATATATATTTTTTTTCATTTGGAATTTTCTTGTTGGAA
AAGAGTTTAAAGTAGTCATGATAAAAAATGTAATTTTACGTAGTAAATCAAGAATAGATTTAGACTGTGCTATTA
ACAGCACCTATTAAATACTGAAAAGTGATTTTTAAATTTTATGTGAGGCTTGAATGGAGTCTAAAGTATTATTAC
TCACATTAAGTGTATCATCATGTAAAGCCCATGATTTTATTTCTTAAATATTTTGTGTAATAGTTACTTATTTCAAC
AGTAATTTCAATAATAAAATTAATCAACTTTACAGTTTTCAAAGTTTAGCAGTTGCATGCTGTAATAAATACTTC
ATATTTATATATTTATAAAGTGACAGCATAAGTCATTTTATTAGTCCCTTGAGGATGCAAAAGTTTGGATTATACG
AGGAGACGAGAGAAAAAGGGAAGAAAGGGCATTTTCAGAAATATGCTACCGATATGCAAAATTCACAAGTCCTAAGACAG
TAGCAGGGGTCGGGCAGAAAAGTCCATCCTGCTCCTCTTGTGGGCCTGGAACAATGGTGTAAAGTGAAGGCCTGTT
CCCCTTCTCTTCTACCTCCAGCTCTGTCTTACAGAGCTACGGATACCATGAGCAAGTGTATGAACCTTACGGTTT
TCTTCTCTTGGGAGAATGTAAAGGAAAGATAACTTGTAGAACTTGTAGATAACTTGTAAAAAGGAAAAGAATTCAG
GGTGAGAGGGGGATTTGTTGAATTTGATAGAGGATGGCAATTACCAATATGATGAGTGATTGAGAAACAAGTCTGTG
CAACAGGTTTGAATCGAAAATCTTTGAGGTGTACAGGATCCTGAAATGAAGAATGGGCATTTATAGCAGTATGTCA
GAGAAGACAGTCACTCCTAGTAGCTAAAAGTGTTGGCAAAAGTATAGTTCAAGTGATTGGGTAGGAAAAACAGCAAA
CCAAGAGTGGAGCTGATGGTTGCTACAAAGGTGGAGTGGTAAGTCGTGACCAACTGGTACTTCTCTGTGCTCTGGT
TAGCTGCTGACTGTTTTCTCAGACTGTGGTAGCAGGAGGAGGTTGGAGTTAGCAGTCAATTTGCATATGAGACTGCCA
TTTTAAAAAATTTTAAATTTTTCATTTTTCTGACTCTCAATATGAAAAGCACATTGTAGACAAATTGAAAAATA
TAGAAAAATTATATAAGAAAAATATAGTCTCACCAGTATGGAACAATGCTAACTATGTTGCATAGATTTTTTAGATTCT
CATTCAAAAGCAACTCTTTGACTCCAGTGATGCAATGCATGTAACATATGCAATGTGCAATTCATTTTTAAAGGGA
ATAAACTTACGATATATTCATAGGTCATTTATTGTGTGTTATATACCATTGAAAATATATGAATGCTAAATTATTAG
TAAACATGCAAAAACATTGGCAAGATCATTTTGTGTGGAAGGATATATTGTATCTGAATAACTCTAGAATACCATA
AATCATCAAAGGCAACATTCTTATTTTCTACTAATACAGTTAGAGAATACCTCTTCGGCTACCTTCGGTTGCCTTT
TTTATGCTACCAAATGCTGTCTGTTTTACAAGATTTTAAAGGTTAAGCATATAATTATTTCATTAAATACAATGAGT
GCAATGTACATGTAGATACATTATTAATTTTGGGTAGTTAATAAAAAATAAGGGGAAAAAACCTCTAGAATATCAC
TTTTAATTGTTTAACTGATAAAGTGAAGCTTCATCTTGAAAAATAATTTTCACAAGAGAGCATGTGCACTGGTAGAA
AAGTGCCATTGAAACAAGAGATATTTGGGTTAGAAGCCTCTCTCTACTATTTAATACCATTTTCACCTTTTGGCAAA
TTACTTGGCCTCTGTTTTCTCCAATGGAAAAATGGGAATAATAATTGTTATGCTGCAGGGTTATTGTAGGTGTCAATG
AAATGATGTGTCTGGCACTATAAAAGCACAGAGCCCGGTGCTTGGCTATTAGTAACTGTTTAAATAAATGTTAATTC
TTTCTCTGCCCAGGACATCAGTAGGCAGATGTAGCAATTTAAACTTCTAGTGTTACTTTAAATTCCTGAATGAAGG
TAGAGGACTGAAAAGATATCATGGTATTCAAAAGTATGATCCATTGCTTCTTAAGAATAGAGTTTCAGAAAAGCTTGA
CAGATTCCTGTACTCTGAGGCAGCACCATAGCCGTAATCTGTAGGATGGCTATTGGTTTTGTGCTCACAAATGCTT
GCTTGGGCAGGCCCCAGGAAATCTGGTAGACTGTAAGCCAGTAAGATTTCAAATCTTACTTTACGGCAGTGTTTTT
CACCTTGACTGTACATTGAAATCACCTGGATGCTTTGAAAAATAACAGCGTCAGTGTCCAACCTCCAGAAATACATGA
TTAAGTTGGTCTGGAATGGAGCCCCAGGATCACTGTTTGGTTATTGTTGTTGCTGTGTTTTAAATGCCCCAGTTGAT
TCTTATGTGCAACTGTCTTAGGTAAACATACAGCCCTGGTTTCATATTATTTCTGCCTCAGTCTCTTTTATGACTGGA
AGGTGACCAATGCTTGTTTCTTAATATTCTTTCCATGTGTAGTATTAACACATTTGACTTGTACTAAGTTCCTGCA
GTATTCCAATCTAAATTTTATGTACTACAATAAAAAATAAGAGGATTAAAGAAAGGCATCGCATAGTTTAGTATATCG
GTTATTTAATGCTTACATGTGAGCCTACAATATGAATTATATCTGTCATCTTATTTTAAATATTGACAGAATCTTTA
ATGATAGTGACGAATTATTGATTTATTGGTGTGATAATGGTATTTTATGTTATATTTTTTAAAGTTTTATTGTAAATA
CTATATGTATTTATGGGGTACAGTGTGACGTTTCAGTGTAAATGTTTCATTGTGTAATGATCAAATCAGGTTTCTTGG
CAGATCCATAGCCTCAAACATTTATAATTTCTCTGTGGTGAGAAAATTTAAATTTCTTTTCACTATTTTGAATAT
ACAGCACAATATTGGTAACTTTGTTTCATATTACTATGCAATAGAACACTAGAACTTATTACTCCTTTTCAGTTGATGA
ACAGGCAGTTTTGGATCAAGAATAATATTGAAAGTGATAGAATTTATGAAGTAATTTTTATCCAAAAATATTTTGAA
AGGGAATATATTGCTTCCAAATAATTTATTACAATGTTAAGATATTTGTAAATTTCTAGAATTAATAAAAAATATATTT
TTAGGAAAGAAAATGCCAATAGTCCAAAAATAGTTGCTTTATCTTTCTTTTAAATCAATAAATATATTCAATTTAAAGG
GAAAAATTGCAACCTTCCATTTAAATCAGCTTTTATATTGAGTATTTTTTAAATGTTGTGTGTACATGCTAGGT
GTGTATATTAATTTTTATTGTTACTTGAACTAACTCTGCAATGCAGGAACTATCAGAGTGATATCTTTGTCA
GTATAACCAAAAAATATACGCTATATCTTATAATCTGTTTTACATAATCCATCTATTTTTCTTGATCCATATGCTT
TTACCTGCAG (SEQ ID NO: 269)

[000204] *Homo sapiens* dystrophin (DMD), intron 43 target sequence 1 (nucleotide positions 1057082-1057131 of NCBI Reference Sequence: NG_012232.1)

GTAGGTAACACATATATTTTTCTTGATACTTGCAGAAATGATTGTTTTTC (SEQ ID NO: 270)

[000205] *Homo sapiens* dystrophin (DMD), intron 43 target sequence 2 (nucleotide positions 1127297-1127546 of NCBI Reference Sequence: NG_012232.1)

TTTTAAAGGGAAAAATTGCAACCTTCCATTTAAAAATCAGCTTTTATATTGAGTATTTTTTTAAATGTTGTGTGTAC
ATGCTAGGTGTGTATATTAATTTTTATTTGTTACTTGAAACTAACTCTGCAAATGCAGGAACTATCAGAGTGATA
TCTTTGTCAGTATAACCAAAAAATATACGCTATATCTCTATAATCTGTTTTACATAATCCATCTATTTTTCTTGATC
CATATGCTTTTACCTGCAG (SEQ ID NO: 271)

[000206] *Homo sapiens* dystrophin (DMD) intron 43/exon 44 junction (nucleotide positions 1127517-1127576 of NCBI Reference Sequence: NG_012232.1)

TTTTCTTGATCCATATGCTTTTACCTGCAGGCGATTGACAGATCTGTTGAGAAATGGCG (SEQ ID NO: 272)

[000207] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 44 (nucleotide positions 6535-6682 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1127547-1127694 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATATTTAATCAGTGGCTAACAGAAG
CTGAACAGTTTCTCAGAAAGACACAAATTCCTGAGAATTGGGAACATGCTAAATACAAATGGTATCTTAAG (SEQ ID NO: 273)

[000208] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 1 (nucleotide positions 1127547-1127601 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATA (SEQ ID NO: 274)

[000209] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 2 (nucleotide positions 1127595-1127643 of NCBI Reference Sequence: NG_012232.1)

AAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTTCTCAGAAAG (SEQ ID NO: 275)

[000210] *Homo sapiens* dystrophin (DMD) exon 44/intron 44 junction (nucleotide positions 1127665-1127724 of NCBI Reference Sequence: NG_012232.1)

GAACATGCTAAATACAAATGGTATCTTAAGGTAAGTCTTTGATTGTTTTTCGAAATTG (SEQ ID NO: 276)

[000211] *Homo sapiens* dystrophin (DMD), intron 44 (nucleotide positions 1127695-1376095 of NCBI Reference Sequence: NG_012232.1)

GTAAGTCTTTGATTGTTTTTCGAAATTGTATTTATCTTCAGCACATCTGGACTCTTTAACTTCTTAAAGATCAGG
TTCTGAAGGGTGATGGAATTAATTTTACTGTTGTTGTCATCATTATTAAGAAAGAAAATTATCATAATGAT
AATATTAGAGCACGGTGCTATGGACTTTTTGTGTCAGGATGAGAGAGTTTGCTGGACGGAGCTGGTTTATCTGATA
AACTGCAAAATATAATTGAATCTGTGACAGAGGGAAGCATCGTAACAGCAAGGTGTTTTGTGGCTTTGGGGCAGTGT
GTATTTTCGGCTTTATGTTGGAACCTTTCCAGAAGGAGAAGCTGTGGCATACTTAGCTAAAATGAAGTTGCTAGAAAT
ATCCATCATGATAAAATTACAGTTCTGTTTTCTAAAGACAATTTGTAGTGCTGTAGCAATATTTCTATATATTCT
ATTGACAAAATGCCTTCTGAAATAGTCCAGAGGCCAAAACAATGCAGAGTTAATTGTTGGTACTTATTGACATTTTA
TGGTTTATGTTAATAGGGAACAGCATATGGATGATAACCAAGTGTAGTTTAATTCAACTTGTGGTGTCTTTGA
ATATGCAGGTAAAGATAGATTAGATTGTCCAGGATATAATTTGGTTGCTAAATTACATAGTTTAGGCATAAGAAACA
CTGTGTTTATTACACGAAGACTTAATTATTTTTGCATCTTTTTTAGCTCAAATTGTTTCATGTTGCAATAGTCAATCA
AGTGGATTTGAATTGTAGCCAATTTTTAATGCCAGAAAAATACTGATTAAGACAGATGAGGGCAAAAAACACCCAGTA
GTTTATTAAATACTTTAGATATTTCAAAATGCTGGATTCACAAAAGCAGTATCACATTTGACTTTACAAGTCTTCAT
TCTCAAATATGTTTCCATAGTAAATATGCCCTTTAATATTAAGGAGTTAAGCATTTAAACACCTATTTATATGATAA
GCTATTTAAACACAGAAAATATTTTTAAACCTTGTGTAATTATATGTGTATCAATCAAACCTTGCATGCACACCAGC
GTTGGCATTGTATAGAGAGGAAATGTATGGATTCCCAATCTGCTTTAATATAGAAGATACATTTTAAAAATAGCAC
TGAAGTGAATTTGGGCTAATGTAGCATAATGGGGTTTCTGCCTGAGAGGCAGAAACATATTAGAGTTATATAAAAT

89

GATGAGTGTCTGAATAGATGTGCATAGGTCAGTACTGACAGTATCTGCTACAGAGAATGAGTTTTCTGATTTTTATTAGGA
TACACCTAACATGGCAATCTACTGCCTCAAAAGAACTCTATAGGAGGTAAAGTGAATTTATATTAATACAGATTGAATT
AAAGGATAATCTAGAAAAAGGCATATGATGTAAAAAAATCAGACACAAGTATATTTTTCTGTATAGTCAGTTTTTACA
TTGTGATTTACCAGCTGGCTGCTGAGTTTGACGGCTTCTTAACAGCCACACTGCTGAGATTCAAATGCTGATAGAA
ACTTTGATGGAAAAATCACTGGAGTAAATATTTCTACCATCTGTTGCCCTTCACTGGGACCCTAACGTTAAGAATAA
TTCATACCATTTGCTTGTCTTTATATTTCCCCAGCAGTAATAAAATTCATAAGATTTTGTGTTTGTGGTCACAAAGC
TATCCTGGTTTTCTGTAAGTAAAGGTTACAGCAATGTGTAAGTGTGGGAATACATTTTAAATGAGCTTTTCAAAGTTAT
TCTCTAGTCACCTTACTTTAAGGTTACAGCAATGTGTAAGTGTGGGAATACATTTTAAATGAGCTTTTCAAAGTTAT
TAGCTGGTAGTGGCATGAGAGTTAAGTCTCTTAATACAGTTAAACAGTTGGGCACCTTCATCCTTGCGTAAATATTGT
TACCCTTTTATTGCTGCTTGGAAACTCCTCTGCAACTTTTTTGGCCCTATCCATCTTTTTCAGAAAGTAGTAAATAACC
AATTTACTGGGAGTGTGGTACCAGGCAGAAATTCGAGAGGGGCTTTCAATCCTTGCCCATCAAGTGTATCTTTTTCAG
AAATAAGTATATTAATAAATTGGATAATTTTCACTGGCTTGTATTAGACTTCCGTTGTCAGCATGGCATGTTTAA
GAAGATGACAGATTTTTCATACATTATTGGAAAGAAGCAAGAACAAAAAACATAACTTACTGTAGTAACACGGTAA
AGAAGTGTCTTAAATGCAGGATAAACATGTCATCCCTAAGGGATTCCCATCTTAGAGCATGAAATTATCAAGAGAG
TAAGAGACTACAAAAAATGAGAAGAATGCTGATTGCAAATTCAAAATAGAAAAAATCAAAACAAAACCTGCGCACCAT
CATTCTGGAAGCAATGAGAAGCAGAAATTGTCATTTAATGAAATGTAAGATTAAAGTTAATAGAAGTAATTTTCATG
AAATAATATTTTGAAGGACGATGTTCCAGCCATATTGATCTTCGTGTTTTCTTTTACATCCCTTCTTACTGTTCC
CTAGAATGCTTGTCTTCTACCTTTAAATTTGCTTTTCTCTTACCAGAGGGCTTACCCTATCTCCAGTTTCTCACCA
TGTCCCAATCTACTCCCTCTCAGAAATTTTGTACACTTCCCTTTATATATATTTGTGCTCTAATTTTATATTACAG
ATATGCCTTTTGTAACTCCCCCATCTTAAAGAAAAGCACACACGTACGCACACATGCACACACACAAAATTGAACCTCT
TTCTGGGAGATCTGCTTAACTTTCTTCATAACTCTGTCACCTGCTGAACTGTAGTATGTGTTTTCATGTTTATTAT
CTTTTCCATTAGAATGAACATATTTTGGGTACTTGGTCTTTCTCGATCACCAATATACCTCGGTACGTAGAAAAATT
GATTCATATATTGAAAATGTAATATTTCAGTAGAACGAATAAATACATAAAATAAATTTAAAAATGATACTTTTATTGT
ATTACCTGAGACAAATGATCCCCAAGTTTGTCTTGTCTTTTCATAGCCAAAACATTCTCTCTTACATTGAGCTTCTCT
TCACCTCTTCTGTGTACAGAGCACTTAAATTTTACATATGCCTGATACCTTTAACAATATGATGGCCCTGTTCTCTT
ACCCATTGGAGCATATGTTAAATACCAGAACCCTAGTAACAAACATATATTGTGATCTCATGTGTGCAAAAGCAGAT
ACTGCTTGCTGCTAGGAATACAGAGCTGACTAAGAGCTCCTTTTCTCTTTATGAGCTCACAGTCTCATGAGTTCAAC
GTCTTAAGGCACAACGTCTAAAGCAAAGGGCAGTAAGTAAACACTCCAGAAAGTACTGGATCTGGCCTAGGACAAAT
GGTGGGTTGTTTTTCCAGCTGTTATTTTTCTGCCCCCTAATTGACAGTCTCCATTACACCTCTGGGATACCTAGT
CTGACTTGGGAAAACCTGACTTTGGGAATCAGAGGCAGTCTCTCTTGCTTATATATGAGGAACCTAATGGATACTT
ACTGTCATTAGAGAACTCTGCTTCTAGCCTGGCTCCTTTGTAAAGAAGGTTGAGTCCCTTGGAGAGCCTGCAGA
ACATAACCATTTGCATGTAATGAACAGTTTGTAACTTTGAGATTGATGTGCAATTTCTATTTGACAAGGGAAAAA
CAATTAGGATTAACCGTGGTCGTATATCCCAGAATACCAACGTTGTTTCCACACTCTAAGTGTGTTGGGTCAATTAT
ATGAGATTTCATAATTTTGTCTGTTGTACCCACGTTTGCAATTACCATTCACTCTTAATTTATTATACCCTATTAAAA
GTTTTTTTTGGTAATTTGTTCTTATTGCTACTCAGGCATTAAAAATGCTGTCAGGCTGTGAAAATGAATAAATTTAATG
TGGCAGCATAGTTCTCAAAATCCTGGCTTTACAACCTCATAGTACAGGCTTGATTGTAAATCCTAGTTAACATGGAT
TTATTTGAAAATCCAATTTTACTGCTAATCTTAAATAACACATTTTTTCAAACATTTTATCCTTGAATTTCTATTTT
TTATAATTTATGGCTGTTGTATGTATTTACAAAAGGACAATGTGTGTACTTTTAAATACTAGTAATGGATTGCTGAA
ACAACCTGTAACCTTTAAACAATGCAATTTGTAAAAAAATAAACTGTGCAGCCTGGCTTAATGGAGGCTTATGAACAT
ATGATTAAGATATATGCTATAATAAGCAAATTCACCTCAACTGATAGTTTCATAGGAACCTTTCAAATTTAATCTCATAA
CCAGTGCTATCTTTCAAAGAATGGTCAGGGCAATTTAACGAGTACATGACCACGCAAGATAATTTTCATTGAAGATG
GCTGACACTGTTGAAATATTTCTAGTCTCCTTGGGATATCATTAAGAGCAGAAATTTGAAATGGAATGTAATGAT
GTTTCAGAAAAGATAAGTAGGTAACCTCTTAATACGTTTTGTGCTGTGTAACAAAGTACCTAAGACTAGGTAATAA
TTTTGTAATGAACAAAAATGTATTGGCTCAGCATGTTCTGGAGCTAGGAAGTCTAACATTAAAGGTGTCAGCCTCTGGCG
AGGGCCTACTTGATATGTCATCACATGATGGACGATTAGAGGGCAAGAAAGATCAAAGGGGGCTGAACCTCCACTT
TTATAAGGGAACCAAACCCACTCGTGAGGGTGGAGCCCTCAATCCTTAATCACCTCCTAAAGCTCCCACCCCTTAAT
ACTGTCACAATGGCAATTAATTTCAACATCAGTTTTTGGAGGGAAAAACATTGAAACCATAGTAGTGATACTGACTA
CTACCACACAGGGCTTGGGAGGCTACCCTAGCTGTTGCACCCAAGAGATGAATCTTCTAATGTGATTACCTTTATCA
TTTTTTTTTACTTTATTAATAACTTTTATTTTACATGTATACTTTTGTCTACCCACCATTTCATGTCTGACCACTG
CTACTACTATGTCCTAGCATAACATTCCATACATCCTTAAACCAAGCAAAGGGTGGAGTTCCATCTTTAAAACTA
AACAGGCATTTTGGACAACACATTCTTGGCAATGGAATCTGGACAACATTTATCAAACATGGTAGGGAAGGTTCTCA
CTCTGCATTATCAAACGACAGCCAGATATCAACTGTTACAGAAACGAAATCAGATGGAAAATTTTAAACAAATTTGT
TTAAACTATTTTTCTTAGAGAGACTTCCCTCCACTGCCAGAGATCTTGAATAGCCTCTGGTCAGTCATCTGGAAGCAAT
TCTTCACATAATTCATGAACCTTGGCTTCCACTTTAGGAAGAGAACCCACTTTTTCTATACTTGCTTGCAATTTTGTCT
TTAATGTCTTCTACAGAACTAGGTCTTTTGGGTGTTTTAGGAGTTTTTCCCTGTTTTGAAGGATTCTTGTCCTTTTG
ATCTTGGTGTGACGGTTTTTGTGCTTTTCCATTCCGATTTGACTTTTGTGCATTTTTTGGCTGGAGTATCTCATATA
GATTTCTTCACTGGCGTTTTTCTTCACTTTTCCATTCATCATCAAAATCATCATCATCAAAATCATCATCTTCATC
AGCAGCAAGTTTTACTTTTTTCTGTGGAACCTTGCTACCACCTCCAGGAGCAGATCGCTTTCCAGATATACTTATGA
GTTTCACATCTCCTCCTGTTCTGCTCTTCTGACTCTGTATCTTCTCTCCAGCTACTAAATGCTGTCCACTCACATGC
ACTGGCCCTGAACCCACACTTCAACCCGTAAGACCCTGATGGTGTATTTTCAAAGCCCTCAAGGGAAACCATGGGCTG
TACAGACATTTTCAAAGCTGCCAGTGTACTTTAATTGAGACTGCCTTTGTAACTCATTGCCTCTGCTTCAACAATGT
GCAATTTATCCTTTGCCCCAGCCCCCTAAACTGACCGTTCTTAAAGATAACTGTTGCTCAATTTCAATTATTATCCACC
TTAAAGTGATCATCTTTGTGCGCCTTTAGTTTCAACACCAAAAAAGATAGTTTTTGGGGCCTCAGAGGACTCATGTCCAT
CATCGTCCATCAGGTGGCAGGACGCACTTAGGTGGGAGAGAAGGCAGATGATGATAAAGGACCCTGCTCAAGAGAA

91

AATAAAATCACAATGTGAGGTCTCTCTTTAGAGCTGCAAAGTCCAATTCAGTGCCCCCTAGCCACATAAGATACTG
AGCTCTTAAAATGCGGCTAGTACTAATTGAGATGGGCACTGAGTATAACACACATGCCAGGGTTTGAATACTTAGAA
CCAAAAGGAAGTAAATGCTCATTTATTGCATGTTAAAAATTATGGTTTTATTATAGTTGATTAAATAAAATATATAA
TTAAATTGACTTCATTTTGTCTTTTAAAAATGTGGCTATGAAAAATTTCAAATTATATATGTGTGTGATTACATATGT
GTGTTTTACATATGTAACCTGATGTTACATGTGAAATTTGATTGTTACATGTGACATGTAAACACGTTACCTAACAC
GTGCATATGTATGCAACACATATGTAACGTGTTACATATATAACACGTTACATATGTATTGTTACATGTGTGCTTGC
ATTACACACATGCATAATATGAAATTACATGTAATTTCAAATTACATGTGTATATTTTGAAAATTACAAATTACGTA
TTTTGTTATTTTTGTCTTTACAAAGTCAAATTTACCTATTTAATAAAGCATCATGAGTTTTTTATAACTAGTAAACT
TTGAGACTTTTGTAGGAGAATAAATAATGCTTATTATAAAAACTGATTGGAAAAGTGAGCTGGAGCAGGGAGCGGAG
GAAAAAGGACTAGAGATCACCTTTCTTCCCAGCTCCGCTCCTCTCCCAACCTTTTTTCTTTCCATTCTCTCATCCCA
ATTCAAAAGTGCAGAGTTCACAGTTGGTGTGCTGATTTAGAAAAACAGATATATAAACAGCCTTAAATTTTCTCCAGG
CTTTTACAATGAAAAGAAGTTCAATATCAAAAAGTAACAATATAATCTGTGGAAAGGTATAGGGGGCTATGTTTTTGA
GGTAGAACTATAGGTGCTCCTGGCCAAGCATGGTGGTTCAAGCCTGTAATCCCAGCACTTTGGGAAGCTGGGGCGA
GAGTATTGCTTGAGCCAGAAGTTTGAGTCTAGCCTGGCTACAGGGTGAAACTCCACCTCTACTAAAAATACACAC
ACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
CTACTCAGGAGGCTGAGGCGGGAAGATTGCTTGAACCTGGGAGACAGAGGTTGCAGTGAGCTGAGATAGCACCCTG
CACTCCGACCTGGGTGACAGAGTAAGACTGTCTCAAAAAAAAAAGAAAAGAAAGTATAGGCACCTCCTTATATG
CAGCTGCTCACACCCCTCCTCCTTCACACCCCTCCCCCTTCACACCCCTCCCCCTTCCCCAAAATTTGCAAGGGGAA
AAATGTGTGTAATTGGCAGTATTTAGTGGCGTGCAACCGTGAGTCATCAGACTGCACATCCTCACTTCTGCTAGTGG
CTCAGTACCCAACAGCACTCAGTGAAAACTAACTCATTTCAAAGGTGAAAACAAGTGAGTTTGGCCACCAGGGAGTG
TTCAAACCTGTCAGTGCTGAAGCAATGTGGAGGGTGTCTGTAGTTTGTTCAGGTTGATATTTGTGGTCCAACCCC
TAGCTGAACTACTAATTATTAATATCTGTCTTGATGGTGCCTCAGGAGAAAGCTTCTCAAAGGGAATCAATGTTCAA
ATTATAGTAGGTATCTTGCCATGGAAGTTATTGAATTTTAGCCAATACTTGCTACTCTTTCATTTATAGTGTGAGA
ATGCAGTGTAATGAACCTGACTCTCACTGTCTGACTTGCTTTCTCATCGCATTACAAATAAGCAGCTCAATACGT
ATACAGATTTTCATATTTTAAAGTTTACTTTATTTCTTATTGTACATCGCTGTGCTGATGGAAGAGAAAAGGA
AAAACACTATTGATTGCAAACTGTTTTATCTTTGGTGGCTTAGATTTTTTTTGTATGATATGTAACGTCTTGCTATA
CCTAAGGCAACACGAAGCTAAATAGATTTGCATATAGCATGTATTTTTTCCAATTAATGTTTAATTTTGTTCAGAG
TATACTGGGGACATTTTGAATAATGGAGAAAAAGTACAAAAGAAAATTCATAATTTACCACCTATCAGCACAGTGAAA
TTTTATGAAGAAACATAATTTTCATGTAAATCATAGTGAACCTACGGTAGGTTTTATTTAATACAGTAATTGGAGAG
CTGGTAGGAAGACAAAACCTGGTTCAAAAGAGAATACAAGAAAACAAATGCTTCTATAATGAGTGAATTTTTAAAAAG
TATTCTGGAATAAGATTAGTGAATAAGATACTAACTCGTTGATACCTACAGCCTTTGGGGTTATATCCTCTACTG
GGTAAAAAGTCATTTACATCATATCAGTTTTCTAAAATTTGCATTGAACCTCATAGCGTTGTAACATGTGTGGGCCC
AAATTAATAGTAAACAGTAAGAGTTGCTTTACTCTGAAAAATTTGAAGCTCTTGTGAGGGTGTGAGGAGTTTGTAG
AAAACAACGCTACCATTATTTTGAAACACACACGATCATCTTTTGTTTTACTTCTAAGTTTTGGATAATTTTTCTTA
AATTATCTTATTATCTTATCCATTTTCTTAATTTCTTAACCTTTTAAATGTTTCTCCTAGGCACTTTTATTGATTT
TTGGAATATAGTTGATATGTGCTGAATTTTTATCATCCAGTTTTAATTCTACTGAAAAATCTAAAAGATGTTTCATCA
ACTACTATATTTCAAATGCATACATCCCCTTTTCATGCTAAAAGAACTGTATGGGAAACACAGTCTGACATTTTCAGG
ACCTGGTATCATTAAAAGTCTTGACACTGTTAAAAATTAACAACGCCTTTTTTAAAATCAAAGGATACAAAAGGGCT
GTGTTGGTCAGAGGATACAAAATTTAGTTAGATAGGAGACATAAGTTTCATGAGATCTTTTGTACGACATAGTGACT
ATAATTAATAATAATATGTTTTCGAAAATTACTAAGAGAGTCGATTTTAAGTGTCTCACCAGCAAAAAAATAGTATG
TGAGTAATGCATATGTTAATTAGCTCATTTTAGCTAGTCCACATTTTTCAATACAATGTGTTGTATAATACGTGAT
ATATACAACTTATATTTTCCAATTCCAATAAGTAAAAATAAATGTAATTTATTGAAAATAAAATAAATGTAAGAAC
ATCCACTTTTTCATATGAACCATGAGATATTTTCTGTATAAAGATTAATGTCCAATAAAATTTTGTATGTTAACAGA
AACAAAAATGTTTAATATTTAAATACATATTTTGCATGCTATTGACCCCTGAAGTTCACTGTGGGCTAAGTGAACC
AACTATATCTTAAGTCAAAAATGCTGAAATTTCTTCCCCAAATCCCAAAGCTCATGAAAACATAAACAGAAAATTTCC
AAATAATTCTACAGGGAAAATAAGACACACTATTTGATCTGATCAAAACAACGGGATGATTATGGTTAATAATGAGTT
ACTTGTACATTTAAAAATAACTAAAGGAGTGTGATTGGATTGTTTGTAACACAAAGGAGAAATGCTTGAAGGGATGG
ATACCCCGTTCTCCATGATGTGATTATTACCCATTGCTGCTGTGTCAAAACATCTCATGTACCCTACAAATATAT
ACTCCTACGATGTACCCACAAAAATTAATAAAAAAGAGAGGGACCCGAAGATAAGCTAATATTTAAGCTCATCAT
ACTTATTAAGATAAGCAATACATACCGAAAGTAATAGCATTTAAACCAGATGTTGGGGGAGGGTTCTAACTTGTTT
ATTAAATTTCAAAGTCACCTGTCTTGTTTTTCTTTTGTTTTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
CTCTGTCACCCCAGGCTGGAGTACAGTGGCGCGATCTTGCTCACTGCAAGCTCTGCCTCCCGGGTTTACGCCATTC
TCCTGCCTCAGCCTCCCGAGTAGCTGGTACTACAGGCGCTGGCTACCACGCCCCGCTAATTTTTTTTTGTATTTTTAGT
AGAGACGGGGTTTACCGTGTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTGCCACCTTGGCCTCCCAA
AGTGCTGGGATTACAGGCGTGAGCCACCGTGCCAGGCCACCTGTCTTGTTTTATCATGATCCCAGAGTATATATGT
ATGTGTACAGCTCATCTAAACCCCTTTTTCTTTCAACATGATCAATAGATTGAACATTGGAGATATTTTATAAGAAAT
AATGAAGACAACCTCAATCAGCACATATATATATAATGTGGAATCTATAATGATTGCGAAGCCTGAAGCAAACCTAA
ATATTAGTAATAGGTTCTTTTTTCCATGGTATATCCATTTGAATATATAACATAAATGCCTTACATTTGTTTTAA
CTAGTTAAGTTTTATGTTGTAGTGTGATGAAATGGCTGGCAAAAGTCAGAACTCAGGAAAGTTTTCAGGCTTATAT
CTGGAGCCTGGTTTTCTTTCTCAAGGTAGAACCTCTGTGAAGTGAAAAATTTTTTTTATATCTGGAGCAATAATGT
AGAAGCTTAAATGATTATTTCAAGTTGTCTATAAGCCTATTATTTCTTTTACATTACTGAAGTGAAGACAGCATTAAT
GGCTAAATGCCATACTTGGCTATAATTTATATTGTTTAGGACTGGAAATGAGCCTGAAATGTACATTTTTTTTCCAAA
ATAGTTTCATGTAATATTTGAAACCTGACAAGTAACCTGATGATTTTCATGGAATACCATCAAATATAAATGTGAAGTT
TTAAAGACACAGGGAAATACTCAGAATAAACCCCTTAACCACAGGCCAGCAGAAGAACTAGACTTGAGAAAATGAAT

GGGAAGATAGATAGTAACAAATGACTTCTTTGGCAGCCTTATATATGCTTAGTCTTATAGACTGTTTTATGGATGCT
CTGCACTCTATTTCCAGCAAGTATGGCATTGGAACAGGACCACACGAGACAACTATGAGTTCACATTTCCCACAA
CTGCACAGATAGAAAGAGGGAACAACAGAATACTCCCTTTCTTCTTGAAACAATAACTTCTGTTGAAGCTCACTGGC
TTCTTTTTCAGCTGTTTCTGCTAGCTCCTCCTCCGCTCTTGACCTCTAAGGCAATGCTCTTCAAATTTCAAGACTG
CTTTCTAATTGAAACAAAACCTTATAAGCACATTTCTTCCCACAAAATGTACATTTATTTGTAAATCATATATGAATA
TGACTAAGCATGTAAACGTATGTGAAAATAGAAATCAATAAATATAAATGCAACACAAAATAGAAGCATTACAGTT
TTCTTTTGTGTCCCAGTGAGTTGTTCCAAATTCCTCGGAGGTAGGTATGTCACAGTTTGAGACTATACCTTCAATCC
TAGGGTTTCTGGTTTCGCTCTCCTCCTAGGTGATAGCATCCATTTCTACGGACTTAACAGCCATCTTTAGTTGAATA
ACTCCTCTATCTTTCCATCCCATATTTCTCTTGATTCCAAACCTGCTTGTTACCTGAGCATATGACACAATTCATT
GGCTGCCGCACATGCAGCTTTGACATTTTATTTAAAAATCTTTCCCTTCCCCAGCCCTCATCTATTTACAGTAGTA
TCTTCTTCTTATCTACTTGATTGGTAAGCAGAGTCCACATGATTCCATCATTATCTCCCATTTTATATCTAATCTA
TAAGCAAGTAATGCAATGCAACTTCTGTCTCCAAAAATTTATTTTGAATTTGCCTTCTCTTCTCTGCATCTCCCC
ATCTTAGGCCAGGTACCTCTGCCCTCTTGCCAGATTAGGTACACATTCTTACTACTGTTGTTATTTCTCTTCTTAT
TCAATCCTACACCGCAGCAAAAATGGATCTTCTCAAAATGTCAGCTAGATAAAGGCATTTCTGTGCTTAAGGCCCTCA
TGGATTTATCTTATTAGGATGAACACCCCACTCTTTATTATGGCTTAGAATAACAATGAATTACAACACATAATGAAT
ATATTATATTTCTATCTTTACCATTTTCTTCTTAAGTCAACCTTTCTCAATCCATATAGGATAATCATATTAGTGCT
TCCTCACTTTCTAAAACATCTCAGGGCCTTTGCACGTGTTTCTCTGTTCTTAGACCCAGAATGCTCTTCTTTTCTC
TTTGTGTAGCTAGGTGCTTCTTTCCATTTACGTATCACATGAAATGCAGTCATTCCCTCCTCTTCCCTCACTACCT
CACAAAAAGTTGATGCCTCTGTTAAACCATGAATGGAATTTTACTCGGCAGTGAATAGAGGAAAAACCAATGGTAAA
AGCAACCATATGAATGAATGAATGTCAAAAAATATTATGCTGAGCCAAAAGTCATAGACACAAATATGGGTATTTACA
TGAAGTTAAAGCACAGCAAACTCAATTACGGTAATAGAATTAAGAAAAGTGGTTACCTCTGGGTGAGGGTTGGAATT
GAGTGGACAGAGGCATTAGTGACTTTTTCGGGGTAATGGAATGTTGTCTATTTTGTTCAGGTGGTGAATACATAGA
TACATTCATTTGTCAAAACACATCCATCCAAACACTTAGACTTTTGCACTTTATTATATGCAAATTATGCCTCACT
GAAAAAAGTTTGTTTTCAAATTTATATCAACAGTTGAAATCTTTTAAAGATTTGATTCAAATGAGATTAATCTGT
ATCCATTGATGATGATAGTTTGTATGTAGTTAAGGTTATTGGAGATAATTGAAAGTTATACCTACAAGAAGG
CTGCATAAATATGAAGTTTATCTGCCTTGATCTTTAATAGCTTTTCGCGATTTCAACTTCTTCACAGCTCTGTAAGAAG
GCAGTGTGGCATGTTGAAGCAAGCATGTGTTTTAGAGTAACACAGAGCTGGTATACAACCCCATGTCTACCAATTAT
CAATGATGTGGGTATGTTGCTGGATCTCAATAATCTTCCACTGTGAAATGGAATGTAACACCTGACTCACAACGCAA
AGGTATTTACCTTATGTAATATAATTCCTGCGATCTCGGGACCTCCCTTAATCCCATCCACAGATGCCAGGTAAAG
ACCCCATCACAGACTAGAACAGTTGGGATGTCAAAATGAATAAATATTAATCGAAGGGCTATTGTGATTGAACAC
CACGCAGTAGGCACTCTCTAATACCTACCGTCTCCCTCCTTTTGGGGGAAACATTCTAAATGTGCAAAAAATAAAG
GGTTATTTGCTTTCTGGCACTTGGGATCGATTTATTGAGGATATGTTAGCAGAACAGCAAAGGTGAAACACTAAAAG
CACCATCAATACACAGGCAGAGGTGAAGCCATAAAGCCTTTATTTTTTAAATTAATGCACAATATATAAGAGGTATG
TTAGAATGAACGTCCAATCCCTGAAAGGATATACGAAAGACATTCAATAAATTACATGGGCATGTTTTCTTAATGTT
CAAAATATTGTTTTAATTAGTGATTATGAGTTTATTCATGTGTCTGTGTGTTGTGTTATATTAATCTTTTCTTGCA
TTGCTATAAAGAAATACCTGAGACTGGGTAATGGATGAGAAAAAGACACTTACTTGGCTCACAGTTCTGCAGGCTGTA
CCGGAAGCATAGCAGCATCTCCTTCTGTGGAGGCTTCGGGAAGCTTCCAGTCGTGGCAGAAGGCAGAACGGGAGCAG
GCACTTCACCTGGCTAGAGCAGGAGCAAGAGAGACAGAATGAAGTACCACACACAGTGTAACAGCCAGATCTCAGAG
AACTCACTCATCATCATGAGGATGGCACCAAGAGGATGGTGTTAAACCATTTCATGAGAAATCCACACACATGATCCA
GTCACCTCCCACCAGGCCCCACCTCCAACACTGGGAATTACATTTCAAGATGAGATTTGGGCGGGGACACATATCCA
AATGATATCCATGTTTAAATCAGAAAAATAAAGTTAACAGTAACAGTGATTTTACTTTGTAGACCTTTGCTAATGGC
TGAATCTAGCTCCATTTCCGAGAACAGCCTGCGGTATACACATTTTGAAGATAGTTGATTAATGAAAGAAGCCTTA
TCTGTAGTCCTTAAGGCCATTATGGTTTACATATATGATGATAAATATCCAAAGTAGCCATTGCCAGTTAACATATATC
CAGAGTCTAAAGGCCACTGGGCGACAAAAGTAAAGATACATAGCAATTGTTACTTTTATATCAGTAATCTTTGTA
TATTTTAAATGGATATTTGCATTTGAGGATATCCACTTAAGAGTTAGGTACATGGCTCTTACATTTAAGTAACATTT
ACTTAAATTTCTGGCTGCAGCAATTCCACATAGGTAGAAATGAAGTCTGAATTGAGTTGGGGGTCTTTGCAGTGCTC
TCTCTGTTTATTGGCTATTTTGACAATGCTGAGAGATGTGGTTAGCCATTCTTTTTTCAATTTATATGGCAACCTAG
AGAGCAATTAAGCCTTCTCCCTTAACTAGATGTATGTTTTACTCATTCTCGGATCTTTATGGCTGACTTTGAATCC
TAGCCTGTGGTAGAAAGCATGGTGTGAGAAGGAACATAGAGTTAAGACTATGCATACTTGGCTTTGAGTCTTGGGTA
TCATACCTCCCTCATAGAGTGAAGGAACAGGGATTCTTCTTGAGGCCAGACCCGGCATCCATGTTAAGAATACCT
GTGCAATTTTGTCTTCTGATATTTAAGGTGAAATGCATGTTTGGGTCAATTGTGAGGATTATGTGAGATGTTACTTT
TAAATATAGGCCCCCTTATTATATGCTCTCATAGTTTTCAGGCAACACTTGTCGTATTTGTAACCTCAGTTTTAACTG
TAATGTTTTCCATCAATGTCCCTCTTACCTGGTACAGGGGCTCTTCATATTTCTTGGATTACAAATCTGTGAATGCAAC
CATGCATCAAAAAATATTGAGAAAAACAATGAATGCCTACCTCTGTAAGTATGATTTATAGGTGTTTTTCTTGTCAAT
ATTCCCTAAACAGTACAATGTAATAAGTATTTATATAGCATTTACATTGTATTAAAGTATTATAAGTAATCTAGAGAT
GTTTTAAAGTATATAGGAGGATGTGTGTAGGTTGTATGGAAATAGTATGTCATTTTATATGTCATTGAACATTTGT
GGATTTGCTATCCGTGGGGATCCTGGAACCAATCCCCCATGGATACTGAGGGACAATTGTATTATAAGCAGCAAGAG
GGAAAGGAATCTGTCTATTTTGCCAAAAATCGTGTTCCTGGGACCTAGCATAGCTCCTGGCAAAGAGTATACAACAA
ATATGCTATTGAGGAGAGAACAGAGGGAACCATATCCCCCTATTCTCGCTGTTTCTCATGTAATGAATAAACAGTC
AAATCTTACAAGAGATTTTAAACAGTCAGAGAAAAGTTGGAAGTTAGTTAGTTGTTTATAGTATTGAGAAGCCTCGA
CGCTGTGTCTATAGGTAATGAAAGATCTAGGGAAGTTTACAGGGGAGAAGAAGAGATGATAGTTGTCTTCAAAT
GTTTGAAGGACTGTTACGGACACAAAAATTTAAACTTGTGCTGAATAATTCCAAGAGGTACACAGTCTCTCGATAGA
AGCTAAAGTGGGGGGTGACATTTGACTCAACAAAAAGCCATCTAAATATCAGAACTTTCAAAGCAGGAACCTGGTGC
CTCAATTAATAGTGTGTTTTCTAGCACTTATGATACCTGATCATAGGCAAGATAATGAAAAATTTGGGACCTGGGAGT

TATACATGGGAATTTGTTTATCAGTTGGGTGATTAGGAGAGGTGGCCTTAAAGTCCTGTTGTGTTCTAAGAGTCTGT
GATTCTGAGTCTTATTTCCCAACAAGAGAGGTACAGAGCAGAAAGATGGGATTGGGAGAAATAGGATAAAGATACCAG
GAAATCCTAAAGGTAAGAAAAGGAAGGCAGACCTGAAGCTAACTCTATACTTCAGGTGCTTGCCTAGAGCCAGCCCT
ACCTACTTAGAGAATGTTGAAGAGCCAGTTAAAAACATCTTTAACACGGATGTAAAAACAAACTATCAAAACCTGAAG
ATTTTCGAATGTTCTAACCTACTCGTCAGTTGGGCTTTTTTCACAAATACTTCAGTAAATAGGCATAAATTTATTTTT
TAATGATAGAAAATATCTCTTAAAGAACTTATAACTGTGGATAAAAAGCACCACCATAAAAAATCTTGTGGTGAAATAT
ATATATATATATATATATATATATATATATATAAAATTTTAAATATGGTTAGCTAGAATATGACGACAATGTTTATGAA
ACACAGAGACTCTTGACAAGTCCCATGTATACACTATAAACTTTAAGTTATCCACTATTCACTACTAAGCTTATA
CTTAATGAGTGTCTGCTGTGTCACTTATTGCGGAAGGCACAGGCGGTATAGCATTGCACAAAACATATGTGGTCTCT
GATGGAGTTTTTTCAGTCTAGTGGTGAAAAGCAGTGAATGGGTGTACAGATGTTAAATAATTGTACAATTAGTTGCATG
TGTAACGTCAAAGTTCAGAAGATGACAATTGATCTACGGCAATGTTTCTCAATCTCTGACGTTTTGAGCCAAATAC
ATCTTTGTTGTGGTGGACTGCCCTGTCCACTATAGGATGTTTGGCATCACAACTGACCTCTGCCCATTAGATGCCAA
TAGTACTCTCTTCTTTAATCACAAATTTGTCCAGACATTTCCAAATGTCCCTTGGGGAGCAAAATCATCCCTAGTT
GAAAATCACTGGTCTAGGGGGAGGTCTTTATGAGGAAGTAACATCTAAGAAAGCTGGTATGTTTACATATAGCTACA
GTCTATTACACATGTATACATATGTAACAAGCCTGCATGTTGTGCACATGTACCCTAGAAGTTAAAGTATAATAAAA
AAAATGTAACAAAACAATACAGTATGATAAGTGCTATGGGACCAAAGATGAAAGGGTCTACTGCACAGTTATGAAC
TCATAGTTAGGCTTTTTGGGGTCAAAATTTTGTCTGAAGATATTTGCCACCCACGTGACCTTTGGCAGGTGACTTAGCT
TATTCATGCCTCAGTTTTATCCAATGTGAAATGGGGCTGGAAGTCCCATGTACTTCCTAATAACTTTGCGGAAATA
ATATGTGGTTATATAGGAAAAAAAAAAAAAAAAATCCTAGAAGTATGCCTGCTGCGTAGTAAAAGGAAGGAGAAGGATAAA
GAGAAATCTGCATTTTTTCTTCTGTAATGGGGCAGATAGTAAATATTTTAAAGTTTTGTGGCCCAAATAGTCTCTGTC
ACATTTACTTGTATTCTGCAGTTGTGGCATTGGAAGCAGCTATGGACAATACTTAAATTAGTAGGTGTGCCTGTGCTT
TCAATAAAATTTTATAAATACAAAGTTTGCAAAACAAAGTTGTTTTTTTTTTTTTTGTAGTTTGTGACACCCTAGT
AAAGAAGCACCATTGTCAACGTTAAAAATTATCAAAATTTTATTTTTTCAAAGTTTTCAAATTTGCTTTGCTTGGTCT
AGCTCATGAAATAAGTCAAAAGTAGCAAGACCTCCACCTCTAAAAATAATAAGTAAATGATAACCTCAAAAGGAAAG
AAGAAATATTTTTAAAGAAGAAAAATTATTGTTAAATAGGATTATTGTGCAGAGAAAACCTAGGAGACTCAATTTTTA
AAATCTGTGAAATAATTTTTAAAAATACTTTATGAATAGATACATAAATAGCTTTTATTCTATTTAATGACTATAAAATG
CAAATGGAAATATTTTCAATTCACACTGATGACAATGTATAAAATTAAGGAGGAATAAAAAATTGTAGACCCTATAGGTGA
AAAGCATAAAAAATATACATAAGAAAAAGCAAAAAATTGACTACGTAGGATTGTTTTAGGATTTAAGATTTATTGTCTAT
TAACTTGCAATACCAGCCAAGTTAACATTTGAATTTAATACAGTTATAATCAGAATGCTTTTGATGTGTTTGGGGG
CAATATAATTTCAAAGGAAATAGGCAATGATGTAATTTAAAGTTTATATAGAAGGAAATTGTGTGCGTGTATGTGTG
TGTATAAATTGGAACAATTTTATTAATAAGCATATTATGGCAGCAACATACACTTCCAGATTTCTACTATACTTTG
AAGTAATTGTGATCAAAACCACAGTGTGCTGGCATAAGGCTAGAGAAAATGGGTTAGTGGTTTACAAGTGAGAGTCCA
GGAAAACATCCAAATAAGATTGGATATTTTAGTCTGTGTGGATAGCCTATTTCACTTAATAAATAGTGTCTCGTAA
TTGACTATTCATGTACCTATAAGTTTAACTATAGACCAAAAAACGCCCTACTAGATTAAGGAGCTAACTAGAAATA
TAAATTCATATAAACAATAAAGGAAAGTGTAGGACTTTATAAGCTTCATGGGAGACAGATTTTTGGTAAGTCAGGAA
GCCTGGAAGACTTAAAAACATAAAATTTGGCAGACTGAATTAAGTATAGTTTAAAGCTTCCATAGAGCAAAATAAATC
ATAAACCAAGTTTTTAAATATATAATGGATTTAGAGAAGGTATTTACAAAAATATATGACTAATGGAGGTTAATAAT
AACAATATGTAAGAAGGATATGAAATGGCATTTTACTATAAAGGTCAAAACAAATGACCTATAAGCATAATAAATCAT
ATTAATCTCCACTAGTAATAACTACACACATCTACATAATATAGATGTTACGCCCTGCATTTGATTTACTTTATCTGT
CTTTTGGCAGAACTATTTGTCAACAGATAAAAAATTTCTATATCATTACCAGAAAAGGTATATTATTATAATGTTTATT
ATGTTGCAGTTGTAAAAGAAATAACAGCTTTTCAATTGTTTACAAATCCTATAGAACATTTACTGAAATACATTTAC
ATTTTGTGGCAAACTTGGATTTAAATACCGTGTTCGTGCTTTGTTTTATGCCGTTTTCCCATCTTTTCCAGGAAT
TTGATTGTGCTTTCATTGAAAGCTAAAAAGAAAAAAATAAATCTGTTTTGTTTTGTTTTAAAAAATAGTTAGGGGTT
AAAAAGTTGTACGTTGTCTTCTGTAAAAATAAAAAACAAGTTTTCTTTGTTTTCTTGGAGGCTTTATATTAAATGGAT
TTTTAATTCATAGACAGCATATTGTGATGAAATTTCCCCATGAGCTTCACATTTTGTTTTCAATAGCAGAACTAACT
TGTTTGCAGTTACTGCCCTTCTGAGAACAGTGTCTGGAATAATTTTGACATACATATGTATCTCTTTTTTAAACAT
GTGTTAATCTTTTCATAAAGAAAGTTTTCCAGCTGTGTACCTGTGACTCCAACCTTTCTGGGGGGACAGGGATATG
AGATGTTGGAAGGGAATGGCTTGAAGAAATAAAGTGCAAAAGACGTAATGCTTTCCCTGTGGTAGAAATGTATTAGT
GACCCTGAATGACCTTCTACTCTTGTCCCTTCATTTTTCCACAAAGTATGGTCTGGGCAATTATAAAAAATTGACAT
TTGCAGTGGGCTCTTCTGTAAAAGATGCTCAATCAGAAATGATTTATTTTAGAAAAAGAGATGATATAAACATATAT
ATCCCTGTCTCGGAAGTGTGAAGGTTGAAAAGCAAGGAGATGATCTTCAAAGTGTCTAAAAATATTGATTTGTAACA
TCGTTTTATGAAAGTGCTTCAGATTATTTTTTTCTTGGATGGCCCTTATGCTTTGGTCAGTTGATGCTAAAAATCT
GAACCTCTTTATTTTTAAAAAAAACTTTTAATTTTTGAAAAAGGAAGTTACCGGTGCTGTCTAATTTCTTTTTAGATAGT
CATTAAATGTAAATGTAAAGAGTCATTCTGAGAACCACATCTGCTGATATGTTCCGTTAAATTACAAGTTCTATGTGTA
TTTGCTTTGCTTTCATACAATGAATCTTCTTTACTCTCTTCCCCACCTGCCAGAAATTGCCCCACTCAACGTTCCATA
AAAGGTCCATTTTCAATCGCTATATTTATTTTCAAGAGCAGAGATATCATATATTCAAATTTTAGTTACTTTCCAATA
TCAAGCTAATAACTCACACAAATAAATCAAACCTACAGCAAAACAGCAATCTAGCATTCAACAAAACCTCCCCAATGC
ACATATTTCAAGCTGTAGATATGTATCATCCACCATGCTGAAATAATGTACATGTTCAAATCAAATGGAAAACCTAGA
ATCAAAATTTGTTGATTACTTCTTATCAGGGCATTTTATTTATTTAAGAAAAATACAAATTAATCATTTTTCAGGAA
GACTAATCTTCTGGCTAAGATTTTTTTAGCATAATGCTTAAAGTTAATTTGTTGATCTTTATCTATAAAATCAAAGGTG
GACTAAAAATGCAGAAATCAATCAGGTAGTCCATTTTGCATCAGGTGAAATATATAAAGCATAAAAACAGCGAGTTACA
TTTTCTAACAAAATTGAATTACAGTGAGTAAAAAGTGACAGGACAAAATGCATTAAGAAAAGATGGACTGAAATGGATA
GAGTAGAATATATGCATCTATAAAACACAGTCATATATAATACTCACTTCTTTTTTTTCTTACGAGTGTGAGATTAAATG
GAAGAAAACAACAATAATAACAAAACCAGTGTGATGTGTGATGATTTACCTTTTAAATTAATAAATTTATTCACCTTCAG

AGGGGAATTTTCTTTCTTGGGTTAGCTCAATCATGTCAGATCTTGTTCATTTAAAAGGTCAGTTTACTTGCCTTCTG
AGGTTTTTTGTTTGGGAAAAAGAAAAAGAAATAGATTTTTCATTGGTATCCTGGGTAGAAATTAATTGTTTATCATTCA
TTTTAAGATCTCCGAGAGGCAGAAAAAGGGGAACGTGCAACCCCTTTGTCCCTCTGGATCTCAAAATGAAGGGATA
CATTCTGCTACATGAAATGTGGAATTAAGACCATGATGCAACATGATAAACACACAAATTTGGGGGTGCTCTGTG
CTATACATTATTGAATTTTCCATGCTATACACTTTTGGATGTGCTGTGCTATTTATTCAGTTTTTTTAAATAAA
AGTTTTTGTAGACTAAATTGCCCTCTCTACTTTGCATCGTTTTTGAACAAAGGATTTTCAAGACTGATAAGCTCAAA
TGTATCATTATTATTGATTCAAGTAGCATTCAATTTTCTTTAGAAGTATAATTTGTAGATATTTTAAACACAGAAAAC
TTGCAACACTGCTCATGATAGGCACCTTATTATATATTTTGAAGACTATATGGATAATGATTCTAACCTTTGACTT
TTCCTGTTTTTGCCTTTCATTTAGAAATTAAGCAGAGAATCAAATCCATATTCCTGGGGGCGATGCTTGGACAACAGTA
TCTCTTTTAAAGATCTTTGTGTGAGTCGAAGGTGCAGCCAGACTGGGAGTTATTGTGAAGAAACAGATTTCAGGAAGGT
TGAGAAACTTGCCTAAGGCTAATCAGATAGTTACTGGCAATGTTGTTTCTAAATCACTGTTTGGCTCCCTCATTCAA
TGAATCTACACTATGTGGGACTGCCTCTTGCTCCTGACATCTTTTGCTGCTGAAATAAATGAACCTCAAAGCCTAGAA
GGTAGAAAAGAGGGAGTTTCAGAATTATATTCAGGCACAAATACCAATAAGGCTATTGCCCCCAGAAGTGAACCTTCT
CTTGGTTTTAACAGATAACTATTTAGCTGTGAGGTACAACCTGAGGAAGTGGACACACAAGTTATCAGGAGATTCTGAT
GTGCCAGTTTATATTTCTTGTACAGGTAATGATTGCAAAATTTCTTAAAAACAGCTGTCTCACAGTGGAGTAACCTG
GGAGTACATGAAGGCATTCCAAGGAGTAGGCACAGATAGTTTAAAGGGAATTTATTTCTAGATCTTCTACTTTATTT
TGTACTCTTCTGAAAACCTGAATTGCCTGAAAAAAGACATCTGTAGTCAAGACCTCAGGCT
GTTTTCTCTTTCTAACCCTTGCCTTTTCTAACCCTTCTCCCAATTTAAGAAAAAAGCCTTATATTTTCATCCAAC
TCTGATCTTACTAAGGCTTCAAACAAAAAGCATGAATGACTTTCATGACAGGGCAACATAGCTTTTTTGCAAGAAG
AGTGGTTGCTAACTCTTTGCTTTCAACTGAACCCGAAGAGAAGACCTGATAAGTTGTGAGCCGATAGATCATTA
ATACGTTTTGGTAAGCAATCATCATGTACTTTTAGCATATGCCATAGCAGGAGCACAAATGATTAAGCAATGCTACT
ATAATACAATTCCTTCCGTTTCTTTCTACTCACCTATTTGAATAAGATTTTTCATCATTTACATCTATACAGACAAA
AATTAGGGATAGAATTGATGCTGAAGCCTTTCCAATTGTAGAATTAATTTATATTTCTTGAAGGTGTATAAATTGT
TAAATACCCATCCATCTTATTAAGAGATGTATTTCAATAAAATTTATTTTTATGTTTATCAAATTTTATAATATA
CATATATTGTTTGGTCAATTGCACGTTAATAATGTAAACATACCTCAATTGAAAAGGTTTGTTTTTTACATTTAG
GACCTTACAGTAACAGAAAAAAGCACTCATTGTGTATACATCTGTTTAAAGAAAAGTATCTAGGTGATCAATAAGA
TTTTTTTTCAGGCATAAACATATATCTTAGTTTTTAAAGATATCGATATTTTACAATGTCCCTCAAATTATATTTTTCAG
TCATTTTAAGAATGAAAAGTACATTTTGAATGCGGATTTTAAATCTGCAAGGGTTGACTCATTTTTTCAAGAGTCTTTT
TAGGGGATACAGAAGCAAGAATGTTTGGAGTTCCCTGATCAGTATCTTTAAGAGAAGGTATTTGTTGGTAGTTCCCTA
GCAAATTCACAGCCTGATGCTACTTAAAAGATAATAGTAATTTTAAATAATGCTTCTGATAAAAAACATTCA
TGCACACTCAGTTTAAAAGATATTTAAACATTTGTAGTTGTAGTTTGGGAACCTCATGATACAAGTACAGTCTGTAA
ATGAAGCTCTTAGTTTGCAAATATCAGAGATAAGCTATTTAAATGCAGAAATGAAATGCCCCTGATATATGCATAA
ATTAGTGTCTCATCTCCATCTTGTGCTAGTTAGAGTATTTTGTAGATTCTCTCTATGTATACATATATATATATATA
TATTTATATATATATATATATTTGTGTAGCTGTGATGTGTGTTTGGACTAATGGGTCAAAGGACAGTACTAACC
CAATTCAATAATTAAGAAAAACATAATTTTGAAGATTAGCTTTATGGTAATGTTTGAATTAATGAGTAGATCAGA
GAAGAATAAGGGCTTTCCCTTATTTAAACAAGCTTCATTTTTTTATCCAAACATTTACTTAGCTGATTAAGCTTCAC
TTGTTTTATTTTCTTCAAAGCATTTCATTTCAGGTGGGTACTGAGTAACTGAAATATCACACCAGGGAACCTCAACACC
ATCCAAGTCTTAAAGGCTTCACTTGTTTCACAGTTGGCATTTAGTGAATGTCTAGGCTACTGATAATATTGTGAGTAA
GTTGGCAGGGATCATAAGAAATGATAAAATACAGTTCTTGAAAATGTTATGGTTTGAAGAAAAGATCTATGTTTGA
ATTAGACTGACTTGGATTCAAACCTCTGGCTGTACCTTTGGGACAAGGTGTTTCAGAACTCTAGCCTATGTTTTTTT
CTGCAAAATGATCCTCTTTTCCAGGATTCCTGTAGAGATTCAAAGATATGTGAATGTTTGAAGAAAAGATAGACTTT
TGATCATTGTTAATTCCTTACTTTCCCAATTAGACTGTAAAGCTGGGAAGAAAGCTACACAAAAGATTGAACAA
ATTATAGCTGACAGACCATAGCAAAAGATACAGGGCAAACTTAAAGGGGAAAACTACACATTAATTTATTTTAAAC
CATTAAATAGCACTAATCTTTGTGATATATTACAACCAACCACTCAAATTAAGTAACTGAATTAATTAATGCCTG
TTTTTTTCTGTTTACTGATGTTTTTCAATTTGCTTCATTTCATTTATTGGAAGATATAAAATGTGTTAGACACTGTTAGG
TGCTGAGTGTATAAAAAATCTTATTAATACAATTTAAACACGCACACACATATATATGTTTATAACAATTGATGCC
ATGTATGTACTGTTTATATGCCTATACATTATTCACAGACCTGGGGGGAGGGGGATGTAGAGTCTTACCAGAACCA
TAGGAATCTTCTCATATCAACATTTCCCTTTGAAGTTTGTTCATGAGGCACCATCCAGATAATACTACCATCTGCAA
TGTGGCTTGAGAAGATGTTAGATTTTTTTTATTACACATAATAAGGCTGTAAAGTATTTCTGTATTTAGGTAGAGGTA
TGTAATACAATATGTATATAAAATTACATATCCAATAAAATCTGGTGTAAATAAGGACTAGCTTCTATGATAATAT
AGTCTAAAGGCTTTTCATTTGGTGTATAGAAATTATGTGAAATATGTTTCTGAGTAGAATTATTCGCATTTTCAG
CTCTCTGACAGTGAAGAAAAGCTAGAGGGAGAGGTGAACAAGAGAGGGAGCATAATGGACAAAGCTTTGCTGGAAG
CCAAACCACCACTTCATATGTCAAATCTGACAGGCCTCCCATTTTAGGTGTGCTGTTCATTGAAGCTTTTCAGCTGCAC
CTTGCCTGTGGCTAGGCTATTTTCAAAGATTAAAAATGCGAAAAGTGGAAATTAATGCAACTTAATTCCTCAATTTAAA
TTTCCATTATTTTTGAAAAGTAAAAGATTAAAAGAAATGTATAATTGCAATTCCTGGTGAAGAGGTAATTATAGGAA
AGGTGGGATGATTTTCAAGTGGGGGATATAGCTTACTGCAGCAGAGAGGAATCTAAGCTATCATTTCTTTGAAATTG
GTCTGGAAATATGTTTTACATGGAAAATATACTATATTTTAGGAATTTCCCTGTATATTTACTGTATCCTTTTCT
GTTAGAATATAAATCTGAATTCCTATTCCTGTAGATCTGCCTCCGATTATATTAGCTCTTCTGAAGTTATCAA
AAAATATGAGATATACAAATATTCATATATGTCAAAGCAATTTATTTTAGGTTAAGTAATAAACCAATGACCTTTA
ACCGGTAATATTTCTGGTTGTTTCAAAAAAATCTATTCAGGTAATAATGTCTTTCCACTTAAGCAACTGAAAAA
ATACACAATACTTAACATTTGGTTAATTAATACTACTCCAGACAAAAGGATTTTCTGTTTTCAAGTTATCTTAGC
AAGCTGAGCAGGAAGCAATGATATATCCAATCAGAATATCCATGGAAGCTCTGCTACAGTTTCAAAAAGTTCTCATC
AGGCAGCTTTTAAATGCCTACTCTGAAAATGGTCCAGGTTAAAGAACACAGCTTCTCGTCAGATAGCAGTATTG
CTTGGCCATGTTTCTTCTAGCACAAAAAGTACCTGCTCTTCTCTGAGTACCTACATTTCAAGGACTATGGCTTAC

96

AAACTGAGAAAGGAAAAACAATTTAGAAAAGTGGGAAATATTATGCACAGAATTAATAAAAAAGAGAAAAATCTTGAAA
AAGTCTTCAATACCTCACTTGGAAAGGTGATTTTGAAGAAGAACTGATGGACAACTAGAGTCAGCCATGTAATGATG
TAGGGGCAAAGCATTCCGGGCACAAGGGACAGCTTATGCAAAAGACCTTAAAAATGAACTAGCTTTGTATGTTGGAGA
AGGATAAAGAGAACTAAGGTATCTATAAGGTAATTAGGAAGAGGATGAGTTATTTAGTCCCTTAGTCTTTGAAGCAC
ATTATCTCATACTTCAATTGAGTTTATTCTTAGTGTCATTCTTCTGGATGCAATATTTGAGATAAATGTCTTAATGA
ACGTTACCTCCCTCCGTAGTAATGCCTGAGTGTCACAAAACTTTTTTGTTTACATACGTAGCCATCTAATGGAA
ACATAAAATAGGAATCAAAAGTTGAGTTTCATGTACAAAAGGTAAGGACTGTACATGTGGTCATAACAACTTCAAAA
GCACCTGAAGGTAACCTTTAAGGAAGATACAAAGGCTAGGAAATATCTAGGATCCATGAAGACAGACTTACTTAAGG
TCATAGTGTGTCCAGAGTTGGTTCCCGCGGTGGGTTCGTGGTCTCGCTGACTTCAAGAACGAAGCCACGGACCTCT
GCGGTGACTGTTACAGCTCTTAAAGGTGGCACGAACCCAAACAGCGAGCAGCAGCAAGATTTATTGTGAAGAGCAAA
AGAACAAAGCTTCCACAACGTGGAAGGGGACCCAAAGCAGGTTGCCGCTGCTGGCTTGGGTGGCCAGCTTTTATTCCC
TTACTGTCCCCTCCCATGTTCCATTTCTGTCTATCAGAGTGCCCTTTTTTCAATCCTCCCCACGATTGGCTACTTT
TAGAATCCTACTGATTGGTGCATTTTACAGAGCGCTGATTGGTGCCTTTTACAATCCTCTTGTAAGACGGGAAGGTT
CCTGATTGGTGCCTTTTACAATCCTCTTGTAAGACAGAAAAAGTTCCCCAAGTCCCCACTCGACCCAGAAAGTCCAGC
TGGCCTCACCTCTCAATAGCATTAGAATATAGTTTCACGAGCATATATGAATCAAACTTACATTTGCCAATTTTA
TTTGCTTGTATGTGTTTCCAACATGTCTGTCTTAGGGCCAAATGTTTCCCTAGAGAATAACTATTCCAACATATC
TTAGTTGCTGTATTTTTATGCAACCTTCAACTCTCCATACTAAAATGTCTCCAGAATAGAAAATAAATCTTTTCAAA
GTTTTCAAAAGAGGCTCTCTATATATTCCCTTAAAGTACCAGGCAGACATATTTCTAGGTTTCTAACATTGCGTGT
TGCCAGGAAGTATATCCAAACCATCACAAAGTTATTCATGTAACCAAGCACACTTATTGGAGTGCTTCTGCTTCTGTT
CTTGCTTGAATTTGGAAGCTCCTTCCAGGAAAAAAAAAAAAATATCTATAGAAGGGGAAAAAAGTAATTTTACTTTGA
AAATAAAATATACGTGAGCAATAGTTTTATTCTGTTTTTAATTTACCATAGCTTCCAAAGACAACATTGTTTTATAG
TAGGGGTTAGCAAGTGTTTTCTGTAATGTAAACGTAAAGGGCCAGAGAGTAAATATTTTAGGCTTTGTTTTCTATAC
TCTGTTGCAACTATTCAACTCTGCTGTGTAGAATGTTGAAGCAGTCATAGACAATAGAGAAATGAAGATGTGTCATTG
TGATCCAATAAACTTTATTTACAAAAATGGCAATGGGCTAGTTACGGCTTGAGGGCTGCAGTTTGCAGACTCTCAC
TTCAGAGCTAACAGTTGTTGTGTCAGGAGTCACCTGTTTTTGGAAACCTACAATGAGGTACTATAACACCAAAAAAGAT
TATCCCTTCTTTTTCTCTCACTTTTTGAATTATGAGAAGAAATAGAAAATGATGTTAATGATAATGTCCAACCAG
TGTAATTATACTTGTGTAGAAACACAGCTGGAAGCCTGTTGTCCAGTCTTATTTCTCCTCTGTGATCCTCATTTTCAG
AGGTTGAAGTCATAAGTTTGCCATGTCTACTTTCTGACAGGGGAATTATAATAATGTGGAGTCACCTTTTGTGTGTG
ACTTTGACAATGCTTCATTGACTTACTCACCAATTTTCTAATTTTTATGAAGACTTTTTGCCGAAATGTAGACTCAG
TCTTCTCTCTGTCTACTCTTTCTATAACAATTAACAATGAACCTTATTTACCTTTTTTAACATCTTTTTAAAAATTTT
CTATACACCTTGAAAATGTGAATACAAAGTAATGCTGCATCATGTATATTGCCTTATTCACACATAGCCTCTTATGG
TATATCATATAAAAAATGGAACAATACAGCAACAGGTTGAATGAACAGTAATCAGGTAACAGGAAAATGAGATGTCTT
TAATATTTCACTTAAAACTCAATTTCTTAAAGCATAACATATAAATATTTGGAAGTATAGTTAGAAGAAAAATATCT
TTAAATATTTTTAATTGATTAGTCTTATTTATAAGATAATTTTTAGGAGGCTGGTTGCGGTGGCTCACACCTGTAAT
CCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCATGAGGTGAGGAAATCGAGACCATCTGGCTAACACGGTGAAAC
TCCGTCTCTACTAAAAATACAAAAATTAGCCGTGCATGGCAGCGCATGCCGTGAATCCCAGCTACTCGGGAGGCTGA
GGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCCTCCAGCCTGGTGA
CAGAGCTAGACTCCGTCTCAATAAATAATCATAATCATAATAAATTTTTAGGAAGCATCAGAAATATATAAGAAAA
AGATTATTTTCTTAATTGCTTTACTAAAAACACCTCTATGATTTTTTCAGTAAACTTGATTCTTATGTATGTGTGA
GTGTGATCTGCCTCTCTTGGGATACTACTGTACTCATGAGGAGTGATTTTTTCTCCAACGACCTCTTTGTACAGTC
AACAGGTCACAGGAATAGTGTACCCTAAAAAGCCACCTGCCACATGCTGCTGAAAAATGTAAAAGTACACACATAC
ACACACACACACACACACACACACACACACACCAAAATCAGGTATCACAAAGCTGAAAAATAAATGAGTCCAA
TTTTTTTTTAATTGAGCAGTTAATGTCTTAAAAACAAATCCTATACTGCAACAAATACTTAGCCAGATCATTTCTGA
TACCTCCAAACTGTGGTGTATTTCCAAGATACCTCTATGATCTTTGATTGTATCCACAGCTTTTTCAGTTATCATGCAA
ATACCTTCAAGTTTTATCTCATTTCTCAGTGCAAACTCATTAAAAATTTTCAGCTGAATTTCAATTTTTATAAACATGT
TGTGAATGTCCTCTTTATATAAGCAAGGTTGTAAGGAACTGGCCACATAAAACAGAAAATTGAATAACATATGGTTTC
TGGCCTTAGTGATCTCATGTGTGAGTTAGGCATATGGGCAAAATCAGAACACTATAGAGTATAAGTCTAAAATGGTA
GTATTTTATAATAGAGGATGAAGAGGGTGCTGTGGGATCATAGGTGACAGATATAACTCCCCTTGTGGGACTTGAGA
AAGGCTTCACAGTCTGGAACATTTAGTTGCTATTGAACACAAAAATAAGACTCACTGTTGAGAGAAGGGAGAGGGAG
GGCATTTCATCAATCAAATTAAGATTCTGTGGCATAATTCGAAACTGATGTTTTTAAAAAGAGTAATGTTTATTACATTC
CTCTACATAAATTATATTTCTATGTAATATGAATGACAAATATTTAACACAAAATGCCTTATAACATTTGAATGAAA
TCCATCATATGACCTGTTATCTATTTCCATTTCTTTTTGCTCATATCATTATGAACAATGACCTGATAAATTTTTT
ATAAGACTTTTGCTGAATTAGTAAAGGATTATTAAGTTTGAATGAACAAAGCTGACCAATCATTACAGGCAAATTTGA
CCGTTTTTGTGTCGCTTTTCTTATTTCTGAAACCATAACAATCCCTGAAATGAATAAGTACATATTTGATAACTTCC
TAAATTAAGGCTCAAAACACTGGTAATCTACTGGGCTTTTCAATTTGTTTCTTCTATTTGTCTAATCCTATCTATATTT
CTTTATATGAGCTATGAAAATATTAGATTTATTAAGTTGTCCTTTATCTTAATAGAGAAGAAATGTTTTCTATGACA
TTAAGAGGAATTTGATTTTTTTCTTTAATGATCTACTTTTAATTTTGGTAGAGTAGCATTGATAAGATCAATATTAC
ACATTGTTAAGTATGCATTACATGTTGATAAGATAAATATTACACTTAAAAATATGTTTATCAAATGTATGAATGATA
AAAACGAATTTCTGAAATGTATGGGAAAGATCTTGAATAAAGGTCTATGTACATTTCAAGGATGTCTACATATGCAAA
TTATCATAATATAAATACTATTGAATATGATTATCTTCACATACTTTCTTTATTTTTTTCATCTCTTAGATGAAATTTGG
GTATTGTTTTCTTATAGCTGGAACAAAGCATTACAGAGAATTTCTAGTGTGATTTCATTGAAACTCACTGTTATATG
AGTTCAACAAAGTTTAAATTAGTCCATGACTTAATCATCCTTTTATAAATCCTATCACTAGTATTCGGTAAGGACAAA
GTCAATTAATAAATTAGCAACAGAAGCATTAAAAAGAGGATTAATAAATACAAAATAAGGGATGTGATATCTTTACG
TATTGCTGAGATGTTAGTGCTAAGGAAAAACTTCCCTGTTTATAATGTGAGGTGGGAAAAAGAAGAACTATTATTGT

ATATTTCTCTCTCTAAAACTGCCTATCTGACTGTGTTTTTCTGTGTCTAGCCGTATTAACAGATGTTTAAATTTTACT
CACTTTTAGTATATAAGGCATCATAATGTATGAACTATTTCAAAGGCCCTATGATGGCTAATTAATAAAAAATATATT
AAATATTAGCTGGACAAAATAAAATATGTATTAATTTTGGAAAAAGTAGATCAAGGTTTTGCAGATCTTTTCATATC
AATATATTCATTTGCTGAATAAGCTTTTATTGTTTACCAATATTACTAGTTTTATAGAGATGTAGATATCACCACAG
TATGACTAATTTTATAGGGACACAGATAGATAGATGTTATTTTATTCCAATCTTATTTTTACATATAACAGGTATAA
ATATGCGCTTGAAAGGAGTATATCACTTAGGAGTCAGTCAGAAAAAGTAAAGATCTTCTAGTCTAATACAGTGGTTCT
CAGCCAGGGGTGATTCTGCTGCACGCTGAGGGATAAATTGGCAATTTCTGGAGACATTTTTGGTTGTGACAATTGCA
GGAGTGTACTGGTATTCATTTGGTAGAGACAGAGATATTGGTAGACACTGTACAGGACACAGGAAAGTCTCTTACA
ACAAAGAATTATTCTGTCCAAAATGTCAGTTGTGGTGAGGTTGGGAAACACTGGTCTGGAAGAAGGAATTTACTATG
AGGAAGTAGTTACGAAAGTATAGAGACATTTAACAAGCTGAACAAAAGGATAGTGAGATGGCTCAGAGATTAGCAACT
GTGGCATGAAGCCACTACTACGTTTAGGTAAAAATAAGCTACCATTATTCTTATAGTAATAATAATAAATTATT
ATTATTATTATTTGAGATGGAGTTTCGCTCTGTTGCCCGGTTGGAGTACAATGGTACAATCTCGACTCACTTCAAC
CTCTGCCTCCCAGATTCAAGCGATTCTCTGCCTCAGCCTCCTGAATAGCTGGGATTACAGGTGTGCACCACCCCTC
CCAGTTAATTTTTTGTATTTTTTGGTAGAAACGGGGTTTCACCATGTTGGTCAGGCTGGTCTCGAACTCCTGACCTCA
GATGATCCATCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACACCTGGCCCACTCTTTCTTT
TTTAATTATTGAGAAATATAAAAAATATGTCAAAAGTAACAGGTGTGGTGGAGTTACAGCATGCACATAATGGGATAC
AGCCCATTAATCTAATCTCAGATGGAACTAGAAAAAAAAGAGAAGATCTTTGCTAAAGCACAGATTATGTGGAAAT
CATTTAGAAAAATAGCTTATCACAACATTAAAAATTAAATCCTTTAGCTGATCATTTTTCTTTGCTATTTTTCTTTT
AAAATTGAGAAGACAGTGAGTTTTTTTTCTTTATTGTCTATTATCTTGATGTCAAAAAATAATATGCACATTATAAGT
GGGAAAAAAGATAAGTCGAAATGAAATGAAACAATGCGAGGAAAAAAATGTCACAACACTCTTCAATTAGAAAAAT
GACCCCATCTTTCTCCAAATAGAAATGACGTAACTGAAGTAGTGGAACTTTCTCTTCCATGGCAACTCTAGAGAA
GGGGTAGATGGCATGGGATTGTGGACAGATGGACACAGAAAGAGGCCTCATTTATTGTTATTGTTAAACTTTTACT
TCTAGTAATAGTGACACCTCCTTCAGCATTTCTTTATCAATTGTCAATATTTTTTGGATCACCAGCATCACCTTCTA
TATGATGTCTAGAAACCTCCTGTTATGAATTTACACTTCTCAGAGTCAAGACAGAAATGCTGTGAATTTGGGCGATA
AATAAAATACCCCTTTTATTGCTTGTCTTCTTAAAGAAAGATGCCTGTGGGGGACTATAGAAATGAGAAATTT
GTGCTTCTGGACCTCAAGGGACAAATCTATAATAAAAAATTATGCATAGTGATGAGAAATATATATAATGCAAGTTG
TAGAGATCAGTTAACTTATCTTGTCTAGGCAATTATTTCTAAACAATGATTTCAAATCATTAACTATAATATAGCCC
ATTCTATACCTCCATTTTTGTCAAATCCCTGTACACCTTCAAGGACTTGGCCATCCCATAGGCTGCTCTGCTTTAAT
AGAGGAAGATGCTGTAACCTTGGTACCATTGCCAGTTATGAATTTATCCATTAATGAACATTGCATTTAAGGCATA
GGTTTATCTCCTTCTCCAGGTATGAACCTGCAGGATTCTACCTGAAGCTTAAGGGAGAATAAATCCACCTGGGACA
ATCAAGGACAGATCAACCAATCAGCTCAAAGCAGGTGTGAATTACACAGTTTATTTGAGTGACAAGGTAGCTAAAGC
AGGGATAATAAAAAGAAGGGAGTGGGTTGATGTGGACAGACGAACTATGGCTTTAGGAAATTTGGTAGGGACTGAAAC
ATATTTTGTGTAATTTATGTGGGTCTAATAGCTTTTGAACCTGTTTACAAGACCTGTGTAAGTGGTACTGGCATAT
TCATGCATGAGAAAACATCAAGGGAAAACCTTAATAGTTCAAGGAGGTGACAAAGAAGAGAGGAACCAATTATTTTCA
CTAGCCGTCAAAGCAAGAAAATAATCAGCTTGAGCCCTTCGGGGAAAAGATAGGTTAAATATTAAGTAACAGTTTG
TTATTATTCCAAGTGTTTTCTTAAAGTTGCTCCCATACTTTCTGTTTTCTCTGAGGGAATTTAGTTTTTTTTGTGG
TTTTTTTTTTTTTTTTTTTTTATAACTGTCAATTGGTCAGAGCTTGATTTGATGCCAGTCAAATTTTTTTAAAGAGATTA
TGAAACTGCTTAAACTCTTCCAAAGGGAAGATGGGTCACTTCTTAACATGTGTTTCAAGAGGAAGAGCATAAGAGCA
TTATATGGTAAGGCTGAAAGCAGATATCAGCGTTTAGGGGCCATGAAGAGGTAGAGCTCACATTGGTAGGATCATTG
ACTAGAATTCCAGAGATCAAAATTGTATGTTAGTCTAGCATTGGGGAGGACTTGTAGCTAGTATCTTCATTCTAGCT
TGGGAGCCTAGGAATCAGGTTAGGCATCTTGACAGGAATGGGCCGATGGGCTAAAATCTCCTTGAGAGAGATGATT
AATCAGGACAAACCAAGCAGTCATGCCAATGAATTACTTTAACAAGGTTACTTCATATCCTCATCTTTGGGCAGCA
CGGTCTTCAGAGATGGGGCAGGCCCTCAGCTGCATTTGAGATTCTATAAACTAAGGTCAAAAAGATGCAGCAGTGAA
GAAGTCATGCTTATCTTGATAAATCATGTTTTCTTTCTTTTAAAGAAAATGTACATTTAACACATTTTAAACT
AAATATTGACCTAAAATTCCAACCAAAAAATGCTACATAAGTGGTATTTATTTTTGAATTTCCCTCATGCTCCTCC
CACTGTGGGGACAAGGAGTGGTGGTGGAAAGAGAGATCTTTTAGCAAACCTGTGAGTAGAGAATTAGAAGGTAATGGG
AGGAAGGTAAGGAAAACATCATAGATGGATAGGCTCACAAACATTAAAGGCCTTCGTGCCTGTCTTCATGCCTA
TTCATCCCTCTCCAGTATGTGAATCAATGTACTTGTAAATATTCACTCACCTCACATATTTAGCATTAAACCGTGA
TCAGGGACGTTGTTAGACCGTTGGTTACGATGATGTGTAATAATCATTTGTAACCTCAGACTAAGTGAAGTGCTC
AATATAATAAGATGTAATGTTATGGAACACTAAGTCTGTGCTGAAGACTTATCTCCTTTAATCCTAAAACAATCCTG
GTGGGTAGTCTCAATGATCATCTCCAAGTCACAGTTGAGGAAATTAAGGCTTCAAGAAGTTAAGAACTGGACCAAC
ATCACAAGGTAGCATCAGAGTGACAGTTTGATTTCAAAGTGACTTGACTTCAAGGCCACATTTCTTGACGTT
TAATATTGCCTTTCTCAGGTAAATATACCATTAAATGTGATACAACCTAAGCATTGTAATTACTTACAACGTGCAG
AGTTAAACCAGCATTATTTACACTATACTTCAGCTCGTTTATAAGTGAACCTATTATTTTGTGGACTAACCTATGAA
ATGTAACCACATTGAATTCCTCTGTTAGGTACAGGTTTGGTGATTCCAGGGAATAGAGTATGACTGAATGCACAGGT
AGGGGTGAAGTGAACCCGGTCAGAAAATTTAGAGAGCATCGAGCAGATCATTAAAGCAGCTGTCTTTCAAATGTGCAG
AACACAACCTCATTTGTAATCTAGGGACTATCTGTATTGATTCTTCCAGGGAAGTTACTTATTTTTATACATATGTG
GTGTGTTCTGTCCATAATACCATTCTACATGGTAATGCTCAACTTTATTATTTAAAAAACTGCTAATAATGAGGTT
TTTTTTTGTATCACAGAACGAGCAGGAGCAAGTTTCTTTTCTTCCAGTTTTTTTAAAGTACTGCCAAGGAATGT
GATTTTGTAGACTGATTTTCTTATTAAGCAATCTGCATGACTGTTCTTCTACTAGCTTTTACCTGTTTCACTCAT
TTATTAATTCATCAAAATTTGTAGAGTGACTATTGTGTGCCACATACTAATATAGGCACAAAGGATAACCAAAAACA
GACAAACGCTGTCTTTTCAAGGAGCTCATATAGTAATGGGAAGTTAGGAAAGGAGAAAATAAATATGTGGTATTTCA
AATGGAAGTATTAAGTGTTAAGAAGAAAAAGAGAACTAACAAGATAGGGAAAAAGTGACAGGAACATGATGTTTTA
TTTTTTATTTATATATATTTTTTTGAGACAGGGTCTCATTCTGTTGCCAAGCTGGTGTGCAGTGACGTGATCATGGC

TCACTGCAGCCTTGACCTCCCTGGGCTCAGATGATCCTCCCACATCAGCCTCCCAAGTAGCCAGGTCTACAGGCATG
TACCACGATACCCAGCTAACACGTTTTCTTTCTTATAGAGACAGAGTCTCACTGTGTTGCCAGGCTGTTCTTGAA
CTCCGGGGCTCAAGCAGTCCACCCACATCTACCTCCTAAGGTGCTGGAATTACAGGCATGAACCACCATGCCCAGCC
GAAATTGATGTTTTATATATGGCAGTCTGGGCAGACCTCTTTGATGTGATATTTGAACAGAAATCTCAAGAGAGGGA
GTGTATTAGCCCGTTTTTCATACCGCTAGAAAAGAACTGCCCCGAGATTGGGTAATTTATAAAGGAAAGAGGTTAATTG
ACTCACAGTTCAATATGGCTGGGGAGGCCTCAGGAACTTAAAAATCATGGCAGAAAATGAAGGGGAAGCGAGGCACC
TTCTTCACAAGGTGGCAGGAAGGAGAAGTACTGAGGAAAGGGGGAAGAGACCCTTATAAAACCATCAGATTTTGGGA
GAATTCACCTCACTATCATGAGAACAGCATGGGGGAAGCCAACCCCATGATTCAATTACCTCCACATAGCCTCTCCTT
TGACACCTGGGGATTATGGGGATTATAAGGATTACAATTCAAGATGAGATTTGGGTGGGGACACAAAAGCCCAAACAT
ATCATTTTTGCTCCTGGCCCCCTCCCAAATCTCATGTCCCTTTTACATTTTCAAAACCAATCATGCCTTGACAACAGTAC
TCCAAAGTATTAATTCATTTTCAGCATTAACCCAAAAGTCCAAAGTCCAAAGTCTCATCTGAGACAAGGCAAGTCTGTT
CTGCCTGTGAGCCTGTAAAATCAAAAGCAAGTTAGTTACTTCTTAGATAAAAATGGAAGCACAGGCCTGGGTAAATA
TACCCATTACAAATGGGAGAAATTAGCCAAAATGAAGGGGCTACAGGCCCAAGCCAGTCCAAAATCTATCAGGGCA
GTCAAATCTTACAGCTCTGAAGTTGTCTCCTTTGACTCCATTTCTCACATCCAGGTAACACTGATGCAAGAGGTGGG
TTCCCATGGTCTTGGTAAGCTCCACCCCTGTGGGTTTGCAAGGTAGAGCCCTCTCCTGGCTGCTTTTACAGGCTGG
CATTGAGTGTCTGCAGCTTTTCCAGGCACGTGGTGCAAGCTGTTGATCGCTCTACCATTGTGGGGTCTGGTGGACAG
TGGCCCTCTTCTCATAGCTCCGCTAGGCAGTGCCCCAGTGGGGACTCTGTGTTGGGGCTCCAACCCACATTTCCCT
TCCACACTGTCTAGCCGAGGTTCTCCATGAGGTCTTCATTCTGCAGCAGACTTCTGCCTGGACATCCAGGAGTTT
CCATACATCCTCTGAAATCTAGGCAGAGGTTCCCAAATTCATTTCTTGAATTCTGTGTATCCACAGACTCAACACC
ACGTGGCAGTTGCCAAAGCTTGGGACTTGCTCCCTCTGAAGCAATGGTCCGAACGTGTACCTTGGCCCCCTTTATCCA
TGGCTGGAGTGGCTGGGACACAAGGCACCAAGTCTGATGCCGCACACAGTGGTGGGGTTGGGGGGGGGACCTGGTC
CACGAAACCATTTTTGCCTCCTAGACCTCTGGGTCTGTGATGGGAGGAGCCGCAATGAAGGTCTCTGACTTGCCCTG
GAGACATTTTCCCCATTGTCTTGCCTATTAACATTGGGCTCCTTGTTAAATATGCAAAATTTCTACAGCCAGCCTCTC
CAGAAAATGGGTTTTTCTTTTCTACTGCATTGTGAGGTTGCAAAATTTTCAAACCTTTTATGCTCTGTGACCTCTTGA
ATGCTTTTGTCTGTAGAAATTTCTTGTGTGATACCTTAAATCATCTCTCAAGTTCAAAGTTCCACAGATCTCTAG
GTCAGGGTCAAAATGATGCCAGTCTCTTTGTTAGTCAATAGCAAGAATGACCTTTACTCCAGTTACCAATAAGTTCTT
CATCTCCATCTGAGACCACCTCTGCCTGGACTTCAGTGTTCTGTATCACTATCAGCATTTTGGTCAAACCATTTCAAC
AAGTCTCTAGGAAGTTCCAAACTTTTTCCACATTTTCTGTCTTCTTCTGAGCCTCCTAACTGTTCCAACCCCTGCCT
ATTACCCAGTTCTAAAGTTGCTTCCACATTTTCAAGTATCTTTATAGCAGTACCTCACTACCTCAGTACCACTGGTC
TTAACTCCTGCGCTCAAGCGATCTGCTTGCCTCCACCCCTAAAGTGCTGAAATTACAGACATGGTCCATTGTGCCGA
GCCAAAATTGATATTTTATGTATGACACTCTGGGCAGACCTCTATGAGGTGACATTTGAACAGAAATCTCAAGGAAG
GGGAGAAATTATCCATTTACATATTTGGGGAAGAGCATTCCAGGTAGAAGAAACAGAAAATCCGTAGTCTTGAGGA
ATGCCGTGTATATGCAGTATTTTCAAACCTGTTATTTGAAATACATATACACTTACAGGAAGTTGCAAAAGTATT
AAGAAAGATCATGAGTACCCCTTCACTCATCTTCAGCTAATGGTTACATCTTACATAATTATATGTAATATCAAAGCC
AGGAAACCAGGAAATTGATGTTGATACAATCTATGCTTTATTCAGATCTCACATCTTACATAGCTATGCACAATATA
AAAACCAGGAAATTGATATTAACACAATCTATGCCTTATTCAGATCTCACCAGCTTTTACATGCACCTTATCTGTGTC
TGTCATTCTATGCAATTTTATACCATGTTTATAGAGTCATATAACAACTACCCCTATTTTGTATACATGGTACTGAATAG
TTCCAGCGTCACAAAGGAACCTATCTCAAGCCACCCCTTAAATTGTACACCCCATCCAATCTCCCATTCTACTTCTGA
ATCACTAGCAACCCCTAATCTGTTCTCCATCTCTATGATTTTGTCTTTTCAAGGGAGTTTTCTAAGTAACTCATT
GGGGAAGAAAGGAGATGAATTGTTCTAGCCACGGAGTGAGAAACAGAGAGTAAGAGTACCTATTGAAGCAGAGGGA
GTCATTGCAATAATTCAAATGAGAAATAATGGTGATTCTAAACCAGGAAGCTTTCAGTGAAAACAAATGAGAGGTACA
TGGATTCTGGGTATTTTGGGAAGGTAGCATAACAGGTTTGCTGATGAATGGGGTATGGGGTGGGAAAGAAAGAGAA
GAGCCACAGGATGAGTCCAAGGTGGATAAGGTAGAAATGAGAAATGGTAGAAGGATCAAGTTAGATGGGTAGAG
GGGTAAAGGTGGAAGCAATAATTTGTTTTGGAATTGTTAGGTTTGAATCTTGTAGACATCCAGTAAAGTCACA
AAGAGTGCAGTTGGATGAAAGTATGGGATTCAGGGGAAGAGTATGTGCTAGAGATGCAGATTTGAGAGTCATCTGTG
TGGAGGTATTATTCAAATTCAAGTCCCTTGGAAATGAATGGCTATTCAGGCAGGGTCTTCATAAAAATGCTTGTGTC
ATGCCTGTAATCCCAGCACTTTGGGAGTCTGAGGTGGGTGGAACACTTGAGGTGAGGAGTTTGGAGCCAGCCTGATC
AACTTGGTGAACCCCATCTCTACTAAAAATACAAAAAAAAAAAAAGTTAGCTGGGCGTTGTGGCACATGCCTGTAA
TCCCAGGTACTTGGGAGGCTGAGGCAGGAGAATTGAGCCAAGATTGTGCCATTGCATTCCAGCCTGGGCAACAAGAG
CAAACTCCGCTCAAAAAAAAAAAAAAAAAAAAAAAAAAGCTTGTGCTTCAAATTCATGTGAGTCTGTAAAATTA
TCTGGGAAGGCAGTACAAAACTGTCACTTTGACTACGATGTTTCTGGTGACCCATCTTCATTGATCAGTATGGAAA
AGGCATGTCTCTGAAAATCTCTGAGAGTCTTTGATACAGCAAGAACATAAAGGATAAATCATTCTTCTATGTTTCATGG
TTGTAGAGGATCTTGAATGTTTAAATGGCAGAATAGCCAGATCACACTCTGGCACTTCTGTATGAGAGGCTGAGGGAT
GTTACTGATTACCCCCGAGAAATATTTACTACTAAGGGGACAGAGGCCAAAGGGGATACAAGACTTCACCCCTGAGCTG
TAGCGCTCCCTCCTTCCCTATCCTGCTTTTCACTTCTTCACATTGTTTTCTTCTTTTCTTTTATTTATTTACTTTAA
GTTCTGGGATACACGTGCAGAAATGTACAGGTTTGTACATAGGTATACATTTGCCACGGTGGTTTGTGTCACCCATC
AACCCGTATCTAGGTTTTAAGCCCCACATGCATTAGGTATTTGTCCCTAATGCTCTCCCTCACCTTTTCCCTGTGTC
CACATTGTTTTCTTTCTTTTGAAGCCTCTCATTCACTAGGTTTCAATCCTGCCTTGTAGTGTCTAACTCTAAGG
CCTAGGCAAGTATTTTACCGAACCTAGCCTCAGTGTCTCATCTGCAAAATGGATAGTTTTATGATATCTTTCAGCC
CTTAAAGTCAATGGTTCTGACAGCTAGGGTGTACTTCTTGGATATCAGTCATCTCAAGCAAGCCCTCTTTT
TGGACCTTCTTTTTCACACACTTCACATACCTTAGAGAACATAAATACATCCTCTTTACTCAGGGCTTATCTTTAT
AACAGGCTTCTTAATTCAATTAACCTCAACTTTTCAAAAAATATTAGTGACTACTGTGATGTAAATAAATTTGCATTTT
ATAGGGGTCTTAGTAACCCAGAAGGGAGTGGGGAAAAATTAATATATATTGAGAGTTTATTAAGTGCTAGGTACTGTA
AATATTTTCTTGTATTTAATCCTCCGAGTAATTCTACAACAAAGATATTATCATTTGCTATTATGTAAATAAAGAAC

100

GAAGTGTGCTATTTCATTCACTGAGGAATGGGCTATTATAATGAACTATTATGATATTAGAAAATTGTCAGGGCAATAA
GCAAATAATACATACGGTTTTTCAACAAAACCTTTCTAAGTATTGTTATCAGTGGGTTTTGCTTAAATCTTTTTTTACAAA
TTTTATTTATTTTTTTGAGACGAAAGTCTCGCTCTGTCGCCAGGCTGGAGTGCAATCTCGGCTCACTGCAA
CCACTGCCTCCCGGGTTCAAAAGATTCTCCTACCTCAGCCTCCCGAGTAGCTGAGATTACAGGTGTGCGTCACCATG
CCCATCTAATTTTTGTATTTTTAGTAGAGACGGGTTTTACCATGTTGGCCAGGACAGTCTCGATCTCTTGACCTTG
TGATCCATCTGCCTCAGCCTCCCAAAGTGCTGGGTTACAGGCGTGAGCCACCGTGCCAGGCAATAGCCCCATTGC
TCAGTGAATGAATAGCACACTTTATTTTAACTCATTGATATAATGTATATTTATCATCAGCTATACAGGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAATGACAAAAGGATACACACACACACTCTTTATTAACCCCTC
TGGAGCTGTTTACGCAAAACCTTGCATTTTTTTACTTTTCATTACAGTGTGTAAATAAATTTAGCAAATTTCTAATTTGAACC
TGATATCAATTGAGCATTTAATATTTAGCCAAATATTTATCAAGTGCTGACTGTGTTCTAGATGCTGGGGCTGCAAT
TTCGAAACAGACCATTGAGGCCCTCATGGAGCTCACAAATAATGATCTTCCTTAAAGTATCAGGTCTCTGGTTTGT
ACCGTATTTTTTAAATTGTTAAGGAAAGAAAAAGGCCCTATCTTTTTGTAGACAAACATGCCCTAAGTGCTTCCAGA
AATAATCTCCATCAGGTAATGCAGACTGTGTGTGGAGTGAAATTGAGTCCAATCCATGATCCAGCAGAGTTTCAGCC
CAGGATTTCTTTAGAGCCTTTGCTACACACAAAGTTGGCTGATGTGCCATTACAGCATCCCAGCAGCTCTTTCTCTTC
ACACTAGCAATGGCAAAGCTTTGTGCGGAGGCATTGCTGGCTGCTCTGAACTAAAAGCATCCGTGGGGACCGAAAGA
GGTTTTTGCACACCTTATTAAGGTAGGCAAGTGTGTCTGAGTGTGTGTGTGCCTAAAAGCTGGAAGACATCTGTTGA
GAGGAAAGTGCTCTTCTGTGGGTCTGGCAGCTTTCTGTAAGTCTTCTATTCTGATGCAGGAGCGTGTGAGCAGTGG
GTGGGAGGAGATGCTTTGGTACTTGGAATGCTGAGGTCCGGATTAAAGTGGTATTGTAATAGCTAGTTAGAGGCAGAA
TAAAAAGCTGGGAATCAAAGCATTTAAAAATGCATCCTTCCATTATTTGCTCTCAAGTTAAACCATATTCATTCTAG
GGGAAATTAAAAAAAAAAAAAAAAAACACAGCAAGGGCAAGTAGCCCAAAATCTGTAAGGTCTTTGAGCTTCTCTGTTCG
TCCAGCTTTTGAAGTCTTCTACAGCCAATTTGTTTGGCTCCTCTGGAGGGGGCAATTCATATCCACTTCCCTCTCC
TGGAGCATTTCTTTCTTCTATACTCCATCAGGGAACAATAGAGTTTAAACAGTAACAGGCAATTTTTTTTTTTTTTCA
AAGCTTGTGCCCTCTTCTGCGTTTAAAGGTGTTTTTAAAGAGACTCCTGCTAGGGGAATCTTGGCGCCTGTGTGTTA
AGACGGCAATTAACCTTTTAGTATCAGTGCTTACATTAATTTTCTCTCTTTCTGCTTTACTAAAGCAGTCATTAATA
TTCAGTGTGAGTAGCAATGAACCTTTATCATAAAACCTGCTTTGCTTAGAGAACCCTGATTGTTTTCTGAAAGCAGC
CTTCTCAGTTTTATATATACATAGCTGCCTTCCCTTGGAAATACAAATTTGCTTTGTGTCAATTAAGAAACACTAGGTT
GAACCTCTATACTGTGTTTTATCTGAGAAAAATACTACTGCAAAAAAGTTTGATTGTTTCAAGTTTTAGGATGAAAAAT
TTCTTTGTAACAAGTTATTTGAGTTGCATACTATGTCATCGTATATCTCTTTAGTTCAAGTAATTTTGAATTAACA
TACGGTTATGTAAAGAAGATAATGATTTATTTTTTATTTATATTTTTTAAAGTTATTAAGTGAGGTTTTCTTTTCAG
TAAGAGTTTAGAAAAAATAGCCAGAACAAGTAAGTGGACTTGGAAGATAAAGATACCTTTGCACCTCTAAATTTTAC
CTTTGTACACTTCGGTTGTGATTTAATCATTGAAATGCCTCTGCTTTGAAGTAAATGCATCACTTATGGTGTATGCT
GTGTTTTAATAAAGGGAAAACAGTTATGGGTCTCTGTGTCACATTTGAATGTTGTTATTTTTTGTCTGTATTTAATA
ACCTCTTTTTTCTCTTGTGAGGTTTACTTTGGAATGAGGCATGTTCAAAAAATAGGCTGACATTACAGCTTCTATGTT
TTAAATTTAAATGCTGTCTGTGTTTTATCAGTCTGGAATGTGTGGGAGAAAAAGATACCAAGTTTTATTATTTAGA
TTTAATTGTAGAATTGCAGATTGATATTTTTCAATGCATTTTCATTATAGTTTCTGCCATGGAGGCAGCGTGAGGGC
TTTTAGGAAGATGGAGTGGTGTAAATTACCAGGTGCGCACGTTCAATTAATCCTTCCCTGGCTAGAGAAAGCTTCAAGTT
CTTCTCCAGTGGCCCATTCGTAAAGCTATAAATATCTAAATTTGTGTGACCCAAAGAGTCACACAGAATGGTGGCTCT
TTTTGAGTTCAATTTTCATGCACTGTTGCTTTGGTCTTGTGAGGAAAGCTCTGAATTCCTTAGGATAGTCTTGGTTGT
GAAGTTCCAAAAACAAAATATCAAATCATTAAGGATTTAATTTAAAAATACATACTCTTCTTTCACAACTAGATGAT
TGCAGTAATGTGGATTATAAATTTTTTTTTTGTCTTATTTCTTTAGAGCTCCTCTTTTTATTTTGTATGATCAAGA
TTATAGCTGAGATTTTGGTGATTTTTTAAAAAGATTTATGGCTTATGGTCCATCAGTCTCTCCACTACTTCAAACC
TGTGTACCCCTGTATATTATCTGCAGTACTGGAATGTTGCATTGTATGTGGAAGCTATATACGATTTGGTAAAAAA
TAACACTTAAAGGTCTTCGCTAAGAGTGCTTATTTAATCATTAATAATCCCTTAATAAAAAATATCCAGAGATATT
GTCTGTGTACAACTTAAAAAAGAGAAATATAAAATCTGTGATGTGAATAAAATGTATAGCAATACACTCCAATA
ATACCATTCTTATGTTTTCCCTTGTCTCAACTGAAATAACTAAGCTAATAGAGACGTCAGTAAGGAATGTGTTGTT
TCTTCATAATACAATACTACAACTCATCTGATAAGAACAACTGAGAGTGAAACGTTAACTTTCTCATTAGAAAGATT
CAATTTAACACATATATACAAATACATTTTTAAGATAATGATATTTGCAGAGTTTTTGTATTCTATGGAGTAAAGGA
GAATTATCACATATTCAAAGTAAAGGTATAAAATACATCTTAATGTTTTACTTAAATTTTAAAGGGTCCAAAATATA
CTAAATTTGTTTTTCTAATTTCTTCTATGTTTAAACGTGCCAGAGTCATTGGAAATAGGACATTCTTTTTCTTAAG
AAGATTTTGGCCAAAATATTTAAACTATTTTCTTTTCCCTTGATTTTACAATTTCAATATTTCATGGATTTTTCTAC
TTTTAAAAATAACAGTAGTTTTTATGATCTTAAACAAATGTTTAAAGGGCACTTTCGCTCTCTGGAGACTATACCATC
CACATATTTATTATCAGCAAAAGAAAGGGCAGGGCATACTTTTATTTGAAGTTGAGTATAAAAAATGTGTCTGTGTGT
GAGTGTTATTAAAAAGATAAGTGAAGAGACAAATATAGAATCCAGGAACATTTTCAGCCTGGCTTTTACTCTCTCTA
AAAATCTAATGAAACCTTGAGCATCTCTTATCTCAAGGTACATTAGGAACTGTCCAACACTATGATCCGATGGGAG
ATCAGTATATTATATAAAGAAGAAAAATTTGTTGTTAGTGAAAGTCAAGTCTTTTAAAAAATAATAGTTACAGCAT
TTGCAATATACAAGCATAATAGATTTACTCAACGCCCCACCCCCATCTTTAAAAATCAATTTCCGACAGTTGTCTA
CTTTAAATTTGAACATATTTGCTACCTGGAGGGAACATTGTAATGTAGCCCATATGTGGTATGCATCCTGAAGAAAA
CCTGAAATTATAGAGGAAGTTATCCTGCCTTCTTCTCTGTTGAATGAGTTAAAAATATATTAACAATTTGCCTTTC
ACTTTGTATTTTACATTTTGTATCTTTGCATATTTACATATACATTCATGTGTACAAGGGCATATATCTACAGGT
CAGGGCTATTTTAAACAGCTATTTTATTTGAATATGCCAGGGAATACTCCAAGATATAAAGAAGCAGTTATTAGATAC
TATGTGAGTATAGAATTAACAGCCATCTTTTTTAAAGTGAAGAGAAAAATTAATTAATTACATACAATTTCTAACCT
CAAGACATTTTCTTTCTGGAGACAAGGAATACTGAGGTGCTCACGATAGTGAAGACTCAACAAGACCCTAATAAAAT
AGATGAGGATAAGTAAACTACAATAGCCAATAAAAAACAAAAACAATAAACCATGTTTCGCTGGCATGTTGGTGA
GTATCTCTGTAATATCTGTCAATAAGGGTCTCTGTAGATTTGGAGTAATGTTTCAGGAACCTGCTACTAGAGAAGA

CAGTGGAGAGGACTCCAGTGGCTAAATTCTGCTGCCTTTGCTTCCAGAAATGTAAATAATAAGGAGGTATTGTGGCA
TTTCTGGAAGCAGTAGTCTTGTTCATGGTCTGACTGTATAAGAAATGCCCTAGAGAAACATAACCTCAGCTGACTAA
ACTCCCTTGATGATTGTCACTTTGTCACTGAACTCTGACCATACTTTTGCCCTCAGAGGCAAAAGACGGGTGAGGA
AGTGATCTCCTCATCTGGTTTTTAAACAAGTATATAACTAGAGAACTGGATTATCTCCTAAACCCACTCTTGTCCTT
GGAAAAAGGGGAGTCATCCTATCCGTTTCTTAGCCAATTTATGTATACTCTTAGTTTGAGAGCATGAGAAGGAAAAC
TATTTTCTTTTCTTACCTTGGCTGGGTTTTAAGAATTTATTTTTAGTTTAAATCAAAAATAATTTTTAAAAGGTAGT
AAGCCTCTCATAAGCAGTTTGATCTGTTCTAAAATAACTTCAATTTTTCTTTTTTAAACTTTCTTTTATCTTACAC
ACAAAGTATAATAGTAATATGTACTCACTAGAACAAATGAAACAGGATGGAGTCACATAGAGAAATATATCATATTC
TCCCTATCCCCTCCCTTAATATTAACATTTAGGTGTCTATGTGCTTCTCCATTAAATTTTCATTGCAAAGGCCATAATT
TTCTTCCAAGAGTGAGGAGTAGCAGCACGGTAGTTTGGACCTGATATAGCTCTCTTTCCCTAGCCTTTTGCTTAAAGT
GCTTTCCTAGGGGCTGACTTTACTTACCTAAAAGATGTTTCAAGCAAGGGCTCACATTTTTTGGTAGCAGAAGACACTT
ACTGATTGCTCTCACTAATAATTTTGAAAGGAATGTCAAAATCTGGGAGGATCATGAAAGAAATATCAGAAATTTCC
TTTCAGCTGCCATTCTCCTTAATACTGTTATCAATAAATTCAGCATCTCATATGTGATAGCAAAAAAGGTGCTGCCT
TTTGTTCTTGATCCTGAGGTTCTTACCTAATACCATGGTAGCAATAAAGATGGTGAGAAAATTGCTTCTTCTATGG
TGTTTAGGTCCTGAACGAGCACCCCTCACCTCCACAGACGGTGGCAGGTATTCAAGCATTTTACAGACTTTGGAGTTA
AATATAGCAGTGTTATTCTAATTTAGGTATGCCACCACCAGCGGCACCGGCAACTGCAATAGGAAAAATGATTGGCA
ATGCCAGCTATCTGATGTTTTTCTGTCAGGTGCTGTGCTGCTTCTCACAGTATTACATTCCATCCTCACAACAAGA
GAGTGCCAGTGAGTGTTGCTGTGTGCCAGTGCCAGGCTAAGGGCTTTGAACACATTACCCTGTTTTATCCTCATAA
CTTTCCACGTTATTTTTTATTCTGAATGAAGAAAAAAGTTCTCTGTAGAGATGCTGTCTATTGATCCACTCATATCCT
TTCACATCCGTTTAAACATTTTCCCTGCTGTGCTTTTACTCCCAACAACCTAGCTCCCTAATCGCTCTGTTGGAGGGTG
GCCTTGAGGCTGCCAGAGCCTATTTGGTCTGTGTAAAGAGAGAGATGGATCTATCCTGGAATTTATGTCCCTGTGTG
TGGGAAGCCCTTAATCAATGACTGCTGGTTGCAGACACATAAAATACGTGAGCTTTCTTGTTCCTCAACTGAGAAATTC
AGAAGTGTGAATGGCACTGCCACCCTGGGCTTTTATGCCATATATGTGTTTGGTCTGTTTCCCTTCCCAATCTCACT
TCATTTTCCCTTACCAAGTGTTTCTTGAAAACACATCCCATTAGATCATTTTTTGCATGAAGCTTCATCTCAGAACCCTC
CATTTAGGGAACCCAACTAAGATATTCTCTAAAATAGAACTTTATTGATAAAGTTTCCAACTGTCTTAGTAGAT
GGCCAATATAAGACCAAGCCAAATCTTTCTGGGTCCAAATTTCCCTGTCTTTAATTAATAGACTCCATTACAACACAT
TCTTCAATCTTTAGTCAGCAAAACACTTACCACGTGCCTATTTTATGGCATATTATATTTATACCATAGTTAGGATAT
TATGGTTCATGAATATTTTATATCTGTACACCTGAAATTCTATTGACCTCTCTGGGCCACAGTTTTGCATCTGTAAA
ATCAGCACAAATAATGCTACTTATCTCATAGAGTAGACTTAAAAACGAATGAAATGATATATGCCAAGTGTGAGAAT
CACAATTGGCAATTACTCATGCTCATTAATATTAGCTGTTTTTATGAGTATTGTTTCATTTTCGGTGCATAATATC
CTATGCAAAGAACAAAAGGTATTGGTATAGGCATTGAAACTTGAAGCATAGAAGAAAAAGTTAATTAACCGGTGCC
CACTAGATGCCTCTAACTGCTGGCTCCGTGTATCCCTTTAGCCTTGGCTCGTCACGAGAAAACCTTGGAGACATTTT
TGCTGGACTCAGCAGATCAATTTAAGAAAGATGAATGACATTTTTCTTGAATGTATTAGTCATAGCTGCCTTTTT
CTACTTTCATATTTTGGAGTTCTTAGAAAAAATTAAGGACTCCTTTTTTTAAAGAAAATGGTATAAAGAAAATGCA
TATCACTTTGTCACTTTATTATTGTAACCTCATCAAAGTATTCAGTGTAAGACAGTAGCCAAGTGAACCTTCTTG
TAATGCTCGGAAACCATTTTAGCAATGGTAAAAATTGCTGCAATTTATATTCGTCAAATTGCATGATTTGACTTATTT
TAGAAAAGTTATTAACCTTCTGAAGAGAATGCTTCAGAAGCATTTAAATGAGTACAAGTTATCACCAGTGATATACAT
AAATTTTCATTTCAAATATACCTTCTAGAACTGTACTTAGTTAGCTATAGTATTTGTACAAGGATTAATTCCTATTT
CATTTTGTAGGAATTTATTTATGAATGTCTATGGCTGCCAGTGTAAGCAGACTTAGAGCATCATCTTTTACAATA
ATCTTTTTTTTTTAAATCAAAGGGGAGATATCTGGTAAAACAAAAACAAAAACAATAGTTTATCTGCATTT
TTATTAAGTCCCTCTGTAAGTCATCCCTGAAATGGGATATGTAGAGTCTTATATTTATTTTCTCAGAAGCTTAT
TGGAGGTGATATGAAGGATTTTAAAGACCTACTAATAACAAAACAACATTTAAAATTAATTTTCAAATACCTTA
ACAAATCTTATTTCTCCTTATTTTCAAATTTCTTAACTAGTTTCTTATTACTAACATAATATCTTCTGATGTAGT
CATAATAATATCTAAAATGACAGGTCTAAGTAACTTACATGGATTAATTGAGTCTTCTAAATAGTAAAGGTAGATGGC
ACTATTACTTCTATATGAGAAATGAGGAAGTAGAGGTATAAATAAGAAATTTTTTGGCCGGGTGCGGTGGCTCACGC
CTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCTGATCACGAGGTGAGGAGATCGAGACCATCTGGCGAACACG
GTGAAACCCCGTCTCTACTAAAAATATAAAAAATTAGCCTGGCGTGGTAGTGGGTGCCGTGATGCTCCAGCTACTCGG
GAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGTGGAGGTGTCAGTGAGCCGAGATCGCGCCACTGCCTCCAG
CCTGGGTGACAGAGCGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAGAAATTTTTTTGAGTGTATACAGTTAGA
AAATGGCAAAATGGGAATTCAGACCCAAACAGTAAGACTCAAGGATACCTTTCTTATCAGTATGCTAATATGAAAAC
CTAAGCATACTAGAAAATCTAAGTGCCAGTTGGAACCCAGAAATTAACATTTTGGTGTGTAACCTTCTGGCTGCTTTT
TCTATGCTAACAAACATATATGACATACAAAAATACACACATACACAAATTCCTGTTCACTACTTCTTTTATGTTAA
CATCACAATGTACCGTACACAGCTGTATTATTTTATATTTGATTTTCATATTTTTTCTAAAGTCAGTGTATTTGTCAA
ATATCAACTTATCTATTTAATAGGAATATGGGATGATCTTTGCTTATACATACATACATATGTATATAAAAAACAAA
TCAAGTATTTTAAAGCGTTCACCAGAAGTCATATGTCAATCAGTAAAGTATATAATTTTTTGTGCCAATGACATATA
TCATAAAAACGCTACCTATCATAGAATGAAATGAAACACAGCAATATTGGGACACCTATTTCAAGCAACAGCTTT
GTGATTTATTAGCTATCTCACATGAAATAACTCATTAACCTGGTATTCCAAGCAGCAAAAGAAGGATCACTTAGGTC
ACTTGCAAAATAATACAAAGCTAGGTTTAGGGGTGGGTGCGCTGGTGGGATGTAGATGAAACCATATGGGCCCTT
GAGTTTATAATTGCTGGGATCTGCATGGTGGGTATATGGATGTTTATTACAGTATGCTAGTGAGTTAAGAAAGAAGA
GGAATTTATTATTGATCTACATCATAGAGTTTATGCAAAAATTAACGATAATTTATTTTTAACTCTAGAGGTATAG
GTACCATCATGAAGGGACCCACAGAAGTGTAGTACCGAGTAATTAATTGGAGCTGGAACAGATACCTGTGTGTCAGTT
GTTCTGGTTTTTGTGGTCAATTGTTCTTGCCTTTGCAAGTTACCAACTCTAAGACCTTGGGCAATACTTTAAGTCTTGG
TTGTCTCATCTGTAAAATGGGGAGAGCAGTAAGTGTCTTAAAGGTTTATTCTCATGTTTATATGACTTACGGTATGTA
AAACATCTGCGTTTAGACACATAGAGGGTGCTTAATGGATGATTGCTCTCATTATTAGGCTACATCTAATCTATGAA

TTTAAAACTGTATAGAAATATGTGACAGATTCTTTAAGAGCCAAATACCAACTACAGTGAAAAATACCTAACACTT
GCTGAGCTCTTAGTATGTGTGTCAGGCTTAACTACCTTAATGCTCATAGCAATCCTATAAGATAGGTACTCTTGTTATC
CTATTTTATATCTTCTAAAATTGAAGCAAGGGAAGTTAAATAATAGGACAAAAGATCATACGCTATCTATCCATATAT
ACCCATCTGGCTGTCTACCTGTCTCCTTCCATCCATCCATCCACTTATTCATCTACCCATCCATCCACTCAGTTACT
TCTCTCTCTCCCACCATCCCTTTCCCTTTCCCTCTCCCTCTCCCTGTCTCTGTCACCTCTCCTTTACTTATCTATCTA
TCGATGGATCGGTTTATCTATCATCTATCTATCTATCATCTATGTATAGTTGTTAATAACACTAACATTTTATAA
ATTACAAGACTGAAAAATGTTTTTCATTAACCTTATGGTAACAAAAGACCACATTGTGAATAAAAAAAGCAGTAAACAC
AGGTCTCTGCACATATGAAAGAGATGTCCTAAACAGGAAGAGATGTCCTAAACAGTAGGGATACATAGTATCATACA
ATCAAAACATGGCAGCCCTATAAAACTTACAAAGCAATTTTCATGTAAAGTTATTTTCATTTGACTCTTACCACAATCTA
TGAGGTTACTATTTTTATTTTTCTCATTTTTACAGGTTAAATTTAATATGGCTTCCAATAAAAAAATTAGTATGGTTAA
TAAATATCTTGACGTCTTGCTCCTATAATCCTACCGATAGTTTACAGTAATTAGTAAAATAAAAAATAGGAAAAAT
ACCTTTGATACTAGTATTAAATTATAATCATATCATTAGGTAATTTCAATTTGTGATTTTCAAGAATCTGTAATATG
GTAGCTTCTTCTACTGACATGTTTGAATTCATTTTTAAGGCTTATAATTCACAAGTAATCTATATATTATCTAAAAT
GTAAATGCACATTCACATGGAGATAATAAATTAGCGTGAAATGGCTGTATTTTGCTCTCTATAATTTTTAACATACA
GGAAATCACTGTTGTCTCAAAAATCAAGGAAATATAGTATTTGAGGTGAACTTATTCTTTCTACTATTAACACATTT
TAATATAGTTCTCTCACAGTGCAACAGAGCAAGAAGCTTTCAGACACATTTGCTGCTGCAAGGAGCATGCTGTGCTG
AACTTAAAACACCTTCCCTTTCAAACCTCTGGGACTGTTTTTTTCCAAGAGACTTCAAATGCACTAAATTTAGCAT
CCGTTGGAGGCACACCCAGGCATATTATAGTGAAAGCCCCAATAACTGAATGTGTTACCCTATTACAAATGTTTAT
GTGTGTATATGCCTTATCTATGATGTATTGCAAAATACAAAAATTGTGTTATTATTACAGTAACAAAAACACTTCC
AGCAATTTCTAACAGTGATCTCTTTTGAAATAACTTACATACATGTGTGTCATGGGTCTTAACTTTGTCACCTTTTAT
GTTTCCATCATGTTGTTTTAGCCAGTGAGGGTTTTGTTGGTTTTTCATTTATGATTATATACTTTCAAAAAATAGAT
TTCAAAGTGTGAATTTGATTGATTGATTGACTGATTCATTGAGACGGTGTTCCTCTGCTGCCCAGGCTGGGGTG
CAATGGTGCATCTCGGCTCACCACAACCTCTACCACCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCTAGTAG
CTGGGATTACAGATGTGCACCACCACGCTGGCTAATTTTTTGTTATTTTTAGTAGAGACAGGGGTTACCATTGTTGG
CCAGGCTGGTCTCGAAGCTCCTGACCTCAGGTGATCCACCTCCTCAGCTTCCCAAAGCATTGGAATTCAGACGTGA
GCCACCGCGCCAGCCCGTGAATTTTATTTTTGAAAGACAAGAAATGTCCTTGCTTAATTGCATAAATAGTTTAAACATC
ATGAAGACTAAATATGCTTTTTAGCCATGACAATTTTATTTATTATTGTTTTTCATTTTTAATTTTTCTCAAAGATCCT
CATCAGTGACTCTTTTTTGGTCTTCTTATAAGCGTATTTTAAACAGGACATAATAATAAGATAAATCCCAACTTTTT
AAAGTTGTATCCGTATGTATTACTTTAAAGTGCTATTAATATAAACGAATTAGAGGCAACTTTTATTCAATCAGATT
TTAAGTAATTTTACCAAAATATGGCCTTGATAATGTCTCTGTAAACAGGTTCTCTGTAATATACATGCTGAGGATTG
GTTTGTCTTTGCTTTTGATACTATTTAATTAGAAAAGTAATGGGGAATCCAGACCCTTCTCATTTAATAATCCAGA
GAAAAATCAGTCCATGTTCTAATAGTTTAAATTTTTCTACTAAAACCCATGTGAGAATCCATATGAGTGGAAATGGAG
AGGAGTTTCACTTCAAAGTTGGCAGATTTGAGATGATTCTATGGCAACAGAAATGTGCTTGAGGGAAATCAGTTGCG
GCATCTTCTATAATTGTGTACCTAGATTTTGCTTAGGAATTTCTAGATTTCCATAGAACATTGTGACCTCAAATG
CTTTATCTTAATAAAGAAATAAAGCAGATTAGAAGAATTATTTGCCATACAGTTTGTGGGAGATGGGCAAGTCTTAA
GAGTTTATTAGGTACCCAGAACGAAACATATTTTTCTTGGGCTCATAATCACATTGAAATACAAGGATTTAGTTATA
CACAGTGACCAGTTAGTGAATGACAGTCTTCAGTATCTAGTAGACAGTAAACATATAAAGATGTATTTGTGGCCGGG
CACGGTGGCTCACGCTGTAATCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGACCGAGACC
ATCCTGGCTAACACGGTGAAACCTCGTCTCTACTAAAAAATACAAAAAATTTAGCCATGCGTGGTGGCGGG
CGCCTGTGGTCCCAGCTACTCGGGAGGTTAAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCA
GAGGTGAGGCCACTGCACCTCCAGCCTGGGCGACAGAGGGAGACTCCATCTCAAAAAGAAAAAATGTATT
TTTACTTTTAACTACAGCAGAGACCCCTGGCAGCCTACAGCATACAATTAGTGTTCATTATTAGATTGCAATGGATT
TAATGTGAGGGGTCAATTACTTGTCTAACCAGTGAGCCTAGCCTTGTCTCAATACTGCCTGCCTCATGAGGGTGAA
CTGTGCTGGAGAAATATATTACAGGATTATCTGCAGATTTTTTTTTAAATGAGTGTTAAGTCAAAGTCTTGTGAA
AATTCAGAGTAATAAATTATTATGAAGTTGTGTAACAGGTAAAGGATAGTTTCTTTTACACGGGTAAAGATTAAACA
TGAGGAGGAAAACTTTAGCAATGGCATTTAATTCATTCAATATATTTATATTGAGCTCCTTTAAAAATACAGGGCC
TTGTGGTGGGTGCTGAGGACAGAACAAAAACCAAGTAATACATGAACATAACCCCTTGATTTTCATGATCTAGTAGACC
TATAAAAGTTGTGATATCTGATGAAAAGAAAAATGGTAAAGATATTCCAAACAGTGTATGCAAATCCAGAGATAGGA
TGGAGGGGCTCTACCTGAAGGATGATGATAAGAAAACCGTGTGAGTGAAGGGTGATTTGTGGAATTCAGATAAAAT
ATCAGTCTTGAATGCTGAGTGAATACTCAATGATTGACTAGATCCCATGGACAGTAATTTCTTCAATTATGACGATG
CTAGTGTATTGACTATAACTATCATTCTCCATGCCAGGCATTTGCCATTTGGTAAATGTATAGTGTGCTATTCTA
ACAAGCATGCACAGAGCTTTTACTTTAATGTATCCATGAGTTTATTTGGGGTTCAGAATTTAGGTAAGCTTTGCAAGG
TCGTAGCATGGAGTAAATATCTGAAATTCAGACCCATATCTAACTAAGTTCAAAGACTGTACAGATATTTCTCCTC
CTTTGTGACAGAGAAGGATAGGAATGGTTCCATATTATCATGGACTTAGTCAGATGTTTTAAAAATTATAATGTCTGT
GTTAATGAAGAAGGGATGATATTCAGTGATATTCTTAAACCGTTACTTTGCTTAATGCTCTCGACTTTTCTGTGAGA
TGGATAGTGTAGATAAAATCCCCAAGGGGACTCAGCAAGTGCAAGTAAACAATGAACTTTAAAGCCCTTTGTCAA
AACCTCTCTTTTTCTCAGAGGATGGAAGGGCCGTAAAGGTTGGTGAGGAAGGATGGACCATTTCCTATGTAGTCTTC
TGACAATATTCAAACAAAAGGAGAGTCAGCAAAATCCCCCTTGATGTGGGAAGTTTTAATAAATTTGCAGAGTGTCT
CTCTGGAGTAGACATCCTCTCTGCAATCGTGTCTCTATATAGCCTCAGGGCTTTGGGTAGGTAAATCCTTCCAAG
GAGAGTCCTGGAGAGGGCTGTCTACCCCCCTTGACCATCTCTAACATTATTCTATAGCTCAGCTCCTTGTTTCTG
TTTTCTGCCTTGTTTTTGTCTGAGTCTGCAATTATGATGTAAGCACCATGAAGGAAGGTATGTTGCCAGTGTGTGCA
TCAGCATATCCCCGTGTGTAGCAGCGCAAGGGATATAGTGAGCCCTCAATGTCTATTTGTAGAAAAAAGAATGAAC
GTATCAACGAAATCTGATACATATTCATTGTGTCTGTTATCTCCATCTCTCTTGTCTGCCTTGTATCTTGCCATT
TTCACAAAAGGCCCAAGGCCCATCATTTCTTGTGTAACTTCCAGAGTGTTAATTTTTTAAATTTAAATTAAGGCTTT

104

TCCCCCTTCCTGTGTCCATGTGTTCTCATTGTTCAATTCCCAATATTATTTTCTAAGTGGCAGTGGAAGAAACATGGA
AAGTTCTACTTCATCCATCGGTGGATTAGAATTTGTATACCATGAGATGATTAATTTTCAAAACCAGTTTGAATCTC
ACAAAATAATGACCCTGTTTTTTGAAGGACAAGGCAGAAACAAGGAACTAGGCTGTGCCACGTTCAAGTCACAATCTC
TAACATTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTAACTCTCTGTTGCTTGTTCACTTTCT
CTTGTAATCTGCATTGATTTGCTACCTGGCTATTTGTAGATTGACTTCGGCTGCCAGGAATGGAATGTTTTTCATAA
AGGAACATATGCCTTAATGAAAGTACCATAAGAAGGGAGTAGAGTGTGACCAATTGCC TAGGTAATAAGTAGTGACA
ACAATGATATTATTCTAGTATAAATGGAATCAGTTTTCTTTGCCAGGGGGCATGATAAAGAAGGCCTGGCTGGTA
TATACTAGGTGGGACACCAACAGTGCCTAGAATGTCAATGGATCAAACCTGAGGGAACCAGAAGTTGAAAAGACA
TATCCCAAAAGAAAGCATTGTGATGTTTAAGGGTTGGCTTACTTAGAACACAATGAAAAATATTACTAAAATTTAAAC
TATGATTTTAGCTATTTTTAAATATGACAAATTTAAATAGCAGAACATTTTAAATAAAACATTACTTAAGGTCCACAAT
TTTTCTGTAAGTCTAATACATGGGTCATTAATAAATAAAAAATTTCCCATGATTTATGGAATCAGATTTTTTTAATACAA
CGAATTCTAAATGGTTTTATAATGCCAATTCCAATTAATATCCTAATTATAACATGTCATCCAGAAGGGTTAATGAC
TAAATTTTATTAATATTTGTTTTCTATTTATTTTGATTTGTGCAGTTTATGTGTATAGTAACGATAGCTGCAAATTA
GATACCATTAGCATTAAATAAGGTATATATTTTAATAGAAAAATTAAAGTTAAGTATTTGAGCTAGCCTAAAATATTC
AACAACTTAAATTTGTTTTTTGTGGATCACATTTTTTTGAGACAAAGTCTTGCTCTGCTGCCAGGCTTGAGTGCAG
TGGTGCATTTCATGGCTCACTGCCTCAACCATCCAGGCTCAGGTGATCCTCCACCTCAGCCTCCCGGGTAGCTGAGG
CTACTGGCGCACGCCACCATGCCCAGCTAATTTTTTGATTTTTTTTTTAGAGATGGTGTTCACCATCTGGTCTCAA
ACTCCTGAGCTCAAGCAATCTGCCCACCTTGCCCTCCCAAAATGCCGAGATTACAGGCGTGATCCAGTGCACCTACC
CCTGTGAACCACCATTAAATAGCTAATAAAAAGATGCATGTCAATAAAAAATAAACAACTTACTAGAATGATTATGTGA
AAATCATTTATTCTTCCAAAGCATGAATTTTCAAACACACCTTTTGTTACTGTTTTAAGAAGGGAATCATTTCCATA
TATTTGCATGTAAATCACTTTTAGTCTCAGAGAACTTTCCATAAAAAGTTTTTTTATTACTGCTGTAACCGATAGAGC
TAGTGGACTATTAATTTAAAAAGCTGTACATAAAAAACACATCTATAGCTCAAATAATCTAGGATACCTTTTAGTTTG
GGGAAATGTAGATGAAAATGAAGTAATTACAGAATCCTTGTTAATTTTCAGATTTAGACAGTCTAGGCAATATCTTT
CAGGAATGAAGAGATATGTGTTTTTGGCATCTTGTTAGAGTATATTTCCATTGTAATTTCTTTTGTAAGTCTAGAC
CAGATGTGGCCATAAAAAATAGACCCCTACTACAATAATATATTTCATAGATAATCCAATAAGCTCAAACTTATTGC
AGTAGGCTTAGAACTCTGTTTGCACCCATGGAATTTATATCAGTTTTTTGGCAAATCCTTTTCATCTCTGAGGATACTT
TTTCATCTCACATATACCCTATTTTCTGAACATTTTGCCTTCAAAGTATACCTCATTATCAAGAATTTCTCTTTAT
TCATCTGACTTATACAAGTGGCAATAACAACGCTCTGGTTCCCATGAAGTAACCAGTGACCTTTGAAATAATATAGC
GCTGGAAGAAAGAAAAGGAAAGGGAGACTGATCATTAGCAACTCTTTAAAACCATGTCACCGTTAAACACATAGTT
TATTTTATCTTTTTTTTGAATTTGTGAAAACCTATATTAGCATCTTCACGGATGTCTCCTTTGTTTACATCCCCGCT
TCTGTGCCCTTGCTGCAGTAGAAAAAAAAGGACATGTGTATCCCTATTCCCATTGTCTTCTCATTCTACATGAGA
ATGAGAATTTCTTTAATTTCTTCTCTATCTACATGAACCCACTTCCATTATCTGTTTGTTCAGTTCTTTAAATGCCC
TGAAGCTAGCTCTGTGACTGGGCAGTTGAAAGTCTGGACTTAGCATCAGGTTAATTTGAAAAATACTTATTGAGCC
ACCACCATATGTGAGCCACTACTGTAGATGTTTTGAATGTGTGAGTGAACAAAGCAGAAAAGATGTATGCCCTCTGG
ATTCTTGGGGGTCTCAAATAGTGAAAGACAGATACGATAAGTATATGTATAGTATGTTCAAAGTGATAAGTGCTG
TGAAAAAAAAGAAGAAGGGTAAAAATAAGAGATGGCTCATGCTGGAGTACATTCCAATTTTAAATAGGGTATCATGGT
ATTCTTCATTGAGAAGGTGACATTTGAGCAAAAGATCTCAAAGAATGAGGCATGGGGTTGAATCATGTAGATATCAGC
AGTAAACTCATTTTGGGTTTCAAGTAAACAGTCAATGCAGAATTCCTAAGCCATCGGTTTATCTGCTGTTTGGGGCTGG
TTATCTGCAGTGTGGCTAGAGTGAAGTAAGTGAGAGAGGTTTAGGAGAGAATGTTAGTGAGGTGAGGGTGGACCTTT
GAAGCCATTGTAAGGACGTTTTTCTCTTTCTAAGTGTGAGAAGATGATGCTGACTGAGACCAGGGTGATAAGAAATA
GTCATATTCTGAACGTGTTTGGAAAGTGGGGCCAACAAGGATTTCTGGATGAATTGGATAAGGGGCATGGGAGAAAAA
TGGAGTCAATGAATGGCTCCAACGTTTTTGTCTGATTAACTGGAAGGGATAAAAGTTGCCCTAAACTGAAATAATAAA
GACTATAGATAGAATGGGGCGATTAGGGAGGCATTAATTTGGATATCTGTTAGACATATACCCAGATATATTGAAT
AGGCAATTGAATAAATACCTTTAGAGTTGAGCAAAAAAGGTCCAGGTTGGACGTTTAAATTTTCGGAGGTGTTTGAT
AAGATAACATTTAAAGCTGTGATATCAGATTGTATCACTAAGGAAGAATATAGATAGAAATGACAACGTGACTAAGG
ACTCTAACATTAAGAGGTGGATTGACAAAGGAGAAAAACAGCACAGGATAATGAAAAGGAATGATCAGCCAGGCATGG
TGGCTCACACCTGTAATCCTAGTACTTTGGGAGGCCGAGGCGGGCAGATCACGAGGTGAGGAGTTGGAGACCAGCCT
GGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGTGTGGTGGCACACACCTGTAGTCCCAG
CTGCTCTGGAGGCTGAGGCAGAAGAATTGCTTGACCTAGGAGACAGAGGTTGCAGTGAGCCAAAAGATTGTGCCAC
TGCCTCCAACCTGGGCGATGGAGCGAGACTTCATCTAAAAAAGAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAGAA
AAGGAGTGATCAATGAGATGGGAAGAAAAACAAAAGTGTGTGGTGTCTCCTCAAAAAGTACGTTCTATTTTCAAACC
TACATTTTGGGTCTCCTTTTACTATATCCTGACTTTCTAGCTATATAACCAAAAGGAGAAAGCAGTAATTTTTTTAG
ATATAACATGTTAATAACTCTAAGGGTATTCAATGAATCTGAATAATTCAAGTGGTATAATGTGAAAAATATAGTAT
TCATAGGAAAAGGAACAGAAGTTAGCTCAGGAAATGACTTGAATGAACACCGAAGCCAAATCTCCAGCGCAGGTCCA
CGTATTATTTGTCTCAGTGGTTGAATTAGCAGCAAGATTCCCTTAGTAGGATGAAAAAGATGTTGTGAGCATCTGTA
TCTACATGACTGAATTAATTTCCCTCAACAATGAAATGTAGTTAACGTAGTATCTCGAAAAGAACCTAAGTGGAAAT
TCAGGGAACCTAAATTTCAACCATGGTTTTGCTGCTGACTGATTGCATTCACCTCAATCTATCATTAACTCCTTG
TGCCTCATTATCCTCATTTACCAAATAAGAAAAATGAAATATTCCTCCTTCCCTACCTCACTAGGATGTTGTGGAT
TTAAATGTGTGAGAGTGTCTTGAGATGCATAAAATTTGATGGAGTGTTTTATTTCATGAATTCAAGGCATCTGAAGTA
ATTTGACCATGATGAGCAGTTGCTTCTTGCATTTTTTTAGAGTGACATTTCCGTTACTGACCCACCCATTTATGAC
AACATGTTGCCTAATCTAAATTTAGGTCAAAACAAAATTGACCTTATAGGTAAGCATTATATCTATTAAATATTGTATT
TTTTGTATTATTTTATAATATTCATCATTACCTATTTTTCTCATGCAATATATGTTACTGAACACATATAGATTAATA
AGCCTTCATCCCTAAATAACAATGATGGGACCTTCCATTTTTATATCCCTCTGGCATTAAAAATGTGCTTTTATAGC
CATCATCTCCATTGATCTCTCAGTCCCTTGAGGTTGATATGACAGATATGCTTTTTTCCATTTTAAATTTACGGAAT

106

AATAAACTAAGCTTATACAAAGCATATTGGTCAAGGAATGTTGCTGGCCTTATTAATTAGATAGCCCAGTTAAAAGAA
GAATTTTTTAAATATAATTAATGTTAAAGTAGGATGATAGTATATAAAACGTGTCTACTGTCTGAATACAAACTAAA
CTGTTTTGGTTTAGCATTTACCTCAAGATCTCTTAATATCCCCCAAAGGGTCCCTAAAACCACAACCTTATCTTTGTGC
TCATGAAGTAGAGAAGAGACAGTTAATAGACATTTCTAGCTGATAGACTGTTGTAGAGCAGAGAACGCTCTGTGTTT
TTGAAAATTAAACATATGAATTTGCCCTCTTCCCCTATTAAGGAAGAAGAGTTTCTTAATTGTGCGAACACATCAA
GTGAACATATTCAATTAGATTTTTGTGACCCAGGGTATAAACATCTGGTTAAGGTTACATATTTCAAAGGAACAAAAC
ACTAGAACTCTTGGTTTTAAATCTCATGGCTGGAGGATAATTTGCAGCAGAGATTATCTGGCAAGCATAACAGAAT
TGCTGAGACTGTTCTAAAGATGTAAGTGTGGTGTGTTGTGTCGTGAAAATAGCTGTTTACATCTATTAAGTGGATAC
CGATGGTTGAAAGTGCCGTCTATGTCAAGTTTTTACCAAATCAACTTTTGCCCTCACTGTGTGACACCATTTTACCTA
ATCAACTTGGACTGCTAATGTCTTTTCCCCTGGCACCACCTATCTGTCTCTTTTGCAAAGCACAGAAACGGCATGCAT
GATTGTAGTTTATAAAACACATGTACCAATGTGGTCTACAGCTTCTGTTGAGTTCGAGAGGGTCAGTTTCTGTAATC
TCTTCTGGCACAGAGTCAAGAACAGCTTCACTTTCTCTCTGCTACCTCTCTACCCGTAAGTGTGAACCCATCACTTT
GCTAACACTCAGGAAGGGGATTACACAAAATAGAGCAGGAGCCCTCTGACCTGAATATGCATCTGAGCCCTAGCCAT
AGAGCTTCTGATTACAGTAGATCTGGGATGGGGCTAAATATTTGCATTTTTAAGTGTATAAGTGATGCTGATGCTGC
TGGTTCCAGGACCACATTTTAAGAAATATCGATAAAGGTGGAGAATTAAGTGCAGCTCAGAAGACCTGAGTTCTTG
CCCCAGCTTGACTTTTACAATCTAGCAAATGGATAAAACTCGCAGGACTTCAGTTCTCTTACATCTACACAGTGAGTG
GTTAGATTGGCTTTGTAATTTAAAATTAAACAGGGTTTGATTCTGATTCACTACACAAGGTTCCAAAGAAGGAATGA
TATCTCCTTTCACTTTCTTCACTTTGTCTTCTGTCCCTAGGTAATCTTATCTATGTTTCTGATTTAACCTAACTAATG
TTTCTGCAAAGCTTCTAATATTTACATCTCCAGCCCTGAAACTCTCATTGTAATGCTAGTCTTATATACATACCCCC
CTGCCTAATTGACATCTCCACTTAAATGTATCAGAGGCAACTCAGACTCAACAAGGACCAAACCTGAATGTTTCGACCT
TGTCCTTCAAACCCGATACACATCCAGGTTCTCCATCCCAGTGAATGACACTATCCAGTTAAGCAAGCCAAAAGTC
TGGATTTTTTTTTCTCACTCTTCTCACTGTCCGTCAACTACCATTATTAATCTGTCACCTGGTCTTACTGATTTA
ACCTTCTCAATATCTCTACAGTTTTTCTTTATGCCCATTAGTATCCTAGTGCAAGCTACCATCGTCTCTCATTGGAA
TTAAGCAGTAACCCCCCTACCCACCAGACTGTTCTGCCTACAGATAGTGTGATATTTAATAAATATAAACTAGCC
TTGGCTAGATTTCTCCTTCAAAGGTTACATTAATTTAGCCTTAAATGGTGTGCAAGCTTTGCATAGTCTGTCTC
CTTGTCTATGTTGGCAGTATTTTTTACTATCCCTCATCTGCTCACTTCTCTGTACTCCAACCTACACTAACTTTGTT
TTTTTTTTTTTTTAGATTTCTCTAACTACAGTGCTGTAATCTCTTTTTCTTTGTCACGTACTATTCCGTTTGTGAGG
GAATCTGCTCACTGTCTCCACCCACTCCACACACTCACGTTTTTCTGCCCCGTCTTACCGGTCTTGATCGGTTGTGAC
TTGCTCAGGAAGGTTTCCCTGGTCACCCCTCCACAAATGAATTAAGTCTCTTGCTGCATGCTGTCTTAGTGCTC
TTTATTTTTCTCTCTCATCTTAATTCAGTTTGTAATTACATGTTATTTGTGTGAGGATTTGATTATTATCTGTGT
CACCCACTAGATATTGGGCATTCTTTACTTACTCACCCTGAATTCATAGAACCACAGTAATTGTACACAACAAATA
TTCAAGAGAAATTTATTGAATTGATGAATGAAAAGTTGTACCTTAACATGTTCTGACATGTATCCAAAAAAGAGCT
CCCCTTTGGGGTCTATTAGGACTTTGGACCTAGGTAAACGTAACCTAGTTTCGCTCAGGTTTAAACAGTAGAAAGT
AATTGGGTCTCTTTTGCATGTGGCTTTTCTTAAGGGCTAACCCTGTCTTCGGAATGAGTCAATACAGCAGAGCTGTTG
AAAGCAGACTCTAGCTTCGGACAACGTTGGTCCGAATCATGGTTCCGTCACTTCTTAGCTGTGTGATTTAGAATAAA
TTAATGTTTTAAAGCTTTGATTTTCTCTTCTTAACTCTGGAGATGCTAATAAAGCCAACCTTCGTAGAGGTATTGCGA
TGAGTAAATAAGCATAATTTGCTGTAAACACCTTGCAGATTGCTGTGTATGCTAACTAATCAATAAATTGAAGCT
CTTAACATCATTATATTAGATATTTCCAGCATTGAGTATACTATCAGGCATGTGGTAGAAGCTCAATATAAAGTTTT
GTTAAATTGAATAGATTCCATATATGGTATTTCTACAGCATTATGCTCCTTATTTAAGTGTCTCTAAGTATTTTTTA
AGTATCACCTCACAAAAGACAGATGTTTAATTCATTACACATGTGAATTGTTTTAGATAGAAAAATAAAATAAAAAA
TCAAACATTGAAATCAATAGTGTACCTTACCTTAGGATTACACCATAAAATTTCTACCAATCGAGAATAAAGTGTAC
AGTCTATTTCTTTCTAATACTTTTAACGCAACAAATGTTTATTGAACACTTACTACTTCTAATCTATGACAGACAT
AAAGATGAATAAAGCATGCCACAATGTTTAAAGGAGCTCACTATATCAAGAAAGCGGATTACACAGACAACCTCT
ATAAGATAAAGTGGTAAATTTAGGCTGGCTGTGAAACAAAGGATATAGGTATAGTTAAGAGGTGGAATTTATTTT
ACTTCGAGGATTTTCACTTTTATATTCTTTGTCTAACCTTTTCACTGTTTCTCTTTCTTTCAGAAACAGAGCACCTT
TTTTCTGACACATTCACTTTCCCCCTATGGAGTAGAGCAGTTGTTTTCAAAGTGTGGGTCCCAGATCAGCATCACGGG
GATGGTTAGAAATGCCATTCTTGAGCCTCACAACAGACCTACTGAAACAGAAATTTCTTGGAGAGTGGAGCCCGCAG
ATCTGTGATCAAGCCCTGTAGGCAATTCTAACGCACACTCAAGTTAAAGAACCACGGGAAGAAAGGTCCATCTGTGTA
ACAAGACAGATTTTTTTTCACTTAGCATCAATTTTGATCATTATATATATATATATATATATATATATATATATAT
ATATGCATGCTCACAAAACCATTCACCTTACTAGGTTTTAGTATTCCCCTTCTGTATTCTATGTGGTATGTATGTAT
ACAAGATGAACACACATTTACCTGAGACAAGGTAAGACTACACATGTCTCATTGTTGGGACCAGAGGCTGTAATCTTA
CTCAAGGTCAAAGCGTCTTCACTGCTTTCTTTCACTGCTTTTCAAAGTAAATTTCCATGTAGGTGTCATTTGTTT
TCTTTTTGTGTTTTAGAAAACCGATTAAAGGGGTGAAGTCTGGCTAAACTTAGTGTCAGGACATTTACTTAGATAAAA
TTATTTTTAATTTATCTTGTAATGTTCAATGTGAGAAGAAAAAGTCTTATGAGTAGTGTATTCCTTAAATAACAACAA
TTTTAAAACTACCACTGAAGTCTGTGAGAGTAGTTTTGCTCATTTGTCTAGATAAGAGAAAAAAGGTTACATTAG
GGATTGCAATTTGTCTGCCAAAGTGCAGTTTATTTATTTCAGAAACATTTAGAGAGGAATGTGTGAGTTCTGTTGCAG
GCACTGTGCTGTGACGGGGAGCTCAAGATGATCTCAAAAAATTTACAGATGGGGTGGGCAGGGGGCACAGAGAGAT
GTATTTAGTGGTTTCAATACTATTTAGACTGTGGCCAGCATTTCTCTAAATGCAATCCAGATAACACCTTACAGAAT
CATCTGGGCAGCTTGTATAAAGCTGTAGACTCTTACCCTTCATCCCAAACCTATTGAATCAGTGTCTGTGTGTGAAG
ACCTAGATTGTGACTGGTAATTATACCAAGCTTCTAGAAGCAACTCTAGGCCAGTAATACTACATCAGATCAGAACTGCT
GGAGGGTTTGTCTATACCACAGATTGCTAGGTTAGCTTACAGATTGCTGGTCCAGTTAACTTTGGTGCAGGTCCAGAT
TTTGCATTTCCAGCAAGTTACCAGGTGATACTGATGCTGCTGGCCTTGATCGTGCTTTGAAAACCACTGCTTTAGCT
ACGCTATAGGAAAAACCATATAAGGCTTTTATACTGGCCAATGACTTCACAGGCCCTGAATTTTAGAAAGCCCCCTTC
TGCAGCTTGGCCTATAGATTCTGAAGGAAACAGAACTAACACAAGAAAGCTAGTTAGGAGCTAGTTAAAAATCATCTT

108

ATGTAATGGAGTGAGGCTTAGAAAACATGAGGAAATTTACTCAAGCTATCCATTTATTGATGTGTCCATTTGTGTTGT
CAGGGAAGAAAACTTTTTACTCCCCTCTTAGGTTCACTACTTGGGGGGCTGCAAATTAAGCTGACGACAGATAGA
TTGGCAATAGAAAAGACAAAGTTTATTTCAGAGAAAGTATGTGGGAGCTCACAGAAAACATAGCTCAATGAAGTTAGAA
TTTGGGGCTTATGTACTATTTTAAACAAGGGTTTGTAAAAAGAGAGTGTAGAAATTTCAAGCCACAAAGTTGGTGGGA
AATATGAAAGAACTAATGAAAGGTAATGTTTGTTTAGTAAAGTCTGTTTATGTAATTTTCTTTTCCCAGCGACAA
CTTCTCATCTCTGGTGACAGGAGTCACTCTTACCCCTGGTGCAAGAACTTTTCTTAAAGGAGGATTTAAACAGT
TGAATTATTTTCAGAAATCTTTGCTTTTAGGCAGATAGGGGGAGTACAGAAAAAGCCCCTTCCCGTATCTGTTGATCC
TCAAATGGCTTTAGCTCAAAACAATTTTACATCACGATGGCATAATGTAGATCTCTTCAATGTGTTCATTTTATCC
ACAGATATTTGTGAAGTACATGATATATGCCAGGTACTTGGGATACAAGAATACATAAGTATGTCCCTAGTCTCGTA
GAACTTACACTCTAGTAGTGAGCTAGAGAATAAATGATATTATTTATTATATGCATACACATATGATTTTCAGATAGT
GATCCATATTGGAAATAAAGCTGGTTAAGGGAATAGAAAATGATATTGAAGGTGGACTTGTTTAGATTGGGTGGATT
GGCATGGCTTCTCTAGGGGGCAGTATTTGAGCAGATATGAGAGCAGATATTCTCCAATTTGGGCAAAAACATTCCAG
GCAGAGGAAACAAGGGCAAGGGCACTGAGTTCAAAGAGAGCTTGACCTAGCCAACAAATAGCAAGGATTCAGTGTA
AGAGAAGGTGGGGAAGGAAGGAGGTGCAAGTATAGGCAAGGGCAAGATCACACGGGATCTTGCAGGCCGTGATAAAA
GAATTTAACTCTTTTATAATTTTACAGGACATCATTGAAGAATTTAGAAAAATAGAGTGGAGATACCTGATCTGCT
TTCTTCAAAGAGTTCATTCATCATTGCTGAGTAGAGTTAGACTGAAATGGAAGCAATAGTGAATACAGGGAGATAG
CACAGGAAGCCACGTTACTAGTCCACATCAGAGGTGGTTTCAAGTACAGGTGGAGTGGTGGGGTCAGTTAGAGAGCTG
GTATTTAGGATACATTTTAAAGACAAAGCTGACAGGATTTGCTGTGATGAATTAGATGTAAAGTATGAGAATAATTG
AGAATTATTTCTAAGTTCTTTGCTGGGGAAAAAGTGGAGGAGGAAAAAGTTAGGGTACAAGGTGTGATGAAATCAAGA
GTCTCTCTTATTATCAGAGTCTCATTAGATATCCAAGTGGAAATGCTGGAAAGAAAGTTGGGTAGATCAGTCTGAAG
CTGAAGACAGATACTGTGACTGGAATAATAACGTAAGAGTTGGCCGGACACAGTGGCTCACTCCTATAATCCCAGCA
CTTTGGGAGGCCAGGATAGGAGAATTACTTGAGCCCAGGAGTCCAAGACCAGCCTGGGTAAACACAGCGAGACCTCGC
CTCTACACACACACACGCGCGCAAAAATTAATCGGGTGTGGTGGCACATGCCTGTAGTCCCAGATACTCAGGAGGCC
GAGGCTGAAGGATCACTTGAGCCTGGGAAGTCAAGGCTGCAGTGAGCCGTGATCACACCGCTGCATCCAGCTTGGG
CAACAGAGTGAGACCCCTGTCTCAAAATAAATAAATAATGTGGCAGTCAATAGGCCCTTAGATGGTTTAAAGA
CATGGGACTGGATGAAGTCTTCTAGGAGGAGAGTTTGGGAAAAGAGCCCGAGAATTGACTGCACCTTTTAAAAACAGG
AGGAAGAAAAAATACTCAAAGGAGACAAAAGCAACTTCTGTGATTTATAGAGAAAACCAGGCAAGTGGGATGAAG
AAAGTCCTTCATGATAGAATCAAAAAACAGTGTCAAATGTTGAAAAATACAATTAGACAAACACAAAAGAATAGACCAT
TGGGTTTTGCAATATGGAGCTCATACTTGACCTTGATAAAAAGACATTTTCACTGGAAGCATGCATCAAAAACTATT
TGTGGTAGGTTAAAATGTAGTAGGAGGTGAGGATATACAGACAGTGGCTTTCACTGTGCAGATACTGCTGCTCATGC
ACTAATTTAAAGACATTTGTTGAGTATCTACTATGTTGTATCCATTGCTAAATAGTAACAGCTGGGTTTAGTCAGGT
AGAACAGCATCAAAATCATTATAGTATCCCAAGATAGGTACAGTAAATCTGTGAAGGAATCAGAGTAGTCTCTTCT
CCAACAGAGCGTAAGACCCAGCTTCACGGAGAAGGTGGTAGATTAGCTCATCTGGGAGGCTGAGTAGAAGCTTGTCA
TTATAGAGGGAGAACATCAGAAGTGTGGACAACAGCTTGAATAACCTTGAAGGACAAAAGAGGACGGTCTGCCCTG
GAAATATTAAGAAGTCTCACATGATTAGACACAAGATATTAGGGGAAAGGCATAAGGTGAATTGAGTCAATGAGGTG
AAAGAGAAGCTAGCTGGAGGAACAGGCGATCATAAAATGAGTAAAGTATATATTCAAAGATTCTTTTTAGAAGGGC
TACACAGGATGGATAAGGGGAGAGAGAGAGTGTGAGGCACAGAGACAAAATTGGAAAGGTGCAATCATAACCAGAGACA
TGAAAAACCCATAGAAATCTGATGTAGATTATGTGGTCCCCAAGGTTGAACAATTAAGTACGCTTTTCAAGTTGTTATG
CCCATGATATTAACATATTTTATAACTGCAATAAGTGTGAAAGCTAAAGATAAATACAAACAATGTAATTCTTATTC
TGTGAGAAAATGTTGTAGCTGGAAGTTAAACATGTTTCTTAGCTAAAGAAAAATATTGTGTGATCTGGATTACTTAA
TGTTATAATTTAGCAACAAAATGTTGACATTGAGCCTTGCAATAATCAAAAAAGTAGTCTATTCAATAACCACATTT
CAGAAAAAATAAGAAAAATATTAGAAACAATGATAAATATCTAGTAAATTTAATTTCAGTATTTTATTGTTTATT
TGGATTTAGGAAAGGCAGAAATGTTGAAATATTAATATATATATCTCTGTAATAATATAAATTTGTGTCTGAGAGGTAGG
AATGAGGGCATGAGGTCAAAGTTTGATAATGAACCTTCAAAGCTATAACTATGATCAGGAAATTTAAATTGGACAATA
AATTCCTAGAATCGTCAGGAGTTGCTTGTGAAATCGAGAAAAGGAAAGGATATACACAAAAATAAAGAACAGCCAATG
CTCTCAAAGGAGTCTAACTTTTATAATAGTCTTCTGTGTTAGAGCTGAACTCTTCTGGTTTTAGAAGGACACTCTGTT
GCCTGGAAATAGGGCATGGAAAAAGTCATCAGAGTCATGTCATCTTTTCACTTCTTCCCATGAACGAAATCGAGGCCCT
GAAAAGTCACCTGTGTTTGTGTTTATTGCAACTAAGATGTGCATTTTTAAATTGATACATAAATAATTGTACAT
ATTTGTGGGATACATGTGATATTTGATGCATGCATACCATGTGTAATTATCAAATAAGGATATTTCTGTATCCGTC
ACCTCAAACATTTACCATTGCTTTGTGTTGGGAACATTTACAGTATTTTATTATAGCTATTTTGAAATACAAAATAG
ATTGTCATTAACATATAGTCACCCCTACTGGATGCACCTTGTTTTTAATATTTCTGAAAACAGATACGTCTCATAGGTG
ATGGTGTACAGCTGTGCATTAGTTATTATTGCTGTGCAGGTGCAAACGTAACCTATTCATATTGTTGTCAATTAAT
TAAATAGTTACATTTATTTATATGCGTTTATTATACTAATAAAACACAATATTGAGATAGTTGAGCTCTAGTTTTGAC
TCTGCTGTTAACTAGCTGCGTTACTTTAATTTACTTAACTAATTTGGCTTTCAAATTCCTGATAAGTAAATTAACA
CATGAGTTTCTCCTGCTATAATAGCCTGAGAAATCGGTGAAACACATGAATTCAGATGTTGATGCTATTTAATAGCG
GGATTCCAGATATCTACTTGCCATTATGGGAGGGAGAGAGGAGGTGGACTGGAGGCTGTGATTTCCCTAGGAGGTTG
TTAAATTTGGCCAGGTGAGGAAAGCTGAGACAGACCATAAATATGAAGCATGATACCTAGCCCTCAGTGTGAAAGA
AAATCAAATCTCATCTTTGTGGTCTAAATATCAGTATGATACAATCCTCTGTGTAGACATATCCTCTGCCCTATTGT
TTTCTTTCTAAAAGCTAAAGCCAGGTGTGATCAGATCCCTCCGTTATTTACAAATTTCTGATGATGATGATTCTTC
TAATATCTACATTTCTTACCATTACCATGATGTCCAAAACCTATTATAATCTATTCTGCTCAAGTGCCATGTTGTG
GTCACCCATATGCACCTCTAAACCCACCATATGACCTTCCCGTGTCTACTTGAATACAGTTGGCCCTCTACCTCGTT
GTGTCTTTGCATTGCCTATTTAATTGCCTTTCCATTCTCTAAATCACTCTTTTCTGCTGGACCAGCAACATCAGCACCA
TCTGGGAATTCATTAGAAATATAGATCCTCAGGCCTCATCTCAGACCTGCTTGATCAGAAACATTGGAGAGTGGAGA
TGAGCAGCCTGTATTTTTATCAGCCCTCTAGGTAATTTGATGCACACTAAAGTTTGAGAACCCTGGTCTAGAGCAT

TCTTCTTTAACTCTCTTCTAAAAATTATTAGAATGAATTCGAGGGACGGGATCTCCTTGAAAGCCAAGAACATTTCT
TTGTCATCTTTCTGACTTCAGGGCGTAGTACACTTTTTGGCCCATAAATTAAGCTCGATAAATGCATTCTATGCCAA
TAAATCAGCTAATCAAATATATTATTCATGCCCTTGAGGTATCTGAAATTTGTTTGCAGAATGTAATATATAACTAT
AGAGTAACAAGAGAATAATTTATTGCCATAGATAATAAAACAATATCCTCTGTATAATAAATCCTAGCCTCTGCTCA
ATGGGCAAAAACGGGACTGGGGTTTCAGATTTTAAAAAGATTATTGGTAATTAAATCACCTGGAGAAGCACTTGCTG
CAGAGATGGGACTTGAAGCATCATAATAAACTGTTGTTTATTATGATTGCGTCAGAGCTGATGGAATCACAGGGATT
GTGTGAGGTATGGAAAGTGGTTGACATTGAATTCAGGCTGCACAGTTGGGACTTGATATGATAACCAAAAAGAAAG
AATGTCCTGGGGTGGTAGCAAGCTCTAAATTTAGACAATCTAGGCTTATCCTAAGGAGAATATAGATACAGATAACTG
AAGTTTGATTAAAGGGAACCTGGTGTATCAGAAATAGTAAAAAGCTGTAGTTAGTCTATGCAGCTATCAGCTAGCCA
CATAATACTTTTTGGGCAAAATACATTATAAAACCAAAAAGAAATGACATGGCTTATCTCTGTAACAAAGTGGCTCATTGTT
CTTTATTCTACTGTTATCCTTAAGAAAAAAATTTTAGTAAATTTGTTATGCTATACTCAACTTCAAGAAGGGATAGC
GCTTATAAAAAAATTGTTTAAAGAAACAGGCCTATTTCTCTTTGGGAGAAAGCCACGGAGAAACGAAAAGAAATGGAAC
GTGTGTTTCTGCCAGATGGCAATAAAATGTAGGGTAAATTTCTGTCTTTTAAACTGTATTTTTTCCATCCCTCTG
TATATACACATATCCTAGGACTGTTATAAAATGCTGCATGCGTATGTGAAAATGGAACCTTATTGGGCTGTTTGATG
GACCTTTAAATATATTTGTTGGTTTGGGGTACATACTAGCTATGCAATATAATCCGCATTATTTCTTATGTAAACA
ATGGATAAACTGTTTCACAGTCCAGACATTTATTTGGTCACTGTTTGTAGAATGTCTATTTTATTTACTTCTGAATT
TGTATTCCAGAGATCTGCCTTCAATGTTGGATACTTCCACTGTAATATTCTAGGAGATGCTCACTTTCTTTTTTCAGC
ATCTGACACAGTACCATCTGCCTCCTCTTTTCTTGCCACAAGTAATAACAATTTTATAAAGGAGGATCACATTACAG
AATTATAGGTGGTAAACTTTCTACCACCAGATTTACCCAAGAACCTGAAACACATTTTTTCAAAAGGAAATAGAATG
TCCTTCTTGTGACTACATCGGAATTTTGCTTGCAAGCATTATGCTTTTTTTTTTCCCCCTAGTGTAGCTAGCCATGTGG
AACTGAAGCCATTAGCCAGCTCCTCATCCTATAAAATGCTATTACCTGGGAAAAGAGGCAGAAAATATACTCTCTTCT
CCAGTTAGAGTCTAAAGGAAGAGAACAATATGGGTAGTTGTGTTTACCACAAATTGATAGAATCCTTTATTTTAAA
TGCTAAAACCAAAATAACTTGTTTATATGACTTCAACATTGACTATCACACACTGTTGCATGATAACAGAGTGAAAAC
TACCTCTATTGGATTTAAGTGGGGAATCTATGTCTCATTCTCATTCTTTTTTTACTGTGGAACACTAGTTGATTCCAG
GATCAGCCTTAGCTCCAACCTGCCACACTTTGAGTTTGGTTTTTCACTTGCATTGTACAGGAACTTCTTATAGGA
TAAATCGAGGAAGATTTTACTCTGCAACGTGTTGCAAGAATTAACATTTAAAGTGGCAAAACCTTCGTGTGTAGGTT
GTCTCCCCAGAGAATGTAAAAATGAATTGAAGGCAGCACCTAATAGGTAAACGACAGCCAATCAAACAAGAACAAT
GAAATTTGACTGGCAAAATCAAATTGAAAAATGTATAACGCTGAATCTCAGAATATAGGAGGATGCATAGAACTAAG
CTGTACTATTATAAAAGTCATAGCCATTGAAAAATAATGACTGGTTAATTTGGTTTTCTTTACCTCATGGATGTGAA
TGGTTAGATTTTGATGTTGGTGTATTTGACGTGTGTTTGCAAGAAGTTGCCTTAGTCGGCTCGCATTTAGGATAA
AAAAATATTTTAAGAAATGTTTAAGAGATTATGTTGGAGACATTAGAAAACAAATAATTATGCAGAGGGCAGGACT
ATCAAAATATAATAGAAAAATTACACCGCTCTTTTATGATTTCTCTCTTTTTTGGCATTAAACACAAAACCTTTATGAT
TACACACACCACGCACTCCAGAAATGCTTAAAGGAAGATGAGAGGAAAAATCAATAGAAGTAGCAGGCATTTCTGTG
AGGACAGCAGAATGATCACTTCATCTCTGTATTTTTTTTTTTTTTCAAATTTCTGTATCTGTACAATGTCTTTTCCAGC
TCTAATATTCTGTGATTTGGTAATTTCCGCACTCAGATTTCTTTAATGAATTTTGTATGATATTACCTATTTTTAT
ACCAGATATTACCTGGCTCTAATTTCTTTTTTACCCTAGGAAATAAAAGTATCGGGTGAATTTCCCATTTTTCTTATG
TTATTGATACAGGTCTCTGTTGGATATCCCCACGATTAACCTTCTGCAGCATGTTTCGATGGTGGCTTAAAGAAGAA
ACCATGTATCAGAGCCCCCTTGTCTATATAGACTTTTAGATAAAAGAGAAATACATATCACAGAATTATTCTGGGCGCA
TAGAGTCTCTAAATGCAAAAAAAATTTGTATTGTAGCTGTTGATTCTTCTCAGATAGATTGAGTGTAGAGAGAGAG
CATTTCAAAAACCTGAGCAGAAGAAACACAGTCTGAATCAAATAACATGAAATTTTAGCTAACAAAGTAAATAACACTT
TTTTCAGAATATGCAATAATATTGGTTTATTATGAAAAATGTATAGGCTGATAGATGAGCATAGAGAAAAAATTAT
AAATATCTTCTTTAATATCACTTTCCCCAGCAAAACCACTTTTAAACATTTTGATACATTTTTCATGTTTCAAACATTTCC
TAATAGTCTTTTTTCTGTATATAAATGAATTTTAAACATTCGTATGTTTATGAAAAGGCAATAAGATACTGTCT
CTTTTATAACAGGCTTTCTGAACCTTCACAACATGACGTGATTCTAACATGCTCCTTGTGTTCTTAACTAATAAAAA
ACCTCACGTTATTTAAAAAACCATCTTAAACATAATTATCCATTAAGAGAAGAGGTTGGGGTAGAGAGTTTCAGACT
ATCAATATCAAAGTTATATTTTCTGTAAGTATTTTAAATTTTAAAGTGTAGCTATAGGTATATGATTATAAAACCAAT
AGCAGAGAAAAGATAACCACCTTTGAATATAGTTTTCTTGGTTCCATGAAAATGGCCTCCTTTCTTTTTGCCAGTCC
CTCAGTATCATTAACCTCATTTTTCTGTAAATGCCATCATTGTATCACATGTCCTCAGGAAAAGGCACCTTTTCTCTTT
TAAGCTAGTGTGTTGTTCTGTTCTAATTTTATGGCAATTTAACGAGTAACAATCCTGTTTCTATAAATACTGTTTCC
TAATTAATCTATTGCATTCTATCCATGAGAATTTAGATGACTTTCTTTGTAAGAGAAATCTCTGTAGCATGAGATTC
TTCTTTGCTCTTAAATTTCACTTTTTCACATTTTAAATGACCTGATAGTATTTTGTGTATTGTGTGCTGATTTTTT
TTAACCAATCTTACCTTGTGTAACATGTAAGTTGTTTCTAATATTTGCAATGATCAAAATGTGGATCCAACCTCACT
AAAGCGTTAAGAATCTAAAAACAAAACAAAGAACAAAAAGTTGGCTGTCTCTTGCTTGGACCACCCCGTGAGTTACT
ATTTTCTTGTGTTCCGGTCACAGTTCATCCTAAATCATTTCACTACACAAAATGTTTTTTAAAGTTTGGGACAGGGGG
TAGAGAATGTCAATTATTCCTCCAAGGCAGTCATATGAGCATTGAGTATCATGTGGAATAGTTGTTACTTGTAAGT
TATGGGGCATCAAACCCAGTCAATATGTTTCTGGAATTGAAAAAGTCCCTGGACATTCTAATGATACTGTTGTTTCC
TTTGACCTACTGTTACCACTACTTTGATCTGTCAACACTGCCCCGTAATGGTTAATTTTGTGCATCAACTTGACTGG
GCTACAAGGTGCCAGATATTTGGTCAAACATTATTCTGGGTGATTCTGTGCAAGTGTATCAGATGAGATTAACAT
TTAAATTTGGTAGACTGAGTAAAGTAGATTGCCCTTCCTAATGTGAGCAGACTTCATGTAATTAATTAAGGCCTGAA
TAGAAGAAAAACACTGACCTCCCTGAGCAAAAAGGAATCGTTCTGCCCCACTGCCCTTCAAACCTGGGACATGGGCT
TTTTCTGCTTTCAGACTTTAAACCACAATATTAGCTGTTCTGTATCTCAAGTCTGCTCACTTCGATTGGAACACTAC
ACTATCAGCTCTCTCGGGTCTCCAGCTTGCTTGTTCACCCTGTATACCTTGGGAGTTGTCTAGTCTCCATAGTTGCCT
CCATAATTGCATGAGCCAATTTCTTACCACATACAAACACACACAGAGACACACACACACACACACACACACACA
CACACATATAATTATATATGTGTGTGTATACATATTCTCTTATTCTTTTTGTTTCTCTAAGGAACCTAATATACTC

CTTATTACTCTTTTCTACTGCCTTAGAGATCTTCAAGGCCAAGAGCGTAATCCTCCATCCTGGCTCTTTTTTCCTAATC
ATTAATGATCAACTCATAGCCATTTAGCTCAACTAAAAATAATTTGTTTCATGAAGCTTTTACACTCCCACATACTGAG
GAACGTGGTACCTAAGATCAAACAGTCACTGCCTCATCAAATGCATTCCCTCTTCAACCCCATACAAATGTCCCCAGA
TGGAAGTCACACCATAAAAAATATTAGATCCCATTTGACTTTTCTGCTTTCTCAAGGATCATTTGCAGAGCTTGAAAAAG
ATGGCTCCTCCCTTTGCCTAAGCAGGTAACTTGGTGTAAGAGTACATGTAAGATTGGGCACAAAGGAAAAATAAATC
AGTTTTGCCTGGGTCTAAGAAACATTTCCCTCTGCCTCATGGTAATTGTACCTGCCAGTTGATTGCATTACTCAAG
TGGAGACCATGAAGTGAAGTGGTAGAACAAGAAGAAATCCCTATAATTTTATTAAGTATGGTGAAAAATACAGATAT
GTAGAGAAATGACTGGGATTAGATGGAGCAAAACATAATTCGAGATCCTGATACAAATTTGACTTCCCTGGCTCAAGG
GAGGGAGCAGAACATTTCCCTGCTACATGGGAATAATAAATGCTGATAAAAAATGCAGATATATCATAGACTACA
GAAGCTGAAGTGGATTCTTATGGTCCCTACTCAGACAGCCTCTCCTTCAGATGAAGAACTGAAGCACAGAAAGCT
CATCCTAGTGTTCATATTGAAAAACCCATTCAAGTCTATTTTAATAACCTGTTACCAAAAAATGAGGGAAATAATTT
AACTTTAATGTTTCACTTTGCATTACCCTTTTCTGACTAGACTTCTATCCTTTTCTTGAGTTGAGCTCATTAATA
CTATGAAATTATGGTTATGGGTAGAGGTTAATTTTATACCTGTCCATCTTCTGGCATCTTATTTACACTAAAAATCA
TTTTTAAATGGCTTCATTTTAAAAAATATTATTTTCAGTTGACATTTTAAAAGACACATCATTTTATGTACTACAGAAT
ATGCATTTTATACTCTCCTTTATTAATTTTATTATTTTCCAGGTAGACCAATCAAATGAATCAGAAATTTCTTGGTTA
GATCTATTAGACAGCATAAGTATGTTTTTCATCATTAATAAAGATGAAAACACAATTTTACTTTAAAGTGTGTTGAC
GTTTCCAGCCTTTATAAAGTCAACACTTAATCACATCTGAAATTTGCAGGAAAAAATTTTGAAAGCCTTCAATTATT
AACATTATTTTCGGGAGAAAAAGCCACTTTGCCGCAGAACTTTCACTTTTCTCTCGTGAATTAAGTCTGATACAAAT
ATTCAATTATGGTGAAGTTTAAACATAATAGAGTCTAGCTACTTCCACAAAAATACTATTCAATGAGTTTCTACATTG
ACATCTAACTGACCTTGTAATTAATGTTGTACACGATCCTTTTATTATATGCTGGATTATCAAATATGACTTATTAG
CAGTATAAAGACACAAAGTTCTGAAATGTAATTTATAGCCATGAAAAGGAACTGAGCTTTGTGTGACAGTTAAATTT
GAAGAGATCAGGTGATTATTATGAAGCATGAATAATAATGCATATTAAGTCACTGTTTTTGTGTTAAATCATTAATAT
GATTGTTTTAGAAGAAAGTCTACCTCTATCATATGGGCAATAAAATGTGTATAAGAGCAAACATTTGTGTATGTGAA
ATAACTCAAATTAAGAACAGTCTTCCACATTAATCTTACAGTTTTTAAAAATTTAAATCATTTAATGTATCACACAT
AGCTTTTATTCATTTTAAAGCTATAAATGTTACAATTTCTGTTTAAAGTCTGTTAATAAGCTTTGTAAGAGCAATCTG
TATAAATATAGAATTTGTCATTATTCTACTAATAGCTACCATTTATTTAGTGCTTGTGAGTGCAAAAGTACTGCAGCTG
AGATCTTTGCATATGTTCTCTTAATGTTACAATTTCTTACCTGAGGCATTTCTGTTTCTGCTGGAATATGGTCTCTCT
GAATTGAACAAGGGAGGCATTTTTTGGTTGTTATGATGAAAGGTGGACACTGCTGGCACTAACGTGTGTTGGTAAGCG
ACTAGACTCTTCATGATGCGTAAACAGTGTTCCTCATAACCCCTGCACATTCAAATAGAGGAAAACCTTGTTTATAG
TTAATTTCCCCTAGAATGTAAATCCATTTAACATATAAAACACAAAGCGTGTTTTGTGTGGATGTTTTTTACTGGAGC
AGGGAGACAGGAGAGGAAATGCAGTTTTGATAGTTGCTGAATTTTTCAAGAATGCAGCAATTATAGAACAATTTCTA
GAAGTTTCCCTAGGAGCTCTTTTCCATAGCAGAAAACCTAGGACTTAATAGCCTTGCGACTCATGGTACTTGAGTGTTT
CATACAACCTACCTATATTAGGGGACATTTGAAAAATTTCTACATTAAGGGGATTCTTAACATAGGCGCAAGTGTC
TGGCATCTTCAATAGGTCTTCTGGTGTGGCCATGAAAACATTCACACGTTTCAAAGTATTTTAAAAATAAAATAAAC
ATATATTGTTGTGTTATGAATTATTTCTTTCTTTTTTATATGATGGTTAGATCACTGTGCAGACAAGTTTATGAGA
TCTATTCAATTTCAATTTAGGGTGGTAAATGAGGGTGTTACTAAATGTTGGTTCTAAAAAGGGAGACATTGGGTATTA
CAGAATTCAGAACAGCTCTAAGCCCTGTGCACATTTAGCATTAGAGGACACAGGCAAATCTGGCCTCCAGTCTCGGC
AGCTTCTTCACTATGTATATGATGTTGGGTGGGTTGCTTTACCTCTCTAGTTTTTACTTTTTATTTCTAAGCTAGGGC
TATTCATAGTTCTTTATCATGTGGTTACTGTGAAGTAGCAAAGCACCTGACATAATTAGAGCAGATAAAATGCTCAA
CAAATATTGCTTATCAGAAGGATTATGTATTACCTCCCGAAATACATCAAAAAATATATTTTCCAATTCAAAGAATAT
GTAGTACAAAAATCATGCCTAAATTAACAGAGTTGCAGTAGCCCAAGGAGAGAGAAGATAATCATTATTGATTTCTTCT
TCCTTTTGGTAAAGAGTTCTCTGTCTCTGCCTCCTCAGTTGTTGTCCATCCCACTCCCCACTCCCAAGCCAGTGAA
CTCTGAGGGGTTTGCTGCGGTGGCGGTTCTGTGATCATTTGCTGCCAATGATGAAAAACAAAAATCATGCAACAGA
ACACTATGCCTGTGAGCTTAGCTCCCTTCTTTCTGCTAAATGACATCAATCCTATTCTTTTGTCTAAAGGATATC
CTAAATGAATAGCCACTGGGGGGAAAAAAGGTTATATAAGATTGTGCACTGTGTGAACTGATGCAACCAGATCAAT
GATGTGAATTTCTCTTAATTTTACTGGGATCTAGAAAACAGGTCTCTCAACTTAGCAGTGTTTACGAATATAATAG
GCCTTCTTATACATACATCTGAAGCCAATCTGAGTCAGGAAGAGTCGTGGTCTGATAAATATTTTGAAGCTTGCA
TTTTGTTCTATTAAAGCAAACCTGTTTATTAATAGTGTGCCTTATTTTTTAAAGCAAACATTTATAAACAGTAGTCAT
TACAGGCACCTCAGTGACGGAGTGATCAATTGTTAGACCTTTAGGAATCGATTGTTTCTGTTGAGCTTCGGCTTATA
ATTGAAATGTCATCAGAAGGAGTGTAAGACATAGCTTCAGGAGAGGCCATTTATGCGCTTTTGTGTTTTCAGCTAAGTT
ATAGAGTCATCATGTGAAGAAAGATTCTTCTCTTAGTAAAAATCCTTTAATGGTTGGAATAACACTTGATATTTAAT
ATTTCTTTTCTACTTTATATCCACATTTATTCAAGTGCTAACGCGTGTTGGGCGAGCAATGAAGCACTTTATTCCAACA
TTATAGTTCTCATATCTGCGTATGATTATTTTTTCAATTTATCGTTAGCATATATATAATGATGACTTTTAAAGTACAC
TGTATTATATTCACTGGAATAATGATTAGCTATTAATAATTTGAACACTATCCAGGAAATTAAGTGAACATGTCCTAC
AAGATAAACCTCGTATGATATTGTCTCCAAATAACAGTGCTAACCAAGAAGAGTGCTACCAAGTTCAAAGTAATCA
CAGGGAGTAACCTAAATGCAGCTCCGTTGGGTTAAAAATAGTTTCTCTAAATTAATGTTCCCTAAGTTTGAGATCG
ATTTCTACAAGGGGATAAAATGTTTTTATAAATTTCTCAGTGATAAGTCATGTGATTAAGAACCCCCAACTTTTTTTC
CAAAGACATTTGCATCTCTGATCAAAATAACAAGATCCAGTCTTAGTTATAAATTTGGGGAATTTTCATCAAAATAAG
GAGCTACTCGTTGCATAAGAAGACTAGTACAACCTAAAGCCAATTTAATTTCAATGAATGCATGATCAGCTCCATTG
CCAATTGAGTGTTTTTCTTATTCATCAGAAGATGGGTTCATCATCGTTTTCATATCAACTGTTTCTCAAACCATATT
GCCCAATTTAAATAAATATAGATTTGTCTCGAAATTTCAAAATTCATGTCATATTTTATAAATAGCCTATGGTCTTATT
TATTACTTTTAAATATTTATAGATATAATATTTTTTATTCTAAAGTAACTGTGTTATACAACCAAATTTATTCATTTAAA
TATGTGACTTTTTTAAATAAGTAAATGACTTATTTAAGTAAAGTCATTAAAAATTTTCCAGTCTGTCTTTCATCCACCT
GATCTTTGAATGAGTTAGGAACAATACAGGAACTAATACAACTTAATTTTGATTACAAAAGATGAAATCATTTCTG

TTATTTATTCAACACACTATGTGTCAATAAAATCTTATACTGTGAAAGAATTTCGTCTAAGTCCATTTGCTGTTGCTT
GTAACAGAATACCTGAAAAATGGGTAATTTACAAAAGAAAAGGAGTTTACTTCTTACAGTTACGGAGGCTGAGAAGTCC
AAGGTTGAGGGGCCACATCTGGTCAGAGCCTTCTCCCATCCAAGTACTAACCAGGTCGAACCTCAGTTAGCTTCCAA
GATCAGATAAGAGTGGGCGCGTTTAGGCTGGTGTGGCTGTAGACTTGTAGAGCCTTTTTGCTCATGGGGACACAGC
AGAGCCCTGAGGCAGTGCAGGACATTACATGGCAAGAAGGCTGAGTATTCTAATGTGTTTCATGTCTCTCTTCTGT
CTTATAAAATCATGAATCCTACTCCCATGATAACCCATTAACCTATTAATTTATGAATGGATGAATCCATTCCATAAG
GGCAGAGCCCTCATGATGCAATCACCTCTTAAAGGCACAATCTCCCGGTGCTGCCACGTTGGGGATTAAGTTTCCAA
CACATGAAATTTGGGGGACACATTTAACTATAGCAAAATGTATAAAATGTTATATAGAAGCAATGTTCTTACTG
ATTATAATTGTTATATTGGTAAAGTGTTAAGTCCTCTAACCAGGGATATATTTACAGCTTATTATAATAGTTTTAAA
TTTACAATTCAATATGAATAACATCTGGTAAAAAGTTCTTTTCAAGAAATGGGAAAATTAGAAATGTTTAGAAGAAAA
TAATTTCAATAAATATTAAGTTCAAACCTGGATTTCATAGTTTATGTGAAATTTCTGGGAACCAATTGCAAGGGGAGAAAA
TAGTTACAATAGCAATGGTGAGGATGAGAATAAGAGCAGGTATCAACGTTAATTGAGGGTGTGTTATAGTTCTAATC
GTGCTATGCCCACTACATGACTTTTCCCTGTGTGAGGTTTCCGAGCTTCTTCGTAGTAATCCTAAATTGAGCTGGAG
AGAGGCTAGGGTAACCTTACTCACGCTCATAGAGCCATAGAGTAGTAAAACCTGTATTTGAACTCTGGCCTGTCTGAC
ATCATTCTGTGGTCTTTTAAACCACCACTGCTTCTCCATATTAATACTCCAAATCTAGGTGAAAAGAAGAAAACCTCA
GAACATGTTCTGCAACAAAATATAACAAAATATAATGTATATAAACACTTATACATAATATCATAATATCTTTACT
ATGAAAAGACTCTGATACGAACATTTTACATAATTCATGCAGAAGTGTTAATCACATTGTCTGTGATGAGCTGTGTA
TGTATCTGATAAAATTTCTGGCAACCAGACATCAACTCGTAGGCATAGATCTGTAACACTAAATATTTGCCTCGAGAA
ACTTAAAGAAAATAAAGACAAATGAATGAATAGGAACATGGAACCTGAGTACAAGATAAAATCCTCCTAAAGCAATCGA
TGTACTTGCTGCTGCGTTATTGTTCTAAGCAAAAAGCATGGCGAAGGGAGATGTGAAGCTAAAAACAGAATGCTT
AGAAGGAGATGATAGCAGGAGGGAAGCAAGATGGGACCAAGCTCCCAAAAGGCGGGCTTTGAACAAAACAAACAGA
AAGCTAAGCCTTTGACGGATGCACGGGATGCAAGAACTTTAGTCAGGAAAGAGGAGGCGAAGAAAAACCTCCAAA
GAAAAGGTGAACAATATTTTAAATAGGCAAAATGCAGATAGCAAGAGATATATACCATGCTATGTTTTCTCATTGCA
GCTGAAGACAAAACCTGGGGTTATTTATGCTTTGAAAAAGCGTAAATCTAAAAACAATTTGTGGAGGAAGAAGCGATGA
AAACACGTTGTTAATACAGAAAACATGGCTCCAAGGCTTTAACTTCCTTGTGAGATAAATGCATTTACATTTCCGCT
AGTAGCTAATATATATATATATATACATATATATATATATATCTGGGAAAAATAATACACAGTGATTTTTCTTTCTTTT
TCATCTACTTATGTGAGAAAAAAGTAGGCTATCTGAAAGCTTTTTCAGTTAAATGAGGAAGAAAGTTAGGTGATCTTG
TAAATAATATATATGTTCAAGATAATGTAAGGCCCTTGTGTAGTTTTTCAAACTTATCTTTAATAGCAGTTTCTTCT
GGGGATGGGGTAGTTCAAAGTTGAAATGTTAGAAAAGATGTTAACTTTTTTTCTTTTACTTCTCCCTTTCAGGATG
GAATTAACAAATTTGATTACAAATAGATCTCAGAGAGAGGCAAAATGCATTGAATCCAGAAGTAACATAAAATTAGAT
CATGTTTAGTTATGCCCGAGGTCACATGGTGATAAAAAATGAGGATAAACTGAAATTTGTCTGTGAGCCAGATTAGTTT
ATTTTATGCCAGTCTTAGGAAAAAGACACATCATGGTAGGATACATCCTTTTTTTTTTTAATTATACTTTAAGTTTT
AGGGTACATGTGCACAGTGTGCAAGTTAGTTACATATGTATACCTGTGCCATGTTGGAGTGCTGCACCCATTAACCTC
TTCATTTAACATTAGGTATATCTCCTAATGCTGTCCCTCCCCCTCCCCCACCACACAGTTCCAGGGTGTGA
TGTTCCCTTCTCTGTGTCCATGTGTTCTCATTGTTCATTCCCACTAAGAGTGAGAACATGCGCTGTTTGGTTTTT
TGTCTTTCGATAGTTTACTGAGAATGATGTATTCCAGTTTCATCCATGTCCCTACAAAGGACATGAACCTCATCATT
TTTTCTGGCTGCATAGTATTCCATGGTGATATGTGCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTTGG
GTTGGTTCCAAGTCTTTGCTATTGTGAATAGAGCCGCAATAAACATATGTGTGCACGTGCTTTTATAGCAGCATGAT
TTATAGTCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGTATTTCTAGTTCTAGGCCCTGAGGAA
TCGCCACACTGCCTTCCACAATGAACAGACACTTCTCAAAAGAAGACATTTATGCAGCCAAAAACACATGAAAAAA
TGCTCACCATACTGGCCATCAGAGACATGCAAAATCAAAACCACAATGAGATACCATCTCACACCAGTTAGAAATGGC
AATCATTAATAAAGTCAGGAAACAACAGGTGCTGGAGAGGATGGGGAGAAATAGGAACACTTTTACACTGTTGGTGGG
ATTGTAACTAGTACATTCTTAACATCAATTTATTTCTTAAAGCAATGTTTCATAGGGCACACTGTAGGCCATAGATT
TGCCTCACAAATTTAAAGGCCTAAGCCCTCAACATGCACAGCAGTATACCTCAGAGACTATTTGTAAAGATGACGATT
CTGGAACCTTTTTAATGACCCCAATCATTAGCAATGATTAAAAATTAATATTCAACATTCTATATTTACCAAGGCAATA
AAGTAGACTAATCTATTTTAAAAGGGTTTTAAAATGAAGAGATGAAACAAACCAATGATTTTGATTTAACTTCAT
GAAAACATAAGTTGCATTAATCAGGTGATTTTGTGTTTATGAGCATTCTGATTGAAGTGATCATATTTAGCCCCGGGA
GAATAAGAGAAGGTAAAGTATGGGTATGGCACTGAATTTACTGAGATGATTATATTGTTTGAGTTAAAGAACTTGTA
TTAAGAAACAAGTATGTGCCAAACATTGTGCTAGGAGCAAGCAATGCTAAAATTACATGGGTAGAAAGAGAGAATGA
AATATCTAGAATGAGTTAGAAACATCAGTGTTTTCCAATGTGGAGCCCTGACTTCACATGAAAATTCTCATTTTCAA
ACAAGGTAGTTTATGAAAACCTGGACTATTAGCAAGACAGGTTGGGCATGCCATCAGTATAGTACCTGGTGTAAAACCT
AGAAATTTTAATCATTGTGCTTTCATTTTATAATCAGTAAAATCCAAGGTAGGACAACTTTTACTTTTTCTGTAT
AATGGACTGATATTTGAATTATACCCAACTTTAATTTTTTGCAGAAATTATGCTTTATTGTTTCTTAAATGGTA
CTATAGATCTTTATTTATTTCTATATATTTATATGATTTTTACATATATGTGCATTTACATGTATATACATCCATAA
ACTATATACATATATACACATAAAATTACAAATATGTGTACCTACGTACATATATATGCATATATCACGCAAAATACAG
GCACATTTTCAATACCCCTTTTTGATTTTTTCTTGAAGAGCATAGCATCTGAATTTATTTATGGATTTATTTTTAA
TTTATGGTCATGTTCTTTGAGTGCTTTTGGTGTGTTATCTGGTTGCCCAAACTCGCTAGCATTGTAAAGAAGATGTG
CAAAGCCTGAATCTAGACTGACTTTTCATATTGACTTTATTAGTCAAAAAAAGTAGATGAAAATGTAACAGTCCGTGT
TCTGAACCTGAAAACATGCAAAATGCCATCGTACAGACTTCATTAACATTATTAATGCTATGATATAGTAAAAGA
ATTTGTAACTGTCAAGTGCTTTGTCAACATTAGGAATTTAGTTATTTATAGGTATTTCCATATACATGTTGTATTTA
GAATTCCTTTAATTTTATACTTAGGGTTGATTTGTATTTTAACTAAGTCACTTTTATATATCTGGTCCCATTATACA
AGTATACTTTTCTTAGGATAAGAAAAGTGATCTTTATATATGTTTATCAACCCAAATGCCATCAGTGATGGACTGG
ATAAAGAAAAGGTGGCACATACACACCATGGAATACTATGAATCCATAAAAAAGAACGAGTTCATGTCCTTTGAAGG

GACATGGATAAAGCTGGAAGCCATCATCCTCAGCAAACTAACACAGGAATGGAAAAACAGACACCGCATTTCCTCAC
TCATAATTGGGAGTTGAGCAATGAGAACACATGGACACCGGGAGGGGAACATCACACACCGAGGCCTGTCGCGAGGT
GGGGGGCAAGGGGAGGGAGAGCATTAGGACAAAATACCTAATGCATGCGGGGCTTAAACCTAAATGACGGGTTCATA
GGTGCAGCAAAACCACTATGGCACATGTGTACCTATGTAACAAATCTGCACGTTCTGCACATGTTTCCAGAACTTAA
AATTTAAAAAACTTTAAAAAAGAAGTGTAGATACTGATCCAAAAAATGTTTCATTAAATGGGGGTAAATGATTAT
TTCTAAGTAGACTACTCTTGAACCCCTGAATCTTTAAGAAATTTCTTTTGCTATTGAAGCCATTCAAACCTCTATTTTA
TTAAAGCTGTCTGTTATTCTAGTAGATTTTAAACAGTAATACCTGAATACATTAGAAATATGCAAATCTGCATTACAT
ATGGCATCTGCAGAGCAGAGGAGTTTGGTCATCTGGACTCATGTCAAAGTCTCCGAAAAATCCGCTTGCTTGAATGA
TGGTTGACTCGCTAATGCTATGCGTATATAGTCTTATTTTAAAGTGATTGAATGATGTGGCTAATAACCCCTCTGTTA
GATGCACTCAGAACCTCACCTACCTGGGTCTCAGCTCTCCAGTGAAATCTCTACTTTAAGTTTATTTTCTAACATG
GTAAGAGCCTTCAGTTTATGTTATGCTCAGGCCCGTCACTGTGAATAAAAAATATTAGAAATGGACTTTTTTTTTTTGT
ATTTTTTTAATGGATCCCTTGGAACCTTTAAAAAATTTATTTATTTGAGCTTTCTACTGTTATCACAGTGTCTCCTAA
GCATGGCCTCCCGTTTTTTGTTGGTAATATAATTTCTTACGTTATTCAAATTAGTAACCATTATTTTTTCTCATGGCTA
GAATTCTGGAACTATTAGGAAATCACTGAGCATAATTGAATGGCTGTTTATTTGAAGAGCTATGTCAAGGCAGCAT
AGAGTTGTATTTTCTTGACGGGGCTCTGGAGTCAAAGAGCCTGGGTCAAACCTTGGCTCCACCACCTTCTATCTGT
GGGGCATTGGGCGTGTTACATTTGTGAACTTTTGTCTCCATTTGTAAAGTGAGGTTTGGGGGATGATTAAACCA
GATAACTCATGTGAAATATTTAATGGAAATGTATTTGGTAGGGGATTTATTTATTTTAAATTTGGATTGCACATGAC
ACATGTGAGGGATCATGCTATGCATTTTGGATAGAAAGATGGCTAAGATATCATGCCTGACTCTTAAAACTTACCT
AATGGTAAATGACGAGTTAATGGGTGCAGCACACCAACATGGCACATGTATACGTGTGTAACCTGCAATGTTGT
GCACATGAACCTTAAACTTAAAGTATAATAAAAAAAAAAACTTATAATCAACTGTAGTAGAAAGAGATCTGAATGG
CTTGCCATTTAGCTAGGCACATGGTATATGTGCTTAATTCATACTAGCAGCCACTACAGTTGTCATGATTAATAATG
AGCTTCCAACCTGCACAGAATGCTTTTAATCCATAGAAAAATCAAATCAGAAACAAGTTTTTGTAAATTAATGTGAAA
GGAGCAACAATTAAGATGCAAGATTGACATTTATTTCTAAATTTGGTTCTATTTTCTTTCACATTTACAAAATTTAT
AAGAAAATCTTTTATTTCTATGTGATATAAAGAAGTAAAGTACTTTGATGTGAATATTGTTGCCAGTGCTGTTC
AACTTTTATCCATAATTTACTAAGCACCTTACATTTAGACAAAGGCATTATCCATCCCTTTGGGGAGGATTTAGATG
ATTCATACACAGACCTGGTCTCGAGGAATTTAAGATTTTCTTTGGGGAGGGAATAAGGACTTTAAACCACTCAAGA
GTACTTAGAGAATTTTCTGAAAATAATTTTATCAATGAAAACCTGTTATATTAAAAAGAACTGTCATTCTGACTTCC
ACAAATCTAGGCTTGAAACTATGGATAACGAGATATTTTCTATTACTCTCACTCACGTCAATTTTACAAAAGTGAAAA
GGTACATTTTAACTAGTGAAAGAATAGAGGAAATGGAAGTAGCTCGAGGCAGTGGACGATGATTCAAAAAGACAGGG
CCCTATTATTTGATCAAGTTATGCAACGACTCTGGGCTGTTTCTTACCTCTGGAAGGAGGAATAATCTCCAAGCC
CTTTCAGACTCTTTTGGTAATTCACCTCCAGCACATCTTCTAAATGCCAGCATTAACTGTCTCTGATTTGTCTCAT
GTTTTTCTAGCCCCATGCTCTCCTGTTGCGCATTTACCCTCATGCAAGGTACAAATTACACCCATCATCACAAGACA
CTTGCTCAAGTCCCATTGCCCCCTTGAAGACCTGCCACACCTACTCTCTCAAAAACCATCATTTTCTGAAAGTCCTA
TACAGCTCATTTTGGTATTTACAGTGTACTGCCACAAGCCACTAAGCATCGTTTTGTGAATACATGACTTACAGACTT
AGCTTGAGTAAAGATACTTGAAAATGAACACCATTCTTGCTATCTTCCATTTTGTATGTACCCTTCAGGCCTATG
AATTTTAGTATAATAGATAACCAATAATTATTTCTTGGTTCTTTCTGACATCTGAATAACCCATGCAAAGTGAT
AGAATGTTTTTCTATAAGGAGGTCTTACACTGGAGATTGTGTATTTCTTAATGCTGTTGAAGGAAGAGATGTGTATC
TAAATAAATAGACTCTAACAAACATTAATTTATATTTCTATTATCTGTTTTGTGTATTGAGATATCTCACAAAAAT
AACTAAACATTTTGGCATTATTGATATTACATATTTGCCATGAATATTTGTAATGAAGAAAAATATATATACATCA
GTAATTATCTTGGCAAACCTCTTCAATTATGCAATATTGTTACATAGATTACATATCTAAGTGAACACTGGAGTTTTA
ACAATATTGTGTGTTTATAAATGTTTTATTTATTTATTTGCCACTAATTTCTATTGCCATTTCAAGAACTATGTGAAG
TTGTTCTAAAGACTATTAAGATATAGGTGACCATGCTACTGCTTCTTAAAGGCAAAATATGTGTAAGAC
TTTTTAATGTGTTAAACAAACGTTGAAGTTTTTAACTGTTTAAACATCAGTAGGACTCTTGAATTTATTTCTTAAG
AGAGTAAATTTTACAACCTTGCAAAGCATGATTAACCTCTTGTAAATATAAAACCATCTCTTGTAGTTATGTAGCATTT
TGTTAATGAGCAAGAACCATTGTGGTTCTTTTTTACATTTCTTAAAAATAATTTCTCCGTAACCTCATTGATATCTCC
AGTAAATTTAGATAAGCTTTTTTTTTTAAAGGAGGGTTAAAAATGACATTTTAACTAATTTTTCTTGTAGTTATAC
AGAGTTGAACATCTGAGGGTTTTATTGACAGTCATAAAAAATTTGTTATTTTCTGTGAAATATAGAGAATTTAAT
CATTATCATATTATTAATTTCTGTGGGCCATTGTCTTAATTTCTAGAGGCACAAGCTGTTTTTCTATCCCACTGAAATAGA
GGAATCAAAGTATGTTCTTGTCTCAAAGCACAAAAGTGACATACTACATAGTATGCTTCTTGAGTAGTCGTAAATCT
CATGTGTTAAATTACATCCCAAAGATTTAGATGTTTTATGACTTTAATAATTTATGGTAATTTCTAATCTGGCCT
TTGTTGACCTGTCTTGCTTTTTTAAATTTTTAGTTTTTTCGACAAAATAATTAACATATTTTAAATAATCTTCCAAAGGT
GTTTAAATGGCATTGTATAGAGATAGCTGAAGGCTTTTGAGCTCTGTGTTGTAAACACTTTCTTAATAAAACATG
AATTGCTACCAGATGATCCAGCAATCCCCTACTGGGCATTTATCCAAAGAAAAGGAAATCAGTATCTTTGAAGAGA
TAGCTTTGTTCCCATGTTTACTGCAGCACTTTTCATACTAGCCATGATATGGAATCAACCTAAACGTCCATCAGTGG
ATGAATTGAAAAGAAAATGTGGTATGAAACAGAAATGCTGCTTTAATTTATATTAAACACACTCATATTTCTCTCA
GCTGTAAAGTATTGAGTTATAGATTTAAAGAATTTCTATTGTGAAGACTAAAGTGACTATTAAAGTAAGAAATTTAT
TTTCCATTATATTTAACTTATTTCTACTTTAATGTTAGCGCCAATGAGCAAGACTATTGAATACAAAACTAATTA
AGTAGTGGTGATAGTACAGTATATAAGGGAGAACATTTCTTTAGAAAGGAACAATAACAGGGAGCAATAGAAACAAT
GAATGAGTGTAAGGTCACTTAGTGTTAAAAAGCACTAAAAATATAGTACAAATAAGTTGCGTTTTAATAGTGATTTTAT
ATAATTACACCTTGATGTTTTATTGTTTACAAGAATTTGTCAGGAAGATTTCTCTAAAGACCAAAGGCACCTTTCC
CTAAATAACTCCAAAGCCAGTCTGTGTTTCTATAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTGAAAATAA
CGTGATGAACATTTTTTGAGGAAGTATAAAAAACAAAATACTCCACTGCATAGCTGTTTCTGCAGGTATTGTATTGATA
TATTACATTATTCAGCTTTGGAGTCTCCACATCCAATGTTACATCATCACTCTAAATTAACATGTATAGATAAATG
AAATAAATGAGATAGCATATGAAAATCTCATAGCCCAGCCCCGCACTATTTAAATAGAAATACCAAAGAATTGTA

TTCTCATCTGAAAGCTATTTAGTGGTGGTGTTCAAAATAAAAAATTCCATCTACTGCTGTTGCTTCCATTGTATCTT
TTTCTCTGCGGTACTGAAAGAGAAAGAGACCCAGAAAGGGGCCCTTGCTGGAAGTGTCCCTCTTTTAAGCTGTTGCTGC
TTTAAGCACAGGGTGGACAAATGTAATAGGAGTTTCATAAAGGTGGAATAAACCCAGCGGATTACGGTGTGGGTGAAT
ACTTTCAGATGTTAACCAGGAGCTCTGCTTGCATGCTGGGAGTTGCCCATGCCCTCTTCTAGATTGAGGCACATTATC
ATGCACAACCTAACTCCAAGAAATCTTTAAACCACTGGAAATGAACCCAGAACATGTCCTAAGCCAGCCTTTTC
ATCCTGACACCGAATCATAGCATGAGCCAGTCTGTCAGGGATGCTGCTGCTCTCTAGGCCAAATTTTAAATGTTGAAA
TAATGAATCATGTTTTCTTGAAAACCATGTACACCAAAGAAAAAGTTAGTCATTTTATAGATGATGAATATTAACATT
TTCTTAGACAATCTGATAAATTATCAGATCTCACTTTTGGCTCTTTTAAAGACAGTTATGCCTCAGAAAATATTAATA
AACCCCCAAGCCCTTATACTGATCAGTATGTTCACTACTAGCTATGAGAAATCTTGAAGTTCTTGTAAATTATTGTA
TTATTTCTTACTTTTCATTTTATTAGTATGTGAATAATATTTTAAAAAATCTAGTGTATGCTTGTATATATTTTA
ACAACATGACTTTTAAATTAATGTCTTGATAACATTTCTTCTAGTGTATGTTTTCAGTAACATGATTATTAACGTAA
CTTTAAAAACCTGTGGATTAGATGGGACCATTTTAAATGTTTTAAACCTGGAAAACTGATGGCTTTAGGTTTAGT
TCAAGCTATAGATCACCTGTGGAGAATGGAAGTCCAAAAAATAAATAGCTGTAGCAGCCCTTTGAGTATTCTAAA
ATAGGGATGTTATCCAGAGCATTGGTTTCTAAAGCTTCCATTATTTATTGATGTTGAGCTTTTCCAGGATTTAGCTACA
ATATTTACTCAACATCTAAGCCATGCTTTTTTATCAGTCATGTTTTATATCTTTTATAATCAAACCTGCTTATCACTG
AAAAAATATATAAGTTTCTATGTATCTGGAAGAATTCTCTGGTGTCTTCTTAGATATGGATTTTGATGTGTGGAATA
AGAATTCATTTCAAGGATAACAGAGATGTTGTCTGAAAAAATCGAAGAAAATCAGCTTTTCTTTAACATTCTGTC
AAAGCTCCTGACTATTAGTTTATCAGCACTGTTTTGCCAAAGGTGCTTCTCTTCTTCTTTTGAaaaaaatCATCT
GCTGCTGCTACGCCGCAAGTGTGTTCCCGCTGTGCTGAGAGATGTGTGGCATAAAAAAATGGGCATGGCCTGAGT
TAAAAGTGCTACATTTAAGCCAGAGCTGGCTTATTTATTAGTTGTCTAATCATAGGAAAATGACAGAGCATGCTTTT
CTCTTGCAATATCCGTTGCTGAAAATTAACACATGAGCAGAGCTTTCAGAGAGGTTGACTGGCCTCTCAGACAGCA
CCTCATAGGATGGCCTGTGTTGAAGCATCTCCTTTAACCAGGGTCTGTCCCTCAGCATTGGGTTGGCTCACCTAGAT
TGGATTGTCCAGCAGAAAAAACCCTAATTCAGAAATCATATCCAAACCGGAATACTCTTTCATTACATTAC
TTGTACTACCTTTTTCAGAACTGGATACCTGAGTGTGTGAGGGTAACTTAGAACTTATCTCATGGTTAGAAAGTTT
AGAATTAGAGAGCGATGATGAAACGGACTCATGATCAGAACGCAATGGAGCAAGGAATGAGATGCTCTTTGAGGA
GTATTTCCCTGAGGCTGTGGATAACGCTGACGAATAATCCCACTTAAAAAGTGGGTTGACCCTCTAGTAGCTGTA
AGGTGGGAGGGTTCTTTCTTCAGAGATAAATCTGTGCTCTTCACTTGCCCATTTCCAGGTTTTCATGTAGGTAGAA
GAAACACCTGTAATCTGAAGACACTCTTCCCTCAGCTTTGTTAGTGACAGGGATTTAAATATGTCTTTCACACATTT
TCCTTAGATAGTTAAATTTCACTTTTCTGTTTGTCTTCTGAAAGTATTCTAACTCCCCCTCTAATGGACTTCT
AGAGCTTTCTAATTCTATGCAATTTCTGTTGATTTGTTCTGGTAACTTTGAAGGTAATCTCTGATTCAACTTCTTG
GAGATTCTATCATGTCTCTGTTTATTAACCTTTATGTTACTCATGGTTTCTTGATGAGGACTCATTAACATAAT
GTAAGTAGAAAATTATTAACACATAATATTTACTACGGGTTGTTATTTCTGATAGTAGCTAGCTGTAAGATTCCAA
TTGTTCTTCAAATCTTTGTCTCAGTGATCTCTGTGTAGTTCTTGACTACTTCAAATAACTTCTTAGAAGGATAGGGA
TTTAATAATCTCTTAATAGGAACACTTAACACACTGCTGGTGGGAACGTAAATTAGTTCGGTCTGTTGAAAGCAGTGT
GGTGATTTCTCAAATAACTTACAAAAGAATTACCATTTGACCCAGCAAATCCCATTTATGGGCATATACCCAGAGGAA
TAGAAATCATTCTACCATAAAGACATATGCACGTTGTGTATGTTCAATTGCAACACTACTCACAATAGCAAAGACATG
GATTCAACTTAAATGCCTATCAATGAACAGACTGAATAAAGAAAAATGTGGTACATATACACCATGGAATACTATGTG
GCCATGAAAAAGAATGAGATCATGTCTTTGCAGCGACATGGATGGAGCCAGTGGCCATTATCCTTAGCAAACCTTAT
ATGGAAACAGAAAACCAAATACTGCGTGTCTCACTTATAAATGGAAGCTAAATGATGAGAACATATGGACACAAAG
AGGGGAATAACACACACTGGGGCTACTGGAGGGTGAACACAAGTGGAGGGAGAAGATCAGGAAAAATAATTATTG
GGTACTATGTTTAGTACCTGCGTGAGAAAATAATCTTTACACCAAACCCCGCAAAATGCAGTTACCTGTATAGCA
AACCTGCACGTTTACCCCTGAACCTAATTTAAAGTTATAAATAAACGTATCTTATTTTTCAGTACAATACACCACA
GAGTAGAAGGGTTAAAGAGATTGCTTCTGAGGAGGTGAGATGGGGGTAAGGACAGCACAAGAGCATTTTGGGGGGT
GATGAAGCTGTTCTGTGTCTTGCTGCGATGAGGCTACACGACTAAGCCCTTGTCAGAACTCACAGAACCTTACTT
CAAAAGGAGCGGATTTTACTACACATCAATTCCAATAACAAATACTTTGTCTTTAAGCAAAGGGATACCTAAATATA
GCGTATTGAATGGATCTCCAGAAAAACACATTTTTTCAAGTTTATGTTTTCAGCCTAGGCCCTCATCTCATCCAGGAAACC
TTGTCTTGCTTGCTTTACATACATGTGGCAATCAGTAGTTTCTTTTAGGGCTCGGACTGAACACTCAATGAACCTC
AATCTTAGCGCTTGTGCTAGCAGATTGACATGGTTTATTTATATGTGTCATTCTCTGTAGTAAAAGGAAAGGATCAA
GGCCATTCACTTTTGTAGTGATTGTGCATGGCAGTATTGGCACATAGTAGATTATTAATTATGGAACCTTCTGTTTT
CACACACACACACACACACACACACACACTTCAGAGCTATTTTCAATTTAAATATTTGCTTTAGTCTCCAAAGC
CCCTCTGCCTCAACACCAACCTTCTATCTCATTATTCATCAGCTTTTCTCCTATTACGAAACTACTTAGGAAAGCC
CACTTATTTAGCTTATGATGGCAAAAATAAATATTTGTACTTTTTTTTTTTTTTTTAGTCATCGCTTCATAGAACAG
CCTCTGTCTCTGCTTATGCCATGTCTGAATATATGCTGGAGGTAAAAAGAGTTCCTGGTTGAGAGCTTCAATTTGA
GAAACTATCTGAGATTACTTTCCAGGTTCCACCGTGGAACCTGTCTGACCTTGAACAAATGACCTCGAACAAGTGGC
TGAAATCTCTTCTATTTTCGTCAACTGTAAAAATGGGGGAAAAACCATGTCTATCTCATGGGGTTTATGTGAAGGTTAAG
AAATTGCTTATTTCAGTGTTTAGCACAGTGCCTGATATGCATAAAGCTCCTAGGAATATTAGCTGTTATTGTATTTCC
TTAAGAAGCCCATAGCTCTATATGCCCTTTCATTATATGTTTTAGTAGCCCAATTTAACATATGGATAAAATATTT
TTAAGTTAAATGATTTGCTAATGGATTGTTGAACGAGTGGCAGACACCCATATTATAGACGAAGGTCAAGTCCATAA
CATACAGTACATTTCCCACTTTTCATTTCCCATACCAAAATTCATTATTCTCTGAGAACTCATTATAGAAATTCAT
TGTGAGATTATCTGTGTGTTCCAGCAGTGCCTTATATCCAGAAATAACACTGAGTCATTGTCTAGATGTAGCAGA
GGTGAATCCTCCAAAGAGAAGCCTCAGAGTGGCCAGGTTTGCCAAGTATAGGGATGCCTTGATTACTGGCCTTACT
CTTTATGCTCGTGAATTCCTAAGTTTTATTCTCTCTGTAGTCATAGATTGGCTTTTAAAGCTACAAGCTGAAGAGAGA
GAAAACCTCTTCCACCTCGTTGGAATATGTCTCTTCAATCCATTTGAGCCAAATTTAGGACATGAGACTGCTCTTAGT
CTAGAACCAGTCATCAGGAGAATTCAGGTCTGATTGACTCGGACTAGCGGGTCAATATCAGGGCAAAAATTCACAC

GCACAACACGATGTATCAGTAAGGAGAACCTCAAAAATTATTTCTTAACGTCCAGATCATGTTTCCTATTTTTATATAT
CTATTTTCTCACATAAGTCATTAAAAATGATGTACCTGTGCGGGTCCCTTAAATGATACTCAAAGATCTTGAATTATAG
GCTAATAACTAACTTAATAAGCTGCAGAAATTAACATTTCTGCTACGTTTATGTAGCATTTTTCCCACATGTACTTCA
GAGGCTTGAGAAAAGACCCTGAAATAATGACTGAATAACAGCTTTACTCACTTAATTTCAAATTTGTTAATTTCTTCT
GGGAAATACCGTCAACATCCATTTTATTATTTTCTCAATTACATGTACGTTTCTACATCAGTGGATAAGTTAAGGA
GAAGAATTCCTCATGATAATTTTTTCATGCTCGAAAATTTTGAATCAATTTTTTATTTTACATTATACTCTTTCCCT
AGTCATTAGAAAAGGGAGTGGTGGTTAAGATAGGCAAGAATGCTTTATAAGGATACTACTCTCGTTTCAATTTCTTAAC
ATCAAAAACCTTAACAGTGTGTAGACTATAAAATAAAATATCTAGGGATCAGAGCATTGTGCTGAACCTTGCAGGTT
TTTTAGTCAATAATATATATGACGTGTTACAGAAATCTTTGTCAACAAAGTACTTTTGGAGCTCCAGGCCATTTAA
GTTGGTTTTTTGTACTTTTTCTTTTTCTTCGGAAGACTTTTTTTGTTCTATTTACCTGGAAGTGTTCTTTTTGGTGA
CTGTGAATTAATAAGAGACCAATCTACTAGGCAGGAAAAAACCTTAATTAGATTGTTGACACAGACAAATAAGAATG
TCAATTAGCATCTACTGTCACATGCCTCTCCAGACTGCTTCTAGGATGAGTGGCCTCAAGCAGCTACATCATCTTTA
TACTCCTAAAGCATCAAGGAACTTGGAGTGACAATTCATATCATGAACACATCCACAGTGATGATGATTGTGCTTC
TTCCCCCCCCACCAACAACAAAGGATGAATGCCAATTAATGTATTTCAGTTTTTTGCGTCAAAGGCTGGATCACTTGT
GCAATGAGGGTAATCATCCTGACCAGACAGGCCATACAATCCATATTGTGTGAATTAAGATAATATGCGTGAAACA
CCTTACTCTGGATGTGGTTCATAGCAGTAGCAAAAAGATGAAAACCTATGGTATGCTAACATTTTAGAGATCTGTACT
CTATTTTAAATAATTTTATAAAAAGTGCATATACAATAAAAAGTGCACGTATCACAAGTATATGCCTCAAAATCTAAA
GCCAGTCATGTAATCAGCATCCACTTCAAGAAAAGAAAAACAAACAGTACCCCTGGTTCCTCTTTGCAATCATTAGTC
TCCCAAGAGTAATCACCGATCTGATCTGTGACAGCATAGATTGGTTTTGCCCCTACTATATTTTTGCTGAATTATACA
ATATATGCTCTTTAATGTCTGGCTTCTTAGTGCAATTGTATTTGTGTATCAGCTATTCTCTTGTGTGTAGTTATTTAA
CAATCATTTTATGGGCTGCATAATATCCATAGGGTAAATATAACAGTTTTATTGATAACTTAGCTATTACAAATAG
TGCTGTTGCAGACATATATTCTATTACATGTCTTTTGGTATAAGAATTTACACATTTACATGGGTGTATACCCAGA
ACTGAGATTGCTAAATATTGGGGCACATTGTATACATTTTGATTTAGTAGATAAGATATTGCCAGATATCGTAAATG
CACAGTTTGATAAATATAGAGATTTATACTTTTTCTAGAGAAAAGCCATCAATATCAGTGTATGTGTATATATATAC
GCGTGTGTATATATACGTATATATATACGCGTGTGTATATATACGTATATATACACACATATATACGTATATATG
TGTATATATATACGTATATATATACACATATATACATATATGTGTGTGTATATATATATGAAACAACCTCAGAA
GCAGAAAGATAACCCCATGTTCTCACTTATAAGTGAAAGACAAATAATGTATAAACATGTACACATGGACATAGAGTG
TGTAAGTATAAGCATTGGAGACTGAAAGTGTGGGGGTGTGCAAGGGAATCAGTGATAAATTAATGGCTACAATGTACA
TAATTTGGGTGATGGATACACTAAAAATCCAAAGTTCACCACTATCCAACATACTCACATAATAAAATTGCACTTGT
ACCCCTTACATTACATACAATAAAAAATTTATTTAAATAAAAAATAAATATGTGTATATGTATGCATACATACATATGC
ATATACATATGTGTTTGTGTGTGTGTATATAACTTACACTTAAAAATAAGCATGGATGCTGCAATGAATGCTCAATTT
ACAAGGGTTGTCCATCCAACTTGTGGCAAGTATCTCACCTCTCAAGTTGTTTTCTTTTTCTTCATATATTTCTTG
CTTTTGTCTAGGAAGGAATAATTTGGCTTGCTTTCAAGAGTGTACAGTCAGCATGATAACCCAAACACTTAAGACA
CGTGCTAACCCATGTGGATCCCTTGAGAGAAGGAAAACAGTGGTCCTTTTACTGGGCAGATAGAGCCCGGGGCCAGG
TTTTCGTGGCTTGAAGATTTTCAGCTTCTCTGCGCCTCTCAGCTCAGTGCTCTGGAAGCAATTTACAACCTGTGAGGC
CATACTCAAAGGCCCTGTTATTAATTTCCCGCCTTCCGAGACCCCATTTTCAGAGGATCTCAATTGCTCTCAGAGTGA
ATTTACTGTTTCTGAATTCCGTAATCCCAATAGCAGGTCTGTTGTCTCATTAGATAGCTTAAGTTAGAGTCGGCA
GTGTAATTGGCAACTGAGCTACTAAGTATCCAATGCTTATGTGGAAAAATATGTTCCCTATTGCAAACAACCTGATATT
CATATTCAATTTGGCACCATCATCTATCTATAAAGCAGATACTACTTGTGTTTATTAAGTTTTATCCCAAATAATTA
TTTTAGTAATAATGCTTGAAAAATAGGCCTTGGTCATTTGCATGTCTGTATATGGCATATCCTGAGTCTTTGTATGTA
TTAGAAGATCACTCGTTTTGACTTGATGGTTAATAAAAGATGTCCCTCACTTTGGGCAGAGACATTTGAAAAAGG
CACTCCAAACAGGACCTAAGAGGTGAATGAGATGAGCTCTGAATCAGGTCACACGGCCTCAGGAAGGAAACATCT
TGGTTTTTCACATCCCTCACTTCTCGATGTCAATGTCAATACACAAATGACCCCTCAACACACACAGGCACATACA
CAAACACACACTCACTCACTCACTGTATTGTCTCTTTCTTGACTAAGTCCCTTCTTACTAACTCAAGCTCTAAAGCT
TTTTTACTTACCTAAGGTGAGTGTGTGAGGATTTGAGGTTTCAATATTAATAATTCAGAAACATTTAAAGTTCAATTT
AAATATTAGTAAAAAAAATCTTGACAAAAATACAATTATAGACAAAAAGAAAATTCAGAATATTTGGAATTTAAGGT
TGAGGTTACAGCCCTATTTATGAAATATTAGAAGAAAAATGCTGGAGAGAATAAAGCAGGTTTATGAGTCTGATAGA
AAGCATAACCAGATGATTATGCATATATTTGCATATGCAAAGCTTTCTAGGCAATCTGAACATTTAAACCTACAAAT
GTGGCTGCGATGAACAGCCACAGAAGAGCAGGCTAGAACAGAAGAGGAGGCTAGAACAGAAGAGCAGGCAGAAGTTG
TAAATGAAATGTTAATTTTCAATGGTTGATCTCCAAGTACTGGAACAGATTTGTGCTGTTTTCAAGGTTTTGGTTC
AAAGAATCCAGTAGTGTATTGAATTGTTTTGTGGCACTTCCCTGTTATTTTGTCTTTGTAAGCTACCTCAATCCATGA
AGTGGCTATGAGCCCTTATACAACACTGTTGATTTTTTTTTCTTATCTACGCAAAAGATTTTTGATTTCAGGGCCA
GGCATGGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCCGAGGCAGGCGGATCATGAGGTTCAGGAGATAGAGA
CCATCCTGGCTAACACGGTGAAAAACCCACCTCTACTACAAATACAAAAATCAGCCGGGCGTAGTGGCATGTGCCGG
TAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGTAGCCGAGATCCTGCCACTCCACTCCAG
CCTGGGCGACAGAGCCAGACTCCATCTCAAAAAAAGAAAAAAGATTTTTTATTTCAGGTGGCTATCAGACTC
ATTAAATAGAAGCCTTAGGTTAAGTTCACGGGTGCTAGTTGGAAGCCTCCATGGACTATGTTTATAAATAATAGA
AAGGAGTTATGCAGGACTTCTTGAAATGTTATTTAAAAAGTCAGAATAGGCTTTCTATTACTTGTCTGAGGTCAAAT
ACATGTAGTGCTTTCTGACATTTTCATCCAGGCTGTAGCTAGGACAATAAGAGGTGCTTAAAAATATTATGATTGA
GTAAATGAGAAAGCCCTTAGAAACATAGGAACAGAGTACCCTTGTCTTGGATCTAATATTGACTCCCACGCCTAAA
TCCCTTTGGAGAAGCTCCTTTATTTTCTCTTCCATCAAGAGCAGGTATAAAATTAAAAAACCATTTAAAGGGGCCATCT
AGCTCAGCTGAAGCTTTTCATCACACATGTAGGGGAGGTATGGTTGGGAGGGATCTTTTTATCCTTTAGGTCTTCAAT
TTACATAGGACTTTTGAATAATCAAAATAGCCCCAAAGAGCTGATCTTAGGACTAGTTGTAATTGAGACTATTTCTCC
ATGGGGTAGAAAAATCTAGTTGTAGGAAAACTGAGAAAGTAGATGTATGTTAACCTCAAAGGCTGTTTTTTACAAAGG

ATGTTAAAGCATCATCTTTGCTCAGAAAAGGGAGCAATAAAACAAATGAGTGGAATAACAAAAGGAAATAATGGCCA
GGTGCAGTGCCTCACACTAGTAATCCCAACACTGGGGGGCTGTGGTGTAAGGATCGCTTGAGGCTAGCAGTTCAAGA
CCAGCCTGAGTAAAATAGGCCTCATCTCTACAAAATAGATAGATAGATAGATAGATAGATAGATAGATAGATA
GATAGCCGGGCGAGGTAGTGTGCCCTGTAGCCCCAGCTACTCAGGAGGCTGAGATGGGAGAATCGTTTGAGCCCAT
GAGGTCAAGTCTATGGTGAGCTGTGCTCCCTCCTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGATCCTGTCTC
GAAAACAAAAGGCATACTTTTTAGATGTAATGGAATAGAGTACTTCCAAACCTGGCTGCCTGCTGGAGTTGTATTGG
AAGAGGTTGCACGACTTCAGTGGAGATGGCCTAGATGCCTGCTCAGCAGTCATCTAGTTAAAGCAACTAAGAACATG
TAATATGAAACTGCAAAAAGAGATCGTGTACGTAAATCACTCTGGGCTCCTCAGATAGAGTAATAAACACAACCTCC
TGACAGCCAAATAAAAAAGAGAAATAATACAGCCCTTGACTTCCTTGGTTGCTTTGACATACTAAGTAGGTGTTACAG
GTTGGGTTCTCTGGGAAACAGACTCTAAAAACATTTTTATTTTTACTTTTATTGTTGTTATTATTATTATTATTATTA
TTTTAGACAGAATTTTGTCTCGTTGTCCATGTTGGAGTGTAATGGCACAATCTCGTCTCACTGTAATTTCCGCCTT
ATGGGTTCAAGTGATTCTTCTGCCTCAAACCTCCCAAGTATCTGGGATTACAGGCAAGTACTACCACGCCTGGCTAAT
TTTGTATTTTTAGTAGAGACGGGGTTTCATCATGTTGGTCAAGGCTGGTCTCAAACACCCGACCTCAGGTGATCCACC
CACTTCTGCCTCCCAAGTGCTGGGATTACAGGCGTGAGCCACTACGCCCCGCCAGACTCTAAAATAAAGTTTAATA
TGCAGAATACTTATCAGGGAATGCCACTGGACCAATACATATTCAAGAGAGGGCTTAGAAGCAGGATTGGACAGAA
AGAGAAGTTGAGCTGTAATGCAGGCCCAATAACAGCCTTAGTGTTAAGCAGGCTGAGAGATTGAGCAGTTAATGAGA
CAGTCAACCCAAACAGTTTTATAGGCATCAAAGTATGATCAGCATGGTGTGAGTTTCTGTGTCACTTGTCCACA
GTATGATACCAAAATTAAGAGACAGATGACATGCAACACAAGCAGTGTGCACTCTGTTGTTGAGAAGCCAATTTT
GTCATGCAATTAAGCAGTTTTTATACTCTGCAGCTGTACTTTAAGGGGAGCTGAGATGGAACATCATATGTCTCACC
TAACCAGAAAGGCAGATGAGAAATGTTCTATCGCCACCTCCCACAAGGTAAGGGACTTCCCTAAAGATACAGAGGTG
GGTGGAATATTGCCTTGGTAGACTTCCTCTCAAGACTGCCTATCTTCCCATGTTGGAAGGATCACAGAGCATTGTG
AAGACGTGGGTCAATCTGCAGTTGAACTTTGTGTATGTGGCCTATGTGGATACTTATAATATCATTGGGCACCTCCA
TAGAGCTGTTTCCCAATTGACCAAAACATATGGGAAGCTTCAGAGCTTCGAATGACCCTTCAGAGTAGTCTGAGAAC
AGTGAGCCTTACTACTCTGCATTAATCAGTCATTGGATGATAGCCTTCTCAGAAATAAGTCATGACCTTGTGCAAG
GGGGCTCTTCATGGCTGGGACCACCCCTAAAACCTGAGAGCTGAAGGCTGTCTGCCACCAGCCCTCCACCTGGGG
ACAAGTTCTTTATTGAAGGGAAATCTGAGTAGTTTCATCAGCGTCCATCAGAGTAGTCAAGCCGTTGATTCTTCTCCTT
TTATGACAACATTGTGCTTATTGTTATGTAATCCCTTTCCAGAACATTTTAGGTTAAGTTTTAAAAATAATGCATAT
AAATAGACAATTCAAATACTGGGGAAAAAAGCTTGCATTATATTGTTATAGAAATGTGCACACTTAAAGAGCTGA
TTTCTTCTGGGTATTTACATAACTTTATTTAAAAATCCATCCATTTTAAATTAGCTGTTTTTAATATGCAGTTAGCT
AAGATATTATAAGCCATATATTAGGCTAATGGACATTTAACAGCTTAGTTAAGTTCTTTTAAATGGAATGCTGACAA
ACCTTTGTCTGTAATTATAGCAACACTGTGATTACAGAAGGAGGTGCCTCTCCTTGTGTTTGCAGCCCTAAAATTC
CATGTGGCTATAAGTAACAAAGTCCATTATTAGATAAACACAAGTCATACTTGGCATTACTTGCATTACTCGTCTCC
TTGCTTTATTTGAATCATTTTTTTAAAGTTGTAATGTTTTTCAAACTCAGAATAGTGCCAGTTAATAATATGAT
TCCTCTTATATTATGAGATTTTTAAAAATAGTTTACCAGTTTCTGTTGGCCTCTATACCCATTGGCAAGTCCTAGCC
ATTGTGAATTAAGTAAACAATTCTTTATGGAAATTTTTTAATCCTTAAACCCCTATAAGTTTTTATTCATCATGTGAG
GTCACCTGTCAAAGGGTTTAAACATTGAGAATTCACAAAAAGTTTATCAAAACACCTATTACAGGACGTGCAATTTTGG
GCGCACTGGGATTTTCAAGAAATCAAGATATGATTTGTATCGACATGGATATTACATTCTCTCACAGGAGAC
AGAAAACAAAATAACTAGAAAATATACATAAAGAGACTTTAAAAATGGGGTAAAAATTACAGATTGTGACAGGATGACC
ACTTTGGTTTCAAGATATCTAGGACATTTTTTTCTTTTTTTTTCCCTCCCTCCCTCTTTCTTTTTTTTTCTTTTTCTT
TTTTCTTTCTTTCTTTCTTTCTTTCTTTCTGCTTTTCGGAGTCTTGCTCTGTTGCCAGGCTGGAGCGCAGTGGTGCAA
TCTCAGCTCAGCTGCAACCTCTGCCTCCCATGTTCAAGCTTTTCGTGTGCTCCGCTCCCAAATAACTGGGACTAGA
GGCATGCACCACAGGCCAGCTGATTTTTGTATTTTAGTAGAGATGGGGTTTGACCATGTTGCCAGGCTGCTCT
CAAACCTCTGACCTCAAGCGATCCACCCGCTCAGCCAGAGTCTGGGATTACAGGCTGTGACCCAGGAGGCC
CAAGCAAGGACATTTTTTTCTGAGCCATGTTATTTAAACAGAGTCTGAATGACAAGAAGGGGCCAGCTCTGTGATG
TAGGGGAAGAAAAATATGTTCTTTCTACCTTTCTAGGCTGCCAGCTGGAGTCTTACAAAGTTAGAGTGACAAAAGA
CAGATTAAACAAGAGGAAAAGCCTAGAAAGTTTATTAATAATTCAGTGCACATACACCTGGTAGAACTCAGTGATGA
GTAACCTCAAAGGGGTGGTTAGAATGTTGGGTTTATATAGCATCTGAACAAAGAACAGTAAACTTGTAGAGAAATGAC
AAAACAAAGAAAAAAGGGGTTTAGGTATTTAGGGTTGCCAACTGTAGGAAGGTAAATATATGGGAGAAACATGGAG
TATAGTTTGTGTTATGCCAAGTCTATCTTGAGATCAACTTTTCGTATTCTTCATGGCCATAACAATTTCCAGGAGAG
AGGGCTTATAGCAGTTATCATTTCTCAGAAGTTTCTGCTTTTATTTAGACAAGGGAAGCACTGGGAAGGCTTCTTTT
TGCTTATATTGATTCTTACTTGCTCTAACTAAAAGTAATCTTTATGTCAAAGTGCCATATTTTGAGTGGTATATA
TTGATCTCCTATAATAACAATCAAAAGGAACAGTATTCTAGGCAGGAGTACCCTAATGCATAGTGTTTGGTGTA
GACAAGTTAACATATTGAGGGGCAACAACAATAAGCCAATATGGCTAAGACATTGAGGATGAGTGAGTTGGAG
AAGTAGGCAATGGCCAGCTCATATAAAGACTTGTTTCGTTTTTATAAATGTTTAGATTTTATTGTAATTATGGTGGC
AAGTGATTGGAGAGTATTAGCTTCACTTTGACTGGCTTATCGAAAAACGGAATGTAGGGGGTGAAAGTGGAATAAAAA
GACCAGTCATTAATTGAGTAGTCCGTGTGAGAGATGATAGTGGCTTGACAAAGGACGATTGTACTGGAGAGATTGAA
GCGACTGATTTGAGATTTGTAGTCAACAAGGCTTAATTGGTAGGAGAAAAAATAAATCAGTGTTAACTCTTTAATG
TTAACTTGAATAATTATGATGAGGGTATTACCATTTATTGAGATGTAGAATATTATAAAGTAAGAGCAGATTTGTT
CAAAAAGTATCAAGAATCTTTATTTGGACATGCTAGTTTGGGGATGCTTATTAGAGACCCCTAGGAACTGAATATA
ATGTGGATTTTAGAGAAGAGCTTAGGGCTGGCAGATGACATTAAGGATCTGTCTAGAGCCATGGCGCTAGAGACCT
CCAGGAGAACATAAATAGTCTCAAGATCAAGCCCTGAGACACTCAGATGTTTAGAAGTGGAACGAAGAGGGGACATC
CAATATAGAATACCAAGAATTAGGAGGGGAATCAAGAGAGTGTGGCAATATGAAAGATACAAAAAGAGTGTTGAAGG
GAGGGAGTAATTAATAACCAGCATGTTATGAGGGGCTCAGTATAATGAAAAGATAAGTGACTATTGGATTGGCAAC
ATATAATTTTTTGGTGATCTGGACAAGAGCAATTTGAACAGAATGATGGATATGGAAGGTCCAGAGGAGTAGGCTGA

GTAAATAATATAAGGTGGGAAAAATAGATACAAAGATTATAGACAACTTTTTCAAGAAGTTTTACTGTGAAGGGGCAC
AGCAAGCTGAGACAGTGAGGATAAAATAAGACTCAAGGATGGTAACTTTAGAATAAGAAATTTCAATCTGATGGGA
TTTAAGTGTTAGCAAGGAAGCTTTAAGAAAGTTATTTTCCCCATTAGAATGATCTGAAAAATGTTTTAGAACATTCTT
CTTATATTCTATTTTATCACATTTATATAACTTTTCAGAGAATTGAAAGAGGTATTAAGTTATTATGAAATTTTCTGA
GATTAATAAGATAACAATTATAGGATGTTTTCTTTTAGTTGAAAATACACCTACTCAGCCTAATTTTTATAACTTCTT
ACTGAAGTATAATATACTTCAGTAGAAAAAGCATGCCTAATATAAAGGTGCAGCTAGATGAATTTGCACAACTGAAC
ACATCCCTTTAACCAGCACTTAGATTAAAAACAGAACCTTGATGATACCTCAGAGGCCCTTCTGCCCTTTTTCAG
TCTCTCCGTGCTACCCCATGGATAAGCATTATCGTGATTTCTAATACCATAGATTAATTTTGCCAGTTTTTGAATT
TTATGCAAATGGATCTATTTTACCTAATTGTAAATATAAACATTGTCATAGCAAGGCACCTCATTGCCTTACACTGA
AAATTACATTGACTCTTTGCCACAAGCTTAGACTTGCTTTCTCATTTTTATTATCATCAAGCCTATAGCTTTTACACT
ATACCTTGTTCTGCTCTTCCCTACTCTATTTCTTGGTAGATATTCTATATCAGTCTTAGAGTGCAGTTTGCAGAAC
CCCTCCATCAGAATCTCTAGGGAGCTTGTTAATAATGCAGATTCTAGGCCCTCCCATGGTTTTATGAATCTGAGA
GTGAGGCAGACAAGACTATACCCTCTCATGCCTCTATAATGTAATAATGTCTTCTTAGAATGTTCTTTGCTGCATCT
CTTATTAAAGAAATCTTATGGGCCGGGCAGGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGCCTGAGGCGGGC
GGATCACATGGTCAAGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAAAATATAAAAAATT
AGCCGGGCGTGCTGGCAGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAAAATGGTGTGAACCCGGGAG
GTGGAGCTTGCACTGAGCTGAGATCACGACACTCCACTCCAGCCTGGGTGACAGAGCGAGACTCTGTCTCAAAAAA
AAAAAAGAAAGAAAGAAAAAAGAAAGTCTTATGTTTCTTTATGGCCAGAGCACAACTTGTCTATGAAGTCATCTA
AAATTTCCCACTAGAGGTAACATCTCCTTCCCCTGTCTAGCTCTTTTAAAGCATTACCTCCATTTGCCTTGTATCAT
AGCTGCTTGTACACCTGTCTGTCTTTCCGCTGAGGTTATAATCCTCTGGAGGGTTCATGACTTTGCATTCTTTGTGT
CTCCCATTAGCAGCCAGCACAGTGCCTTGCATACTGTTAGTTCTAAATAACTTCTCTCTCTCTCTCTCTCTCTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTAGACAGAGTCTCGTTCTGTCAACCAGGCTGGAGTGCAGTGCATGG
CATGGTCACAGCTCACTGCAACCTCCCCATCGTGGGCTCAAAATGATTCTCCTGCCTCTGTCTTCCAGTAGCTGGGAT
TATAAGTGTCTGCCACCACGCTGGCTAATTTTTGTATCTTTAGTGGAGACGGGGTTTTACCATTGTTGCCAGGCTG
GTCTCGAATCTCTGGTCTCAAGCAGTCTGCCCTACTCGGCCTCCCAAAGTGCTGAGATTACAGGCTCAGCTGCTGC
GCGCATCCCTAAATAAACTTTTTTTTTTTTTTGGCATGAAATCTGTAACACTGGAAGATGTTATTGCCTTAGAATAAT
TAAGAGATTAAATGTAGAATCTCAAAAAACATTCATTTTTTTCCATGAAAACCTTACCAGGCCTCAAGGGATAGGAAA
ATTATGGGTACAGAATTGAGAATCTGTAGGAACTTGCAAGATAAAACAACGGTTTCACAAGAAAGACCTTGTGGAGA
GTTAAATTTTCAGACAGTTGTAATAACTTCACATTAAAGTTTTGTCAAAAAATAAGTATCTGCATGTTTTGTTGCC
TTCCAATGCCCTCATTTTATTTGATTTTTTCCCATAGTAACATAGTGAAAGCACGAAAATGTGTTTCTGTGTTTG
TGTGCTGTATGTTAATTGTGACTGTTTCTATTGCATTGTTATTGCAGAACCTAGGCACGCACTCTGTAGGCTTGGG
TGCTTTCTCCAAGTAAAAAAATCCTACATATGGATAAATTATTTTTACAGCCAGTGTTTAATTTTACAAGTGGTCC
CCCTCCTTCTGTTTTTAGGATGGCAGAGAGAATACATATTTACTTACCATTATCACTTACTCATGCTTTGAGCTTGA
AGGAAATGAGACAGAAAAATGAAGTAACATTAACCTCTCTCTGGAACATATGTTTCTCATATTAGAGCTTTATCTGAG
GAGTTCACTTCTCTCTCTTCAATGCTTTGTTCTCTCCAGTCGATTCAAATGTCCTCTTAAAGCAGAAGTTCCGAA
CCTCTTTCTGTGACTTCAGGAGAGCATGAGAATGTAATAAAGTTTTAGGACTAAATTTTCAAAGACTTTTTCCAC
TCAGCTCTCTTTTCTCTTCCGTTTGTGTTGTCGTTGTTGTTGTCGTTGTTGTTGTTGCTGCTGCTGCTGCTG
TTTTTCCCCTTCCACTTCCGTAACCTGAGCTCTTAGGGTCCATCTGGAATCTGATTGCAATTAAGGAGGCTAGTTAGTAAA
TATTTTAGGCTTGTGCTCTTTGTGCGCAATTACTCAACTACGCTGTTGTAGTATGAAAGCAGACAATACATACCTGAA
TGAGCATGTTTTGTTCTTAGCAAACTTTACGCACAGAGAAAATTTGGATATCGTATAATTTTTATGTGTTGCAAGT
TGTATTATTTCTGTTTTGATTTCTCCCCAACCATTTAATGTAATCCCATCTTAGCTTGTGTGCCATACGCACAG
GCAGATAATGCGAGTTGTGCACACAGGCTATAGTTTCTGACTTTATGTTCTTAAAGTAAACAGATAAATCACTTCTCTT
TTTTCAAACAGTCCACTAATCTCCCTTTGTATTAGCCCTTGCAATGTAACGCGCTTTCTTATCATCTCTGATTTT
TATTCTGAGAAAATACTGTATATTGTTCCCATGCACTAGGGTTTCGGGGAAATTTAAAAGGATGTAGGATCTCCTTTT
CATTGGTCTTAAATTTGCACTGGGGAGGCAGGTTCATGTTTATGAACAGATAAATAGTATCATAATATAATCATGCAT
TTCTATGGCTAGCATTTAGAATATAGCTTTTGATGTCATGTGGTTTTTATATGGTTGATTATTTTTTTCTTATTTA
TAAATGAAAAAGTTTTGAGAATTTTTCTATCTCCTTAATGTATTCCCTTATTTGAGGGAAAAGTATTTACCTACTACA
TAGGAATTTATCTTAAATTTTTCTTTGTCTATCTATTTTTATGGAATATAATCGAGCAACTATTTTACTAATTAATA
CTTTAATATCATTATGAAATGTTCTCATATTTTTAACCTTATAAGATCAGATAATTGCTATGCCAATCTATGGTTG
AAATGGGTTCTTATACTTAACGCTATGCTCTTTCTCTGAGATGTAAAAATATGTTTAAATCAGAATTTATATAGGT
GTCAATTCAAAATGACAGTAGTTTCAATTTTTGATTAGTATAAATGTTTCACTAATTTCTATTCTCTTATCTATTA
AGTCACCAATAAAGTATATTTGTTTTAAATATTTAACAGTTTAAATATTCTTTGAAAACCTTATGAGTCTAAAGTA
AGAACAATTAACCCATTCAATTTGCAAGTGGGATAGTTGAATTTTACTTGCAATCCAGGGATTTTTGACAGTTTGAA
ATATACATACATACCATGTATGTTTAGGAAAAATTTAAAAAGAGGGGGTTGTAATAATAATAGTTCTTCCATGA
TTTTTTAGCCATAATGTTTATAATATAAAATATGTATACTCTTGTTATTGAATGTAGTATGTTTCTAATTTACCAGA
AGGCAAGAGAATAATCCTGGAGAATTTCTCAAGGCATCTTCGAACTCTTTGATTTATTGCTCACATATAGTAATTTG
CCAAATGACGCCCTAGTGAACCTGAAAGAATTAATGCCCCGTCTTAAGTCACTTTACCAGAGGACTGAAAACCTGCA
GCAATTTGCCAATTAGAGGAGGAAACAATCACTTGCAGAGTCAGGAGTACTGGATAAAGGAGCTAAGAGTGTTCG
TTTTTTTCCCCTTCTTACTTTAAAAATCCCAATTCATCCCATGTCTTTCTTAAAGGCTAAGTGAAGTAGTAAGTACG
TTTTTGCAACATACGAATTTAGCAGACTGGCCTTGTTTATTTTTGGCCGGAACCATTTACACTTATTTCCAACCT
CTCCTTTATTTGTTGGTTGATAATGGGCTAATTTTGAATCTTTACTGTCAAAAAGAACATTAAGAGAAGCAGCCCTGC
CTGCATCGCAGGCTATGTCTGTCTTTGCCGAGTATTAACACTAAAAAATAAAGAAAATACTAACAAAATGAC
AAAGCATTAAGAAAATAAACTAGATGTTAAAGGAAATGAGAAAAATAGGAAAGGATGCTGTACCTGGAGTGATTTTT

TTTCCCCAGGCTACCTAAGATGATCAAAAAAGAGCTAATTTCTCTTAGGTTTCTATTAAAGGAATTACTAGAAATATCG
GGCACACCAGGAAACTTTATCAGTGGACCTGTCTGAAACCAATTTTCTTAATGTATATATGATAATTTGTTACCAC
ATCCCAGATTATTTTACAGGAATTAATAATATATTTGAAACACTGACAGGGGAAATTTGGGTAAGACATTGATAGATAC
TACAATCTGTACTTGAAACTGCACTCAAGGAATTCGTTAGTCAAGAAAAGAACACAATGACTGTGGGCCCTCTGGGT
TTTGGAACCTCTTTTGTAAGCATTTTTTTTTTTCCCAATAGAAAGATATTATTTTGAAAAGGTTAAATAAAAAAT
CTTTGTTCACTATATAGTTTCTCCTAAGGAGTAAATTAATTTATATAAAATATTGCAATATAAATAACAATTTTAA
AATCTCAAAAGAGCAGTGTTTTAAAAATAATGTAGAAACATTAAGAAATGACTTCAAATGATAAGAATGTCATTGGA
GAGCAAAGGGTTTTTAATATTACATATCGTGGCAGTATATCAGCACCCCAACCGCTCAAGATACAGAGTTCTTTTACA
AAAAATCAAAACAGAAGGAAATGTGCCACCTTGTTCATAAACTATATTTAAATAATAAGCCAGGCAGATAAAGTCACTTT
CACAAATAATGAGCAAGCCCATGGTAATATAATTCATTTACAATAAGATTTATCTCATGGAATTTCTTAGACTGTGCT
TTGAAATTTAAATAATTCTGATAAATGCCAACAGAATAGAGAAAATCAATTCCAGAGCAATTACTAACACGTTGCATT
ACCTTTCTAACATTAATATTTCTCTTCATACATATCATTGAAGAGAAAAATGAGGATGGAAAAATAAAAAGATCAGGTA
ATATATTTGCTTTCTCATCTAGGGTTGTTATGATCTTCAAGATGAAGTTTATTTTTTACTCCTAGCAAATGATATT
CTTTTTTATTTTAGTTTTTATTATTTTATTTTTCTGTAAATATTGGGGTACAGGTGGTATTTGGTTACATGAGTAA
GTTCTTTTTTTTGATATTTCTGAGATTTTTTTTTTATTCTACTTTAAGTTTTAGGGTACATGTGCACAACGTGCAGG
TTTGTTACGTATGTATACATGTGCCATGTTGGTGTGCTGCACCCATTAACTCGTCATTTAGCATTAGGTATATCTCC
TAATGCTATCCCTCCCCCTCCCCCACCCACAACAGGCCCGGTGTGTGATGTTCCCTTCCTGTGTCCATGTGT
TCTCATTGTTCAATTTCCACCTATGAGCGAGAACATGCGGTGTTTGGTTTTTGTCTTGCATAGTTTGTGTGAGAA
AACCACGAGGTACCATCTCACGCCAGTTAGAATGGCGATCATTAAAAATCAGGAAACAACAGGTGCTGGTGAGGATG
TGGAGAAACAGGAACACTTTTACACTGTTGGTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGAT
TCCTCAGGCATCTAGAACTAGAATTACCATTTGACCCAGCCATCCCATTACTGGGTATATACCCAAAGGATTATAAA
TCATGCTGCTGTAAAGACACATGCACATGTATGTTTATTGCGGCACTATTCACAATAGCAAAGACTTGGAACCAACC
CAAATGTCCGACAATGATAGACTGGATTAAGAAAAATGTGGCACAATACACCATGGAATACTGTGCAGCCATAAAAA
AGGATGAGTTCACGTCCTTTGTAGGGACATGGATGAAGCTGGAACCATCATTCTCAGCAAACATTGCAATGAGTA
AGTCTTTTTAGTGGAATTTGTGAGATCTGTGTCACCCATCACACGAGTAGTATACACTGACCATTATGTTATCT
TTTTGTCCTCGGCACCCCTTTTCTACCCCCAAGTCTCCAAGGCCATTGTATCATTCTTATGCTTTTGCATCCTCA
TAGCTTAGCTCCACGTATCAGTGAGAACATATGCTGTTTGGTTTTCCATTCTCTGAGTTACTTCACTTACAATGATA
GTCTCCAATCGCATCCAGGTCATTGCAAATGCTGTTAATTCATTCTTTTTATGGCTGAGTAGTATTTCATATATATA
TATATAGACACACGTACATACATATGTATATATACCGCAGTTTCTTTATCTACTTGTGCGATTGATGGGCATTTGGGT
TGATACTTGCACACACATGTTTATAGCAGCATAATTCACAATTGCAAGTGATATTCTCAGGAAGCATGATGTAAGTG
ACAGAGACTTACTTTGTAGACTGCACTCATTCACTTGTCTCTGAATGTGCTCTAGGCAGCCTGAGTTTCTACTATG
TCAGTGTTACATAGATGAGAAACCCCATGGGTGGTTTCCACAGAGGCTGCAATACTATTTTTTGATACCAAAAATCTG
TTTGGTTTTGTGAGCCCCAGATGCCCATATGGAAACTGAAGTGTGATACCTCTTTGTAGCCCTCTGATGAACCTGC
ATGGTTCACCTTCCTCAGCAGTTTGAGCGGGGTGGGGAGAGCGCTGCTTCCTAGCCATCCGATTGGCCTGAATCAT
CAAAAATGCTATCATGAAACAGGTTCTGTTTATCTGCTCCAGATTACACCCATCATGTTCTAGAGTGCTGGTTTCAT
GCTTGAATCTAGATCAAGCCTGCTTTCTCCCTGCCTGTACTCCCTGTGGCTACCTACAGTCCTGCTGCTGACAGA
TAATCTAAACCAATAGCACCTAATTAGCCTATTTGCTCATGTGTTTTTCCATCGTGGTATAATGTCTCTCTGTCA
ATTTAGGGTGAAAATGTAGCAACACGTTGCTGATGGTTAATTTCTGGAATGCAGGTAATGAATGTGTTTTTGCTTA
TCCAAGTCTTCCCATCAGATGTCAAATATAGAAGAACAGTGTTTCAGAGGTCTAAATTTAAATTGGAGTGAGAAAT
CACAGCGCCCCCTGAACCTCAGGCAAAATGCACTCTGACAAGTCAACCAGATATTCACAGATGGTCTGGAGGATTTGAA
GCCTAATTTGGTGAAATAAAATTAATGAGTGAAATGTATGCAGTCATTAATCTATCACCATACTTAAATGCTTC
ATTGAAATTTCTTTTACTGCTTCAAATGAAAAAGATCAAACACTGTTATAGAAAAGCATTCAAACCCCTACATAA
CATAGATAAAAATTTGGTTGGAGACTTACAGAACTTTCTCTGCTGCTTCGAGAAAAGTTACAGTGCCCAAAATCTATT
GCTATTAGAATATTTTATTGTATTCAACACTCAATTTCTACCTAATATATGTATATGAGAAAAATATTTTTACCTATA
AAATAATTATTATTACCTTTTAAAAATCTGACATTCTTCTTTTTTCTAAAGAAACATATTTAGATTTAGCTTTTTAT
TTTTTTTTTGTGTTGATACATAGAGATTGTACATATTTCTAAGATTCTAGTGATATTTTGATACAAGCGTATAATGT
GTAATGATCAAATCAGGGTAATTGGGATATCCACCATCTGAAACACTTATCATTCTTCTTTTTCAATGCCATCATAC
CAAAAGGAAGTAAATAGAATTTCAAATATAAGGACAGCCATGATTTTACATACATGCCCTACGATTTCCACCACAAACC
ATAATTACGTCCCCCAAACCTTTAACATTTAGATACTTTGTCCAGGTATTTTCATGATAAGGATTGGGCTATGACT
CTGTTACAGAAGGGCCAAATGACTAAAATGTCTCTGAACAATATTGATTGCAAATATTCTACCCAGTTGTCAGGTCA
ATATGTTCCAATTCGGAATTTATAACATTGTATCTCTACTCCCAAACCATCCAATCTCACCTACCTCACTTCCATAT
TATGGTGGGTGATCTCAGATTATATTTAAGCTCATGGTTACTTGTCAGTAGATATGGAGTTTAGCCTAACTTTTGA
AATTTATGCTGAGATTACCTTCTCATTATAGAATTAAGTAGGCAGTTTCCAAGTTTAGATTTAGCAGGCAGTTTTT
TTCAAATCACTTAAAAGTTATATTTTTTTAGGGCATTGAACAGGTTTGAAATCCTACCAAGATGTCATGTACACATA
GACCAATAGAACAGAATAGAGAACACATAAAATAAACTGCACAGCTACAGCCAACTGTTCTGTCGACAAAGTCAACAA
AAAAATAAGCATTGGGAAATGGATTAAAGATTTAAATGTAAGACTTCAAGCTATAAGAATCCTAGAATAAAATCTGG
GAAATACCATTCTGGACATTGGCTTGGGAAAGAAATTTTGTACTAAGTCCTTAAAAGCAATTGCAAAAAAAAAAAAAA
AAAAAAAAATGACAAGCAAGGACTTACTAAAATAAAGAGCTTCTGCATGGCAAAATAAATGATCAACAGAGTAAACAG
ACAAACACCAATGGGAGAAAACCTTTGCAAGTTATGCATCTGACGGTGGTGTAATATCCAGAATCTATGAGGAACC
TAAACAATTGAACAAAAAATCATAAAACATCAATTTAAAAATGGGCAAAAAGACATGAACAGACATTTCTCAAAA
GAAGATATACACGCAGCCAATAAACATGAAAAATGCGTCAACATCACTCATCATCAGAGAAATGCAAAATCAAAACCGC
AAGGAGATACCATCTCACACCCGTGAGACTGGCTTTGTTAAAAAGTCAAAAGACACCCAATGCTGGCAAGGCCGCAG
AGACAAGGGGATGCTTATACACTGTTGTTGGGAATGTTAATTAGTTCAGCCACTGTAGAAAGCAGTTTGGACATTTT
TCAAAGAATTTAAATAGAACTATCATTTGACCCATCAATCCCATTACTGAGTAGATATCCAAAAGAAAACAAATGG

119

TTTCAATAATCAGTTTCTAATCCAAAATTGAATATCAGTTCCAACTCTACATTTCAGTTTCTGTTTTACTTGTGGG
CTGGCTTTTGGTTCTGTTTTCCACATAGATCCTCTCTGTGTAAGACAAAGCCATTTGTGCAGATTAAATTTTACTGA
GCGTGTTAACCTATTTAAACATTTCATCCAAAAAGACTAGTATGAATTCCTCATATGGCAAGCTGCTTGTGTTTTAAA
CTTCCATTTATTCTAAAATCCTTTTTACTTATACTTTTTAAGAAACGTATTCCCGATATACAAAAGTAACACATGCT
CATTAAAACAAATTAATAATAGTATTGTATAAAGAGCTGATACATTTCTGCCTTGCCCCATTTAACTTTCTTAAGTG
TTCATGTGAATCATCCATTACATCAAGACATTTATCTGTATTTCATATGAACGTGTTTTAATATATATAACATATAT
AGAATTTTATATAAACTTTCCTTTTAAAATAGAAATGAAATATATGATATATTTATTCTGTGTCTAGCTCTTGTC
CGTAATTATTCAAGAACATATTTCTAGGTTAATATCTGTATTCTTAGGTAGCATTCACTAACTCCTCATCTACTTGT
TTTCTTCCATTCTAATTGTGTTTAAACATTTCTTCATACAAATTGGTGTGCATTTGGTCTTTCTTCATGGAGGGTGCAT
AATGTTTCATTCTCACCAATTCTTTACACTTTACATAACTGCTTGATACGAAGCCAGACCTTATAAATATCAACAAAG
CAGGAACACTGTAATCAGCTATCAGTTTCAGTTGAGCTGAATGACCCTGAATATGTGTACACATATTTTCCAGGAGA
TTTTAAACTGACACCTCAGATTTCTAAGACCTGGAGAAATCAGCATGAGAAACATTGATCTATATTATCCGTGAA
ATGATTTCACTAAATAGTGAAGCATCTCCACATGTGGACTCTGTAATTTATTAGAATAAAGAGTTCATGTGCTTCT
GAAGAACTGAACTACTCTTCTGGCCTCCGTACATTGGTTTCTTAGCTATAGGAAGGCTGAGCATGTTTTTCCATG
CGTTTCCCTTCTAGCTCATCATTTTAGTGACAAAACAATCTTTCGTGGTGTGTCTAGCTATAGAATTGTTTCAGA
TTCATTTGACCAAAGGTGGCAAATACAACAGTCCCAACAAAAACAAAAGACCTATTACAGAATGATGGAAATGACCC
CAGGGAACAATGGCACCTCCACATTTCTTAATTCCAAGGTTATAAGCAGTGGTGTGGACAATTCTCAATTCCAATGC
TGAATCGCCTTCTAATTTCAAATACCTGTGCTAAAAATTATTTACGCTCTACTGAAATAATGAACCTGGACCCACCAG
GAATGGCCGATATGCTTGTAGTCAGAGCACAACTGTAGAAAAGAAAAAATCAATTTTAATTTATAGAGGTATGATGATA
GCTGTTTCATACTGTTTTTCAAGCATGAATGGCCTGCTCAGTAGTTTCTTGTCATCGTACTGAGACACTTTAATTT
CTTACCAGCTGAGATGAGGAATACGAGCCCAGTGTGCAGGTGAAATTGGTTAACAGGAGCCATTAAAATTTGGAAGA
GTCAGAATAGCATCAATCAAAATGCTTTCAGTGTAGGAAGTAAACATGTACTAGCCTGACCCACCTGTCTTTTCTTT
TAGGTATGTTGGTAATATTACAATCATTTTGAGGTATCCATAAACAACCTGCTTAGATCTGAAGAATTGTATATCTTT
CTTTACTCTGCCCTGGCCTGGGGTTATGGTTCTCATTGAGCTCTAACCTTTTCAGAAAAAATGTAGAGAAGTGGTT
CAAGAAGAATGCTTTATCTTGCTTCATAAAAAATGATAGTAGTTTATTGAAGGCTTACTATGTGCCAGGCCAAA
GTGCGTTTTATTATCGTTCCCATTTTCCAGGCAAAAGAACTGGAGCACAGAGAGGCTAAGTGAGTTGTCCAGGATGG
CTCAGCTAACATGCTGCAGTTGGGATTTGCACCCAGACCAACTTCTTTTCAACCACTGTCCCATCCTGTGTCTTCTC
TACTCAAAAAGTGTTCAGCTCCAAACCTGAAACTTTAAAAGAAAAGGAAATCCTTAGTGGAAGACTAGGTTTTAGT
CACAAATTATCTCCTTCCCTTACATTATTTGTCTCTTTTTCAAATACTCCAAGCTTTGATTAAAACCTGTCTATCTACTA
GGAACATTGTAGAATTGCTAAGGTGGAATTGTTAAAAGAACTCAATTCCAATTAACCTTGCCATTGATTACTGTGTG
TTCTGGAGGGGTGTTCTTTCTTTCAGGTTAATGATGCTTTATTGTATATCTCAAAGATTAAAAATAACAATGAAGGA
AGTAGCAAACCGGAACCTTCTCTACAATGCATCTTCAATCTCGTGCTTTAAATGAAGATAAAATCATGGCTGTGGT
AAGGTTGCAGGAAGGATGATATAGATTAAGTTTCTTGCAAACCTGCCCTCTGAATTTTCAATAGCTGTAGAAGGTATT
GGTTTTTCAAAAAATTGACAAATTGAGGATTCATTACAGCAGTTTTTTTTCTAGGTCTCTTACCAGAAAGTGATCACTA
AAAAGTGATAGGGAACCACTCAAAGTTGGATAGATCATTATTTTCACTTAAGCATTTTAAATTTCTTGAAGGAGCTTT
ATAATGCAACAAAGAATTTACAGTCCTGTGTACCCGCTTAAATTTTCTAGGGTCATCAGTAAACTCAGTGGAAATAA
ATTAGTTCATGAATATAATTGACCCTTAAATTTCTGTCACTGTGCAAGTAATCGGTGGGTCTGCTGGATATGGCTTTC
GAGCAGACAGGTCAACTTCTTCAAACAGAGAAGAAGCATAGCATAAATTGAAGACAAATAACAACTACTTGTTTTCC
TCCTTCTTTGGCATCACCTATGGATGGAGTATGCATTTATAATTTAACACAATCAAGAGATCTTTATTATCCTACT
TTTGGGTACAACCTGCTTCGTTTCTCTTTGAATCTCTACAGCTATTTAAAAATCTGTTTTGTAAAATCTTTAAAAA
ACTAAAACATCAGATTCATATTTAGGTATCTTACTATCTTATACCAACTTAAGCATCCAGTATTATCACCACCCT
TCCCCTGAGTGAATCCTTAGCACTGGGCTCTTCTGTTTTATCCCTGTGCATGCTGAGCTCTTTCTGGCCCTTCAAGT
CTACTTCCGTTGCAACTGTGTCTGAATGGTCTCTCATGTCTTACTCTTAAATATTTCGGAATTTAAAGCC
TGGAATAATCTACCTTAGTCCAAAAGATATGCTACATATTCTAGTTTCACAATGATCTCACACTGCCGTTGATACAC
AACATTTAATATCAACTTAATATCTATTTTCAAGTTCATTACGAGGTCACTTATGCTACATCTTATATTGTTGCCTTGG
ACTTTTATTATCTCTTCATATATGTGTTTATGGTGCTCCCAACCTCACGAGAAGTTGCAAATACCATGTTAGCTGTC
TGATGGCTTTCTATGTTGTCAGGTATACCATTTCCCAACCAGTTGGCATTCAATGATTAAGTTCATTAACAAAGAAT
TGTATGTGTTGAAAAAGATGTTTTTTTCTTAATGAAGCACTTGTTTTTATTTTTTAAATGAAATCCACCCTCTTAAT
AAATTTTAAAGTGACAATACAGTATTGTTAAATATAAGCAAAATGTTGCATAGCAGATCTTTATAATTTTTTTAAACC
CTACATGCCTGATAGTCTATACCCATTGCACAGCATCTCACCATTTCTTCCCTCCTCCAGCCCTTAGCAACCACCAT
TGTACTTTCTGTTTCTATAATTTTGACTACTTTAGATACCTCATGTAAGTGGATGCGTGCAGTATTTGTCTTTTAC
GACTTGCTTATTTTATTAGCAAAATGGCTACAAGATTCATCCACATTTGTAGCATATGGTAAGATTTCCTTTTTGTG
GCAGAATGATATTCCATTGTATGTATATAACATAGCTTTATACATTTCCCTGTCAATAGACATTTAGTTTGTTCACA
CCTCTTGGCTACTGTAAAAATGCTACAATAAACATGGGAATGCAGATATCTCTTCAAGATCCTAAATTTGAATTCGTT
TAGATAAATATCCAGATGCGGGATTGCTAGATCTTATGGTAGTTATATTTTTTATTTTTTTGAGGAACTCCATATT
GTTTTCCACAAAAGCTGCACAATTTTATATTTCCACCAGCAGTCTACATCTCCAATTTTCTTACACCTTCCACCAACA
CATGTAATGATCTTGGGCTTTTTTTTTTTTTTTTTTAAATAATGGTTATCCTAATCCGTGAGGTAGTATATCATTTGT
GGATTTGATTTGCATTTCCCTGGTAGTTAGTGATGTTGAACATCTTTTCATATAACTGTTGGTCATTTTAATGTCTT
CTTTGGAGAAATATCTATTCAATTCCTTTGTCTCACTTAAAAATTTGGGTTGTTTGAATTTTTGTGTTGTTGTTGTT
ACGTTCCCTCATGTATTTTAGATATTGACACCTTATCAGATATATGGTTTGCAAACTTTTCTCTCATCTATAGGTT
GCTTTTAATCTGTTGATTGTTTTCCCTTGCTTTGTAGAAGCTTTTATGTTTATATATTTCTGCTTATCTAGTTTTG
TTTTTGTGCTGTCTTTTAGCGTCATATCCAAAAAAATTTATTTGTGAAGACCAATGTCAGGAAATTTTTCCCTTA
TGTTTTCTTCTATGAGTTTCATAGTTTCAGATCTTATTTTTAAGTCTTTACTCCATTTTCAATTTTGAAGTTGATTTTA
TGTATAGTTTAAAGTTAAAGGTCCAATTCATTTCTTTGCAATGTGTATATCCAGTTTTCCAGCACCATTGGTTGAAG

121

AGTGGTGTGGGAATAGACAAGAGAGAAGGGGAAAAGACTCTTCAGGAACTAAACTCACAATTTATGAGTATTCTTTA
TTGCCCAAGTCTTTCCCAAAGTCTTTTCATCAAGAAAAGAGGCATTGCAACTCTCCTTTTATAGTTTGTATTTATTCTGG
AGCAGTGATGTTTTGGTGGAGTTGTTCTCAGTGCGTAATTAAGGGCCATGACAATTACAGTTCATCTCCTGCTG
CTCAAGGTACTGCAGATATTTGGATCTACTACTCTCATTCATTTCCAATTAATGTCAGCTTTAGATTTCTTCAGTA
TGCTATGTTATAAAATTTGATTATCGTTGTGCCACCTTCCCACCTTAATTTCAAGCAGGTTTCTCGATTACCTGACT
AAACTAATGAAATCTGACTAACCCAATATCTGTGGACAGTAGTGTGATGTTACTGATTTTTGTATGATTAGTCAAGT
CATATTCATGCCACGTTTTTCATATAGTACCATAAAGGATATTCTTCTCGTGGTCCTTTTCTTTTATTCTGAACATAC
AATGAGAAGACCGGTAAAGTGGGCTAGGAAATTAAGAAAAATACAAATGGCAAAAAATATGGGTCACCTCGAAGTCT
AGAATAGAGAGCACAAATCAATTTTGAATTAAGGGGTGATAAGGTGATTTGGTCAGGTGACTGGTGAAACAGGAAAGA
AACTATACTTTTTGAAGTGTTCATCCATGTGTTAAGATTCAATTTGGGGTCAAGAATCTAAATTTTCATATCCCTGGG
AGTGGAATAAGTAAAAAATATGACCTTGGTTTAATAGCTAGAGGAGCAAGAGTGATCTTTATGTGAC
TTAACTTCTATGTGAAAAGTGAACCTTAAGATTAATTTATGGGGGAATTTACTTACTCAGGTTCTATGCCTAGATGG
TCTGCCCACTAAGAAAATTTCTTCTGTTACTCCATCCTATTTTTCTACTTTTATACTGCACCTGCGAGAAAAG
CATATATTTCTACCCAATACGAAAATTTCTGGGAACATATTTTTCTACATTTCCCAAATTACTTCAAAAAGTAACT
TAGGTTATTTTCATGATCTCCATTACAATGGACAGGTGGCTTATTGAATGTTGTCTGTGAATACAAAGATCCAGAG
TTTAAAGAACAAGGTGTACTTGCATCTCCCACTTAGGGTTTGTCTGTGGTGGAGAGAGAATCTAGTTTGTCTTAAAG
GATGACAGTGAGTCCCCAAAATATCTGATATCATTAAAAGTCTCATATTTGTCTTTCGTAACCTTCTCTAGGGCTG
TCGATGACAGGAGACCTTAACTCCTATGCCTTGATTATGTGAATAAGCACATGAAAATATTTTAGTTATCTTAGTT
CACTTTTAACTAAGTTTCAATTATCACTAGATTCTAAATATCATCATTGAGCCGTTCTTAAGGAAGTATTTTCTA
CATATTCATTCACTTACCTATATCTAGTGTGTCTACTATTTGCCAAGAAAAATTTACTCTCTTAATTCAGCATTC
ATATACTTAACATCATAAAAAGTAGGCCATTTTTAGTTTTCTAAATATTTATTTTAAACATTTCTTTAAATTACAT
TCTATCATTACACTATATTTCAACACTACAGTAAGCAGCCTATTTTGTGATTTTTCTTATATAAAATACATAATTG
AAATTAATAATGAAGTTACCAAGAGCCATTTTCACTCTGGGGAATGCACATTTATAAATATGAGGGTTATTTTTCT
TCATCAGCTTTTCATATTATTAACCTTTGTCTCTTCATAATTACAGAGATGACTAGACACAGAAGGGAATTTAACATT
TGGTGTGCATTTGTCTACCTTACTTTATGTTAGAAAAATACATTTCCATTTGAAAAAATCAGTAATTGTGGGTG
TGATCAAGAGGGCAGCCTGAAAGTCGGGTGATGTGACTCACACCTGTAATCCCAGCATTTTTGGAGGCCAAGGTGGG
ATTATCGATTGAGCCCAGGAGTTCAAAACCAGCCTGGGCAACACAGTGAGAGCCTGTCTCTATTAGGGGGAAAAAA
AAAAAGAGGAAGTTAGCCTGAGGCAATGTAAATGAAATACATATTTCAAGGATATTTATACATGATTCAGTTATT
CATATAAAGATGTGCCAGAGAAGACTATAGGTACGTTATTTTACACTATTTTGTAGGATTTTAAAGAAATCAATGT
GTTTTTATTTTCAAGTTAACTTAGAAAACTTACCTAACTTATACTTCTCATGGACACAAAAGTTTTTAAAGATAGGATC
AAAAAGCCCATGTTGAAGCATTTTGAAGTGGATGAAAAACATCTATTATCTTTAAATTTTATGATATTACTGAT
TGTAATAGACTCCCTTTTTAAGAAATCATTCTTATAGAACATAAGGTTTACATTTACAATCAACAATTTCTATCCT
TACTACAATAAAGGCACATATAAAAAGTACAGTTGCATATTTAGCAGGTTTAAATGTACATTTTAAATGTAGAAATCA
ATTCAATTCCTTTTCAATTTATCAGCATTATTACAGTGATTTCAAATTAAGCATAGGTAACCTTGTATATAGATAAATGAT
GTACACAGCAGTTAAATTTTATTTTCAATTATGTAGTAATTGTATAACCTAGGCAGTATAATTTGTAACTTTGTAT
TTTATTATTATGCTTCTCCCACTTGGCATAAGCACAACTTCTTAAAGCATAATTTTCTATAGACTTAATAACTC
CCTAAAAACCTGTTTTGGACCCCTATACTATTTGATATAGGCAGAAAAAACAATAATCCATGCTCAAATTTGAAA
ATGACTGGTCACATTTGGTATAATACTAAAGGTAAATAAAATCAAGAGTCTATGAACATTTCCGGACCTGCACATTT
GTTTTTATTAATAATGCATAATTGTCTTTAGTGTGTTTCTATTTGTTTATACTCTACTGATTTTAAATTAATAACCAA
AATACGTTTATTAATAAACTGTGCAATCTAAGTTGTTAAATATACTTAACTAGGAAAGTAACTGTTTAAACGAGAT
AATTTATAGAGAAATGTGGTGTATTGCCAATTAGATGTCAAGATACAATACAACCTGATAATGAAAAAGTAGCATTTT
CTTAGGGATGGAATACAGTGTAAGGAACACCCAGTAAGAATACAAAAATTAAGTAAAAAATCTTCTTCTCTGAA
AAACCAAGTGCCCTTCAAGTGCAGAACCTCACTCACTAATTTAGTTAGTATCACTAAAGCCTGATACCTTCAATTTT
CTGGATCATTCAAGCTGTATTTTGTAGTCTTATACTAGAGAGGTAAAGAGCTATAAAACACTTAAATGGTATCTG
ATGTGAAGTGTGGATCACTTTGACCCATCACTTCTACGTCTACATCTTGGATAAATTTCCATTGTTGTATAGATTG
TACAGGTTTAAATGGTGCCTTTGTGGAGGGGGCTCGCTTATAGAAAAATGGAGACTCTGAAGGGATAAGGAATAAATGT
ATCACTTCAGGTCTTTTATTTGAAATGGGGTCCAGAGAGCCTTTTTGTATCAGACTTGTCAAACCATTTCCATTTA
GTAATTATATATGCACTAGCACTTATTCCTACTTACCTCACCTCTTTATGCCCATTTTCTTGTAGTTGCGGTTATGC
ATGAATAATTTATTGCACCCCTTACCAACAATGGAATAAACTTCCATTCTGAAAGCTTTCCATACTCATTTCCAAT
AGCAATAGGGTTTTTTTAAACGGACGTATTACAAATGTACGAGTCAGTTGAACATAGTATTCTCTTTGTAAAGACTC
CAAGTGGATGCATGCTGTTGTCTCAAATCTCAATTAGACCTTGTCTTGTAGGTCCCTTCATTGCCAGTCATCTGTTCT
CCTTCCCCTGACTTGAGTATTTCTCCAGATATAGATAATACATTTTCCCAACTCTGTGTTCCAAGAACTGACAGTGG
CTTTCAATTCATTTTGTGTTGTTGTTGTTGTTTCTTCTCGTTCTCAAGTATCCCGCAGTCTACTGTTTCTTCCCTCCATT
CGTTTGTCTTTTTCAGAGTTTCAAAATCCAGCATAGGTACTTCTTCTAAATGTCTTACCTTCACATACACACACCA
CTTGAGACCCCATCAGCCTCTGTCCACACAGTTTGGTTACATTCATAGACTATTTTTTATACATCAAAATATTTGAAA
ATTTTAGGGTAAATCTCAGTAGTCATTCATTTTGTCTTATTCAACCAATACTAGTCAATCAGCCTGTGCCAGGTT
TTGTTGCAGGTACCAGGTATCCATCCATAAAGAAAAACAACGTCCCTTTGTTGTGGAATTTACATTTTAGCAGGGGAG
GCAAAGAACCCAATAAATATGATAAAATATCAGATTAAGAGTACGATGAAAAAATCATCAGGGTAAAGGAAAAAGG
GAAGCAGTATTTTAGCAAGAGTGGTGAAGAGAGAGGCTGAGAGTGTGACATCTGAGCAGAGACCTAAATCAAGTCA
AGGAATGAACATGCTACTATCTAAAGAAATGAGTCAGGATAAGGAACTAGTAAGAGCCGAGGCCAGAGATGTGAA
TATGCTGTTCCAGGAACACTAGCAAAAGAGACTGGTTGATATGATGTGAAAAATGAGAAGAAACCTTATGATATGTGTCAA
GAGAAAAAATTTTAAAGCATGCTTGGGAACGGAGGCTCCAGATGAAAAAATACACAGTTCAAATCCTTG
TTCATGCATTTAGTTTGTCTTGTCAATCTTGGGCAAAATGTTAAATTTCTGTACGTTTTATCTTCTCATTTTTTAA
TAGGCACAAGGACATCTACTTAATAGGTTTATTGTGAGGAGTAAATGAGATGATATATCTAGGATGCCTGGCATTAT

ATCATACACTTAATAATACACTGAATAAATAATAGTTATGTCTATTTATTTTCCTTATCGTTTTATTATTATTTCAA
TGCACAGACCTGTTTCATAAGATAATGATAAAATATTAGTGGCAGAAAAGTGAAGATGTTATAAAATTATTAGGAGGCGGG
ACCACTCAGTTCAATGTATCTGTTTTAATATAGTCAGCAAAAAGTGTGAAGATACCAACAATTAAATTTCAATGCATT
CTTCCATTTCACTAGTTTTATAAACTGATGAACTACCAGAATGTCAATGTATGAATTGCATACTCATTCTTAACAAA
CAGATTTGCAAAATTATGTGTAAAATTAGCCCTCAGCCTTCCAATTTGTTATTGTCATATTTTCATGGAAATACATAA
TCTGTAAATTTTTGTTTTAATGATATGTGAACTGCCTAAAGTAGAGTCTTGGAACCTACTTCACATTTGTCCTCCA
GAGATAGTGGATAAAAGTGTCAATAAATGAACACTCTATATTTCACTAATCACAGGCAAGGGACAAGGAACAGAGTGG
TCACAAAATACCACAAAATTAAAGCACATTCCAAATTAATATATATGTTTTTATTACAGATAATGTTTGCCTAGACT
CTTTCTAATTATCTGCAAAGATTTTAGGAATGTTTTAATGTTTTAATAATTTACACACCTGTGTATTTCAAGTTCAGT
CAAACACTATTGTTAAAACTAAATCTTCTCATCTCTAATAATAAGATGTGAACCTTATCTTGGAAGGTGGTTATTAGG
ATGGGAGAGATAATGTATTTCAATCAAAAGTAAAAATATTTCTCTGTTTCTATCTTTCTCTTTCTCTGTCTATCTATTT
ATCATCTATATCCAGGTATCTATGCACCTATGTAGACTAGCATTCAATGAACCATAGATATTATTAGTAGTAGAATT
GTTACTAATATTAATAAAGAAGTATTTAAGAAGAAACATGTCTAAAGCATAAGGTCAATTATTACTCTCATGTTT
TTTGGCATATGAAGCCTAAAAAGTGTCAATTTCAAGAGAGTATTAATAAAGATTGTGATAACTGAAAGGTTCTCTGCT
TGAAATTTTGTGTGGTCTTACAAATATATAAACTCTAAGCATTTCAGTGAGCCAATTACTGACTAGGCACCTATGTCT
TATGACTCTTTTGTCTATAGTATGTAAAAACAAAGAGTAGAGACATCATAAAATTTATAGTAGATGGGCACCTAGGGA
ATTACGCAAAATAATTTGTAGATTTAATGTGAACCAAAACATCTGTTCAAGTCAATTTCCACAGGTCTATGTGGCA
AAGAGTATGAGTTCCAGACTGAGGAGAGGAAAAAGGTTGTTCTTCCACAGGGAATAAACTGAGTGTAATAAACATAA
TTTTTCTTCTTAAGCATTATTTAAAAACAAAAAAATGCCATTAAATCTATCTTTCTGCTCTCTTATCAATGCTCC
CTTCCCTTTCAACCACTGTTTCAAACTCCAAGCCTTGGGATTTTATTTTGGCTTTTGGCTTAATGTAACATAAAATG
AGAGCATCACAAATATGAAGCTCATCAAATAATTTAGCAGCATTTTCCCTGTTTTTAACTTTCTCTTTGGAAACGT
AGATTTTCGAAATTTAAGGGCCCCAAATATGAAATGCAATTATAATAGGCCATTTGTTTCATTTCAGCTTGATAAACTG
AATAAATAGTATTGAACCTTTAATGCAAAAAGAACAAAAACAAATAGAACTCTCCACGAAGAACTTTTCAATGTTT
GCATTTCTGTGTGAGGAGGGAAGGGTAATGAATGTGGGAACCTTAATGGAATCCATGTTCTTCCAGTGTGACAAAGGGT
CAAAATGGAGAAAATGGTCACTTTCTACCCAGTACATATATTTAGTTCTATGTGGACAACATAACATAGCTAGTG
CTGGTTTTCAGGCCATAAATGTAGGTATGTATTTTCTACTATTTATAAAGGCAAAATTTCTATTTGTTTTAATGATTT
CTATATAGGTAGATTATTCTGTCTTTAGGATTAAAAAACGACCTGTAGACCAAGAGACTTTCTAATGTCCACCTTAGA
GTATATGGCTTTTACTGTTACAGTTTTCCATTTCTTTGCTTGCCCCCTTTGAGAGAAGGAAAGGAGACATTTGGGATA
CATACATCAATGAGGAGCTATTAATGAATAAATGAATGAAATGTGAGTCAATTTATCCACATGATCATCAATTGCC
AATAATTTTATCACCTCTGTGGGATTAAGTAGAGGTAACAGTTTAGAAATTTGATTTTTTGAAGCATTTAAATGT
TCAAATATATCACTCTGGTAACTAAGGGAAAGTGTATTATTTCTTATGCTTAGTCTTATTTTGGTTTTGCTTTTT
AATTTAAATTGAACACTTATATCAAAGAGCTTGCAGGATTATAAATTTGAATTTTTGAAGCAAAGATCATTTTCTTAA
CATCAAAACAAAGAGTAGATACAATAGGAATAAAATCGGCAGAAAAACAAGAGTATCAAGGACAGACGGGGAGGGTGG
GTCTGTGTAGCATGTATTGCTATGAAGAAATAGCCGAGACTGGGTAATGTATTTTTAAAAAGAGCTTTAATCGATT
CATGATTCTGCAGGTTGTACAGGAAGCAGGACACCAGCATCTACTCAGCTTCTGGGGAGGCCTCCGGGAGCTTTTAC
TCATAGTGGAAGATGAAACAGGAGTAAGCATGTACATGGCCAGAGCAGAAGCCAGGGGGAGGTTGCCACACATTTA
AAAAAAAAAAAAACAAACAGATCGCTCAAGAACTCAGCTGCTATCATGAGGACAGCATCAAGCTGTGAGGGATCCA
CCTCCGTGACTCAAACATCTCACACCAGGCCCAAGTCCAACACTTGGCATTATATTTCAACAAGAAAAAAGTTTA
ATTGGCTGATGGTTCTGCAGGCTGTACAGGAAGTGTGGCACAGGCATTTGCTTGGCTCCTGGGGAGGCCTCAGGGAG
TTTTTGCTCATGGCAGAAGGTGATGCCACACACTTTAAAAAACCAGATCTCATGAAAACCTCACTCACTACACT
GAGGACAATACAAAACCATGAGGGATCTGTCCCATGACCCAAAAACCTCCCGCCAGGCCCCACCACCAACATTGGG
AATTATATTTCCATTTGAGATTTGAGTGGCGGCAAAATATCCAACTATATCAGGGCTCATGTTCCAGTTATGTCAA
CATGCCTGCATTCGAAACATCTGTCCAATCAAGTCTGCTTGTCTAATACTTATATTTTCTTTTGAATACGAAC
ACAAGAAGATTAAATAATAGCATTTCTACTTTAAAAACAGTGGGCACCATATTAACATTGGAATAATAGTAGTAATAA
CGATAGTAATAACAATGATATAGGCTGGGTGCGGAGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGG
GCGGATCATGATGTGAGGAGATCGAGACCATCCTGGCTAACACAGTGAAACCCCGTCTCTACTAAAAATACAAAAA
ATTAGCTGGGCATGGTGGCAGGCACCTGTAGTCTCAGTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTGG
GATGCAGAGCTTGCAGTGAGCCGAGATCGTGCCACTGCACTCCAACCTGGGCGACAGAGCGAGACTTCATCTCAAAA
AAAAAATTAAATAAATAAATAAATAAATAAATAACGATAAAAGGATATGTGTAGGTTTTTTTTTAAATAGGCTGTAA
CATTAAATAGGCATTGTGATTTTCAAGGATATCATCAAACATCTGGTCTTAAGACATCCCCTATTGAATAGGAAGGGC
TTAAGTTAACTTCTCATGAGCCACAATTTCTGATTATATGTTTGGTGTGTGTAATAGCCACCTCAGTGATGATTT
GATTAGCTGGACCCTTACATAATCATTGAAGTATACCCATGTTCCCTTATATACTTCTTTAGTGTGAAAGCTCAA
AATTAAGCAAAATAGTCCCCCTTGATAATGTTTAGATTCTTAACATTTGCTTTCTAAAGCTGGCAAATACTCTCTTCC
CAGTGTCTATGAAGTTAAATAACATGTTGCTTAGTGAGGACTTTAATGTTGCCATGCCATAGGAAGACCTTATTCGAA
ATCCCCCTTACCTGGGAGAATGTGAGATTATTACCCCCCACTTGTTAACACTTTTAGGATTTTAAAGGTGTTTACA
TTTGTATTAGAACAAAATACTATTGAGAAACATTTCTAGAAAAAATTATCTTTCCAAATTTAAATCAGTGGTATGT
AATGTAGGAGTCTGATTATAATGATTAAATACATGGGCTTTGGGCATACTGCCTAGGTGAAACCTCTGGTTTTATTG
CATCACTATTAGTATAACCTATGGGAGTTAACCTACGTAAGCCTCAGTTAATTTTTCTCTCAAATTGATCTAATAAT
CGTCTCTCATAGGCTTGTGTTTATAGATATTTTCACTGTATATAATACTTAGGACAGTGCCTGATATCAGTAAGTC
TCCTTATATGCTATTTTCTTTCTATTTTAAATTTATGCAAGAGAACTATTATGCTTTAACTCAATTAATAATAA
AATGCCCTTGTATTTTCTCATGTCAAAGGAAATATGCAAGTATTGCATTCACCTTAGGTGCCTTTTGAATTGAG
CTTTGCATGGTTAGTTTGTATAAAAGGTTTCACTGAACTTTCTCATAATGATTTTTTTATTGAACATATGGAATCCATT
AAGTGTTAGCAAAAGTCACTATCCACTGAGCTGTGTCCAGGGGCTGACAGTTATGTCTATCTTTGCAAAAAATAAAC
ACATACATAAATGACTAAGACGTATATTACCTGTCTCATCTCTTAGAGCATTTCATTTTTCTTTTAAAGTTTTTT

CTTTCAATGGGTTTTTTTATCTTTGTGAGTACATGGTAGGTGTATATGTCAACGGGGTACATGAGGAAGGTGTATATA
TTGATGGGGTACAAGAGAGGTTTTAAACACAAGCATTCAATATGAAATAGTCACATCATGGAGAATGGGTTATCTATC
CCTTCAAGCATTGTGCTTTGTATTACAAAACATTCTAATTATACTCTGTTAGTTATTTTTAAATGTACCATTAAGTT
ATTACTGACTATAGCAACCTATTGTGCTATGAAACAGTAGATCTTATTCTTATTTTTCTAACATCTTAGAACATTT
CCACAAACACTACCTGCTTGTTAAATATACCTATTCTAATCTTCATATAATCAATTACTTTTTCTCTAGAAATGTA
CTATGACACATCCATGGGGAAAATGTAGTAATCTAATTAAGACTATTTCTCTCATTTTTATATTTAAAGAATGTGC
TCTATCAATTTATTTACTTGTACAGCCGTAGGCAACCTCTAAAAATTTTAAAGTTCTTAAAGTCAGATATTTTCAGT
TAATATTGTGATTATATAGTTGATTTTGTATGAACATGTTTCATCTACCAGAAAATAAATTATACACACACATTGATATG
GTTAGGCTTTCTGTCCCCACTCAAATCTCATTTTGAATTATAATCCCCGTGTGTCAAGGGGAGAGACCAGGTGGAGGC
AATTGGATCTTGAGGGTGGTTTTTGCCCATGCTGTTCTCTGATAGTGAATCATGAGATCAGATGGTTTTATAAAGGG
CTCTTCCCCCTTCCCTCTCACTCATTCTCCTTCTTGCCACCTTGTAAGGAGGTTGCCCTTGCTTTCTACTATGCCCT
TTCTACTATGCCCTTACCTTCTACTATGATTGTAAGTTTCTTGAGGTCTCCCCAGCCATGCTGAACATGAGTCAA
TTAAATCCCTTTCTTTTATAAATTACCCAGTCTCAGGCAGTTCTTTATTGCACATATATGTGTGTGTATGTGTATGT
GTGTGTGTGTATATGTATGTATATATGTATACATATGTGTGTATATGTATGTATATATGTATGTATATATGTATA
CATATGTGTGTATATGTATGTATATATGTATACATATGTGTGTGTGTATATATGTGTACATATATATATATATAT
ATATATATATATATATATATATGAACAGAGAGAGAGAGAGAGAGGGAGGAAGGGAGAGAGGGAGGGAAGCATGGAGA
AAGAGAGAGTAATAGCCTAAATAGAAATAAACTAGCTCCAAGTACAGGTTCTGTCACACTCTCCTATCATACCCCC
ACCAAAGTTAATGTTAACCCTTGAGGCCCTGTTCTTCTTAGTTGTGGAGTACTTTAGCAAAATTTTAAATCTAAT
TATGCCTAATTCAACGACAGTGCTAATTTGAAAGTGTTAGAACTGAAGACCTATAATAATAATGAGAGTTACAAAA
CATAAATAGTGAGACAATGATGAATGTAGTGGATGCATGTACGAGGGCTATCATTGTGACAGTAGAGATGATGCTCAA
GGACAGACAATGAGTCTTTCAATGTGTGGAGAATGTGCTGCTGTTACAGTGATGTACAGGAAAGAAACAAAACTGA
GGAAGTATCAGTAAACAAAACACTCAAACATATGAGTATACAGCTAGAATAAAAGCAACAGTACTAGATGACAATAA
GCCCCAATGTTAACTCAGAAAGCAGAAGGTTTTTAAAGAAATTTGGGGAATACTGTGGCTGATGATACTTATGTCTCAAG
CCACAGATGCCATTTGGGCTCTGCGCCCAAGTTGAATCGGCACCACCTGGCAGTAAGTGGGCAGGTCCACGACTGCCA
GGACATCCCTTCCAACACTTGTGGAGATCACCAGGAAGGGGGGAGAGACCTGCCTTGACAGATTTTCAATGTGGCGC
AAACAGGTCTATTTTGAGAAAAGATGTTCAATAGAACATATGTACAGCAAGGAAGAAGAGATGATGCTTAGTTCTAAA
GCTCCAAAGAGCTGGCTTACACTCCAACCTTGGGGAAAATGCATCCGGGAAAATGCAAGATTAATCTCATCTTAGCCAT
TCTTTTGAATGGATGGACATGACCCCTTTCTACTTGAAGACAGAAAAACATAACCATATTGATTTTCAAGTTTTCTTCA
TTGGTTTTCCATTTAGGATTGTTCTCTCCCATCTTCTTTCTGTGTAGGCATCCCAGTTCCCAAGTGTTCATGAAGCAC
GTATGGCCTTCAGGGGATGTGTCTGTATACATTGTTATCTTATGGATGCACGGTTTTGTCTGCACCTTGGTTCTGAA
TGTCTTTACTCTTGAGCATCTGCCCATGGGTCCCCTTCTCAAGGCCCTCAATTTCTTGAGTTTAACTGCATGGCCC
ATGCAGCTTTTCAAGTAAAGCATCTCTTGCTATGACCAACTCTTTTCTCAGTCAACTCCACACTCTTTTCAAGGGAC
AGGAAAAATGTAGCCACTTGCTGGCTGCACTCTGAGGCCTCAAGAAATTTAGTGAATCTGCCTTTGCCCTTCTTGCT
GATGAAATACTGCCACATCAGGCCCCCTCTTCGAAACCTACAAGCATCTAATTTTCTTGCTTCTCTCCCAACTTTC
TTTTTGACTCCCCCCCATCCAGAGAGTTCTTATGTCTACTGTACTAGGAAAACTCATTCTTAAAGGTATGGTTTTCA
AATCATTCTCTGGTCTGGACTTTAGCTACGGTTTTTAAATGAAGAAAACAACCCAGAGCCAAAATATAATGAACTATT
TCCTTCTTCCACAGAGTGGAACCTGCTTTGGGGTTAAAGGGCCAGTGAACCAAATAGAAAAGGATCTCAGGGAACAC
AGATTGAAGAGAGAGAAGAAAAAATATGAAGGCATTGTTGGTTCTCTTTTGAGTTTAAATCTAGTGGGGATTGTAA
GCACACACACATATACACACACACGCTTACACACACACACCAGTGAAGTTATGAAGGATTTTGTCACTCCAACGACC
TTGAATTTGATTATCTAGGTCAGTTGTTACCAAAGTGGAATGTACATGCCCAATAATATGCGTGCTAAACAGTTGGG
GTAGTGAGAAAAAATACTTTTTATTTATCTTGTCTCTAGAAATTAATATTTTGATTGTATATTTATAGTGTATGT
GATGTGTAAGTTGTGTCTACAAAACACTAGTGTCAATGTAATTTAAATTTACATATGTCTGTGAATATATATTTATA
GGGTACATGCTTAAATGTGTTTACTTCTGAGGTACATGAACATTTTCCCCCAGGCACAGAAAGCAAAATACCACA
TGATGTCACTTAAATGTGCAATGTAAAGAAAGTTGAATTCATAGAGATGTAGAGTAGAATCATGGTTAACAGAGGCT
TGGGAGGTGGAGTGAGGGAATAGAGAGTTACTGTTCAAAGATTACAAAAGTTTCAACTAGACAGAGGGAATACATTTT
GAGATCTATTTCAAGAACATTTTGAGACCCTCACTCTAAGTAATAGGAAATCATTACTTTAGTTAACATATTTGAAT
ATGAGTTGTGATGTTCTATATCGTTTATTTGGATTCTACTAACCCACACCTAGATTTTTTATGGCATTACCTTTTTAC
TCACTGTGAATATCCTACTCATAGACAGATGCCCTGGGAACTTGGAATGAGGCACCCAAGAACTGAGACAGTGAGA
TTTGGGGGCACAAGGATCTATGGATAAGTTTCATCTTAGTGATGATAAAATCAATTTGGCATGTTTACGGACAGTGT
GCATTTTAGAAAGGGTAAAGACTTGGAACGGGATATTTTGAAGCCCAAGTGTTCCTAAATAAATAGCTGTATAATTT
GAAGCAAATAATTGATTTTTTGTCTCTTTGTGCCCTCGCTGTAAATGGGAGAAATGTATTCCTTTCTCATCCTT
CTCATGAGGCCATTGAGAGTATCTAATGAGATCAGACTGTGACATAGCATAATAATTCTCATTCTTGAAGGCCTAT
TATACACTTTGCAAGCACTGTATGTGTTGTTTCTACTTCTCTGTTCTGTTTTCTGGAATAAATATCCCCCCTCC
TTTACATTGGATTGCCATTATTCACCCTGTAAAGGAAGGCTTCATGGTTCTCATTCTCATCTGAGAAAACCTTAGGCTC
AGAGAAGATCAGTAACTTATCTAAAACACACACATACACACACAGACATATCTATGCCCATTTATCTTAACCTAGTT
TCTCTATTTCAGGAGTTATCTCTGCTGTCTCTGCTTCTGATTATAATCTGTGTAAAGCTGATCCAAGTGACACGATTAC
AGGGAAATTGTAAGCCCTTTGAGAGCAGAGACTACCTATTGATATCTACATTTTAAATTTGATTTTAGCCAACCTG
TTTATATGCAATGACTAACAGGTTAGTTTGAAGTGTCAATAAATATCCAAATCCTAGACTAAGTAAATTTATTAATG
TAATGATTTAACTTGATTTTTTTCATTGGCATCTTCCCTGAAGTCGTATGCAAAATGAAAAAAGAAAGTATAG
TGTGTGATTTAGATTGAAATTCAGGAATCCTCCAGGTTACCTTGTGCTTTCCAAATAGTTTCAGATTGCTTAGT
CTGACCAACAAGGTCCTGACACTTGGAACTCTGTCTATCCCTCTAATTGACTTTGTCCCTGATGACCTCGCCGAGA
GATACTCTTACCCAGCTATACTGTGTTGCTAGAGTTTCTCTGATATCCCATGCTATTGTTTCTTTGTTCTCTTC
ATAAGGTACCATTTCCACCCGCCAACTCCTGTTTTCTGATGGACTTTTGTTCACCTTACAAGATCATTGCTAAT
GTATTTATTTTGAGAATAAAAGTGTAGGAAAGGTCACGGGACAAAGCTGTACACCAGACCTTTCCAGACGAACCT

AGTGTATAATCTCCCTAGTCCAACATCATGGCTTAAGGCAGTCGATAGATCCGTCTTAATGTCCCTTTTGAGTTTTCT
TACTATTATTATATGAGGATTTATTTTTGTCTGAATTCCTCCCTAGATTTGCCCTAGAGAGCAATGACTATTTACAG
TTTATTCTCTTTGTATCTCTTATGTTAAGGCCAGACCTTGGCACATATTCTAGCTGATTAGAAGACGTTTGTGTGAA
TGACCAAGTGATTGAACAAATGACCATGTGCTCTGCCACAGTCCGGTCAGTTCTACTTTGGTTTTGGTTATGTGTTG
CCACATTAAAGTTGTAGCCTGGGAAGTTCAGTTGTGAGATGTCTGCAGAACATGAAAAATTGGAATAATGAGGTTAT
TTCTAAAATTGCTATAATTTAAAAATAAATAGTGGTTTATTCCATATATGAATATACACTGGAAACAAAGAATTTCTA
GAATACTGGAGATTTCAATGATAACATCATTGAAATTAAATAAATAATAGGATTATGCTAGTTACTTTCTAATTTACT
AGAAATTGACCGTGTGCATGGCACGTATAATGAGTATCATGGGATAGTTACAAAAAGTGGTGCTTAGTGAGTTTCTG
TGGAAAAATCTCGGTACCAATAAAACGGAGGATTTCCAGAAATCGATATTCTCTCAAAGCTTGACAGTATTTATGCACG
GTTACACTTTGTGTGTCTTTTCGTTTGAATCAATGGAAGGAGGCTATAACTGAAAATTATTGTTTTAGTGATTATAT
CTTTAATAATAAGAGTTTTAAGAATCTATCATTAGAAAATAATTATTCTCAATTTGTAATTTCTCAACATTTGAACAA
ATAAATGCTCTGTGTCTATCAGTTAATCTTGCCCATGAAGATTTAATAAAGCACGCTAGTTTTTACAAATGTGATTT
TAGAGATGGTCATTACTTGGTAAAAATATTTTGTGTTAACACTTCCATGAATATGTTCTGTGGGAATATACTGCCTCC
ACATTGCTTGCTCATGAAGACATGATTTTTTCACATCATCCTATCAGTATTTTGAGAAAGAGATTGATCCCATATTCT
ATGAGCATTTGAACATTCTCTAGTATTTTTGTTTAATCATTAAAAACAACCCTTGAAGTCTATGTGCTACACTGGTTA
TTTCCCTCTTGACTTTCTTTACAGATAACCCCTCTATCATAAACAACCTATCTATATTTGTTGTCTCCACATCATGT
TGCCAGCCCTGCTTTAACACACTGCACATTGACTTCTAGCAGCAAAGGCTCATGGGAGGTACTCTCATCAAGGACAC
TGATGGTCCCTCATGTTGCTAAATTTGGTGGGTCCCTCTACAGTCTTTATCCTAGTTCACCTTATTATGGACCACTGTC
AACTCTGTTCTGCTTAAAAACACTCTGTTCCCTTGCTTATATGACTCTACACTCTTAACTCCTTTGTGAATTCCTCATC
TGCCCTTCCATTAAAGTATTGACGACATCCTTCATAGTTTTGATCTAGGACCTCTTTTCCCTCTTACTTGACATTATGT
GGGTAATCTTGTCTTTGAACGCAATTACCATTCTTATGTTGATGACCCCTAAGCTATAATTCAGCCCAATCATT
TTCTGAGGAAGCTACAAGAATACACAAATGTCTAATAGATCTCTATTTAGATGTCCCTCAGGTGCTTCAAGCTTAAA
ATACTCACCTGAGCTCATCACCTCATCTATAAATCTGCTTCTCCTCCCTGGCTCCCTGATTTATTTAATATGACCA
CCATCCACTTAGTTGAATAAAGCAGAAGCCTGGACACCATCTATACCTCCAATTAATCACTAAGTTTGTGTGTTAA
TACGTTCTTACATTTTCTCTCTAGAAATGTCTTATTTTCCCATCTTTACACCCAAAAACAAAGCTAGATGACCTG
ATCTCCTGCTTAGATTTTCAAAACACTATCTCTTGCTAGACTCTGGAAATTTCACTCTTGCTCCTCTCCAATCTATTT
CTACACCTTAGACTCTGGAATTTCACTCTTGCTCCTCTCCAATCTATTTCTACACAAAAGCTAGAGTAATTTTTTAA
AAAACAAAAATCTGAATGTGTTTCTGCTTAAAGCCTTCAGTAATTTCTTATTTGTTCTTCCAGGGATAGAGT
AACAACCTTTCAGACCTAGTTTATTAGCTAGTTCTTTAACCACAAAAGGACTCTCTCACTTGTCTACTCCCCCTAACAC
ACTTCGCCCTAACCTTTGCCATTCTCCTCTTCCCTTTTCCCTTTCCCTCCAGATGGACTTAAGTCCTTTTCAGATTCTTAAA
TGTTTCTTCTCCAGTCTCTTACATCTCTTTTCCCTTGTAACCTCTAAAAACTACTTAGCTTACGCAAGGAAAAAGGTC
TGTACAATTTCCCGGAATCAGCGATCCTAACGTTCCCTGTTGTTTTTTTTCGTTGGGACATGAATTCATTACAGTGGC
TCTAAACATCACCACCCCTGCCTATCTCTCCCATCTCTACTTTATCTGAGCTTATCCATACTCTTGAAGACTTACAT
ATTTTTTTTTCTACCAGGAAATCATTACTAGCCTTATTATCCCACTGTCCAAACCAATAAGTCTGATTAGGTATCTGT
ATATATTTAATATTACTATATGTGTTTTTCTAACACTCTAGTAGAGGAGAAGGTGTATTTCTTTCTGTTTTTTAGAA
GCCTGTATTTCTGCTATTATAGCTCTTAAGGAACCTCATGCAATTGCCTACTAGAATGTAAGTTACGGTAGGATAA
GAACTGGATCAGTCATATCACACATCCACATATAGGACCTAGCACCATATCTAACACACAGCAGGTACTCAATACAT
TTCTTTCCCAATAACTAAAGAGTTTAAACAAACCAAAATGATTAAATGAGAAGTAACTGTTTTGGTAATTTCTTG
TCCTTACTAGAGTCTAAATTGAGTGATTTTTATATCATCAGTTTATACTCCCTTTCCCAACCCCAATTTCTTTCTT
TTTAAATTTTTTAAATCAAATATGCCTTAAACCTTCAGGATCAGTTGAGTAAATGATGCTTTTGTGCTCTTTTGCA
AAATAATTGTATTTTCAAGATTTTGAATTTAGATATTATAACACACCTTAAATAATAGCTTTAGTCTTAAGATGAAGT
GCTTCTTAAACTCCCTAAGATGGGTTGGACTATGATATGAACATGGACAATATCACATTAATTTGTGTACACAGTT
CTAACACAGGGTCTGGCATATAAGAACAAGTCAGTAAATAGTTGTTGAATGGAATTGAAAAATTAAGTAGCAAAATAA
AGTATTTTGACCTACAAAGCAAGAAATCACATTTTCTTTTGTTCACAGTTCCCTTAGGAAGATAATTAATTTTTTAG
TATTTAAGGATGTTAAATATTTATTTTATGTTCTATTTACTAGGCTTCTTTTATGAAAAATTAATTGGTGAAAAATAG
CGTACATATCTTCTTTACCAGAACATTTACATTTTGGGCAGTAACGCTGGCTTTTGTAAAAAAGCAAAATATGTG
TGAAATTTATGTTTGAGTTGATTTCAATGCATTACATTTCCATTTTAAATCTTCTTTGAAATACTCTATTTTGTGCA
CCATGAAACTGTATTAGATCTTAGTATGTTAGCAATGTTTTGCAGTTTTAGAGCCATAATTTATTTAATGACCACTT
TCAGCATATACGTTTTCTACAGGAAAAATAATCTCAAGAACATGAAAAGTGAAATCTATATTTTGGGTTTCAAAATG
ATACATTTTAGCTAAAATATCATAGTTTTAATTTCTCAGTGAAAAATATAGTGTGGTAATTTATGAAGAGACTCAGT
GTTTAAAAAATTATGACTCTATAGTCAAGTTTATGTTTATAGGACATAGGTTATTCAATTACATTTAAATAAATTAAT
TTAGAAAATGTGATCAATGTAACAAATTTTACCTGTCTTTTCTAAAGCTAAATTTGTTGTTTGAAGTGTTCTTCT
AAAATGCTAATGAACATCAATTTAATTTGTTGAGCTTAGAGTTAGAACTTAAATTTATTTGCCAGAAAATAAAGAAAC
AAATGGATCCCAAAAGATTACACATTAGAAAATGTATGCCAGGGAAATGCTTTTGAATGTGTTCAAGTCATGGCTTC
TAACTCGTAACTTATACTTGTGTTATGTCTGGCTTCATTCCCTTAAAGAAAAAGGAATAATAATGCCTTCGGAGAGC
ATCCCAGCTGTAAGAGCTATGCATTGGTGTCTAAAAAAGCTTCTCACTCCTCATACCATCCTGGTCTGGGAATTTAA
AAAATTGTCATCTTTTGATAATCTGTATCACATAGTCTTCTGCATAGTCATATGAGGTTAGAACTGCCCCATAACTT
TTGCAGGGCCTATAGTAAGTGTGCAAATGGTTGCCTGCATGCCACATATTTAATATTTATAAGGTATAAAGTCAACA
GACTATTAATATATCCTATCTGCTTTCTCTTGACAATTATACAAATCATAATGATATGGACATCTAGATTTCGATTTAG
AATTCTCTCTCTCTCATTTTCTTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
TTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
AAATAGTGCAAGCAGTTTATTCCCTGGCAAGGAATTTGGAAAAAAGCTCAAAATAGCAAACCACTTGATACAATAAAAT
AAATTCCTTAGAGTTTTGTACTGGAATGAGGCAGCTTGGTTAGAGCTAACCCTAAGCCTGTTATTTAGGATACATTG
GCTTTTCTTAAAGCTTAAAAAAAATTTTACTGTGTTAATGACATTTAACATGAGATCTATCATCTTAATAAATACTAC

126

127

TAAGTGCAGTTTTATTGACAGAGTGAGACATACACGTCGATATTGTGACTAGCTGCATGTCTTCTATTATTTAGAGG
TCTCACTCAAATGTAGATTATCAAATCTGTAGTGAAGAGGGTAGAACAGCAGAACTAATGCTGGTTTCCTTCTCT
AGCATTATTTGATGATAAACTAAGATGATAATACCCCCAGGTCTTAGATACCTGCAGTAGGACAGGCACCCTACAT
TTAATGCTCCTAGGAATCCTTCAAAGTGATAGCATAGTTATTATACAGTAATTGAGAAAACCTGATGTTTATAAGTTA
GAAATTTTTCCGAAGTTGCAAAGAAAGTGAATGGAAGAATTATACCAAGTTCTGGCCGGGCGCAGTAGCTCATGCCT
GTAATCTCAGCGCTTCAGGAGGCCGAGGCGGGCGGATCATGAGGTCAAGAGATTGAGACCATCTGGCCAACATGGT
GAGACCCCGTCTTTACTAAAAATAGTAAATTAGCTGGGCGTGGTGGCAGCACCTGTAATCTCAGCTACTCGGGAG
GCTGAGGTAGGAGAATCACTTGAACCCGGGAGGCGGAGTTTGCAGTGAGCCGAGATCGTGCCATTGCACCTCCAGCCT
GGGCGACAAGAGCAAACTCCGTCTCAGAAGAAAAAAGAGGATTATACCGAGTTCTCTTTGATT
CCAAGCCCAAAACAAATCCTTTTTTGAATATATGACATTGTTTCCCTGTTTGCATTCCCCATTCTGTGTATCACACA
TCCTGTGGCCTGATCAAAATTCATTTTTCAGATTCTGAATTTATTTTCCATTGAATCTATATAAACTATAAAGACAGA
AGATATATGTATGTGTGTATACCCACGTTTCTCTTCCAGTGTCAACTGATAAAAAATAGATTTCAAAGTCTCAATAAC
CTTTAATTCCTTTTTTCTCTTAAAAATCTTTAGAACTTGACATGACATTCTGACTCTAGCAGATTTTAGAAAACA
GAGAGGCCATTAGATATTCATACCTTACTATTTCAGATGAAGTATTCAATGCTAAATTATGTAATTTATCTGCTTTGC
AAATTGTATGGTCAGATTGAGTTCCACAAAGGAGAGATAATTTTTAATATAGGCATTCTGTAGCTTCCCTAATTATT
GAATTAGTTTAGAGCAAAATCCTTAAATTGTATCGTTGCTATGCTCAAATTTTGTATACTTGTCCACGTAGGCTATA
TTAAGATTTTCATTGAATTTTGGTTTCTTCTCAGTGATAATCAATATATCAACTCACCCTCAGATTTGCCTTTGG
GAAAATCCAGGCCCTTTTTCTGGATTTTTAGAGCAGATTTAAAAAAGTGATTCTGTATATGTGTTGAAATTAACCA
CATCTCATTGCTTTTGAATGATTGAGGTAATGTATACCTACTACTTTAAAAAATGACTTACTTAGAAGGTGTCCA
TAGTTTTATAAGTTCCATTGAACTGGTTTATATTGTATTTAGAAAAGGAAAACTACTCCTTTTATCCTTAAGGGTGAA
AACCTGGATTTTATTATACAATTAACACATATTTATTTTTTATTATGAAATATATCACAATATAAACGTTTACAGGG
AGTGTTTAAAGTGGTGTGTCCAATGGAAATATAATGTGAGTCAAATACGTAGTTTTCAATTTTCTACTAGCCATAT
TAGAAAAAGAAACAGAGAAATTAATGTAATAGGATACTTTATTTAGCCTAGTATATCCAAATCACAATTATTTAAAT
ATGTAATCAATATAAAAAATTAATAATTATGTAATTAACCTTTTTCTTTAGTAAGTCTCTGAACTAGTGTATATTT
TACATTTATGGCAGATTGCAATTTGCATTAGTCACATTTGAATTTGTTCAATAGCCACAGGTGGCTAATGGCTACCGT
GTTGGACAGCACAGGTTTAAAGAATAATATGAACATCTGTGTTTCCAACATTCTGAGTTTCAAATAAGAAGAACACCA
TCAGTATTTTTGGGAGAAGCTCCCTATGTTACCCCTTGCTAATCACCTTCCCTCCCCCAGAGCCAAAAGTAACCATT
ATCTTGAATTTCTAGTAAACAATGCTCATTTTTTAAAAAACGTATGTTCAACACCTGTATTTGTATCTTTAAAGAGT
AGCTAGTTTTAGTTTGCTGGATTTGAACTTTATATTAAGGGAACCAACCCCATCTCTAATCTTCTGTGAATTTCTT
TTCTCTCAATACTATGTTTTACATATTTACGTTTATCAATGTGCAACTCATTGTATGTATATAACACAATGTATATA
TTTTACATGCGTATGGACATTTGGGTTGTTTTATGTTTTGTTTATCACAAACCACAACACACATGTGTTCTTGTA
TATGTTTTATAGTGCATGTTTAAAAATTTCTCAACAGTATTCGCTAGTAGTATTGTCAGGTATAGGGTATGCACAC
ATAAATAGAAATGATTGATTAGCTGCAATTTGTAGTGCACACATATTTGCTATGTAAGTGATCCATGTTTAAAGACTT
TAACTGAATTTAAAAAATATTTTATTGGAGCCAATCTAAATGAGCTAAGGGTTTGTATTGTTTACATAAGCAAAGAT
TACACTTACTGGGTCAATTCGGTTGATTAACTTTGGATATATAAAATATATAGCTAGTTGTTAAATAGATATAATTA
TTAATTGGCATTACTTTTTGTTTGTATATAAAAAATTTCAAAATATCCATGACTTAAGCAAGGTAAACACCCACTGGGT
GGCTTAAGCAACAGAAATGTATTTCTTGCAAGTTCCGGAAGTTGAACGTCTAAGATTAAGGTGATGACAGGGTTGGTT
TCTGGTGAGTCTCTCCCCATTGGCTTGCAGATAGCCGCTTCTCCTTCATGACCTTTCTCTGTGTATGTGCATCCC
TTGTAGCTGTTCTTCTTTTATGAGGACATTAGACTTATTGGATTAAGGTCTACCCATATGAATCATTTAACCTT
AATTACCCCTTTAAAGGCCCTACCTCCACTTGCAGGGGTTAAAACTTCAACATATGAATGGGGTTGAGGAGACCTAC
TTCAGTCCATAACAGTTTCTATATTCTGAAGATGGTCTTTAATTAACATAACAGTTAATGTTACTTTTACCTGGGAATG
TCTTTTGGATGGGGATAAGCTGATGATGAGAAGGGTTGGTGAATTTCTCATAAGTGTGAAATTTGTGTAGGCGG
GCCAGCATGATTTTTCAATCAAAATACGCTTTGGGACAAAGTGAATCACTACGAGAGGTTTAAAGAAAGCAA
GTTGTAATTGCAACTTTTAAATTGAAAGAAAGACAGGCTTTGTGTATGTCAGCAAGACTGATAACTGGCTTTAACG
TAGATAGTAAGGCAGCAGATTCAATCCACTGATCGTGATCTACTAGTGAATTTCAAAGCCTTATGCAATAGAACTAC
AAACCTTTTCTTGGCCACCTTGCAGGTGGATCCATAGGCAAAAATGAACATTGCAAAAAAGCCGCTATGTTTCAGA
ATTTGTGCTAGGGCTTTAATATCTATAATTTCTCCAAATCCTCACAAATTAAGAATTAATTCAACTTAGCCCCATGA
ATAGGGTGAAAATTTCTGAGATTTAACAACTAAAAATAAGTTATCTGAAGACAGACAAATAGAAAGAGTTGAGATATT
CTATTTGAATGTAAAATTTTCAAAAAGTAGAATGACAGCGTCAGGAATTACAGTCTCAGTGTGTAACACAAGACTTA
GGAACAAATTTGCTGCATGTAATTTTATTGAGATGGGACAAAGTACAGCATACGTAAGGAAGTTTTAGAACAAATAA
GATAATTATTTTACGAGCTTTGAAACATGTGTAAGAAAGATACGAATAAAAGTATAATCACATTTGACTAAAACATG
AATACCTTAAACTGAAAAGCACTGAGATTATCATTATATAATTTTGAATATTTTAAACCACAATGCTTTGGGAGTG
CACTGTAATATTTTAGAATTGGAATTTTAACTTACTGGCTTAAAAAGTAATGTACTTTGTTTTAAATTCAAAGATTA
TCTTGTAATTCAGTTCGATCTATTGAAAAAATTATAAAATTCGGCAAGAAGCCAAAGAAGCAATTAATGTAGCTC
AAGATAATTAAATTTTCATGTTTGGCTTTAGAAATATATTCGTGCTGACATAGTACATGGTAATCTAGTGAGCCCAG
ACAAGTAGTTTTCTCTTTTTGTCAAAGGGAACAATTTGATGCGTGTTCAGTTGCTTAAATAAAATTTTGTATGTGC
TTTCTCATCACAAAGAGAACAATATGATTTTTGAAATTTATTTTACTTTATAAAAGAAAAAAGCCCTCACAGAG
AAAAAGAAAAAATGATGATGTCTTTGAAAAACAAAGTTAATACAGCTTTACATATATTTGACCTACATCAGGGTT
AATATTTTTCAAGGTGAAACATTAGATGCTGGAATTTGCAAAAACAGGCAATCCTCCTTTAGATGAAACGGACACTC
TAAGGGTTAATTTACTTACCTAGACCTATTGTGAAGTAAGCCCTACAGAGACTGAAAAAGTTAAATGCAACTCACAA
AAGTTGCTAGAAGAGTCATGATGTAAAAATAAAATAAGTACACAATGTATGCTGCAAGTATACCTTAGAGCCATGCTA
GGTGCGGTTGAGAAGTTCAATACAGGTCCAAGATAATAGCTGCTTCTCCTATAGAACATGTCTTCTCATTGGAGGGA
TAAGACCTGTGTCTATGAAACAGGCGTAATTACATAGCTCTGGAACATATATGCCGAAATAAATGAGACAGTAAGT
GTTATTGTACTATAAAGAATGAAGAAATCATGATGAGAAGTAACAGTTAATGAATGTTTTCTAGAAAGAGTAGGATC

TGAATTGGCCTTAGGTTGTAAGCAGAGTTTATAGATAGAGTAGTGGTATGTCAGAGTCACCTCTGGGTGCTTAAACAT
ACAAATCCCCAAGTCTCACCCAAATGTGTCTTCAGATGAAAGGAAAAACAAATGACTTGAGCTCCCCCGCAAAGAA
CACGGGTGGTATATTGAGCAGCCAAGGAGTGACCAGAGTGGCAGGCCCATGTTGAGGGACAAAAGAGGACAATTAGA
ATATGATTAATACAAATTTACAGTGGGATGAGTTGTTAGCCTGAGGAGCTTGAATGTGAACCTCTGTGCAAAAAGGA
GTCATTAAATACTTTTAAAAAGGTGGGATGGGAAGAAAAATGACATTCTCAAGACAATTAGATCGAACAGTATTAAG
CATGCTGACTTATTAAGTTATGCACCTTGAGAGGGTGGAAATGAGGGAAAAAGGTCTTTATCTGGAGTAAGACAGGAA
GAAGCTAAGCTGTAATTCCTTACTGGACTGTAAATTATGTGCAGATATATTATCTGTCATGTTTCGTGGGCGCATTCTC
AGTACATAGCAGCTTGAACAGGTACTCGATAAAATTGTCAAATGGATGCATGGAGTGATTTCATGCAAAATCTAATA
TTGTATAGTATTAGAAGGGGGAAAAAAGCATGGCATTATGCTAGCAGAAATGTCATTTGGTATTGAGGATGAAACAT
TTTCAACAGTTTGCAGGCAATCCACTCAAAACATTCTGTCACTTTCCAATAATTTTGAAGGATGTTCTTTCTACTTC
TACCTTATTACACAATGAGTTGAGTAAGATAAAAGAGTCATGTGCAACAAAAACAGAGGGAGATTTTCTGAAAGGCAC
TACACCAGGAAGTTGTTGTAATCTTGCTTCATCTTGCCATCTTGATATACTTCTGGCGCTACCTCCAGGCCAGTTC
CTCGTTACATATGTCATTTACTTCCCACATGCTAGACTCACCGAGTTAATCATTTTGTCTGCAGTTAACACATTTTAG
CAGAGTGTAGGTTTATGGGTGAGAAGGAAATCAATGATGTTTCAATACAGGGTTCTTTTCCCATCCCCCTTATTTCC
ACTTAGAAGTGTCTCTCAAGTCTTAATTTGCCTCTAACTTTTTTCCAGCTTACATTCTTTTCTGAAAAATGCAAC
GACGATGCCAATGTTTGTGACCTGAAATACATTGTAAACATTCTAATACTTTGAGCAGAGCTTCCAACTCCCA
TTTGCTCTTTTATCTCCCTTACCTTGGCCCCCTTTTGAAGGCAATGTGATATTTAATCCGTTTCTATTGATGCTTC
AAAATTATTGAAAACTGGTAATTGTATTTTCCCTTACTTATCAGTTGCTAGTTGACAATGAGTGTGTCGAAAA
CAATAACCAATCAAAAGGTAAAAAGGAGATTCCAGACATATCTGAGAGAAATTTCTTTGGAAGAAGCCCGTAAATGG
AATGGGAATTCAAAACAAAGCCGTTTCCAAAAAGAAATACTAAATGGTCTCTAAATGCAAAAGGATTGCTCCCCAAGCA
TTTTATGGGAGCATAAAAAGCTCCCAACACATTTTATGACAATACTTCTACTCAATGACTTCTTGTGTTGACATATT
TGTTGCACTCGACGTTAGTATTTACAGCTTCTTATCCCAAATATTTACTTAACTGAAGCCCTGATGTTTTTAAAAAC
TTTTCATCTGTGTTTAAACAGCCCATTTTACAGAACTTATTTGTTTTCATCAGGCAGATATTTACTGAGAACTTGCAA
GTGCCATATATTCTAAAAATGCTGATGATAAACTGTGAACACAATAGATTCTCATGGTGCTTATGGTCAGGGCTAG
CACACACATTTGTGAATGATCACTGATGATCAAAAGGCATAAAGCACTACATTGGAAGAAATACCGAGGGATCCGAA
AGTATCTTGGAAACACTAGCAAGTATAGCAGATGGTGGGATTGGTGCTTCAAAGAAGTCTTGTGGAAGATGTTACG
TATGTACCTTCTCTGTGCCAGGCAGTCTAGGAAGTGTGAGAGAAAAAGATGTGCTAGATACCGCCTCTGTCTTA
TGTGCTTGTGCTTTGTGGGGAGGTGAGTAGGATAATCCAGTTCTCATGCAGTGTAATGAGTACCATGACGGAAATG
CACTCCAAGAAGTAGGCAGCATGACCAGAGATAGGACATTTGAGAAAGACTTCACTCGGGTGGTACTATCTTAGTCT
GGGTGCTAAAATAGATGTGATAGATGAGTAAGGGTGACCCGGAAGCAGGAGGGAAAGGGAGGGGCTTTCAGAACAAC
AAGTGCGAGGACATTAAGGTGAAATAGAGTATAATAGTATTCCCAGATCCTTGGGATTGTTCTCCATTAGGCTAAAA
CAAAGGTGTTTTCTCTTCTTTAAGATTTTATGACTGCAGATTGCATAACAGAAGGTCATTTAATAGACCTCTAACT
GAAGGAATTCTTGAATTAATCACAACATATCTTCCATGGCCAGAGAAACCATTGCCTCCTTATGTCGACATTACTA
ACAGCACCAGCACCTGCTGCTCAGGCCAGCGGGAGGGTTGGGTGTTGCTGCCTAGGTAATGCTCACCACCTGATGTC
CTGCCATGAGTAGTTTTGCCAAGTTCCACAAAAAACTTAGTGTTCTATCAGCATCTAATGAGAATTACAGTCATT
AGTTAAATAAAAGAACTATTAGATAAGGAGCAGAATGAACAACACACAATCCATCAGCTTGGTGAATGGTATCAGAT
GGTTTTCTGGGTGCTGGGCAGCTGTGCATCCAAGTAGACAGGGAGAAATATATATGTCCTTTGCCTTATGTACTTGTTT
CTCTAATCCAAAGGCACAGCAATCCGTGGAAGCTGCTATGATAAGGTGTTTAGTGGTGAAAATGCTTGAAGGCCAG
TAGATTATTAAAGTGATGTTTTTAAAAATGCAGATGGAGAGTAAGTACTTTTTATCTAGAGTAGTAGTTCTCAAAGG
GAGGTCCCGGGATCAGCAGCGTTAGCATCACTTGGGAACCTTAGACCTGCATGGGCCCCATTCCAGATCTCACTTGAA
AACTCTAGGGGGGTAGCCCCGCAGTCTTTGTTGTGACCAGCTCTCCAGGGGGTTCTGACACTCCAAATGTTCAAGT
TTCAGAAGCTACTCACAGGCCATCATGCTCGGCATCAAGTAAAGCTTGTAGAACTAGAAAGTCTTGGCCCCACC
CCAAGCCTACTAAATCAGAGTTTTTGGGAGTAGGGCCAAGAAAGCTGTGGGTTAACAAGGTCTCCAAGTGATTCTTA
TTCATGTCAAAATTTGAAAAGCGTCGATCGAAGCTTGGTTCTCAGCTTTGATTGCGTATCTGAATCACCTGGGGAG
ACAGTTGAGCTATTCCGGGCCAGATCACATCTAGACCAATTGAATCAGAATCTATGGAGGCAGGACCCAGACATCA
GTATTTTAAATATTTCTTGAATGATCCAGAGTGATAGCTAAGGTTGAGAAACACTGTTCTAGGATTAAAGGATTAA
TGTGTTTGAAGATATGTTAAGATCTTAGGCAAAATCACAAGGGTGTTAAGAACTACCATCTTCGCAAAAGGAGAATGT
GCCTCAGATATTCTGGTACTGCTTTGATTTTACCTTCAGTAGTCTTACCTATTTTGAAGTATGCTTAGTAGTACTAAT
ATGAGGCTTATTACTAATATGTTAAATTTGTCTTTAATTAAGTGGGTCTAAACGTTTTAATCTTTAATCTCTGAC
CCAAGTAACTTTTCTAAACATTTTCTAATAAGTCTCCACCTTGTCTTCTGACCTTCACTTATGTTCTTTTCAAGGT
TCTTCGTGTGTTACTAGTAATAGTAATGGCAAGTGTTTATGAACTTACTATGTGAAGATTCTAACTGGCTTTTA
ATAATCACATCAGCTCTGGGAGGTAGAAGGTAGGGATCCTCCTTGCTTATCAGGTGAGAAAAGTGTACTATAGAGAA
GTTAGCAACTTTTCCAGGTCATAATATGTGACAGCTAAAGGGAGCATAATGGTTGGAATAAAATAAATCTACTCTA
GTTGTACCGAAGGCTCATATTTGTCTCACGTAATTGATTTGGTGCAGGGCCCAAGGGGTCAATTTCCAATGCTTGGAT
TCCTGGATATGTAGAGTTGTATTAATAATGCTAAAAACCTATTATGTATCATACATCATACATATCACCTAAAGTA
TTATGGAAATGAATCTGTATTATTAAGGGAAAAAGGCTGTGTGAAGAACAACTGAACTTCATTTTAATTGAAAT
AAATAACATGCATCATACACTAAAAGTGCACGTTATGACCCCATGAATTACTTCAGGTGGCTTTGATTTCATGTTACA
TACACTAACAAATATAGAAGAGTGATATAATGCTTCTTAATTAAGTACTAATGGAAGTTTACTATTTAAGTGTCTCT
TATGTAAGAATGTAATGTTTTCTGAAATATCAGAAGTTTTCATTAGGAAGCACTTTTAAAAATAGCAAACTGATA
TGCATATGATTTCCATATACATTAATGAAGTGTAAATGATGTTTATAAATTATAGAAACCAAGGGGATGTTTCAA
ATTAGATATTTGTCTAAATAAATCATGTATGGATTGAACAAATACTCAATTGAGAAATAAATGTATTTCTTTTCTT
AATTATCTAGGATTCCTTGTGTTTATCTCTTCAGAAAGCAAAATGTCTTCTGTCCGTTTTTATTTCCAGTTAAACATTCTT
CAGATTATGTAAATAAGTTAACTTCCAATCCTCTTATTTCTGTTTATCTCACCCTCTTCTAATTTAGACGTGATCA
ATATCTTATCTTTTTGCATTTTCATAGACATCAGGATCCAGAATAATTGAGTGAGCTCAAAACAACATGGCAAGAAT

GATGTTTTTCAGAAAACCTCAGCAATCATTTCGTTTTAATAAAATATTTCATTGCCTACCAACTATAAGCAAAGTATTGGCTA
GGCCATGTGGGGTATACAAAAATGTATTAAATATGGCTCATTCTCCCTAAGAACTTACACCTATTAGACAAAAGTACA
TGCATAAAAATTATAATGTATAATAGAAAAATAATACAAAGCCCTAGAATGCACAGTTGAAGTACGATTTCGATTTAT
TATAAAAAGAAAGATGAATTGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGGCCAAGGTGGGC
AGATCACGAGGTGAGGAGTTCGAGACCATCCTGGCCAACATGGTGAACTCTATCTCTACTAAATATACAAAAATTA
GCCGGGTTTGGTGGTATGCACCTGTAATCCCAGCTACTTAGCAGGCTGAGGCAGGAGAATTGTTTGAACCTGGGAGG
TGGAGGTTGCAGTGAGCCAAGATCTGGCCATTGCACTCCAGCCTGGGCAACAGCAAGATTCCATCTCAAAAAA
AAAGGAAAGAAAAGAAAGATTAAATTTCTGTAGCTAAATCAAGGAAGGCTTCATGGAGAAAAAATATTTCAACA
CACACTTGACGTAGCAGTGGGATCAGGCTGATGTAGGGAAGAAATGAATGACATTCTACACTGAGAAAAGAGATATTC
AGTATATATATGAAGAGCAGTAGAGAAAATAACAAGTGGAATAGACTCAATTTACAATACTTGCCTGCCTGGAGTA
CTCTATACGTTGACTGTAAAGTTGCAGTTTACTCAGAAACAATCCCCTTTCTACTTGTATCTCTATGTAAATCATTTA
TTGGGCCTCCTTTTGTCTCAAAAAATATCCTTGTGGTGGATAATAGATTATCACTCTGTTCTTAAATGAAGTGCCTG
TGTCTATCCCAGTAAAGGGTGCATTTCGGGCCCTTCGTAAGTGCCTCCACTACATGGTTGATTGAAACCAGAGCTT
GGCATTAAAGAGTTAGCTGAACAATCAGATTTCTATTCTTGGAAAACCAAGAATTCAGAATAGATACAGAAGCTG
TATAGCTTTAATAACATGACAGAGTTGTAGCCTTGAAGCTATGTACAATTCAGAATTATGAGGGAGAAGAAATTGA
AGAAACAGTAGCAGCCGGGTAAATGCAGAAACAAATGAGGGAGACACCTAGGGGGTGAAGTGAAGCACAATAATGGAA
GAGAAGTGCAGTGAAATTGCTTGAAGTCTTACTGATGAGATTTCTACTGTTGCCTTGAATCCAGGACCACCTATATG
TTCATTCTTTGTCTGCTCAGAGTTATGACAGATGCTGTATTGAAATCCCCAGAGACTCCCTTATCGTCTCACCTC
AAACCTTACAATAATCCCTTCTATCTTTCTATCCATCCAAGCTGGCTTAAGTAAAGTCTATGATCCATATTCCTAGT
AAACAGAGAAGGGAAAGAGACTGAAGGCAAAGGCCCAATTAGTAGGCTATTGCAATATTTTCAAGGAAAAGGCAATG
GCCATCACATTGTTGTCCAGGAATGAGAATAGAAATGAAAGAAGATAATGAAAGTTGAAAGGACTGGGGGGGCTTG
ACAACCTGTTTAGACTTGAGGAGTCAGATAAAATAGGAAGCCAAAGATAATTCAGAATATTTTGATTTTGATTTTCAT
CACCAAATAAGATAGTAGTACTATGAAGAAAAATGGTTAAAAACAATAATAAAGAGAACTCCTCCAAATAGT
ACCAAGGGAGGGAGTTTAAATAGAGGAAATTAATTCCTAGGTGATGAGAGTCTGAGAAGCCAAACGAGAAAAAGATC
AAAACACCCAGGGATTGGCAGTCGCAGGAAGCTTCTCACTTATGGCTGGGGCTTAAAGCACAAGGTGACATGAG
ATTTTCAGAATTTGAAGTCGTCTGGAGGCAGCTAGGATCAGGTGGGGCCTGTCTGTTTCGGCAGGACCTGCAACCACA
GGAGGAGGATGCGTCAAGCAGAAAGTTGGAACACAAGAGGGGATTTCAGCCATAAGCCACAAAATACCTTCCAGAGCA
GAGAGAAGGAGAAATACCCTGAATTCCGTATTTTCCCTGCCATTTAGTTCCCTGCTATTGCCACACATTGACGTATT
CCATCCAGAGAAGTCCATTGGCATATGAGTCTGGGAAATGTAGTTCCCAGGGGGACATGATCTTAAGGGAAATAGAC
AATGACTGGTGCAACAACCTGACCTGTGTGAGGCAGGAGGGAAAAAACAGGAATAATATAGTTTTTCTCTAGATCCCT
TCATGCACAAAGATGCAAAAGAAATGTGTTGGCTTAATGAGCCATTCTGGGTGGCCCTGTAGGTGGCTGTCTACGA
ATAAGATTTTTAGACAAAACAGAGATGACTTCAAATGTCAACAAGAAAAGTATCAGACAGGAATTAATATTGACTTGA
TCTGTACAGGCGTCAATGATTTGCATTAAGCCAACGATCTTCATTGTTAATGTCTGGGAAATTGCCAGCAGCATT
CGACTACTTGTGTGGATTAGTGTAACGGATTCCCCACTAACATTCAGGAAATCATGTCAAGCACAGAGTGCCTATG
TAAGAGTGGTTGTGTCTATTCACTACATTTCTTGGACTAATAACACACTTAGCCTTCTGAATTGCCAACATGTACA
AAACCAGATTGGGGTTTTTTAGTTGTTTCATGGAACATATCATTATTGGGTAGCTCCTGTAGAAGCAAGATACAGAAA
CTCTAATTAGGAATAAGACAGTCCCTGTACTTCAAAGAGCTCTCAGGGGAGGCACACAAGTAAACAAGCAATTATTA
TCATACGTTAGGATAATACCGTCATGGTGATAACCACTGAGTGATAGCCAAACACATGGAAGAGGTACCCAAGTCTA
ACTTGGGGTAGTCAGAGACTGCTTTCAAGGATATCCGAGTAAGTGTTAGCTAAGACATGATACGTATTTCTAGGAGG
GAAATTTTCAAGGCAAGGTGGAGATTGTGCAGTGACGCCCAGAGCCTGGATTATTTTGGTGACTGCTAGTATTTTCA
AATGACTTTCAGCAAAAGTTGTAGAGAAGATAGAAGACAACAAAGTATAAGCAGAGGCCAGATAATGAGGACCTGGAA
CAGTGGTTTGTCTGGTAAATGTTTAAACAAGAGGCTCTTGGCGGGGAGAGAGTGTCTGATTTCAGCATTTCGCAAA
TTTTGTTGCACAAATGCTCCAGCATAGCCAATTTCAAGCTACCAAGTGTGACGTGATGAGTGAATGCAGAAATGGAAAGAA
ACGGGCAGTAGCACAGCATTGTATAGTTATTTTCAATACCAGATATAAATAGATAAAATATCCAGATTGGTATTTAAT
AGATATGGATGCAAAATTTAAATATATGTACATTTCATGTGCTTCATGTTACTGAATGCGCACAAACATTTCATTATCCA
TTCATTACGTGTTAATTTAAACAAACATTTCTGAGCCTCTGCTCTGTGCCAAACGCAGTTCTAGCTGCTGGAATTAC
AGCACTGAAAAAAAATTTGTCTCACTGAGGTAAGACAAAACATTATTATGCCCATTTTACAGCTGAGAAATTAAG
ACATATGAGGATTAAGCAGTATAGTTAAATCACACAATTTGGTACATGAAGGAATCAAAGAGGAAATCAGCTCTCAG
ATTTTAAATCCAGGGACTCGTTTCTGCTATACCATACTACCTACCTAGTTGAGCTGGATTTTATCATGGTTTCCCTA
TTTTTATCACCATGTGGTTGGATAAGTAAATAAATATATGTGACCTTTCAAATAAATTTGGGTCAATTTTCTTGGGA
AGCTCATCTGGTGTGAACTTTAAATACTGCAATTAATAATGATTATAATACCCTGGAACCTCTGTAGCAACCTCTTT
TGAAGAACTCCAAGGAGCCTCTAAATGTATCAAACCTAAGTTCTTCAAGTGAATTAGTTATCATCTGAGAGTAATATA
GACTTTTTAAAAATGCATTAATTGTATTAACCTTTTCAAGGCCATAGACTTAAGTGTCTTTCTTCCAAATAAAAAATA
GTAATCTCTGTCCATTTTCTTTAGAGAATAATGAAGTAATTTTCAATTGAATATGTAGTCAACATAATTACTTCAATT
CAATCGTGAAGGATTTTAAAAATATTTATGTCTACTAACTTAAAGACATGCATAGATTTCAAGAACTTAAAAATGC
ATATTGCCTCTTTGCCCTATGCCTCATAAAAACAAATATGATAACGTTGTGTGTACAGAAAAACGCACCTGATTGT
AATGAAGGGTGTCTTCAAAGGCCATGAACCTGGAAAGCAACTTATTTACAGAGACCCCCAGCAATAGCAGCTAAAAGA
TTGACTGACTCCCTTTATTTTCAAGTTATCCTTCAGACACTTTTGACCTCTTCTGTGCCTTTCTAGTCATGTGCAAT
CTTGTGGATATCTCTTCTCTCTGTTATTTTCTATTTCTCTGTTTCTATTTGTTTCTAAAAATAATCATGTTT
GAATATAGGATTAGCTTCTTCTTCCATCTTCCCACTTCCCACTTACCAATCTCTACTATACCGCTATGTTATTAATCTTCTGAG
AAATATATCAGGTTTCAATTACATTAGTTACCAGCTCAAAACGTATCAGTGGCTTTCTAGTCTCACAGGCTCAAGTTA
ATCTGCATATTCTGACTTTTCATATTCTGGGTTTCATGCAAACTTTTCAACTTTCCCTCTTATACCTACTTAGGAGGAC
CCTCAGGTTCCATCATGTCTATGTTTCAAGCCAGAAGTTCTCCTGCCTCTTCTCTATGTAGACTCCACATAGACTA
TGATATCCTGCTTCTCTTTTAACTCCTCCATCTTCAGCTCACAGCCACACTCCTCTGTGAACAGTTAAATGATTCTCC

CACCTCTTACCTCCTATAGCACTTATTTTTTCATGCAGCATTTTTGAGACTTAATTTAAATCTACAGTTTTAAAAAATG
TTTTTCTACCACAGTCTCTTATTTCATACTAAAACTTTCAAGTCTATCCATTTTGCTTATACAACCACACCGTTAGGT
CTTTTAGGTCCAAGAATACAAGAGAATGGCAAAGCACGTTGTTTACATCCACACATACTGTGTAAATTCAGGTAATT
TTTTTTAATCCTATGATCCTCAATTACCTCACCTGTAAAAATAGGTACTACTCATACTGCAGAACTCTTGTTGGAATT
AAATAAATGAGTGTATTAAAAATGCTCAACAAGATTTGGCACAAAAATCGGTACTCAGTAAATGCTAATCATTATTCC
CTTTCTCTTCAAAGCTCCACAATTCTGTATTTCATATCACCTCTTTATATCATTGCAAAAAATGTATCCTATTCCAA
CTCTTTCCACCTAGCCTCAACATTTACAAACACTCCTGGTGGGAAGGGAAAGCTTTTGAGGAGAGCACATCTATACT
CATTTACATTTCTCAGGGATGCAAGCTGCCCTGCTTACTGAGGGCATATGTTTCATAGTCACACCGAGCCCAGTGTCCC
CTTATACTCTCAAATGGGCAGTAGCAAATCATCTTGATCGGTAGTAAATGACCTGTCTCTAAATTTTTCACATGCATCA
GATAATTTCTTTTTTAGTAAGTGTTATCTTACATATATGCCAAAAATATCACCATTATATGGAACACTAGCTGAAAGA
AAAATTATTTCAGTAGTCTTAATTTTCTAGCTAACATAAAATCTCTCCATTTTCATCATCCATTTAGATTAAAGACTT
TACTGTTAGCTGAATATTTCAGAGACTTTATTCTGATTTTTTAAAAATTTATGAGGTTTCATAATGTTAAGACTTCAAGGG
TGAGCTGTTTGTGTCATTTATAATGCGTGACTAGACAGTAACTAGAAAAATGGATTGTTGACTTTACAAGATTTCTCC
CCACCACGTCCCCCAAACCTGTGCTGCTGTGTTTGGCCTGAAATCTTTACTTCTAGTCAATCTTTGGACCTAAA
GCCTACCAGCTTTTAGCATCTTTAAGATTGACGTGTCTCTGGGAGACCAATAGATGCTAAACCAAATTTTCGTATGC
ACTTGGCAATATAGGATAATAACAACCATACTCCCTGCAATTGTTTCCTAACACAGATGTAACAAATTACCACAAGC
TGGGTGGCTTAATAGACATTTATTCTCTCAAAATCTGGAAGCTAGGTGTCCAAATCAAGGTCAATTATCCCTCTG
AAGGCTCTGGGAAGAATTCTTCTTGCCCTCTTCCAGCTTCTGGTAGCCCCAGGTGTTCTTGATTTCAAGCAGCAC
AAGTTCAACATCTGCTCCTGACCTCACATAACCTCTTCTTTGTGTGCTTTTCTGTGTCCACTCTTTCTTTATTAT
TATTATTATTATTATTATTATTATTATTATACTTTAAGTTTTAGGGTACATGTGCACAATGTGCAGGTTAGTTACAT
ATGTATGCATGTGCCATGCTGGTGTGCTGCACCCATTAGCTCATCATTTAGCATTAGGTATATCTCCTAATGCTATC
CCTCCCCCCTCCCCCACCCCAACAGTCCCCAGAGTGTGATGTTCCCATTCCTGTGTCCATGTGTTCTCATTGT
TCAATTTCCACCTGTGAGTGAGAGTATGCAGTGTGTTGGTTTTTGTCTTGCGATAGTTTACTGAGAATGATGATTT
CCAATTTTCATCCATGTCTCTACAAAGAACATGAACATCATCATTTTTTTATGGCTGCATAGTATTCATGGTGTATAT
GTGCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTTGGGTGTTTCCAAGTCTTTGCTATTGTGAATGATG
CCGCAAAAGGACACCAGTCTTTGGATTTAGAGCCCCACCTAAATTCATGGTGATGCTATTTGAAAATTTCTTAACATA
TTACATCTTCAAAGACCTTATTTCCAAATCTGGTGACATTCAAGGTTTCAGGGACATGTGACTATTCAGGGGAAACT
ATTCATCCCACCACATCCCCCTTGAAAAATCTGGAAAAATGTAGTAATAAAGGCTTCTGATAAAATAGTGTGGAAAGT
ATTCACGGTTATAAATTACTAAAAAGTCTCACTGTGAGCTCTTAATCAAAAGGCCCTATAAAACATTTATTTGCTTG
ATTAAACTACACATCCGATATTTGGTTTTGGATTTATTATTATTTTATAGACTTGGAATAACTATTTTATGTGAAA
TAGATTCCATAACTGAAGCAGCATACCTCTCAATTTCCCAACATTTATTTTATTATTTTTGTCTTCACACTACTTA
ATAACTGAGGAAAAATCATTTAGACCAAAGTTCACCTTGTTGACACCATCCAGACAGCTACAGGAAATAACAATGG
AAACTAAATCTCTAAGAAAAAGAGTCTTTCATGTGAAATATTGCAGAGTTGATTCTAGATATATAGCTGTTGGAAGA
ATGGATACTATTACATAGATATGGCAGAGTGGTATCCAGCACCTTTCAACAAAGATCTTTCAGAGTCAGTCTTATTA
TGTCTGGAGAATTTACCCAGGGCTTAGGTGCTTTTACTGACAATCTAACCACCTGCACCCACCCACCGTCTAAAGC
TAAAGTTTTATTGGAAGACTTAGGAAATCAGTCTTCGGAATGTTTCTGAGACTGGTACACCCACCACCTTCATTAAAGT
GCTTCACTTCACTTCATTAGACAAGAAGTAAAAATACTTGTTCAGGAAATTATTTATAGTACCATGTATATGGGTATCT
TATTTAATACTACTTAATGATGGTACTACAAGTTATATAAAATGGAGAAAATAAGTCATCAAGTTTGACAATAATGAT
ATTTGATATTATCATTATCTTTTTTATTCGTTCCACAGAAAGTACTCTGTTATTGGTTTAGAAAAATGATATTTGAT
ATAATAAAGAAGGAAAAGGTGGTAATATTCTTTATTTTTTGTATCTTTATACCCAGCTCTTTCACCAATCTCCCC
ATCTCTGTAGTTCTCTCTGGTGTCCCCAGGCAGTGAACATTTCCAGTGGTTAGGGAACATCTCATTGAGTAAGTT
ACATCAACATTTCTTACATTTTCAGGACAACAGGAACATGCCAAATCCTAGCCCATTTGTTCAACTCTCAAGCCTTA
TTATCCTAATAACACATCCATCCCAAGAAAGAATTCATCAAGATCAGAGAGGAATACGTATAATTTTTTATAGTACA
GTATTTAAATGAAACAGCTTTTGGCCCGCTGGTCTCAGTGGGCTCAAGGGGGAATTCAGGATGCTAGCTCATCT
CACACCAAGTTTAATAAAGGGTGTCTTATAAAAAAGCTAATTTCTTGCTGGTAAATTGCTTTTTTAAGTAATCCTTGCT
GTTGCAAGAGACCCATTTCATAGCGCTGACACTGGGAGCCATGTTGGAAAGGCTAGATATGCTCTGGGAGATAAGGTA
AGATCCAGGTGGAATCTTCTCTTTACAGAATGACAATGTATATAGCTAATATTGTCTTTGAGGCTAGTTTGCATGC
AGTTGCTGGTATGGCACTGCTCAGCAGCCTGCTGCAGATAAGAAATGAGTGATGATGCCCTAGATTTTAATGGAACCT
TTAGAGTGCATGCAGCAGTGGGGTGCAGTCTTCAGCAAAGAAAAACGAGCTGACTTGCAGGCATGAGAGATCATCAA
GAAAGATAAAGAAATAGGACATCCACTCTAGGTAGGCAAGGCTTTTTAGAGGATATTATGGAATGAGCAAGAACC
AATTTAATTTTTTATAATGCCACTCCATTTAACTTTAAAAATACAAGGTCAAGGTACTGTGTTTTTCATAATGATTAAA
GATTTGGAGCACTCTTCTGTTGAAACATACTGCATCTGTTTGGCAGAAAAAAAAGTGACAAAGAATAAACTGGG
ATCAGAGAACAACAAAAACATATTCTGTCACTTGCCTAACACAAGTTAAAAAGCAAAGGAAAAAGAGACAACCTCTGA
TGGACATGTTTCATCCTTATCCCAACAGAAAGGATTTATTTACCTAAGGTCCCTATTATTTCAAGTTACTTTGATCCCAG
GATGGTAACATAAAATGTACATTTTAAAAATAAAATGGAAGTATAAGATCAATAAAAAACCACATATCTGTGGATAAAA
CAGCAGATTCAATCTTGTGGCTGAAAGTTTGCTTTAACCCAACATTTGGTAAACTATTCACTCTGTAATTTATTAAA
AGACATACTGTTATTATAAACTATCTCAGTTTGCATCTTGTGGTTCTGTCAAAATTTTCATCCTGCTAATTTCTCAA
CTTGTAATATCTCTGATATACATGATTAATCTATTTTAGGAATAAAAAACAAAACTACCTTTATCTTACGCATTTCTA
GGAAGTGTTTTTTAGATGTAAAGTAGGGGTAATTGATGATAGTGGAAGGATTTTGAACCTGAAGCCAGAACATATG
TCTCTGCCAAAACTAGGTGTGTGACCTTAAATAAGTTACTTAGCTTCTGTAATCTTAGTTTGTGTAGCTTTTTTCT
ATAAAGTGGCACACCTATCCACATCAGATTTTGTGTGCAAAATTAATAAAAAATACTATATTAGAAAGAACTTTTA
GAAAGAAATTTATAAACTGAAATGTACTATACAAGTTTAAATCATTCTCATTATTTTCTTACCCTAAAAATTTTGACC
TTATTTTTCTTAGCAAATGGCTGAATCTGTAAAAATTTAACCCCCACGCAGCATCTGGATTCAAGAGAACTACGGTCA
TTTCTTTTATACAGAATACTAATTATACACATATAGCAAAACACAAGTTTTTTTCCAACCTACTCTGTGTTTTTAAAGAT

TCAGTGTGGGCAGAAAGGAATTTTATCAACTATGTTAGGGGAAAAAAGTCTGAAGAAATGAAAATAATGAGAAAAAGC
ACTGTTGATTTAAGTGCAGGAACATAAACTTCAAGGCAAAATGTGAGGCCAACTGAGTTCATATATATCCTCACAAA
ATGATTTAGTTAATTTAAAACTTTTCTAATAAGCAACACAGGTAATCCCAAATTCATCTTTTATAGCTCTAAGAG
TCCCCATAATTTATTTCAGCAATTATTTACCACCCACTTATTATAAGAAAAAGCCCTGGGATAAGTCTTGAGAAGAAAC
TAACAAAAACAAAACCTTGATTGTTTGTCTCTCAAAAAGCTGGGTCTAAAAATAGGCAAGGTAAGATTTTGTGTTGAGGA
GCCCCGATTTTTCAGCACTGTCCATTGTAACATTAATAAGTTTGCCAAAAATCCTCACTCTGTGGGTGTATTTGCCT
AGGGTGCTAAAATTGCTTAAAACTTTGTATTGCTTAACTAAAAATCACTGAATAGTAAACAGTAGCATTAGAGAT
GGCAGAGACATTAGGTGTCATGCAGTTCAACTGCTTCACCTAGCAGACAAAGACATTAAGTTCATTCTTAAATTT
AACTATCTGGTTGAGGATACACAGTAGCAGAGCTAAAATCAAGAACCTCTTGGGGTTAGAGTTTTTGTGTTATGCATTA
CTTTGTTTTGGAATTA AAAACAGTGCCTGTTTGCTAAGTTAAATTGAAAAATATGCTCTGAAGGAGAAAAACAGCTAT
AAAAATAGACTTAACTTCCAACTATGGATCACAATAAACTAAAAGAAATAATTTCTGTAGCAATAAACTCCAACACT
TTCCATAGGACCAGAAAGGCTTGAGAAAAGAGGAGAACAAAAAATGCTTTGGGGCTTACCATATATATGGAGAAAGC
TAAATGAATAAACAGTTGAAAGACAGCGAGTTATACTAGTAACAATATTACTGATATCGGAGCTCTCACTTATAAA
TTGTATATTATGATCATAGTACTAGGTACTTTATATCTGCTTTCTCATTCTCTCCTCACATTAATTCACATGTAGG
ACAGATTACCTCTTCTGTTTCTATCCAGAGGCCTAGAGCTCAGGCCCTCATCGAAGACAGACAGAGCTATCATCCTT
ATTCTAAAAAAAACCTAAGACCCCAGACATAGCTGTGCTACTTATAGACTAGAATGTGAGAGAAAAAGACAAGCTTT
CATCATGGGCTTAACAACTGAAACACTTCTTCAATTTTGAGATTGAGAACTTAGCTAATGCTAGGTGTAAAGATG
ATATGCTACCTTCATAACCTTGGTGAGGAGAAATTAGCATTTCTCTCAGTCTTAGAAGGAGGATGACCATGAAGGTC
TTCATTCTCTTGAGAAGATAATCAAAATGCTTCACTGCCCTGTTAACGGTTTACTCAATATTCACCAAGAAAAGTAGA
TGGGATTATTTTTGCAGACACTTATACGGGTAATTTATTCTGATAAGCAGAGACATACCTTTAGTGCATAAATTGTT
CCCTTTGTGCTCTTTGTAATAAACATCACCATAGAGAACAAACACGAAGTAATGACATTGAATTAAGACACCATA
GAGGCAACAGCGACTGGAATTTGTGAAAGTAAAGGATAGTGCAAAACAGTTGTGCGTTGCATTCTGCTCTGAAGATT
AACAAAGCTGGGTGAGGCTTTGACCATCATGATGAGCAGGAGATTTTTCTAATGGAAATCCCAATCAAGTTCCTGCT
GCACCCAGAAAGAACCGGCTTACAGAAATCTTACATTTCTTTGCACATACCAAATTGCTTGCGATATTTCTATCACA
GGTTTACTTTCCAGGAAATGTGATCAAGAAATCATGATCCTAATTCCTAGTTAACCTCAAAGTTTCTCAGAACAGT
CAGTGATCAGTGTCAACTTTTGTGCAATGTGGAATCAGAATTGGTCCACAGCTTTTCCGGCCACTGTTTTTAGATT
CATATAATATTAGTGAAATCATGTGAGACTGGTATAGCCATGAATTTATACTTCATGAATAGGCACCTCAATAAATAG
TGGATTAAATCGACCGATTTGATTTTTACCTCCAATAATTTCAAAAAATATCATTGAAGACAAGGTTGTTGAAGCTGT
CACTTTTCTTGCTGAACCTTTGTTGTGCCAGGAGGAACAGATGGTAAAAATCAAAAGTGATTAGAGAATCAGTGGGGT
GGGGGTGAGATTGGAGGGGAGAGGTCTTCCAGTGAGACCCGCTAGCGTCTTCCCTGAGCAGTATGTTAACCCAAGA
CAATTTTAGAAATCTGTGCCCTAAGTTGCTTGACATCCAAAGCACACTTGATGCATCCTACATTTCTAAATATTTT
TATTGTTGTTTCTCGGTAGTAATCATCTGGTTAGTCACTCTAAAAGTCAAGGATGAAATTTTAAATGCAATAAA
AGTGCTACTTTCTCTCTTTCCAATTCCTTTTTGTTTTATTGAGGTATAATTTACATGCACAAAAAATCGCCTTTT
TAAAGTGATAGTTTGTGAGTTTTGACAAACATATGCAGTCTTACAACCACGTCCGTGATCAGAATAGGAAATATT
TTTATCACTTCAAAAAGTTTCTTGTACTCCCGTTGCAGTCAGTCTCTGCCCCACCCAGCCCTGGAAACCACTG
ATAGGTAAAAGCACTTTTAATCTGAAAGGTATTTAATGTATGGCAGTGTGAGTGGTAATAATAACAAGATTTATTCA
TTGGTTCACTGTATTTTTGAGCACTTATATGTGCCCGTTGTATGCAACCCATTATGCTCAACCCCTGCCCTCCTCAC
CAGGGATAAACTAGTGGCAGAGATAGACAAAGAAGCCGTCTCTATCACCCCTATCTTATAGAACATTTCTCAATG
TTAGAAATGCAGTATAATGTGGCCATTGAGAACTGAAATGTGCTTAGTGGGAATGAAGAACTGAAGTTTAACTTT
ATTTAATTTCAATTAATTTAAATTTATATAGCCACATGTGGCTAATGACTATCCCACTGGAAAGTACAGCTTCTATA
CAATATGATAATATGATACATTATAACGCAGGAGTTTAAACCAAGTGCTAAAGCTTTACTATCACCAGGCTCACTGGT
GTTATGTGAAAAGAAAGTACTTACAATAGAAAATAAATCCTTTAAATAGTCACAGACCTGAGAAAGTTTCTCTCAA
GGGAACACACACTTGGCTCATTTCAAAGGAGGTTAAAAACAGTCAATTAAGGTAATTTTCAAGCTTTCTTTGGATT
TCTCATGCTTATTGTATACATAAAATAGGCAATTTTCGATGGGACCTAATAAATCACTGTTTTTTATTTGAACATTTT
AACAAAATTATCAAAACAGCATTGCATTTATGTTCAACCTATTTGTTCTGAGAAAGACAACGATTAAGTAGAAGTCAT
CAAAGTTACCAGAACAAATTTTTGTTCTTATGTTTTAGAAGGCATTGAAGGTGTTTTAAATGTACACTTATAGAGTCA
GAGTACTATGCAACTGTGGCCCTTATAGTTTATCCGTATGCATCTAAAGCCATTGTTACATCTGTTTCTAATTGTG
CATGGATTGTCCAAGATACACAATTGGAAATTCATTTTATTTATCAATTTGAAGAGGTTTACCCCATGTGGTCACT
ATGATCACTATGGAGTCACATTAATTTGAGAAGTCTCCAGAAGTTGCAGTATTTATTTAAATTTCACTTTCTTCA
GAGGAACAAATTTCTCATTTCTGGATTCTGAATCCTCATTAGCCATAAGGTTGTTGTAAGAATTTGCAGCTAATAGG
AACACATCCTGGGGAGAGACCAGTTGAAAAGTAACCTTGGTTCTGAGTGAAATTATACAGAGACAGTTTCTACTTCAG
GTGGTGTGCTAATGAAGCTATCATGGTAATTTTAGCCCATATGATCCCTAAACGACTTCAGAACCACTTTTTCATCC
ACTAAGAACCCACTTCAACCACTGCCACGTTCACTACCACAGTATAATATGGAACACCCTCTGGAATTCAGTAAGTA
ACTTCTTAACTCATTGGCTATAGAGCTTTGCTTTGTAAATCTTTCTTTTGCAGTAAAAGAGATTGTTTCAAAGT
AATCCAATTAGTCCCTAGGCATGTCTAGAAAGGTAGAGTCAACAACAGTAAGGTAATAGTCTTTATAAGATATGTAA
GAAATTATCAGTCATTTACTTTAAAAATAATTTGTACACTTTTCTTTTATATGGTTCTTCTATGTTGAAGCCAGTGG
TCATCCAGTGATTAAGATTAGCCAAACTCAAAAGGCTAAAACTAAATTCAAATGGTATTATTTTGTCTTAATTTTAT
GCAATGCTATGTATTTAAATTTTCAATGAAAGTTTCGTATGGCATTGCTATCAATTTCACTCAGGATAAATTTCCCGTG
GTATTATAAATTTCAAGTAATTTCAATGTTCAATTAATAAACAGTTACTTTAAATGGGAAAGTATGAGTCAAGAGTTA
GTACAAAGGAGAACTTTAAAGATGAACATCAAAAGAACTTACTATTGATTGTTGGTGCTTTTGCTTGCACTTCTC
CAAATTGACTTGACGTTTTTAAATTTGTACTGATAATCATCAGAGTCAAATCTGCTTTTAGGCAAAAAGTATCCGCTA
GTTATTTCCCTACTATGAAAGTGATGAGATGAATTGATCATGTCTCCAGTGATGGATGGATGTCTTTGAGGAAGAC
CTACTGACCTTATGTTTATCTTCTGTCAGCATGGTGTGACTATGTGGAGAGACAGTGTCTATTTGCTAAATACTTTGT

TTTTCAAATAAAAAAGATTTTCACAGATTATGCATTGTAGAATTTATAAGTATTCTTTTATGTCTTTGAATGTGCCAAT
ACAATTTTTTATGAAGTTGGAACATTTTTATCTATTTTAAATGAAATTTGTAAGCCTTCTGTGAATTTCTTTTATTAATTT
TATTCTGAAGAAAATCTGACCAGGTTAGGGAAATCAGGTCAGGTTACGACGTGATCCCAGTGGAAAAGCTGAACGTG
GGACTGTGATTTAAATAGGGAAAGAGGTACTGAAGTGTTGTTTTATTTTTGTTTACAAATCAGCCTTTCTAACTAT
TATGTACTCCCATCCTTCTATCTTTTTCTCCACCAGAACGTATTAACAGGCATGCATATAATTAATGCTTTTCTTGA
GATAATATTAAATTAACCTTCATCTGTCAGGCCGTCTGGGCTAAAAGTACACAGTCAGATCTGGGTAACATTTGAGT
TGATGTAAATATGCCCACACATACTGACAATGCTTACCATTATTTGTGTGAATGAAAAGCAGTGTAATATTGTTTG
TTCTACTAGGGAAGCTCCACATTTTAAATCAAACCTTTGACCGTATTTCTAAAAATGCCAGAGCATCTGGAATTTGTTAA
GGAAGTGTAGTTTTTGTGTTTTTAACTGTTAGGATAGTTGAAATCCAAAGGGTAAAGAAAACCTCAGCTGATTTATAC
GTTTTCTTCTCTTTATTTTAAATGTGATAAAATGTAGTTTTTGTGCATGGGCTGACAAACAGTGGTAGACTACACTAAC
TCTGCGTTTGCTGGGTTTAACTTACCCTCTCAAGGCATGGAATGGGAGCTCACTTCAGACCCAGCCATGCTTCACT
GTCCACTGCCTTCTCATGGATATAGTGTGAACATTAATTAGATGAATTCATAAAAGTGCTTTAAGCTCTTTGGAGAA
AGATACTCGCTGCATAATTATTCTTAACTCCCATACGCTCTTATGATATAAACCATTTCTGCCAGGAAATCCTTTTTTA
GGGATTATCACTTAAATGAAATTTTCATTATTTAAAGCAGGAAGAATATACATCTACTGACAGACGAAAATGTGCT
TAAGGCGACTGCTTTTAAATAGGCAGAAATCCTGAACATATGGAGCCATCCATGCCTGAAAATACTGAGTAATAATGA
AACTGGTAGCAAATTTGGAATATTAATCATCACATTAAGTTGCAAAGAAAAAATAACAAGCCACATGCCCTTTA
AAAATACGTGCACAAATCTTTATTCTAGAAATATATAACTTTAGGCCATAAAAAAGTACAAAAAGTAAATTATTTTAT
GGCTCTGAAAGTATCCTTAATTTACTCAGGTGACAACAATTAGTGTTTTAAAGAGTTAGTTTTCAATCTTAGCTACAA
GTTGGAATTACTCTGGAAGCTCTAAAAAACAACAAAAAATAGAGATGCCTAGTTCCCACCTGCAGAAAT
TCTGATTTGATTTTTCTGGTGCGAGACCTGAGAATAGGAATTTTTTAAAGCTTCCCTAGTGATTCTAGTGTGCCAC
CTAGGTTGCCTTAAGGTAAACCTCATATTATGCAGAACCTAGCAATCACCTATCCTGATTTTATAGACGAAGATCAT
AAGACCCAAGAGGGCAAATTTGATTTATTCAAGATTGAATATACAAATGATAGAAGATTCACATAAGATGCAGTATAC
AGAGTGGCTTGTGGATTCTTGCCAATGCAGGCAGCAGAATTTCTTTAGGGTTCACCCAGTTCAGGCACCTCTTTGC
AGCAGCACTTGACTAAGGTTCTTCTGATTGGATCATTATATGGGCAAAAAGAAAAGCTTAATTGAAAAGAGCTGAA
CCCACATTGTGGAATGGAAGATATACAGTTTACACGTTATAAATGATTAATATTCTAGAAAGTACCTGCCCTTTCC
TCTTCCCTTCCCATAGATGACATCATTGCATTGGTGATTAGTTAGGTTGGTGGTTTCTTGTGTTGATCTTGGTTCTGA
CACAGTTCATCACTTATTATCCTGGCTTATTATCTACTTCTACATTCATTGTTCACTCACTCACTAATTAATTCAAC
ATGGTTTTTATTGTTTTTGACCGGTTATATGCCTGCAACGCTACGTAAGGCTGAGGATATTACAATGAACAGGAAAC
AACCTGAAGTTTAAAGGTATCAAGCCTTTGAGTTACTGTCTTTTATCATAGCTGATATAAAATTGAAGCCCCACTTT
TTTTGTTTTCAATTACTGAAAATTCAGTGCTAAAAAATGTGGATTTTTATTCAACTAGATAAAGTACTACAATTAG
GTTTCCACTGACCTTGGCTGTTTTTGTCTCCAGTTGCCATTACATAAATCTGTGCCACTCACAACCTTAGGAAGGGTG
TAACATTCTCTGTAATAGTTTGCTTTTGAATAGTGTGTTGGATTCACTACTGCTCCTCGCAGTTTGAATAATGACC
ACTGAATAATCAGTGTTTGGAGACTAAATTAGTGCTGCAAAATTCCTCAAATTACCTACTGTTCTTTTCCCTGTCTG
ATGTATCCTCATATTCATATGATTACCCTGAGAAGAAAGATATTGTTGAGAACCCTTTACCTACTCGAAGTTTTG
GTATTTCAAAGATTCACTATTATGTCATGTTGATTACATTAGCACTAATACTATTGGCAGAATTCTAATTCACGTTA
TTTTCTTTTTTTTCCAATTTCTCTCCATGCCTATGTGTTGTCCCTTCGCAGCTATAAAGCCATGGCCGATTTCATGGGT
GCTTTTGTAAAGGCGTTTACAGCAGTCACGTTTGTAGATTTTTGAATGGGACTTAGAGCCCTTTTTTGTCTTTATGTA
TTTCTCTATTTCTCAGCAAAGGAAATGCAGACATGCAAGAAATAGTGATCAAATGTCTGTGTAATTTGTGGGTGT
CATTAAATGGTATAGGGAGAAATAGAAAATAGTTGCAAAGATGCATTTAACAAATAAACGAGGCTTTGAGATTACCA
TGAATGTGGCCCTTCTATGAAAAGTAGTTAACATCCAACCTGCAAAGTTGTAAGTGGATCAGTTTGACTTTAACCTTT
AGCTAATATGAAAATATGGAATTTGTGTGGTGGTGCTCACAAAAAGAAAACCTCATTTTTCTTAATTATCATCAATTA
ACATGTACTGACTACCCATGAGGGAAGTTAATTTGCTCTTGAGTGGAAACCAGTTATTTGCCATTTATTTCTCCCT
TGCTTATTTCCCTCTCCCTCCCTCCCTTCCATTCAACAAAGAAAATAGATAAAGCAATTTCTGATTAGCCAG
TGAAAGCCTCTAACATAAAATTTCCAAAGATGTGCCATAAATATCCACAAAATGTAAAACCTTTTCAATTTTGGTTT
GCATTTTCTTTTTTCTTATTATAAAGGTAATAAGTGCTCATTATAGAATTTGAAAAATATAGGAAGTTGCACGGAAG
ACGAATAAAATCAGCCATAATCCTACAAACCTATTGACACTTGTACATATGTTTGTATCTCTAATGCATTCATTAT
GATAATGCATCTTTTCAACCAATAGAGTAATCACTGGTGACTTTCAAATTTGCCTACTCATTTTTCACTCTGTGGAC
TTACTTTACTACCTCTTGCCCTTTTTCAGTAAATGAATAAATATTTAAGTAAGTAAATACAAATGTAATAACTTATG
CGCTCAAGCACACAGATACACACAGAGAGAATTTGGAACCTCGGAAATGCCATCCTCTCCCTAGGGCCGCAAGTGAG
TTGATAAGCACGTAAGGAAGGATAATCAGGGGAGCCTTCTCGTATTGCCAGATGGCTCAAATTCGTCATCTCTAC
CAAACAACCTATTTGGAGCTTTGAAGAAATATCCATGACCCCTTTGAATTTCTCAGTTTCTTTTCGCGTTCACTTTGAG
AACCAAGTGACAAGTGAATTTCTGACTTGGTCTTTTAAACCTGTTAGCGCAGTTCCATTGAGATTTTGTGGGCACA
AGATTGCAATGAAGAGATCAACAGGGAGAAATTCATTTCCCTATATATGTGCGATTAAATCCGGAGTGCTAAGGGCAG
ATATAAAGCAGGTGCCTACTCTGTATAACTTTGGAATAAAACCATTTCCAAAGGCTGATGATCCTCAAGTCTTGTTC
TGCAATGACTGATGTATAACTTCAGGCCAATTTTTCTCCAGTTAGTCTGTGTCACTGGGAGTCCCATTTCTCGGGG
AGCAGCCCCATGCTTTGTGAGGTGCGGAGCCACAGAAGGTTAATGCGAAAAGAAAGGCCCTTTGCCAGACTGTTTTT
CAGATGATACGTAGGGTTATTAGTTTGTAGCTCCTTAAGAAGATTTTTCTCACCTGTCTACCAACTTATGTTTATTT
CATTGGTGTAGAGGGTTTCACTGGCGGAAGTAAATATTTAGCGGGGAAGGGACAGCGTTTATGGGAATTTTGCCT
AACTTAATTTTGTATCTTTAGCTCATTCTGATGATCTGACTTTTGTGTTTTGTCAACTGAATTTTGTGTCATACAA
AGGCACAAAATGTTTGTCTCAGACCTGTCATCTTATTTTAGCATGGTTAGACAAAAACCTGAGATGCTTTAATGT
CTAACTTATCCAGTTTAAAGTGCTGCAAAATCTCCAGGCAATGTCAATGGGCAACTAAGGGATAAAATCAGAGATTT
AAAGGTGCCAGGTTTCCACGCTTCTAACAGTTGGCGTTTTGGGTGTATACAATCCCTCAGCTTTCTTCTTTAGTTT
ATGGAGTCTTGTGGAGGGAATAGCAGGTTTTTGTAGCTAAAATATCATGCTGTGCGAGTTGGGTCTCTAGTGCATCCTG
AAGAGCTTGCATTATTTACAGAGGCTGGGCTATCATTTTTAAATCCTGATGCTTCAATGCCCGTTATCATTCTTGACA

AAC TCTTCCAGCCCGTGGTCTGTTTTCTCTGTTTGCTTCCATTTACTTTCTGAGCAACCAGCTGAGCAAAGATTT
ACATAACTTTTTGTTTAAACAAACCCCTGTACAGTTCAC TCTTTTCAGCCAGTATGTAAACACTTTTTGAGACACAGTTAC
ATTTTTCTATTTTAGTCCCAGATTCTGTTTATTTGCTACATTTTTTGTGCCCACATTTTTGTCTTTGTTAAGTCTCT
TACAGATTACATGAAAAACCAGAAACCGTGGCTGCTCAAAAAGTCATTAATAATGAGATTTTTAGCTACTGTTTCTG
CTTGTAATTTCTTCATTTACATAATACAGTCTCAAAAAGGCCACAGAGAATTCAGCCTCGCTTATCTCTGTGTTGCA
GATGATGGCTTCTAGCCTTACCCAATCCCAGTGCAGCTTGCTTGCCATCCAGGAGTCGAATTTGTTTCCATCTGACA
TTAGCGTATTA AAAAGATTGGAGATCAACAAGCAACAATGTTCTTGTAGAAAAGGTAATCAAGGTTTAGAGCCTGTGT
GTCATGAGACTCCTAGCATTGAAACCGCTAAGGGGTTGACCACCATTTGCCAAGCACCTGTTTAAAGATTCTTTCC
TATGATAAGGGACCTAAAGTGATTAGCATACTGATAAGATTTTCTTAGAATAACCTATTTATTTTCAGTATTATCTT
TCAAATCTTAATTACCATCTTTTTCTTTTACCCAGGGTCTTCTTTCTACCTCTACGACACATTTAATTACCTATATTC
CCCAACCTGTACCATATTAAATTTTGAATGGAAGTTTTATAGGGTAATTTATTGGAAGGATGGCCTTGAGTGTCAAT
ATGTTCAATGAATGCCCTATTTTGACAAAGAGATGACTAAATGTTATTGAAATCTTTTTAATCCACCACGCTTCTGC
TTAGATGTAAATGCAAATCTGTTCTTTACATTTGTGATTGAATTGAACTTGAAAAGTACCGCCATATTGATTCTTCT
TGCAAATAAAATATAATTACATTTCCCTAAACTTTCTACACTCTCCCAAGAGATTGGCTGGCTTTGTATTGTAGATT
TTTGGTGATCACAGAGGACAATGCATTATCATAAGACCAATAAGATTTATTTTTACCTTGGTAAAGAATTTTAATTT
ATTTCTAGTTTCATTTTCATTTATATCCATCTCTCTCACCTCTGCTCTACAAAAGTATATATGACTATATAAATT
GAAAAAATATCAAGTGCAAAATTACAGAAATAAATAATTAGGTTATTTTAGTGGAGGAAGGTTTGTGTGGGTGGA
GGAGGAGAGGAGTGAGCCAAGAAAAACGAGGGACCATACGTGATCATATTTTTGCAGCTATTTTAAATTGTTTGTGT
ATATACTTTAAATATTATAAAAAATAAAATTTTAAAGTGCAATGCATATTTGGAGCCAATGATGAGGGATAACTTCAGA
AACGTAGCATCATCATCTAGTGCTTTTCATAGTCTTTCAACATTTCCAGATAGTTTTAATGGCCTGCTCATGGAGGC
AATGCCCTAATTTTAAACATATCTCTTCACAACTCTGATTTCTTGCTTCCCTAACATTAAATGCTTCAAAGCTTCTTT
CACCCTAATTCCTTATCAAGAGGATAAGCCAGTTTATTTCTTTAAGAAAACTAGCTACACAAAACCGTAAGTCATT
CCAACATAAATCCTTCACTATCCTCTCTCTATAGATTGGTTTTGATTCTCTCTGCTGAAATTCACCTTCTTTCTT
CAGCTATCCACACGCTCTTACCCTCTAACTTCCCTCAGGAGTGTCTATTAGCTCCCATACAGTGACCACAGTAATAT
AGTAATCCCCTGCTTCTCCTCTCCTCTCCTTACACTGCGTTTTAAGTCTCTCATATTTCTTTATCACCTTTGTA
TCATGCATCGGTTTTCTAGTTGTTTATTTTATGTTGCTTCAATAAATCCATGAGAGCTCAGTCCGCTATCTTTAG
AACATGGAACAGTGCTTGGAACATAATGGGCATTCTTAAATAGCTGTAGAATAAACTTTCAAATCAACAATAATG
TATTTGCCAAATCCATTGGCTTCTCTGCCATTTTATCTTGTTCATACCCTGCGATATTTCCCTTCTTTTTTTTT
TTTTTTAAAGTCTGTAAACCTTTAGCTTCTGTAAATATTCCTAGTTTTTTTATTCCTCTCATGTGTCAAATCATCAGT
TGAGGCTTATTGTTTTCTCTTTCTCACTCTGACCTCACCTTTGTTTACATCTCATCTTCTGGCTTTGGCTATCCTGT
TTTTTATCTCTGTTCCAACCTGTATTTCTAGCCCTACTACCTGGACATGACATGTGGATATCTCCGTATGACCGCAG
TTTCCATATGACTTTGCAAATTCATCCCTGCTCTCCCTCCAAAGTCATCCCACAATTGACTTCCCTGTTTCCCTCCA
ACCTATTAAGGTTCAAACCCACTTTTGCTCCTCCTTTGCAGGCTACACTTTTCTTCTCAGTACCTCTTTTTTTTTCC
AAGTTCTTAGATAAAAGTCATAGTACCTTACGTTGTAATTGCCACTGGTCTGGTCTTTCTGCCTGCTTTCCCTTTCCA
TTTGTAATCACATTATCCATTCCAATCCATTATATAACTGTGATCAGCCATAAAAAATAACATTTATCATATCGTTT
GTCTCCTTAAACCTGTAGTAGATCCCTCTATTTACAAGATCTGGTATAAAATCACCTTCCCTGATATTCAATGCC
TGTTTTAATATAATCTCAATATTATGCGTCATAAATCCCCCTGTGTTCTTGCACTTTTTATTTCTTATACATCTCAT
CAACCATGTCTTATCAACTCTCAAAACCTGTATTGGTTTTTCAGGAAAACTCATAAATTATTTCTTTGTAGACCTTTT
GTTTGTCTCTTTGAAGATCTCTCTCTGAACATAATTTTGTCTGTATAATCAATTTGGAATTCATCAGGTATT
GAAATATGACATGTCTTCTATTGTCTTGAACATTAATTA AAACTTTATTTGACTTTTTATATGCTTACATCTTGTTT
CCTCAGGAGGTGTTAACTTACTAGAAAGTAATAGTTAATCTTATATTTATTTAATTAGATTAGTAGCATACTT
TACACTGTGGTAGGATGTGTAACCTGCTTACACCTTGCTTACGTGAGTTATTAATGTTTTCGTATATTTAATCTAGG
ATGTAAGTACGAAATGTTAAACCTGACCCGATGAAATGAGTAATGAACTATTTGTTTTAAATGTTGTGCTTAACTT
ATTGTACATTTTCTCATAATCACAGCTCAAGTTAACTTTTGTGGTTGTACGTATTATTTCTTGTGAAATGCCAACAA
ACTTAGAGCAAGGAAAAATAACAGGTATAATCATACTATAAAGGCAACCTTAACACTAGCATAGTCTCTTAGCTCATA
TGGAATACTACAATAATGTACAGTGACAAAGAGAATATTGTACTTTCTTAGCACACACTTTTCTACTACTCTACTGTT
GTGGATAAAAAACAGACATACTTTAGGAGAACTATGTTATTTCCAAATAATGCCTTAAAGGTTACTCCAGGAAAAGG
CATTTACATAAACTATCTAGGAAAAGAACCTTTTAAATAATATAAAGAGCTACCCAAAAGGACTGAAGTGTTTAGT
TGAAAAAAGTAAAAATGTGGAAGACTTTGAAAAATAGTTTCTTGCAGTATATTTTCATCGCTTCCACTTACGTTAT
GAAGACATTAAGCGCTAGTTTATCAAAAACCTATTTTGTACATGTCTTCTAATGACAGAACAAATGTCAACATGATTT
TCATCATTGAGAATGCGTAAAGAAACCTTTGTACAGTTTTTTCTATGAATGTTCCCTTAAGATTAAAGCAAATTTT
CAACACGAATTAGGCACTCCGAAAGGAGGAGGGGAGGGAGGGGAGCAAGTGCTGCAAAACTTCTGTTGGGTACTAT
GTTCACTATCTGGGTGATGGAATCAACAGAAAGCCCAAACTCAGCATCACGCAGTATACCCTTGTAACAAACCAACA
CATGTACCCCTGAGTCTACATTA AAAATAGAGATTAAAAAAGGAAATCAGTATATAATCTAATAAATACCTCTCAA
GCTTTCTCATTTTTTAAATAAAAATTTTAGATTATTTTATAGGAATAAAATAGGCTCTTCATTGTATATAAGTTTCA
TTCTGAGTTGCAAAAATCCTCTCTTTATGTTTTTTTCCCGTATTAGCATGTTTTTCTCTGTTTTTCCCACTCAA
CTTGGCTGCCACAATCAGAAAGCACAAAGACAATTTTTCTTGCGCTTGTAATCAAAACCTTAGCATCAGACAAAA
TAACTGCTCCAGGTCTGTCAAATAGATTCATTTGAGCTTTCTTCATGCATTGAATACGGCAGAAATTTCTGACCTGAA
GAAATCTAGCCTTTTCCAAATTTGCTTTAAGAACATTTTGCAATAAAATTAATAATAAAGGAAAAAACACATCA
GGCTAGAATTTGGAACCGATTGTTATTA AAAATCTCAAGTCTATCAATTTAACTTCAACAAATTACTTAAATTTCTGT
GATGGTTAATTTCAATGTGTCAACTTGGCTGGGCGCAGGGTACCGAGACATTTGGTCAACATTTATTTCTGGGTGTGT
TTATGAGGCTGTTTCTGGAGAGATTACATTTGAATCAGTAGAGGGAGCAAAGCCGATTGTTCTCCCTTGTGTGGGT
GGGTCTGATCCAATCAATTGAGGACCTAAGTCCAATCGATTGAAGACCTAATCAAAAAGCCTGATTAAAAGGAACTC
CTGCCTGATAGCTAAAGCTGGAACACCCATCTTTTCTGCTTTGAGCTTGAATTGAAACCTTGGGTCTTCTTGAGT

135

AGTGTAACAACCTTGCCGATTTTTTTGTACTTTCTACTTTTCATGTCTCGCATATATCTCTTTAATATCTAAGTATTTG
AGTCAGAAAAGAGCCAGTACCGAATAATGGGAATCTCACTGAAATGTGATAACAATCTGGGGCCTGGTCTGGGACC
TTTATCTGCAGGACAACCTTGACAAAATATTTAGACCCCCAATTCCTCGTCTTTACCCTAGGAATAATAACACATTTT
TCTGACCTCATACTTCACGTGGATCTCAAATGGAACAATCATCTGATAGCACTTTATGAAGTATATGAAAGCAATAA
ATTATCACAATAAGATAATTGCAATTATTTCTTTGGCATAGTATTAGTGATGTCTTTATCTGTCTGACAAAATCAACA
TTTCTGTATGGTAACTGCCTTTCTTTGTTTTAACAGAAGATCATGCCAGAAAAGATGAGTAGGTAGATACTTAACTT
GTTGTTCCCTGAATCTGGAATGTATTGCAGATGTCCCAGACTGATCTTTGTTCTTTTTTTTCCCTTACAAATTTCTTTT
CACATTGACAAATGTGATATTTCTTTAAATGTGCAATACATAGCTAACCTTATTTGTTTGTGTTTACTAATTAATAA
TCTAAACTGCTTAAAGGAGAAAAATTCAGTTTTAAGTTTTATTGATTTATACCCTTCTTCAATCCACATAGGATTAGG
GTAGTATGTAACAAAATTTCAAACATAAAATGAAATATTGAGTTTTGTATTAAAGGCCAAGGATGAGGAAAAAAAAG
TAAGTATATATGGAAGAAAGATGGTATTGAATGGGAGTTTTGATGGAGCATGTTGACATCATGATAATACCTATTAT
CTTTATATTCTGAATGTCAGAACAAAATTAGAGCAATTTTCCCTTATTTCCCTACAATACGCTGTCTTAATAATTC
TAAGCTTTCTGATTTTCAGTAGTAATCTGTATTTTGCAAAAGGCAGCATGTTTATAAGATATCAAGTAACTAAGTT
TATGGAACCTTGTAACAGCATTTTTTAACAACATTTCTCCCTAGATAGTTTCATGGTAGACATGAATTTATTCAAACTA
GTATGTAGAAAAATACCATTAAACAAAAGCTCTGAAATTATATTAGAGGAGCTGAATAATGTTACTTGAGAAAGAATA
AAATGTTATTTATGATTTTTTGGTATCTTTTACCCACTATATATGGCCATATCTCTGAAAACTTTAGTAATATGTAC
TAATGCAAAATATGGTAGTAAATTATGTCTACAGGTGCTGATACCATAGTAGATAAAGTATGATAACTTTATTTTAAA
ATATCATATTTAAATAATTAATATACAGTACTGGGAAAGACTATTTTATCTATTCTCTCACTCTTGAATAAAAAAAT
CCAGAAAAAATACCTTGTTTTGGTAAAGATTATATCAATTTATTTCCCAAATGGGTAGAGGGTTATTTTTTTCTGAT
CATAAACGTATGTCTCTTCATTATAAAAAATCCACTAAAAAGTGATAGAAGAAAAACCAAAGAATAAATGTAAACAATG
ATGCCATTTTCCAAAAATCACCTTCGACATTTTTCTGGATATTGATACAGTCTAAATCTCTTTTCGGAAGACTCCCT
CCTGTGTAGGTTCCCAACTACTCTGCAATCTTATTTCCCTCTGTTCTGTCTGTAGAAAGGAGACCCATTGTAC
CATGTCAAATAACACAAAATGGTGCACGTATAAGATCATTGTCTCTGTCCATTATTTGCCAGAGGACCTCAAACCTT
TTCAGGTGGTGGGCAACTGGATGTCTGTCTCTGTCTGTACAAACAGAACACAATTCATTATTTATATGGTTATTTCA
TTTTAAGAAATTTAACTTTTCAATAGCTGGAAGAAAAAAGAGTGGTTTTTAAGTTGTTAGAAATGTGAAATTCAA
TTTTCATACTGCAAAAGAGATTCAACTGCAAAACAGGCACACATGTCTGGTGTAAAGAACGAGTTGTCTACAAACC
CAAATTAGCTGCCTCCACGTTGTCTTTGTTAAACAAGTGTGTTGTTGCTCCTTGTTCATCATTTCAGAAATGCTCTTT
AGCAGGAATTGATGGAACACAGTCGCAGTGACCTCTTCCTGTCTTTAAAAATCGAGATGACATTTGCCCATCTGCAG
TGTTAACATAGTTTCTCAAAGACCACTGACAGTGGGGTAGGACTGTATTGCGCAAGTTCTCTCATTTCCTTAGAATA
TAATTGGTCCAGGGCCAGAGATTTAGCTCATTTAGAGCAGCAAGGTGCTCTTTTAAATTCCTTCACCTATTTTGG
GCTTCATTTCCCTTATACGGTTATGCCTTTTCCAGTCTGATGAACATTCTCCTTGACAGAGCAGACAAGCAAAAGGA
GCTGCACACTGCTGCTTTCTGTGTCGTCTCTATCCCTAACCTTCTCCCTTCTGCCCAATCAGTGAACCTTCGTCTT
TCTGTTCTTCTTCCCTCAAATGGAAGTAAAAAGGCCCTGAATGTTGTCTTTACCATTATCACGAGCCTCAATTCAT
TCCAAGCTCAGCTTTTCTCACTGTTTATACAGTTCTATATTGTCTTCTAATATTTGCCCTCAGTTCTCTGTCCCT
CGTTTCTTCCCATGTTTCATACTCTATTAGAATCTGAGCACCTTTGAGGTTGTCCATACAGTGGCACACATCTTTGTT
TTATACTCACTGGGATGATTTGCCATTATATTGTCAAAATTTTATTCTAAAGAGCTTTTACAGGCTTTCTTGAGCCA
TTTTCTCTTGAAATTCAAGATCGTTGAATCTCTACGCTTTTTCTTCTTAATCTAATAAACATACACCCCCACATAC
ACACGTGTGTTTCTGAAAGACAGATGCCACTTGACTCGTCTTATAGATTGTCTAAATTGATCATTGTGTGTGGGAT
AAAAGGGTGAATTGTATAATATCCCTGATGGTTACAGAAAGTCTGTTCTGTATAACCTGATTAGTCTTCTGAACCTCT
TTTAAATTCTGTCTGCAAATGACTGAGGTTTGGAATCAGCCTATTTTCAAGTTAGTTGTTTTCTTGCATAAGAAGGGT
CCATATGTACTGTGTGAAGTAAGAGAGAGAAAGTACTTAGATTGTCTGGATGCCCTGATTGTTAGCATGGCTAAGGT
ATTGTGTAAAGTAAGGAGAGCAGTTAAAAATGATATTGTTTTATTTCTTAAATTGAGGTAAAAATTTATATAAGATGA
AACAGACTTATTTGGGAGAGGAGGTTGTTCTTACATAACATTTCAACCTGTCAATTTAGTTGAGAAGTTTCA
AATCTGTCAAGATACTTTGTATAATATTAGATTCTGCCATCTAATAATTTTCCACGCTTTCTTACTGGGTGTGAC
AGTAACTTATACTGTGGCAGGTGTATAAGTTAGTAAAGATATTAATGCTCAATCTGTTAACTTTTGTGAAGTGGTC
CCACTGATAAAGTGACACCTCAATAAAAAATAAAATTTCCATTACCTCAGAAAGCTTTTTTCATGCTACCTTCCAGTCA
ATTCCCAGCCCCAATAGGCACCTATTCTTCTGATTTATATCACCATAGATTAGTTTTGTCTTTTTTAAAAATTTGTAT
AAATGAAATCATACAAAATGTACTATTTTGATCAGCATACTACTTTTGAGATTTCATCCATGTAAGTGTATCAGCTGT
TCATTCTTTTATTGATGATTAATATTCTATTGTATAGATATACCACAATTTATTTATCTATTCTCCTTTTGATGGAC
ATTAGGTGGTTTTTCAGTTTTTGGCTGTTATGAATAAGATGCTGTGGACATTTGTGTACAAGCCATTTGTGAGCATA
TGTTTTCATTTAGTTTGAGTAAGTCTGTAGAAGTGAATGGCTGGGTGAAATGTTTAAATTTATGAGATATTGTCAA
ACAGCACCTAAACAGTTTTTCTAAAGTGGTTGTGCCATTTTGCAATGCCACCAGTGATGATGGAGAGTTCCAGTTACT
CTACATCTTTGTCAATATTTGGTCTTTGTCTAGTCATTTTAAATTTTTGCTATCTTACAGAATATGTAGGTATATTGTTG
TGGTTTTAACTTATATTCTCTGATTACTAGCACTATTAAGCATCTTTTCATGGATTTATTGGACATTCATATAGAT
TATGTGTGTTGAAGATTATTACCTTTATGATTATTGGGTGAAAAAGTATCATTTTGAGGTCATTCATATAACTTGA
AGACTGGGAATGACAGACATTTTCTGTGTTTTGTTCTTTTTCTTTTTTACTTTATCTGAAGAGTCTACTAGAATGCAGT
GTTGCTGCCTGAGCAGCAGGGCATTAGCTTTGTAAAAGCTCTGTTTCTTGGCAACCCACCCTAATATGAAGTGCA
GAACATTTGAATTGTCTTTGACCAGCTTCAGCATCAGCACTATTTTTTTTTTTTTGCTAGACCCCTAGTAGGTATTTA
AAAGTACAGAAATAGAATTTAATCATGCTTTTTTACCAAAATGTGCTATGCTCTTAGAGATTCTTTCAACGTGCATAAA
AATCTGCAGTTTTACCACATACCAGTAAAAAGAACTCAGTCACTCATTTAGCCATTTAGTAAAAAGAACAAATTA
CTGATGAGCATAGTGGAGACCTCAAAGGTAAAGAGACAATGTCCCTGAAATAAAGACAATCATAAATTTTCAATCA
AAATAATGAAATTTAGGCTGGGCATGGTGGCTCATGCCATGATCCTAGCACCTTTGGAAGGCTAAGGTGGGAGGATT
GTTTGAGGCCAGGAGTTCAAGACCAGCCTCAGCAAAAAAGTGAGACCTGTCTCCACAAAAAATTTTAAAAATTTAT
CTGGGTGTGGTGGTATGCACCGGTGGTCTCAGCTACTCAAGAGGCTGAGGTGGAGGATCACCAGAGCTCAGGGGTTG

GAGACTACAGTGAGCTATGATTGTACCACTGCACTCAAACTTGCATGACAGAATGAGTCCTTGTCTCTAATAATAAC
AAAATTTAATTTTTATAGACTGTGAAAAACCAATTATGTAGATACAGTTCAAGTACAGTATGATTTTATAGGATAGAT
AAGTTTGTCTTGAAAATGTATTTCCCAATTTATAGGATAGATAACTTTTGTCTTGAAAATGTATTCACAATAGAGTTAG
TATTTGGGGCACACCTTTATCCATTTAACAACATGTTTTGAGCACTGCCAGGTAGCAACACGTTACTAGGCACCTAG
AGTGAGAAAAGATTACAGTTCCTGCTCTCATGGATCTCATGGTCTAGTCAACTGGAATGAAAGGATTACATAAGTAG
AGGTAAAGACACACATGATGGAGGATGGAGAATAGTCAAAGGTCTGGAGAATGACCAGGACGTCAGTGTGAGTTGTC
TAATTGCACTGAAGCATGGATGAAGAATTGGAAAGTCATTGTAAGAAGCCTAAAAAGGTATCTCTCAGGGATGCTAT
GAGGTTCTGAATGTTATGTACGCTATTTGGGCTTCAACAGGCAGGCACTGAGTATTCAGTATAAAATTTTGGAGCAGG
GAATCCACCAGAAGAAGTATGCATCTGGAGGATTAATCTGGAAGATTGTGTAGAATGTTATGCAGTGAAAAGAGTCT
GAGATGAAACAGTTAGGAGGGTGTATTAATAACATAGGTGAAGTGTAAATGAATAACCAGGCTGGAGGAAAAGCAATA
ACGATGGAATCAACCGGGCAAGAAGTATAACAATTAGGATCAGTAAAAATAGAATTTGGATTGGAGGAATGAAAAAA
AAGGGACAAAACAAAGTTGAACTGCTGGTATCCATACTGGAATAACAGATGTCATTCAAATAAATAATGTAATGAA
TATAAGAAACCAGTTTTAGGAGTGAAGTGGATGTTGGCTTGAAAATATTTCCCTTTGAGGTTTCAGTCAAATGAAAAG
GTCCTGAAATGCTACGTGGTAGCCTAAGAAGGAAGCGTTTCTAGAGAGAAAAAATTAGAAAAGATTTACATTTGAT
AATTTAATCTTTTCCCTTCATACAAGCTAAATTGATAAGAAAGTAAAACCTATAGTTTTACCACCTCTTTTACAAATA
TCCCTAACCTTTTAGATATTCACATGAATAATTGAGAAAAATCTAACAGATGACTTGCTTATGTCAATTTGTCTGCTT
TATCCTTAGGTTCTCTGGCTTATATATTGTTCAATAAAATACAGATCATTGATATTGTACAATGTACTGATAATGG
GGAGTGAATCCATGCTTGTGCATTCTTTTTTTTTTTTTTTTTTGAATTTGCAGAGGGCGTGCCAGTCAACAAGAGAG
GCACAATTGTTTTATCATCACCTCTTCTCATCTAATTCCATGAAGGAGAGTAGTATTACCATAACAACAGATAATGA
GTTGGAAAACAAGAAACCTAACCTCAGAACTTAAGGCTTGGGGAAAAATAAAAGAGTAATTTGTGTTTAAATGCCTGT
ATAACTTGGCAAGAGGGACATATAAGGCTTAGTGATGCCCAACATGTGCTTAGATGTGGATTGTTAGTTGATGCTT
GGGGGTTCTGTAATCTAAGCTAAATGCTCAAAATCAATTAATTGATGTTAGACACAGAGATCTGCTTTGATCCCTCT
TTATCGTATTTCTAGGCCTTCCCATTTCTCAAGAGCCTGAGAAACGACAGCTTTTCTTAATAACTTGTATTTGTGGT
AGGAGATGAAACCTTTGATAAAAAACACAATTATTTTAAATGTCTCTTTTTCACTCTAGGCTGTTGTATGTATTTCAA
AAAGTTACTTTTGACCTTTTCCAGAATGAGAAAGCAATCAAGAAGATTATAATATCTTGCTTAGTTTCTTGCTCAAT
TTATCAACAAATATTTCTTAAGCAATTATTAAGCTGAGCAGTGCTCAGCGCTGTACTTGGTGATATAGGAAATGGGG
AAAAGACTGTCTTTAAGGCTTTTATAATAGTAATTACCTCAACTTGCTGTTTCTTTTCTTACCATTTCGCCAAAT
TCATTGATCTATCTTGTCTCAAGCAATCGCCATAGTTATATTGTAACACAGCATTTTCTAGGGTGTCCCATTA
GTTGAGAGTGTGACAAGAAAATACAAGCTTATTTATCATTGTAAAACTTGAGACACCTAGTAGTTACCCTAAATTA
AATATTTGTTGGAGTCAGTCACACTAAAGAGAACACTTACTGCATTGAACAATTTACCTACATTAGACAGCATTAA
AGACTATGCCACAGCAAAGGCCCATGGAATTTCTGTGAACACAGAATAGAAGTGTATTAAGGAACAAGCTTAATTTCT
GTTCTCTTAAAGCACAACTTTCTCAAAACATATTTTGAATCACCTTTGACCATTTTTTTTAACTAATAGGTGGG
TGGGAGTTAGGGTAGGAAAACACAAGCAGCTTCATCAAAACGATATTCTATTTTCTTCAAATTTGTGGGGAATCATA
CGGCCTCTCAATTTTCTACATTATGCTAATTATGATATTAATCTCTCTGCCAGCAAATGAAAATAATACATATTAGA
TGAGCAAATGTCAATAATGACAAAATTAGTCATCATGCAGATACTCAGGGATTCCCAAAATATGTTTGGATTATGA
TTGCTAGCTTTGAGTTTGCCAGAATCGTTTCAATAAAAAATAAGGGACTCAAACACATTTGGAGCAAAACTCACATC
ATAAATTTTAGACATAGCTCTGCCAATAATGCTCTCAGTTATATTTTCACTCCTAATATTTCTCTGAGTTCCAGAC
CAGTATCTTCAACTGTCTGATTGATACTCTCTCCTTCATTTCTGTCTCCAATGCATTAAGTCTGTGATTTACTTT
CCAAATGCCACTTGGTTCCATGCATTTCTCTCCATTTCTGCCACTGACTCCTCCTCAATCCAAGCGACCATCTTTCC
TCACTTTAACTACCATGATATCTCCTGCTTGGTCTCCTTACTTCTATTCCCGGGCTCCTCCAATCCATTCTCTCC
AGCAGAGAATGATGACTAGCACCTTCCACAGTGTCTGGCTAATAGGAGGTATCCAATCAATAATTGACTTACAGAGT
GAAAATATAGGCATGGCAATAACAGTAGAAGCACTAGGTTTTAGAACCAATGACATTAGACTTTCCATCAAT
ATTTACAGTGTATAATCAAGTTGACTTGACATGTCTTATTTTGAACCAATTTTGTGGCTTTTTCTATATGC
ACACATACATATTGTATCACCTCTACCCGCCAAATGGCTTTTGAAGAAAGTATTTATGTGGCTCCAAATTGATAATA
CCTCTAGAGAGAAGAGAAATTAGAAATTTTAAATGACCTATGCTTCTTTCGAATATCACGTCTGAGACAGTGT
TTTTGAGTTACGTGCAATATGTTCCACGATGAAACATTTAATGTGTTTCAAGGCGATGCTAGTAATCATGTAGAAAGA
ATTTTATGCCTGAAGTCACATGTTCTATAACCAGGATCACTTAATAAGAAAACAAGTACAGCTGTGGACAAGATGCC
TTTTTATCAGGGAAAGGCCAATTTGTTTTCTTTGCAAACTAAGTAAATGGAGAGAAAAACACAGCCCTTAAATGTT
TTCTATTTGTCTGAAGTTCTCATGAATGAGTTAGAAGGCGAGAAGGATTAAATAAATCCTTGAACGTAGAGAGAGC
TAACATTTATTTTAGCAAACCTAAACCTATTTCGCTTTGCAAAGTTCTGTTCTGTACTTTGTAACAACAGTTTTCTTT
AAAACAAGAGCCACCAATTCAAATGCCTTTACAGAATGATTGAATGCTTTTCATGCCCCACCTAAAGGCATTCAAATC
ATTAATCAAACAAAGTTCTAACGCCAAAACATGTCTGGGACCAGATTTAAAATGTAGCCCTCAGTTTCAGAGGGCAA
AACTTAACATATTTATATTTTCTCTCACTTTAGGTAACACTGTATTGAATCTCTGCTTGAAATTGAGGAGCACGTGA
TTTTTTCTTTTTTGGCCAGGGCAGCATTTCTTGGAAAGAGAAAAGAAAAACAACCCAAGATACCCTTACAAAACATGTA
GTACTTAAAGCTCTTTATGATGAATTAATTTTGGTATACACATTAATAGCAGTGATAATAACAAATCTATATATATA
TATATAATTGATATGAATAAGATAAAATACATCAAAAGGAAATTTCAATTACAATTTGATATTAGGTAAATGTCCCAT
AAAATAAATTGCTACTGTACATAATTTTCTTTCAGTTTATTGGCAGGATGTTTGCTTTGGAAAATAAACAGTCTATT
TCTAGTTTTAGAAGGAATTTCTATTATCTTTTATAGCAACCATTTATCAGGAGCAGATGGGAAATTTGACCAAGAGC
ATATCACTATTATACCTCACAGGAAAAAGAGAGTATTAATGAAATCTAACAGGCCTGCTCCTGACTCTAGTTCC
TGTAACAAATGAACACACACATTTGTATGGTTTTCAGCAATTTGTATTAGTAAGGTACAATAAATGTTTACTGAAATTG
AAAAAAGAGATAACAGGAGAAAAGAGAGGCTAAAAAGGTGCATTTTATTTCTGATCGTTTATTGTAAGACTGC
TCCTTTTTTAAATAATCAAATTTTATTTTATATACAGAGGGTACATGTACAGGCTTGTACAGGGGAATAGCGCATG
ATGCTGAGGTTTGGGGTACAGATCTCATCCCCAACAGTGAGCATAGTACCTACCTGATGAGTAGTTTTTCAACCA
ATGCGCACCTCCTCCTTCCCACATCTACTAGTCCGCGGTATCTGTTGTTCGCATATTTACGTCCATATATGCTCT

138

TGTGTGTAAGTTGGTTGTAATATTCTCCTTTTCAATTGAGCTATTTTTCTGATACTTTACTCTTAAAAATTTTCATTACAG
 GAAAAAAGTAAACAATATTTAAGCTTGACAATCATAAAAATGCTCTGGTGACTATAGATTATTTTAAAAATTTATTAC
 TGTAGCTTAGGGATATCTTGATGGGATGCTCCTGAAAGCAATTAATTCTCAGTTTTTTGTGGCTTCTAATGCAAAAT
 ACATTGACGCAGACAGAATTTGAAATGAATTTTCTTCTAATATAGCAATTAATTTTATTTAAATATCTCTAGAGTTT
 TTTTTTAATACTGTGACTAACCTATGTTTGTCTTTTTTACCTCTCGTATCCACGATCACTAAGAAACCCAAATACT
 TTGTTTCATGTTTAAATTTTACAACATTTTCATAGACTATTAAACATGGAACATCCTTGTGGGGACAAGAAATCGAATT
 TGCTCTTGAAAAGGTTTCCAACATAATTGATTGTAGGACATTATAACATCCTCTAGCTGACAAGCTTACAAAAATAA
 AAACCTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCTGTCTTGTATCCTTTGGATAT
 GGGCATGTGAGTTTTCATAGGGAAATTTTACATGGAGCTTTTGTATTTCTTTCTTTGCCAGTACAACATGCATGTGGT
 AGCACACTGTTTAAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTGCCTTTTTTGGTATCTTACAG
 (SEQ ID NO: 277)

[000212] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 1 (nucleotide positions 1127752-1127796 of NCBI Reference Sequence: NG_012232.1)

TTAACTTCTTAAAGATCAGGTTCTGAAGGGTGATGGAAATTACTT (SEQ ID NO: 278)

[000213] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 2 (nucleotide positions 1127752-1127796 of NCBI Reference Sequence: NG_012232.1)

TGACAAGCTTACAAAAATAAAAACTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCT
 GTCTTGTATCCTTTGGATATGGGCATGTGAGTTTCATAGGGAAATTTTACATGGAGCTTTTGTATTTCTTTCTTTG
 CCAGTACAACATGCATGTGGTAGCACACTGTTTAAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTG
 CCTTTTTGGTATCTTACAG (SEQ ID NO: 323)

[000214] *Homo sapiens* dystrophin (DMD) intron 44/exon 45 junction (nucleotide positions 1376066-1376125 of NCBI Reference Sequence: NG_012232.1)

TTTTTGTTTTGCCTTTTTTGGTATCTTACAGGAACCTCAGGATGGCATTGGGCAGCGGCAA (SEQ ID NO: 279)

[000215] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 45 (nucleotide positions 6683-6858 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1376096-1376271 of NCBI Reference Sequence: NG_012232.1)

GAACTCCAGGATGGCATTGGGCAGCGGCAAACTGTTGTCAGAACATTGAATGCAACTGGGGAAGAAATAATTCAGCA
 ATCCTCAAAAACAGATGCCAGTATTCTACAGGAAAAATTTGGGAAGCCTGAATCTGCGGTGGCAGGAGTCTGCAAC
 AGCTGTGACAGAAAAAAGAG (SEQ ID NO: 280)

[000216] *Homo sapiens* dystrophin (DMD), exon 45 target sequence 1 (nucleotide positions 1376096-1376145 of NCBI Reference Sequence: NG_012232.1)

GAACTCCAGGATGGCATTGGGCAGCGGCAAACTGTTGTCAGAACATTGAA (SEQ ID NO: 281)

[000217] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splicing feature in a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splicing feature in a DMD sequence is an exonic splicing enhancer (ESE), a branch point, a splice donor site, or a splice acceptor site in a DMD sequence. In some embodiments, an ESE is in exon 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a branch point is in intron 43 or intron 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice donor site is across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice acceptor site is in intron 43, across

the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, the oligonucleotide useful for targeting DMD promotes skipping of exon 44, such as by targeting a splicing feature (*e.g.*, an ESE, a branch point, a splice donor site, or a splice acceptor site) in a DMD sequence (*e.g.*, a DMD pre-mRNA). Examples of ESEs, branch points, splice donor sites, and splice acceptor sites are provided in Table 9.

[000218] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an exonic splicing enhancer (ESE) in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an ESE in DMD exon 44 (*e.g.*, an ESE listed in Table 9).

[000219] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of a DMD transcript (*e.g.*, one or more full or partial ESEs listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of DMD exon 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs as set forth in SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE antisense sequence as set forth in any one of SEQ ID NOs: 306-316.

[000220] In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (*e.g.*, 2, 3, 4, or more adjacent ESEs) of DMD exon 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (*e.g.*, 2, 3, 4, or more adjacent ESEs) as set forth in SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESE antisense sequences (*e.g.*, antisense sequences of 2, 3, 4, or more adjacent ESEs) as set forth in SEQ ID NOs: 306-316.

[000221] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8)

consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296.

[000222] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in DMD intron 43 or intron 44 (*e.g.*, a branch point listed in Table 9).

[000223] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial branch point of a DMD transcript (*e.g.*, a full or partial branch point listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point of DMD intron 43 or intron 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point antisense sequence as set forth in any one of SEQ ID NOs: 303, 304, and 318-320.

[000224] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon

skipping, such as for skipping exon 44) is 20-30 (e.g., 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300.

[000225] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a splice donor site in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a splice donor site across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 (e.g., a splice donor site listed in Table 9).

[000226] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial splice donor site of a DMD transcript (e.g., a full or partial splice donor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, the oligonucleotide comprises at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site antisense sequence as set forth in SEQ ID NO: 302 or 317.

[000227] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 20-30 (e.g., 20, 25, 30) nucleotides in length, and comprises a region of

complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297.

[000228] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site in intron 43, across the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 (*e.g.*, a splice acceptor site listed in Table 9).

[000229] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site of a DMD transcript (*e.g.*, a full or partial splice acceptor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site in intron 43, across the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site antisense sequence as set forth in SEQ ID NO: 305 or 321.

[000230] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of

complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301.

[000231] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 268, 272, 276, and 279). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 268, 272, 276, and 279). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 268, 272, 276, and 279.

[000232] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323.

Table 9. Example target sequence motifs

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Across exon 43/intron 43 junction	Splice Donor	282	GGGTAGG	302	CCTACCC
Intron 43	Branch Point	283	TATTAAT	303	ATTAATA

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Intron 43	Branch point	284	TCTTGAT	304	ATCAAGA
Across intron 43/exon 44 junction	Splice Acceptor	285	ACCTGCAGG	305	CCTGCAGGT
Exon 44	ESE	286	TGACAGA	306	TCTGTCA
Exon 44	ESE	287	CGGCGTT	307	AACGCCG
Exon 44	ESE	288	TCAGTGG	308	CCACTGA
Exon 44	ESE	289	GGCTAACA	309	TGTTAGCC
Exon 44	ESE	290	ACAGAAG	310	CTTCTGT
Exon 44	ESE	291	TCTCAGA	311	TCTGAGA
Exon 44	ESE	292	CTCAGAA	312	TTCTGAG
Exon 44	ESE	293	GACACAA	313	TTGTGTC
Exon 44	ESE	294	AATTCCTG	314	CAGGAATT
Exon 44	ESE	295	CTGAGAA	315	TTCTCAG
Exon 44	ESE	296	GTATCTTA	316	TAAGATAC
Across exon 44/intron 44 junction	Splice Donor	297	AGGTAAG	317	CTTACCT
Intron 44	Branch Point	298	CTGAC	318	GTCAG
Intron 44	Branch Point	299	CTAAC	319	GTTAG
Intron 44	Branch Point	300	CCCTGAC	320	GTCAGGG
Across intron 44/exon 45 junction	Splice Acceptor	301	TCTTACAGG	321	CCTGTAAGA

[†] Each thymine base (T) in any one of the sequences provided in Table 9 may independently and optionally be replaced with a uracil base (U). Motif sequences and antisense sequences listed in Table 9 contain T's, but binding of a motif sequence in RNA and/or DNA is contemplated.

[000233] In some embodiments, any one of the oligonucleotides useful for targeting DMD (e.g., for exon skipping) is a phosphorodiamidate morpholino oligomer (PMO).

[000234] In some embodiments, the oligonucleotide may have region of complementarity to a mutant DMD allele, for example, a DMD allele with at least one mutation in any of exons 1-79 of DMD in humans that leads to a frameshift and improper RNA splicing/processing.

[000235] In some embodiments, any one of the oligonucleotides can be in salt form, e.g., as sodium, potassium, or magnesium salts.

[000236] In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any one of the oligonucleotides described herein is conjugated to an amine group, optionally via a spacer. In some embodiments, the spacer comprises an aliphatic moiety. In some embodiments, the spacer comprises a polyethylene glycol moiety. In some embodiments, a phosphodiester linkage is present between the spacer and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any of the oligonucleotides described herein is conjugated to a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or

unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a combination thereof; each R^A is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, the spacer is a substituted or unsubstituted alkylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, or -C(=O)N(R^A)₂, or a combination thereof.

[000237] In some embodiments, the 5' or 3' nucleoside of any one of the oligonucleotides described herein is conjugated to a compound of the formula -NH₂-(CH₂)_n-, wherein n is an integer from 1 to 12. In some embodiments, n is 6, 7, 8, 9, 10, 11, or 12. In some embodiments, a phosphodiester linkage is present between the compound of the formula NH₂-(CH₂)_n- and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, a compound of the formula NH₂-(CH₂)₆- is conjugated to the oligonucleotide via a reaction between 6-amino-1-hexanol (NH₂-(CH₂)₆-OH) and the 5' phosphate of the oligonucleotide.

[000238] In some embodiments, the oligonucleotide is conjugated to a targeting agent, e.g., a muscle targeting agent such as an anti-TfR1 antibody, e.g., via the amine group.

a. Oligonucleotide Size/Sequence

[000239] Oligonucleotides may be of a variety of different lengths, e.g., depending on the format. In some embodiments, an oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the oligonucleotide is 8 to 50 nucleotides in length, 8 to 40 nucleotides in length, 8 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 21 to 23 nucleotides in lengths, 20 to 25 nucleotides in length, etc.

[000240] In some embodiments, a nucleic acid sequence of an oligonucleotide for purposes of the present disclosure is “complementary” to a target nucleic acid when it is specifically hybridizable to the target nucleic acid. In some embodiments, an oligonucleotide hybridizing to a target nucleic acid (e.g., an mRNA or pre-mRNA molecule) results in modulation of activity or expression of the target (e.g., decreased mRNA translation, altered pre-mRNA splicing, exon skipping, target mRNA degradation, etc.). In some embodiments, a nucleic acid sequence of an oligonucleotide has a sufficient degree of complementarity to its target nucleic acid such that it does not hybridize non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions. Thus, in some embodiments, an oligonucleotide may be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the consecutive nucleotides of a target nucleic acid. In some

embodiments a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable or specific for a target nucleic acid. In certain embodiments, oligonucleotides comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain embodiments, activity relating to the target is reduced by such mismatch, but activity relating to a non-target is reduced by a greater amount (*i.e.*, selectivity for the target nucleic acid is increased and off-target effects are decreased).

[000241] In some embodiments, an oligonucleotide comprises region of complementarity to a target nucleic acid that is in the range of 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, 15 to 20, 20 to 25, or 5 to 40 nucleotides in length. In some embodiments, a region of complementarity of an oligonucleotide to a target nucleic acid is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a target nucleic acid. In some embodiments, an oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of target nucleic acid. In some embodiments the oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

[000242] In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides described herein (e.g., the oligonucleotides listed in Table 8). In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides provided by SEQ ID NO: 196-267. In some embodiments, such target sequence is 100% complementary to an oligonucleotide listed in Table 8. In some embodiments, such target sequence is 100% complementary to an oligonucleotide provided by SEQ ID NO: 196-267. In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence provided herein (e.g., a target sequence listed in Table 8). In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to any one of SEQ ID NO: 160-195.

[000243] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 160-195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target

sequence provided by any one of SEQ ID NOs: 160-195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 160-195.

[000244] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of a DMD-targeting sequence provided herein (*e.g.*, an antisense sequence listed in Table 8). In some embodiments, the oligonucleotide comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of any one of SEQ ID NOs: 196-267. In some embodiments, the oligonucleotide comprises the sequence of any one of SEQ ID NOs: 196-267.

[000245] In some embodiments, it should be appreciated that methylation of the nucleobase uracil at the C5 position forms thymine. Thus, in some embodiments, a nucleotide or nucleoside having a C5 methylated uracil (or 5-methyl-uracil) may be equivalently identified as a thymine nucleotide or nucleoside.

[000246] In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided herein (*e.g.*, the oligonucleotides listed in Table 8) may independently and optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides provided herein may independently and optionally be T's. In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided by SEQ ID NOs: 232-267 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-195 may optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides may optionally be T's. In some embodiments, any one or more of the uracil bases (U's) in any one of the oligonucleotides provided by SEQ ID NOs: 196-231 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-195 may optionally be thymine bases (T's), and/or any one or more of the T's in the oligonucleotides may optionally be U's.

b. Oligonucleotide Modifications:

[000247] The oligonucleotides described herein may be modified, *e.g.*, comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide or nucleoside and/or (*e.g.*, and) combinations thereof. In addition, in some embodiments, oligonucleotides may exhibit one or more of the following properties: do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; have improved endosomal exit internally in a cell; minimizes TLR stimulation; or avoid pattern recognition receptors. Any of the modified chemistries or formats of oligonucleotides described herein can be combined with each other.

For example, one, two, three, four, five, or more different types of modifications can be included within the same oligonucleotide.

[000248] In some embodiments, certain nucleotide or nucleoside modifications may be used that make an oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide or oligoribonucleotide molecules; these modified oligonucleotides survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, modified internucleoside linkages such as phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Accordingly, oligonucleotides of the disclosure can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide or nucleoside modification.

[000249] In some embodiments, an oligonucleotide may be of up to 50 or up to 100 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. Optionally, the oligonucleotides may have every nucleotide or nucleoside except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides/nucleosides modified. Oligonucleotide modifications are described further herein.

c. Modified Nucleosides

[000250] In some embodiments, the oligonucleotide described herein comprises at least one nucleoside modified at the 2' position of the sugar. In some embodiments, an oligonucleotide comprises at least one 2'-modified nucleoside. In some embodiments, all of the nucleosides in the oligonucleotide are 2'-modified nucleosides.

[000251] In some embodiments, the oligonucleotide described herein comprises one or more non-bicyclic 2'-modified nucleosides, e.g., 2'-deoxy, 2'-fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), or 2'-O-N-methylacetamido (2'-O-NMA) modified nucleoside.

[000252] In some embodiments, the oligonucleotide described herein comprises one or more 2'-4' bicyclic nucleosides in which the ribose ring comprises a bridge moiety connecting

two atoms in the ring, *e.g.*, connecting the 2'-O atom to the 4'-C atom via a methylene (LNA) bridge, an ethylene (ENA) bridge, or a (S)-constrained ethyl (cEt) bridge. Examples of LNAs are described in International Patent Application Publication WO/2008/043753, published on April 17, 2008, and entitled "*RNA Antagonist Compounds For The Modulation Of PCSK9*", the contents of which are incorporated herein by reference in its entirety. Examples of ENAs are provided in International Patent Publication No. WO 2005/042777, published on May 12, 2005, and entitled "*APP/ENA Antisense*"; Morita et al., *Nucleic Acid Res., Suppl* 1:241-242, 2001; Surono et al., *Hum. Gene Ther.*, 15:749-757, 2004; Koizumi, *Curr. Opin. Mol. Ther.*, 8:144-149, 2006 and Horie et al., *Nucleic Acids Symp. Ser (Oxf)*, 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties. Examples of cEt are provided in US Patents 7,101,993; 7,399,845 and 7,569,686, each of which is herein incorporated by reference in its entirety.

[000253] In some embodiments, the oligonucleotide comprises a modified nucleoside disclosed in one of the following United States Patent or Patent Application Publications: US Patent 7,399,845, issued on July 15, 2008, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 7,741,457, issued on June 22, 2010, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 8,022,193, issued on September 20, 2011, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 7,569,686, issued on August 4, 2009, and entitled "*Compounds And Methods For Synthesis Of Bicyclic Nucleic Acid Analogs*"; US Patent 7,335,765, issued on February 26, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,314,923, issued on January 1, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,816,333, issued on October 19, 2010, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*" and US Publication Number 2011/0009471 now US Patent 8,957,201, issued on February 17, 2015, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*", the entire contents of each of which are incorporated herein by reference for all purposes.

[000254] In some embodiments, the oligonucleotide comprises at least one modified nucleoside that results in an increase in T_m of the oligonucleotide in a range of 1 °C, 2 °C, 3 °C, 4 °C, or 5 °C compared with an oligonucleotide that does not have the at least one modified nucleoside. The oligonucleotide may have a plurality of modified nucleosides that result in a total increase in T_m of the oligonucleotide in a range of 2 °C, 3 °C, 4 °C, 5 °C, 6 °C, 7 °C, 8 °C, 9 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or more compared with an oligonucleotide that does not have the modified nucleoside.

[000255] The oligonucleotide may comprise a mix of nucleosides of different kinds. For example, an oligonucleotide may comprise a mix of 2'-deoxyribonucleosides or ribonucleosides

and 2'-fluoro modified nucleosides. An oligonucleotide may comprise a mix of deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000256] The oligonucleotide may comprise alternating nucleosides of different kinds. For example, an oligonucleotide may comprise alternating 2'-deoxyribonucleosides or ribonucleosides and 2'-fluoro modified nucleosides. An oligonucleotide may comprise alternating deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000257] In some embodiments, an oligonucleotide described herein comprises a 5'-vinylphosphonate modification, one or more abasic residues, and/or one or more inverted abasic residues.

d. Internucleoside Linkages / Backbones

[000258] In some embodiments, oligonucleotide may contain a phosphorothioate or other modified internucleoside linkage. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between at least two nucleosides. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between all nucleosides. For example, in some embodiments, oligonucleotides comprise modified internucleoside linkages at the first, second, and/or (e.g., and) third internucleoside linkage at the 5' or 3' end of the nucleotide sequence.

[000259] Phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent

pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

[000260] In some embodiments, oligonucleotides may have heteroatom backbones, such as methylene(methylimino) or MMI backbones; amide backbones (see De Mesmaeker et al. *Acc. Chem. Res.* 1995, 28:366-374); morpholino backbones (see Summerton and Weller, U.S. Pat. No. 5,034,506); or peptide nucleic acid (PNA) backbones (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., *Science* 1991, 254, 1497).

e. Stereospecific Oligonucleotides

[000261] In some embodiments, internucleotidic phosphorus atoms of oligonucleotides are chiral, and the properties of the oligonucleotides are adjusted based on the configuration of the chiral phosphorus atoms. In some embodiments, appropriate methods may be used to synthesize P-chiral oligonucleotide analogs in a stereocontrolled manner (e.g., as described in Oka N, Wada T, Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. *Chem Soc Rev.* 2011 Dec;40(12):5829-43.) In some embodiments, phosphorothioate containing oligonucleotides comprise nucleoside units that are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. In some embodiments, such phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis, as described, for example, in US Patent 5,587,261, issued on December 12, 1996, the contents of which are incorporated herein by reference in their entirety. In some embodiments, chirally controlled oligonucleotides provide selective cleavage patterns of a target nucleic acid. For example, in some embodiments, a chirally controlled oligonucleotide provides single site cleavage within a complementary sequence of a nucleic acid, as described, for example, in US Patent Application Publication 20170037399 A1, published on February 2, 2017, entitled "CHIRAL DESIGN", the contents of which are incorporated herein by reference in their entirety.

f. Morpholinos

[000262] In some embodiments, the oligonucleotide may be a morpholino-based compounds. Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510; Genesis, volume 30, issue 3, 2001; Heasman, J., *Dev. Biol.*, 2002, 243, 209-214; Nasevicius et al., *Nat. Genet.*, 2000, 26, 216-220;

Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

g. Peptide Nucleic Acids (PNAs)

[000263] In some embodiments, both a sugar and an internucleoside linkage (the backbone) of the nucleotide units of an oligonucleotide are replaced with novel groups. In some embodiments, the base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative publication that report the preparation of PNA compounds include, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

h. Mixmers

[000264] In some embodiments, an oligonucleotide described herein may be a mixmer or comprise a mixmer sequence pattern. In general, mixmers are oligonucleotides that comprise both naturally and non-naturally occurring nucleosides or comprise two different types of non-naturally occurring nucleosides typically in an alternating pattern. Mixmers generally have higher binding affinity than unmodified oligonucleotides and may be used to specifically bind a target molecule, *e.g.*, to block a binding site on the target molecule. Generally, mixmers do not recruit an RNase to the target molecule and thus do not promote cleavage of the target molecule. Such oligonucleotides that are incapable of recruiting RNase H have been described, for example, see WO2007/112754 or WO2007/112753.

[000265] In some embodiments, the mixmer comprises or consists of a repeating pattern of nucleoside analogues and naturally occurring nucleosides, or one type of nucleoside analogue and a second type of nucleoside analogue. However, a mixmer need not comprise a repeating pattern and may instead comprise any arrangement of modified nucleosides and naturally occurring nucleosides or any arrangement of one type of modified nucleoside and a second type of modified nucleoside. The repeating pattern, may, for instance be every second or every third nucleoside is a modified nucleoside, such as LNA, and the remaining nucleosides are naturally

occurring nucleosides, such as DNA, or are a 2' substituted nucleoside analogue such as 2'-MOE or 2' fluoro analogues, or any other modified nucleoside described herein. It is recognized that the repeating pattern of modified nucleoside, such as LNA units, may be combined with modified nucleoside at fixed positions—*e.g.* at the 5' or 3' termini.

[000266] In some embodiments, a mixmer does not comprise a region of more than 5, more than 4, more than 3, or more than 2 consecutive naturally occurring nucleosides, such as DNA nucleosides. In some embodiments, the mixmer comprises at least a region consisting of at least two consecutive modified nucleosides, such as at least two consecutive LNAs. In some embodiments, the mixmer comprises at least a region consisting of at least three consecutive modified nucleoside units, such as at least three consecutive LNAs.

[000267] In some embodiments, the mixmer does not comprise a region of more than 7, more than 6, more than 5, more than 4, more than 3, or more than 2 consecutive nucleoside analogues, such as LNAs. In some embodiments, LNA units may be replaced with other nucleoside analogues, such as those referred to herein.

[000268] Mixmers may be designed to comprise a mixture of affinity enhancing modified nucleosides, such as in non-limiting example LNA nucleosides and 2'-O-Me nucleosides. In some embodiments, a mixmer comprises modified internucleoside linkages (*e.g.*, phosphorothioate internucleoside linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleosides.

[000269] A mixmer may be produced using any suitable method. Representative U.S. patents, U.S. patent publications, and PCT publications that teach the preparation of mixmers include U.S. patent publication Nos. US20060128646, US20090209748, US20090298916, US20110077288, and US20120322851, and U.S. patent No. 7687617.

[000270] In some embodiments, a mixmer comprises one or more morpholino nucleosides. For example, in some embodiments, a mixmer may comprise morpholino nucleosides mixed (*e.g.*, in an alternating manner) with one or more other nucleosides (*e.g.*, DNA, RNA nucleosides) or modified nucleosides (*e.g.*, LNA, 2'-O-Me nucleosides).

[000271] In some embodiments, mixmers are useful for splice correcting or exon skipping, for example, as reported in Touznik A., et al., *LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts* Scientific Reports, volume 7, Article number: 3672 (2017), Chen S. et al., *Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide*, Molecules 2016, 21, 1582, the contents of each which are incorporated herein by reference.

i. Multimers

[000272] In some embodiments, molecular payloads may comprise multimers (e.g., concatemers) of 2 or more oligonucleotides connected by a linker. In this way, in some embodiments, the oligonucleotide loading of a complex can be increased beyond the available linking sites on a targeting agent (e.g., available thiol sites on an antibody) or otherwise tuned to achieve a particular payload loading content. Oligonucleotides in a multimer can be the same or different (e.g., targeting different genes or different sites on the same gene or products thereof).

[000273] In some embodiments, multimers comprise 2 or more oligonucleotides linked together by a cleavable linker. However, in some embodiments, multimers comprise 2 or more oligonucleotides linked together by a non-cleavable linker. In some embodiments, a multimer comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more oligonucleotides linked together. In some embodiments, a multimer comprises 2 to 5, 2 to 10 or 4 to 20 oligonucleotides linked together.

[000274] In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end (in a linear arrangement). In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end via an oligonucleotide based linker (e.g., poly-dT linker, an abasic linker). In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 3' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 5' end of another oligonucleotide. Still, in some embodiments, multimers can comprise a branched structure comprising multiple oligonucleotides linked together by a branching linker.

[000275] Further examples of multimers that may be used in the complexes provided herein are disclosed, for example, in US Patent Application Number 2015/0315588 A1, entitled *Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers*, which was published on November 5, 2015; US Patent Application Number 2015/0247141 A1, entitled *Multimeric Oligonucleotide Compounds*, which was published on September 3, 2015, US Patent Application Number US 2011/0158937 A1, entitled *Immunostimulatory Oligonucleotide Multimers*, which was published on June 30, 2011; and US Patent Number 5,693,773, entitled *Triplex-Forming Antisense Oligonucleotides Having Abasic Linkers Targeting Nucleic Acids Comprising Mixed Sequences Of Purines And Pyrimidines*, which issued on December 2, 1997, the contents of each of which are incorporated herein by reference in their entireties.

C. Linkers

[000276] Complexes described herein generally comprise a linker that covalently links any one of the anti-TfR1 antibodies described herein to a molecular payload. A linker comprises at

least one covalent bond. In some embodiments, a linker may be a single bond, e.g., a disulfide bond or disulfide bridge, that covalently links an anti-TfR1 antibody to a molecular payload. However, in some embodiments, a linker may covalently link any one of the anti-TfR1 antibodies described herein to a molecular payload through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker. A linker is typically stable *in vitro* and *in vivo*, and may be stable in certain cellular environments. Additionally, typically a linker does not negatively impact the functional properties of either the anti-TfR1 antibody or the molecular payload. Examples and methods of synthesis of linkers are known in the art (see, e.g. Kline, T. et al. “Methods to Make Homogenous Antibody Drug Conjugates.” *Pharmaceutical Research*, 2015, 32:11, 3480–3493.; Jain, N. et al. “Current ADC Linker Chemistry” *Pharm Res.* 2015, 32:11, 3526–3540.; McCombs, J.R. and Owen, S.C. “Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry” *AAPS J.* 2015, 17:2, 339–351.).

[000277] A linker typically will contain two different reactive species that allow for attachment to both the anti-TfR1 antibody and a molecular payload. In some embodiments, the two different reactive species may be a nucleophile and/or an electrophile. In some embodiments, a linker contains two different electrophiles or nucleophiles that are specific for two different nucleophiles or electrophiles. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody via conjugation to a lysine residue or a cysteine residue of the anti-TfR1 antibody. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody via a maleimide-containing linker, wherein optionally the maleimide-containing linker comprises a maleimidocaproyl or maleimidomethyl cyclohexane-1-carboxylate group. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody or thiol functionalized molecular payload via a 3-arylpropionitrile functional group. In some embodiments, a linker is covalently linked to a lysine residue of an anti-TfR1 antibody. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) a molecular payload, independently, via an amide bond, a carbamate bond, a hydrazide, a triazole, a thioether, and/or a disulfide bond.

i. Cleavable Linkers

[000278] A cleavable linker may be a protease-sensitive linker, a pH-sensitive linker, or a glutathione-sensitive linker. These linkers are typically cleavable only intracellularly and are preferably stable in extracellular environments, e.g., extracellular to a muscle cell.


[000279] Protease-sensitive linkers are cleavable by protease enzymatic activity. These linkers typically comprise peptide sequences and may be 2-10 amino acids, about 2-5 amino acids, about 5-10 amino acids, about 10 amino acids, about 5 amino acids, about 3 amino acids,

or about 2 amino acids in length. In some embodiments, a peptide sequence may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a protease-sensitive linker comprises a valine-citrulline or alanine-citrulline sequence. In some embodiments, a protease-sensitive linker can be cleaved by a lysosomal protease, e.g. cathepsin B, and/or (e.g., and) an endosomal protease.


[000280] A pH-sensitive linker is a covalent linkage that readily degrades in high or low pH environments. In some embodiments, a pH-sensitive linker may be cleaved at a pH in a range of 4 to 6. In some embodiments, a pH-sensitive linker comprises a hydrazone or cyclic acetal. In some embodiments, a pH-sensitive linker is cleaved within an endosome or a lysosome.

[000281] In some embodiments, a glutathione-sensitive linker comprises a disulfide moiety. In some embodiments, a glutathione-sensitive linker is cleaved by a disulfide exchange reaction with a glutathione species inside a cell. In some embodiments, the disulfide moiety further comprises at least one amino acid, e.g., a cysteine residue.


[000282] In some embodiments, a linker comprises a valine-citrulline sequence (e.g., as described in US Patent 6,214,345, incorporated herein by reference). In some embodiments, before conjugation, a linker comprises a structure of:



[000283] In some embodiments, after conjugation, a linker comprises a structure of:




[000284] In some embodiments, before conjugation, a linker comprises a structure of:



(A)

wherein n is any number from 0-10. In some embodiments, n is 3.


[000285] In some embodiments, a linker comprises a structure of:



(H),

wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000286] In some embodiments, a linker comprises a structure of:



(I),

wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

ii. Non-cleavable Linkers

[000287] In some embodiments, non-cleavable linkers may be used. Generally, a non-cleavable linker cannot be readily degraded in a cellular or physiological environment. In some embodiments, a non-cleavable linker comprises an optionally substituted alkyl group, wherein the substitutions may include halogens, hydroxyl groups, oxygen species, and other common

substitutions. In some embodiments, a linker may comprise an optionally substituted alkyl, an optionally substituted alkylene, an optionally substituted arylene, a heteroarylene, a peptide sequence comprising at least one non-natural amino acid, a truncated glycan, a sugar or sugars that cannot be enzymatically degraded, an azide, an alkyne-azide, a peptide sequence comprising a LPXT sequence, a thioether, a biotin, a biphenyl, repeating units of polyethylene glycol or equivalent compounds, acid esters, acid amides, sulfamides, and/or an alkoxy-amine linker. In some embodiments, sortase-mediated ligation can be utilized to covalently link an anti-TfR1 antibody comprising a LPXT sequence to a molecular payload comprising a (G)_n sequence (see, e.g. Proft T. Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilization. *Biotechnol Lett.* 2010, 32(1):1-10.).

[000288] In some embodiments, a linker may comprise a substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted cycloalkylene, an optionally substituted cycloalkenylene, an optionally substituted arylene, an optionally substituted heteroarylene further comprising at least one heteroatom selected from N, O, and S.; an optionally substituted heterocyclylene further comprising at least one heteroatom selected from N, O, and S, an imino, an optionally substituted nitrogen species, an optionally substituted oxygen species O, an optionally substituted sulfur species, or a poly(alkylene oxide), e.g. polyethylene oxide or polypropylene oxide. In some embodiments, a linker may be a non-cleavable N-gamma-maleimidobutyryl-oxysuccinimide ester (GMBS) linker.

iii. Linker conjugation

[000289] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload via a phosphate, thioether, ether, carbon-carbon, carbamate, or amide bond. In some embodiments, a linker is covalently linked to an oligonucleotide through a phosphate or phosphorothioate group, e.g. a terminal phosphate of an oligonucleotide backbone. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody, through a lysine or cysteine residue present on the anti-TfR1 antibody.

[000290] In some embodiments, a linker, or a portion thereof is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments, an alkyne may be a cyclic alkyne, e.g., a cyclooctyne. In some embodiments, an alkyne may be bicyclononyne (also known as bicyclo[6.1.0]nonyne or BCN) or substituted bicyclononyne. In some embodiments, a cyclooctyne is as described in International Patent Application Publication WO2011136645, published on November 3, 2011, entitled, “*Fused Cyclooctyne Compounds And Their Use In*

Metal-free Click Reactions". In some embodiments, an azide may be a sugar or carbohydrate molecule that comprises an azide. In some embodiments, an azide may be 6-azido-6-deoxygalactose or 6-azido-N-acetylgalactosamine. In some embodiments, a sugar or carbohydrate molecule that comprises an azide is as described in International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, "*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*". In some embodiments, a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker is as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, "*Modified antibody, antibody-conjugate and process for the preparation thereof*"; or International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, "*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*".


[000291] In some embodiments, a linker comprises a spacer, e.g., a polyethylene glycol spacer or an acyl/carbomoyl sulfamide spacer, e.g., a HydraSpaceTM spacer. In some embodiments, a spacer is as described in Verkade, J.M.M. et al., "*A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates*", *Antibodies*, 2018, 7, 12.

[000292] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by the Diels-Alder reaction between a dienophile and a diene/hetero-diene, wherein the dienophile or the diene/hetero-diene may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by other pericyclic reactions such as an ene reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by an amide, thioamide, or sulfonamide bond reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a condensation reaction to form an oxime, hydrazone, or semicarbazide group existing between the linker and the anti-TfR1 antibody and/or (e.g., and) molecular payload.

[000293] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a conjugate addition reaction between a nucleophile, e.g. an amine or a hydroxyl group, and an electrophile, e.g. a carboxylic acid, carbonate, or an aldehyde. In some embodiments, a nucleophile may exist on a linker and an electrophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an


anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may exist on a linker and a nucleophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may be an azide, pentafluorophenyl, a silicon centers, a carbonyl, a carboxylic acid, an anhydride, an isocyanate, a thioisocyanate, a succinimidyl ester, a sulfosuccinimidyl ester, a maleimide, an alkyl halide, an alkyl pseudohalide, an epoxide, an episulfide, an aziridine, an aryl, an activated phosphorus center, and/or an activated sulfur center. In some embodiments, a nucleophile may be an optionally substituted alkene, an optionally substituted alkyne, an optionally substituted aryl, an optionally substituted heterocyclyl, a hydroxyl group, an amino group, an alkylamino group, an anilido group, and/or a thiol group.

[000294] In some embodiments, a linker comprises a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety or a BCN moiety for click chemistry). In some embodiments, a linker comprising a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety for click chemistry) comprises a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000295] In some embodiments, a linker comprising the structure of Formula (A) is covalently linked (e.g., optionally via additional chemical moieties) to a molecular payload (e.g., an oligonucleotide). In some embodiments, a linker comprising the structure of Formula (A) is covalently linked to an oligonucleotide, e.g., through a nucleophilic substitution with amine-L1-oligonucleotides forming a carbamate bond, yielding a compound comprising a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000296] In some embodiments, the compound of Formula (B) is further covalently linked via a triazole to additional moieties, wherein the triazole is formed by a click reaction between the azide of Formula (A) or Formula (B) and an alkyne provided on a bicyclononyne. In some embodiments, a compound comprising a bicyclononyne comprises a structure of:




wherein m is any number from 0-10. In some embodiments, m is 4.

[000297] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (C), forming a compound comprising a structure of:




wherein n is any number from 0-10, and wherein m is any number from 0-10. In some embodiments, n is 3 and m is 4.

[000298] In some embodiments, the compound of structure (D) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a complex comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000299] In some embodiments, the compound of Formula (C) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a compound comprising a structure of:




wherein m is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (F) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000300] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a complex comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000301] In some embodiments, the azide of the compound of structure (A) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a compound comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. In some embodiments, an oligonucleotide is covalently linked to a compound comprising a structure of formula (G), thereby forming a complex comprising a structure of formula (E). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (G) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000302] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000303] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000304] In some embodiments, in formulae (B), (D), (E), and (I), L1 is a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a combination thereof, wherein each R^A is independently hydrogen or substituted or unsubstituted alkyl. In some embodiments, L1 is




wherein L2 is



The image displays 12 chemical structures for the L2 linker, arranged in four rows of three. Each structure is a linear chain of carbon and oxygen atoms, terminated by two wavy lines representing attachment points. The structures represent various combinations of 1,2-ethanediyl, 1,3-propanediyl, and 1,4-butanediyl units connected by ether linkages. The first row shows three structures with 1,2-ethanediyl, 1,3-propanediyl, and 1,4-butanediyl units. The second row shows four structures with 1,2-ethanediyl, 1,3-propanediyl, and 1,4-butanediyl units. The third row shows three structures with 1,2-ethanediyl, 1,3-propanediyl, and 1,4-butanediyl units. The fourth row shows three structures with 1,2-ethanediyl, 1,3-propanediyl, and 1,4-butanediyl units.


wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000305] In some embodiments, L1 is:



wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.


[000306] In some embodiments, L1 is



[000307] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000308] In some embodiments, L1 is optional (e.g., need not be present).


[000309] In some embodiments, any one of the complexes described herein has a structure of:



(J),

wherein *n* is 0-15 (e.g., 3) and *m* is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (J) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000310] In some embodiments, any one of the complexes described herein has a structure of:



wherein n is 0-15 (e.g., 3) and m is 0-15 (e.g., 4).


[000311] In some embodiments, the oligonucleotide is modified to comprise an amine group at the 5' end, the 3' end, or internally (e.g., as an amine functionalized nucleobase), prior to linking to a compound, e.g., a compound of formula (A) or formula (G).

[000312] Although linker conjugation is described in the context of anti-TfR1 antibodies and oligonucleotide molecular payloads, it should be understood that use of such linker conjugation on other muscle-targeting agents, such as other muscle-targeting antibodies, and/or on other molecular payloads is contemplated.

D. Examples of Antibody-Molecular Payload Complexes


[000313] Further provided herein are non-limiting examples of complexes comprising any one the anti-TfR1 antibodies described herein covalently linked to any of the molecular payloads (e.g., an oligonucleotide) described herein. In some embodiments, the anti-TfR1 antibody (e.g., any one of the anti-TfR1 antibodies provided in Tables 2-7) is covalently linked to a molecular payload (e.g., an oligonucleotide such as the oligonucleotides provided in Table 8) via a linker. Any of the linkers described herein may be used. In some embodiments, if the molecular payload is an oligonucleotide, the linker is linked to the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, or to an internal site of the oligonucleotide. In some embodiments, the linker is linked to the anti-TfR1 antibody via a thiol-reactive linkage (e.g., via a cysteine in the anti-TfR1 antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000314] An example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



wherein the linker is linked to the antibody via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000315] Another example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



(E)

wherein n is a number between 0-10, wherein m is a number between 0-10, wherein the linker is linked to the antibody via an amine group (e.g., on a lysine residue), and/or (e.g., and) wherein the linker is linked to the oligonucleotide (e.g., at the 5' end, 3' end, or internally). In some embodiments, the linker is linked to the antibody via a lysine, the linker is linked to the oligonucleotide at the 5' end, n is 3, and m is 4. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000316] It should be appreciated that antibodies can be linked to molecular payloads with different stoichiometries, a property that may be referred to as a drug to antibody ratios (DAR) with the “drug” being the molecular payload. In some embodiments, one molecular payload is linked to an antibody (DAR = 1). In some embodiments, two molecular payloads are linked to an antibody (DAR = 2). In some embodiments, three molecular payloads are linked to an

antibody (DAR = 3). In some embodiments, four molecular payloads are linked to an antibody (DAR = 4). In some embodiments, a mixture of different complexes, each having a different DAR, is provided. In some embodiments, an average DAR of complexes in such a mixture may be in a range of 1 to 3, 1 to 4, 1 to 5 or more. An average DAR of complexes in a mixture need not be an integer value. DAR may be increased by conjugating molecular payloads to different sites on an antibody and/or (e.g., and) by conjugating multimers to one or more sites on antibody. For example, a DAR of 2 may be achieved by conjugating a single molecular payload to two different sites on an antibody or by conjugating a dimer molecular payload to a single site of an antibody.

[000317] In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to a molecular payload. In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to molecular payload via a linker (e.g., a linker comprising a valine-citrulline sequence). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000318] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000319] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 71, or SEQ ID NO: 72, and a VL comprising the amino acid sequence of SEQ ID NO: 70. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000320] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 74. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000321] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000322] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 77, and a VL comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000323] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 or SEQ ID NO: 79, and a VL comprising the amino acid sequence of SEQ ID NO: 80. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000324] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 154, and a VL comprising the amino acid sequence of SEQ ID NO: 155. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000325] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000326] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000327] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000328] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 94, and a light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000329] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92, and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000330] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 156, and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000331] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97, SEQ ID NO: 98, or SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000332] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000333] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).


[000334] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000335] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 102 or SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).


[000336] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 or SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000337] In any of the example complexes described herein, in some embodiments, the anti-TfR1 antibody is covalently linked to the molecular payload via a linker comprising a structure of:




wherein n is 3, m is 4.

[000338] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000339] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a VH and VL of any one of the antibodies listed in Table 3, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000340] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a heavy chain and light chain of any one of the antibodies listed in Table 4, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000341] In some embodiments, the complex described herein comprises an anti-TfR1 Fab covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 Fab comprises a heavy chain and light chain of any one of the antibodies listed in Table 5, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000342] In some embodiments, in any one of the examples of complexes described herein, $L1$ is:




wherein L2 is



; wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000343] In some embodiments, L1 is:



wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000344] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000345] In some embodiments, L1 is optional (e.g., need not be present).

III. Formulations

[000346] Complexes provided herein may be formulated in any suitable manner.

Generally, complexes provided herein are formulated in a manner suitable for pharmaceutical use. For example, complexes can be delivered to a subject using a formulation that minimizes degradation, facilitates delivery and/or (e.g., and) uptake, or provides another beneficial property to the complexes in the formulation. In some embodiments, provided herein are compositions comprising complexes and pharmaceutically acceptable carriers. Such compositions can be suitably formulated such that when administered to a subject, either into the immediate environment of a target cell or systemically, a sufficient amount of the complexes enter target muscle cells. In some embodiments, complexes are formulated in buffer solutions such as phosphate-buffered saline solutions, liposomes, micellar structures, and capsids.

[000347] It should be appreciated that, in some embodiments, compositions may include separately one or more components of complexes provided herein (e.g., muscle-targeting agents, linkers, molecular payloads, or precursor molecules of any one of them).

[000348] In some embodiments, complexes are formulated in water or in an aqueous solution (e.g., water with pH adjustments). In some embodiments, complexes are formulated in basic buffered aqueous solutions (e.g., PBS). In some embodiments, formulations as disclosed herein comprise an excipient. In some embodiments, an excipient confers to a composition improved stability, improved absorption, improved solubility and/or (e.g., and) therapeutic enhancement of the active ingredient. In some embodiments, an excipient is a buffering agent (e.g., sodium citrate, sodium phosphate, a tris base, or sodium hydroxide) or a vehicle (e.g., a buffered solution, petrolatum, dimethyl sulfoxide, or mineral oil).

[000349] In some embodiments, a complex or component thereof (e.g., oligonucleotide or antibody) is lyophilized for extending its shelf-life and then made into a solution before use (e.g., administration to a subject). Accordingly, an excipient in a composition comprising a complex, or component thereof, described herein may be a lyoprotectant (e.g., mannitol, lactose, polyethylene glycol, or polyvinyl pyrrolidone), or a collapse temperature modifier (e.g., dextran, ficoll, or gelatin).

[000350] In some embodiments, a pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, administration. Typically, the route of administration is intravenous or subcutaneous.

[000351] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol,

propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. In some embodiments, formulations include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Sterile injectable solutions can be prepared by incorporating the complexes in a required amount in a selected solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

[000352] In some embodiments, a composition may contain at least about 0.1% of the complex, or component thereof, or more, although the percentage of the active ingredient(s) may be between about 1% and about 80% or more of the weight or volume of the total composition. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

IV. Methods of Use / Treatment

[000353] Complexes comprising a muscle-targeting agent covalently linked to a molecular payload as described herein are effective in treating a subject having a dystrophinopathy, e.g., Duchenne muscular dystrophy. In some embodiments, complexes comprise a molecular payload that is an oligonucleotide, e.g., an antisense oligonucleotide that facilitates exon skipping of a pre-mRNA expressed from a mutated DMD allele.

[000354] In some embodiments, a subject may be a human subject, a non-human primate subject, a rodent subject, or any suitable mammalian subject. In some embodiments, a subject may have Duchenne muscular dystrophy or other dystrophinopathy. In some embodiments, a subject has a mutated DMD allele, which may optionally comprise at least one mutation in a DMD exon that causes a frameshift mutation and leads to improper RNA splicing/processing. In some embodiments, a subject is suffering from symptoms of a severe dystrophinopathy, e.g. muscle atrophy or muscle loss. In some embodiments, a subject has an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, a subject has a progressive muscle disease, such as Duchenne or Becker muscular dystrophy or DMD-associated dilated cardiomyopathy (DCM). In some embodiments, a subject is not suffering from symptoms of a dystrophinopathy.

[000355] In some embodiments, a subject has a mutation in a DMD gene that is amenable to exon 44 skipping. In some embodiments, a complex comprising a muscle-targeting agent covalently linked to a molecular payload as described herein is effective in treating a subject having a mutation in a DMD gene that is amenable to exon 44 skipping. In some embodiments,

a complex comprises a molecular payload that is an oligonucleotide, *e.g.*, an antisense oligonucleotide that facilitates skipping of exon 44 of a pre-mRNA, such as in a pre-mRNA encoded from a mutated DMD gene (*e.g.*, a mutated DMD gene that is amenable to exon 44 skipping).

[000356] An aspect of the disclosure includes methods involving administering to a subject an effective amount of a complex as described herein. In some embodiments, an effective amount of a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload can be administered to a subject in need of treatment. In some embodiments, a pharmaceutical composition comprising a complex as described herein may be administered by a suitable route, which may include intravenous administration, *e.g.*, as a bolus or by continuous infusion over a period of time. In some embodiments, administration may be performed by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, or intrathecal routes. In some embodiments, a pharmaceutical composition may be in solid form, aqueous form, or a liquid form. In some embodiments, an aqueous or liquid form may be nebulized or lyophilized. In some embodiments, a nebulized or lyophilized form may be reconstituted with an aqueous or liquid solution.

[000357] Compositions for intravenous administration may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). For intravenous injection, water soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing the antibody and a physiologically acceptable excipients is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular preparations, *e.g.*, a sterile formulation of a suitable soluble salt form of the antibody, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution.

[000358] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered via site-specific or local delivery techniques. Examples of these techniques include implantable depot sources of the complex, local delivery catheters, site specific carriers, direct injection, or direct application.

[000359] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered at an effective concentration that confers therapeutic effect on a subject. Effective amounts vary,

as recognized by those skilled in the art, depending on the severity of the disease, unique characteristics of the subject being treated, e.g., age, physical conditions, health, or weight, the duration of the treatment, the nature of any concurrent therapies, the route of administration and related factors. These related factors are known to those in the art and may be addressed with no more than routine experimentation. In some embodiments, an effective concentration is the maximum dose that is considered to be safe for the patient. In some embodiments, an effective concentration will be the lowest possible concentration that provides maximum efficacy.

[000360] Empirical considerations, e.g., the half-life of the complex in a subject, generally will contribute to determination of the concentration of pharmaceutical composition that is used for treatment. The frequency of administration may be empirically determined and adjusted to maximize the efficacy of the treatment.

[000361] The efficacy of treatment may be assessed using any suitable methods. In some embodiments, the efficacy of treatment may be assessed by evaluation of observation of symptoms associated with a dystrophinopathy, e.g., muscle atrophy or muscle weakness, through measures of a subject's self-reported outcomes, e.g., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, or by quality-of-life indicators, e.g., lifespan.

[000362] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload described herein is administered to a subject at an effective concentration sufficient to modulate activity or expression of a target gene by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% relative to a control, e.g. baseline level of gene expression prior to treatment.

ADDITIONAL EMBODIMENTS

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to a molecular payload configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
2. The complex of embodiment 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;

(ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;

(vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or

(vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

3. The complex of embodiment 1 or embodiment 2, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

4. The complex of any one of embodiments 1 to 3, wherein the anti-TfR1 antibody comprises:

(i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

(ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

(vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

(vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

(viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;

(ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or

(x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

5. The complex of any one of embodiments 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

6. The complex of embodiment 5, wherein the anti-TfR1 antibody is a Fab fragment.
7. The complex of embodiment 6, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
 - (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;
 - (vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
 - (vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;
 - (viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;
 - (ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or
 - (x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of embodiment 6 or embodiment 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of embodiments 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

10. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide.

11. The complex of embodiment 10, wherein the oligonucleotide promotes antisense-mediated exon skipping in the DMD pre-RNA.

12. The complex of embodiment 10 or 11, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.

13. The complex of embodiment 12, wherein the splicing feature is an exonic splicing enhancer (ESE) of the DMD pre-mRNA.
14. The complex of embodiment 13, wherein the splicing feature is in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.
15. The complex of embodiment 12, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site.
16. The complex of embodiment 15, wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.
17. The complex of any one of embodiments 12 to 16, wherein the region of complementarity comprises at least 4 consecutive nucleosides complementary to the splicing feature.
18. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide comprising a sequence complementary to any one of SEQ ID NOs: 160-195 or comprising a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
19. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
20. The complex of embodiment 19, wherein the at least one modified internucleoside linkage is a phosphorothioate linkage.
21. The complex of any one of embodiments 10 to 20, wherein the oligonucleotide comprises one or more modified nucleosides.

22. The complex of embodiment 21, wherein the one or more modified nucleosides are 2'-modified nucleosides.
23. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
24. The complex of any one of embodiments 1 to 23, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via a cleavable linker.
25. The complex of embodiment 24, wherein the cleavable linker comprises a valine-citrulline sequence.
26. The complex of any one of embodiments 1 to 25, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via conjugation to a lysine residue or a cysteine residue of the antibody.
27. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195.
28. The complex of embodiment 27, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
29. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.
30. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195.
31. The oligonucleotide of embodiment 30, wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.

32. The oligonucleotide of embodiment 30 or 31, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
33. A method of delivering a molecular payload to a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26.
34. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29.
35. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26 in an amount effective for promoting internalization of the molecular payload to the cell, optionally wherein the cell is a muscle cell.
36. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.
37. The method of embodiment 35 or 36, wherein the cell is *in vitro*.
38. The method of embodiment 35 or 36, wherein the cell is in a subject.
39. The method of embodiment 38, wherein the subject is a human.
40. The method of embodiment 39, wherein the subject has a DMD gene that is amenable to skipping of exon 44.
41. The method of any one of embodiments 35 to 40, wherein the dystrophin protein is a truncated dystrophin protein.

42. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.
43. A method of promoting skipping of exon 44 of a DMD pre-mRNA transcript in a cell, the method comprising contacting the cell with an effective amount of the complex of any one of embodiments 1 to 29.
44. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.

EXAMPLES

Example 1. Exon-skipping activity of anti-TfR1 antibody conjugates in Duchenne muscular dystrophy patient myotubes

[000363] In this study, the exon-skipping activities of anti-TfR1 antibody conjugates comprising an anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to a DMD exon 51-skipping antisense oligonucleotide (ASO) were evaluated. The DMD exon 51-skipping ASO is a phosphorodiamidate morpholino oligomer (PMO) of 30 nucleotides in length and targets an ESE in DMD exon 51 having the sequence TGGAGGT (SEQ ID NO: 322). Immortalized human myoblasts bearing an exon 52 deletion in the DMD gene were thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells were trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number was counted and cells were seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells were allowed to recover for 24 hours. Cells were induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no serum. Cells were then treated with the DMD exon 51-skipping oligonucleotide (not covalently linked to an antibody – “naked”) at 10 μM ASO or the anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 51-skipping oligonucleotide at 10 μM ASO equivalent. Cells were incubated with test articles for ten days then total RNA was harvested from the 96 well plates. cDNA synthesis was performed on 75 ng of total RNA, and mutation specific PCRs were performed to evaluate the degree of exon 51 skipping in the cells. Mutation-specific PCR products were run on a 4% agarose gel and visualized using SYBR gold. Densitometry was used to calculate the relative amounts of the skipped and unskipped amplicon and exon skipping was

determined as a ratio of the Exon 51 skipped amplicon divided by the total amount of amplicon present:

$$\% \text{Exon Skipping} = \frac{\text{Skipped Amplicon}}{(\text{Skipped Amplicon} + \text{Unskipped Amplicon})} * 100.$$

[000364] The results demonstrate that the conjugate resulted in enhanced exon skipping compared to the naked DMD exon 51-skipping oligonucleotide in patient myotubes (FIG. 1). This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enabled cellular internalization of the conjugate into muscle cells resulting in activity of the exon 51-skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/Vκ3) can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 44 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Example 2. Exon skipping activity of anti-TfR1 Fab-ASO conjugate in vivo in cynomolgus monkeys

[000365] Anti-TfR1 Fab 3M12 VH4/Vκ3 was covalently linked to the DMD exon 51-skipping antisense oligonucleotide (ASO) that was used in Example 1. The exon skipping activity of the conjugate was tested in vivo in healthy non-human primates. Naïve male cynomolgus monkeys (n= 4-5 per group) were administered two doses of vehicle, 30 mg/kg naked ASO (*i.e.*, not covalently linked to an antibody), or 122 mg/kg anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 51-skipping oligonucleotide (30 mg/kg ASO equivalent) via intravenous infusion on days 1 and 8. Animals were sacrificed and tissues harvested either 2 weeks or 4 weeks after the first dose was administered. Total RNA was collected from tissue samples using a Promega Maxwell® RSC instrument and cDNA synthesis was performed using qScript cDNA SuperMix. Assessment of exon 51 skipping was performed using end-point PCR.

[000366] Capillary electrophoresis of the PCR products was used to assess exon skipping, and % exon 51 skipping was calculated using the following formula:

$$\% \text{Exon Skipping} = \frac{\text{Molarity of Skipped Band}}{\text{Molarity of Skipped Band} + \text{Molarity of Unskipped Band}} * 100.$$

Calculated exon 51 skipping results are shown in Table 10.

Table 10. Exon 51 skipping of DMD mRNA in cynomolgus monkey

Time Group	2 weeks			4 weeks	
	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate dose ^b	0	n/a	122	n/a	122

ASO Dose ^c	0	30	30	30	30
Quadriceps ^d	0.00 (0.00)	1.216 (1.083)	4.906 (3.131)	0.840 (1.169)	1.708 (1.395)
Diaphragm ^d	0.00 (0.00)	1.891 (2.911)	7.315 (1.532)	0.717 (1.315)	9.225 (4.696)
Heart ^d	0.00 (0.00)	0.043 (0.096)	3.42 (1.192)	0.00 (0.00)	4.525 (1.400)
Biceps ^d	0.00 (0.00)	0.607 (0.615)	3.129 (0.912)	1.214 (1.441)	4.863 (3.881)
Tibialis anterior ^d	0.00 (0.00)	0.699 (0.997)	1.042 (0.685)	0.384 (0.615)	0.816 (0.915)
Gastrocnemius ^d	0.00 (0.00)	0.388 (0.573)	2.424 (2.329)	0.00 (0.00)	5.393 (2.695)

^aASO = antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO dose.

^dExon skipping values are mean % exon 51 skipping with standard deviations (n=5) in parentheses.

[000367] Tissue ASO accumulation was also quantified using a hybridization ELISA with a probe complementary to the ASO sequence. A standard curve was generated and ASO levels (in ng/g) were derived from a linear regression of the standard curve. The ASO was distributed to all tissues evaluated at a higher level following the administration of the anti-TfR1 Fab VH4/Vκ3-ASO conjugate as compared to the administration of naked ASO. Intravenous administration of naked ASO resulted in levels of ASO that were close to background levels in all tissues evaluated at 2 and 4 weeks after the first dose was administered. Administration of anti-TfR1 Fab VH4/Vκ3-ASO conjugate resulted in distribution of ASO through the tissues evaluated with a rank order of heart>diaphragm>bicep>quadriceps>gastrocnemius>tibialis anterior 2 weeks after first dosing. The duration of tissue concentration was also assessed. Concentrations of the ASO in quadriceps, bicep and diaphragm decreased by less than 50% over the time period evaluated (2 to 4 weeks), while levels of ASO in the heart, tibialis anterior, and gastrocnemius remained virtually unchanged (Table 11). This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enabled cellular internalization of the conjugate into muscle cells *in vivo*, resulting in activity of the exon skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/Vκ3) *in vivo* can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 44 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Table 11. Tissue distribution of DMD exon 51 skipping ASO in cynomolgus monkeys

Time	2 weeks			4 weeks	
Group	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate Dose ^b	0	n/a	122	n/a	122
ASO Dose ^c	0	30	30	30	30

Quadriceps ^d	0 (59.05)	696.8 (868.15)	2436 (954.0)	197 (134)	682 (281)
Diaphragm ^d	0± (144.3)	580.02 (360.11)	6750 (2256)	60 (120)	3131 (1618)
Heart ^d	0 (396.03)	1449 (1337)	27138 (6315)	943 (1803)	30410 (9247)
Biceps ^d	0 (69.58)	615.63 (335.17)	2840 (980.31)	130 (80)	1326 (623)
Tibialis anterior ^d	0 (76.31)	564.71 (327.88)	1591 (253.50)	169 (110)	1087 (514)
Gastrocnemius ^d	0 (41.15)	705.47 (863.75)	2096 (474.04)	170 (69)	1265 (272)

^aASO = Antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate dose.

^dASO values are mean concentrations of ASO in tissue as ng/g with standard deviations (n=5) in parentheses.

Example 3. Exon-skipping activity of anti-TfR1 antibody conjugates in Duchenne muscular dystrophy patient myotubes

[000368] In this study, the exon-skipping activities of anti-TfR1 antibody conjugates comprising an anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to a DMD exon 44-skipping antisense oligonucleotide (ASO) are evaluated. The DMD exon 44-skipping ASO is a phosphorodiamidate morpholino oligomer (PMO) and targets a DMD exon 44 splicing feature. Immortalized human myoblasts are thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells are trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number is counted and cells are seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells are allowed to recover for 24 hours. Cells are induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no serum. Cells are then treated with the DMD exon 44-skipping oligonucleotide (not covalently linked to an antibody – “naked”) at 10 μM ASO or the anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 44-skipping oligonucleotide at 10 μM ASO equivalent. Cells are incubated with test articles for ten days then total RNA is harvested from the 96 well plates. cDNA synthesis is performed on 75 ng of total RNA, and mutation specific PCRs are performed to evaluate the degree of exon 44 skipping in the cells. PCR products are measured using capillary electrophoresis with UV detection. Molarity is calculated and relative amounts of the skipped and unskipped amplicon are determined. Exon skipping is determined as a ratio of the Exon 44 skipped amplicon divided by the total amount of amplicon present, according to the following formula:

$$\%Exon\ Skipping = \frac{Skipped\ Amplicon}{(Skipped\ Amplicon + Unskipped\ Amplicon)} * 100$$

[000369] The results demonstrate that the conjugates facilitate enhanced exon skipping compared to the naked DMD exon 44-skipping oligonucleotide in patient myotubes. This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enables cellular internalization of the conjugate into muscle cells resulting in activity of the exon 44-skipping oligonucleotide in the muscle cells.

EQUIVALENTS AND TERMINOLOGY

[000370] The disclosure illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure. Thus, it should be understood that although the present disclosure has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this disclosure.

[000371] In addition, where features or aspects of the disclosure are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

[000372] It should be appreciated that, in some embodiments, sequences presented in the sequence listing may be referred to in describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides or nucleosides (e.g., an RNA counterpart of a DNA nucleoside or a DNA counterpart of an RNA nucleoside) and/or (e.g., and) one or more modified nucleotides/nucleosides and/or (e.g., and) one or more modified internucleoside linkages and/or (e.g., and) one or more other modification compared with the specified sequence while retaining essentially same or similar complementary properties as the specified sequence.

[000373] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted

by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (*i.e.*, meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[000374] Embodiments of this invention are described herein. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description.

[000375] The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

What is claimed is:

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 160-195.
2. The complex of claim 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;
 - (ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;
 - (vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or
 - (vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.
3. The complex of claim 1 or claim 2, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

4. The complex of any one of claims 1 to 3, wherein the anti-TfR1 antibody comprises:

(i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

(ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

(vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

(vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

(viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;

(ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or

(x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

5. The complex of any one of claims 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

6. The complex of claim 5, wherein the anti-TfR1 antibody is a Fab fragment.

7. The complex of claim 6, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of claim 6 or claim 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of claims 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.
10. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.
11. The complex of claim 10, wherein the splicing feature is an exonic splicing enhancer (ESE) in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.
12. The complex of claim 10, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.
13. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-195 or comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
14. The complex of any one of claims 1 to 13, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
15. The complex of any one of claims 1 to 14, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.

16. The complex of any one of claims 1 to 15, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via conjugation to a lysine residue or a cysteine residue of the antibody.
17. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.
18. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
19. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 16 or with the oligonucleotide of claim 17 or claim 18.
20. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 16 or with the oligonucleotide of claim 17 or claim 18 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.

1/1




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/73529

A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61K 47/68; C12N 15/113; A61K 31/712; A61K 31/7125; C07K 16/28 (2022.01)

ADD.

CPC - INV. A61K 47/6807; C12N 15/113; A61K 31/712; A61K 31/7125; C07K 16/2881

ADD. C12N 2310/11; C12N 2310/314; C12N 2310/3233; C12N 2310/3513; C12N 2320/33

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic database consulted during the international search (name of database and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	US 2020/0046854 A1 (THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM) 13 February 2020; paragraphs [150], [154]; page 28, line 2	17 --- 1 --- 2
X --- Y --- A	WO 2020/219820 A1 (AVIDITY BIOSCIENCES, INC.) 29 October 2020; paragraphs [0004], [0117], [0226]; claims 40, 59	17 --- 1 --- 2-3
A	EP 1479771 A2 (DOMANTIS LIMITED) 24 November 2004; paragraph [0051]	2-3
A	WO 2021/068761 A1 (SUZHOU QIN PHARMACEUTICALS CO LTD) 15 April 2021; claim 3	3

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 October 2022 (10.10.2022)

Date of mailing of the international search report

DEC 09 2022

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/73529

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-16, 19-20
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
-***-Please See Supplemental Page-***-

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Group I+, Claims 1-3, 17-18; SEQ ID NO: 160 (oligonucleotide targeting DMD); SEQ ID NO: 33 (CDR-H1); SEQ ID NO: 34 (CDR-H2); SEQ ID NO: 35 (CDR-H3); SEQ ID NO: 36 (CDR-L1); SEQ ID NO: 37 (CDR-L2); SEQ ID NO: 32 (CDR-L3); SEQ ID NO: 75 (VL); SEQ ID NO: 76 (VH)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/73529

****-Continued From Box No. III: Observations where unity of invention is lacking-****

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I+, Claims 1-3, 17-18; SEQ ID NO: 160 (oligonucleotide targeting DMD); SEQ ID NO: 33 (CDR-H1); SEQ ID NO: 34 (CDR-H2); SEQ ID NO: 35 (CDR-H3); SEQ ID NO: 36 (CDR-L1); SEQ ID NO: 37 (CDR-L2); SEQ ID NO: 32 (CDR-L3); SEQ ID NO: 75 (VL); SEQ ID NO: 76 (VH) are directed towards complexes comprising a muscle-targeting agent covalently linked to a molecular payload.

The complexes of Claims 1-3 (each in-part) and 17 (in-part) are believed to encompass the first named invention of Group I+ and are the claims that will be searched without fee to the extent that they encompass SEQ ID NO: 160 (first exemplary oligonucleotide targeting DMD); SEQ ID NO: 33 (first exemplary CDR-H1); SEQ ID NO: 34 (first exemplary CDR-H2); SEQ ID NO: 35 (first exemplary CDR-H3); SEQ ID NO: 36 (first exemplary CDR-L1); SEQ ID NO: 37 (first exemplary CDR-L2); SEQ ID NO: 32 (first exemplary CDR-L3); SEQ ID NO: 75 (first exemplary VL); SEQ ID NO: 76 (first exemplary VH). This first named invention of Group I+ has been selected to encompass the first species of each of the genera found in claims 1-3 and 17 based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines.

Applicant is invited to elect additional oligonucleotide sequence(s), CDRs, with specified SEQ ID NO: for each, CDR or with specified substitution(s) at specified site(s) of a SEQ ID NO: and/or CDRs fragments with associated VL and VH, represented by SEQ ID NOs, such that the sequence of each elected species is fully specified (i.e. no optional or variable residues or substituents), and available as an option within at least one searchable claim, to be searched. Additional sequence(s) will be searched upon the payment of additional fees. Applicants must specify the searchable claims that encompass any additionally elected sequence(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be SEQ ID NO: 161 (oligonucleotide targeting DMD).

No technical features are shared between the sequences of Groups I+ and, accordingly, these groups lack unity a priori.

Additionally, even if Groups I+ were considered to share the technical features including: a complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides; an oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to a sequence; these shared technical features are previously disclosed by WO 2020/219820 A1 (AVIDITY BIOSCIENCES, INC.) (hereinafter 'Avidity').

Avidity discloses a complex comprising an anti-transferrin receptor 1 (TfR1) antibody (a complex comprising an anti-transferrin receptor 1 (TfR1) antibody; paragraphs [0004], [0117], [0226]; claims 40, 59) covalently linked to an oligonucleotide configured for inducing skipping of an exon 44 in a DMD pre-mRNA (linked by PEG (covalently linked) to an oligonucleotide configured for inducing skipping of an exon 44 in a DMD pre-mRNA; paragraph [0004]; claims 59, 92-93), wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides (wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides; paragraph [0004]); an oligonucleotide that targets DMD (an oligonucleotide that targets DMD; paragraph [0004]), wherein the oligonucleotide comprises a region of complementarity (wherein the oligonucleotide comprises a region of complementarity; paragraph [0004]), optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to a sequence.

Since none of the special technical features of the Groups I+ inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by the Avidity reference, unity of invention is lacking.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/73529

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

a. ☒ forming part of the international application as filed.

b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13ter.1(a)),

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.

2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.

3. Additional comments: